US8343937B2 - Methods and compositions for treating flaviviruses and pestiviruses - Google Patents
Methods and compositions for treating flaviviruses and pestiviruses Download PDFInfo
- Publication number
- US8343937B2 US8343937B2 US11/527,124 US52712406A US8343937B2 US 8343937 B2 US8343937 B2 US 8343937B2 US 52712406 A US52712406 A US 52712406A US 8343937 B2 US8343937 B2 US 8343937B2
- Authority
- US
- United States
- Prior art keywords
- alkyl
- acyl
- monophosphate
- phosphate
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active, expires
Links
- 0 *C[C@H]1O[C@@](C)(N2C(C)=NC3=C2N=C(C)N=C3[Y])[C@@H](C)C1C Chemical compound *C[C@H]1O[C@@](C)(N2C(C)=NC3=C2N=C(C)N=C3[Y])[C@@H](C)C1C 0.000 description 59
- DSLJUCPUBGVWDU-WJZIRSFSSA-N CC[C@H]1O[C@@](CBr)(N2C=NC3=C2N=CN=C3NC(=O)C2=CC=CC=C2)[C@@H](C)C1C.CC[C@H]1O[C@](Br)(CBr)[C@@H](C)C1C.C[C@@]1(N2C=NC3=C2N=CN=C3N)O[C@H](CO)C(O)[C@@H]1O Chemical compound CC[C@H]1O[C@@](CBr)(N2C=NC3=C2N=CN=C3NC(=O)C2=CC=CC=C2)[C@@H](C)C1C.CC[C@H]1O[C@](Br)(CBr)[C@@H](C)C1C.C[C@@]1(N2C=NC3=C2N=CN=C3N)O[C@H](CO)C(O)[C@@H]1O DSLJUCPUBGVWDU-WJZIRSFSSA-N 0.000 description 1
- FKVBXJUMGBAXAU-IYOZZRMGSA-N C[C@@]1(N2C=NC3=C2N=CN=C3N)O[C@H](CO)C(O)[C@@H]1O.C[C@]1(O)C(O)[C@@H](CO)O[C@H]1N1C=NC2=C1N=CN=C2N Chemical compound C[C@@]1(N2C=NC3=C2N=CN=C3N)O[C@H](CO)C(O)[C@@H]1O.C[C@]1(O)C(O)[C@@H](CO)O[C@H]1N1C=NC2=C1N=CN=C2N FKVBXJUMGBAXAU-IYOZZRMGSA-N 0.000 description 1
- ABLLUJVGGPUQQY-FBJPCAQISA-N C[C@]1(O)C(O)[C@@H](CO)O[C@H]1N1C=CC(=O)NC1=O.C[C@]1(O)C(O)[C@@H](CO)O[C@H]1N1C=CC(N)=NC1=O.C[C@]1(O)C(O)[C@@H](CO)O[C@H]1N1C=NC2=C1N=C(N)NC2=O Chemical compound C[C@]1(O)C(O)[C@@H](CO)O[C@H]1N1C=CC(=O)NC1=O.C[C@]1(O)C(O)[C@@H](CO)O[C@H]1N1C=CC(N)=NC1=O.C[C@]1(O)C(O)[C@@H](CO)O[C@H]1N1C=NC2=C1N=C(N)NC2=O ABLLUJVGGPUQQY-FBJPCAQISA-N 0.000 description 1
- PPUDLEUZKVJXSZ-KQMUTXFVSA-N C[C@]1(O)C(O)[C@@H](CO)O[C@H]1N1C=CC(N)=NC1=O Chemical compound C[C@]1(O)C(O)[C@@H](CO)O[C@H]1N1C=CC(N)=NC1=O PPUDLEUZKVJXSZ-KQMUTXFVSA-N 0.000 description 1
- IPVFGAYTKQKGBM-XTSMLKGCSA-N O=C1NC(=O)N([C@@H]2O[C@H](CO)C(O)[C@H]2F)C=C1I Chemical compound O=C1NC(=O)N([C@@H]2O[C@H](CO)C(O)[C@H]2F)C=C1I IPVFGAYTKQKGBM-XTSMLKGCSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- This invention is in the area of pharmaceutical chemistry, and in particular, is a compound, method and composition for the treatment of flaviviruses and pestiviruses.
- This application is a continuation of U.S. application Ser. No. 10/602,135, filed on Jun. 20, 2003, now U.S. Pat. No. 7,163,929, which is a continuation of U.S. application Ser. No. 09/863,816, filed on May 23, 2001, now U.S. Pat. No. 6,812,219, which claims priority to U.S. provisional application No. 60/207,674, filed on May 26, 2000 and U.S. provisional application No. 60/283,276, filed on Apr. 11, 2001, the disclosures of which are incorporated herein by reference.
- Pestiviruses and flaviviruses belong to the Flaviviridae family of viruses along with hepatitis C virus.
- the pestivirus genus includes bovine viral diarrhea virus (BVDV), classical swine fever virus (CSFV, also called hog cholera virus) and border disease virus (BDV) of sheep (Moennig, V. et al. Adv. Vir. Res. 1992, 41, 53-98).
- Pestivirus infections of domesticated livestock (cattle, pigs and sheep) cause significant economic losses worldwide.
- BVDV causes mucosal disease in cattle and is of significant economic importance to the livestock industry (Meyers, G. and Thiel, H.-J., Advances in Virus Research, 1996, 47, 53-118; Moennig V., et al, Adv. Vir. Res. 1992, 41, 53-98).
- Pestivirus infections in man have been implicated in several diseases including congenital brain injury, infantile gastroenteritis and chronic diarrhea in human immunodeficiency virus (HIV) positive patients.
- HAV human immunodeficiency virus
- the flavivirus genus includes more than 68 members separated into groups on the basis of serological relatedness (Calisher et al., J. Gen. Virol, 1993, 70, 37-43). Clinical symptoms vary and include fever, encephalitis and hemorrhagic fever. Fields Virology , Editors: Fields, B. N., Knipe, D. M., and Howley, P. M., Lippincott-Raven Publishers, Philadelphia, Pa., 1996, Chapter 31, 931-959. Flaviviruses of global concern that are associated with human disease include the dengue hemorrhagic fever viruses (DHF), yellow fever virus, shock syndrome and Japanese encephalitis virus. Halstead, S. B., Rev. Infect. Dis., 1984, 6, 251-264; Halstead, S. B., Science, 239:476-481, 1988; Monath, T. P., New Eng. J. Med., 1988, 319, 641-643.
- DHF dengue hemorrhagic fever viruses
- antiviral agents that have been identified as active against the flavivirus or pestiviruses include:
- a compound of Formula I or a pharmaceutically acceptable salt or prodrug thereof, is provided:
- a compound of Formula IV or a pharmaceutically acceptable salt or prodrug thereof, is provided:
- a compound selected from Formulas VII, VIII and IX, or a pharmaceutically acceptable salt or prodrug thereof, is provided:
- a compound of Formulas X, XI and XII, or a pharmaceutically acceptable salt or prodrug thereof is provided:
- the invention provides a compound of Formula XVI, or a pharmaceutically acceptable salt or prodrug thereof:
- the invention provides a compound of Formula XVII, or a pharmaceutically acceptable salt or prodrug thereof:
- the invention provides a compound of Formula XVIII, or a pharmaceutically acceptable salt or prodrug thereof:
- the ⁇ -D- and ⁇ -L-nucleosides of this invention may inhibit flavivirus or pestivirus polymerase activity. These nucleosides can be assessed for their ability to inhibit flavivirus or pestivirus polymerase activity in vitro according to standard screening methods.
- the efficacy of the anti-flavivirus or pestivirus compound is measured according to the concentration of compound necessary to reduce the plaque number of the virus in vitro, according to methods set forth more particularly herein, by 50% (i.e. the compound's EC 50 ).
- the compound exhibits an EC 50 of less than 15 or preferably, less than 10 micromolar in vitro.
- the active compound can be administered in combination or alternation with another anti-flavivirus or pestivirus agent.
- combination therapy effective dosages of two or more agents are administered together, whereas during alternation therapy an effective dosage of each agent is administered serially.
- the dosages will depend on absorption, inactivation and excretion rates of the drug as well as other factors known to those of skill in the art. It is to be noted that dosage values will also vary with the severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens and schedules should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions.
- HCV is a member of the Flaviviridae family; however, now, HCV has been placed in a new monotypic genus, hepacivirus. Therefore, in one embodiment, the flavivirus or pestivirus is not HCV.
- antiviral agents that can be used in combination with the compounds disclosed herein include:
- Inhibitors of serine proteases particularly hepatitis C virus NS3 protease, PCT WO 98/17679), including alphaketoamides and hydrazinoureas, and inhibitors that terminate in an electrophile such as a boronic acid or phosphonate.
- Llinas-Brunet et al Hepatitis C inhibitor peptide analogues, PCT WO 99/07734.
- Non-substrate-based inhibitors such as 2,4,6-trihydroxy-3-nitro-benzamide derivatives (Sudo K. et al., Biochemical and Biophysical Research Communications, 238:643-647, 1997; Sudo K. et al. Antiviral Chemistry and Chemotherapy 9:186, 1998), including RD3-4082 and RD3-4078, the former substituted on the amide with a 14 carbon chain and the latter processing a para-phenoxyphenyl group;
- Helicase inhibitors (Diana G. D. et al., Compounds, compositions and methods for treatment of hepatitis C, U.S. Pat. No. 5,633,358; Diana G. D. et al., Piperidine derivatives, pharmaceutical compositions thereof and their use in the treatment of hepatitis C, PCT WO 97/36554);
- S-ODN Antisense phosphorothioate oligodeoxynucleotides (S-ODN) complementary to sequence stretches in the 5′ non-coding region (NCR) of the virus (Alt M. et al., Hepatology 22:707-717, 1995), or nucleotides 326-348 comprising the 3′ end of the NCR and nucleotides 371-388 located in the core coding region of the IICV RNA (Alt M. et al., Archives of Virology 142:589-599, 1997; Galderisi U. et al., Journal of Cellular Physiology 181:251-257, 1999);
- Inhibitors of IRES-dependent translation (Ikeda N et al., Agent for the prevention and treatment of hepatitis C, Japanese Patent Publication JP-08268890; Kai Y. et al. Prevention and treatment of viral diseases, Japanese Patent Publication JP-10101591);
- miscellaneous compounds including 1-amino-alkylcyclohexanes (U.S. Pat. No. 6,034,134 to Gold et al.), alkyl lipids (U.S. Pat. No. 5,922,757 to Chojkier et al.), vitamin E and other antioxidants (U.S. Pat. No. 5,922,757 to Chojkier et al.), squalene, amantadine, bile acids (U.S. Pat. No. 5,846,964 to Ozeki et al.), N-(phosphonoacetyl)-L-aspartic acid, (U.S. Pat. No.
- FIG. 1 provides the structure of various non-limiting examples of nucleosides of the present invention, as well as other known nucleosides, FIAU and Ribavirin, which are used as comparative examples in the text.
- FIG. 2 is a line graph of the pharmacokinetics (plasma concentrations) of ⁇ -D-2′-CH 3 -riboG administered to Cynomolgus Monkeys over time after administration.
- FIGS. 3 a and 3 b are line graphs of the pharmacokinetics (plasma concentrations) of ⁇ -D-2′-CH 3 -riboG administered to Cynomolgus Monkeys either intravenously ( 3 a ) or orally ( 3 b ) over time after administration.
- FIG. 4 depicts line graphs of the results of the cell protection assay of ⁇ -D-2′-CH 3 -riboG against BVDV.
- FIG. 5 depicts line graphs of the results of the cell protection assay of ribavirin against BVDV.
- FIG. 6 are line graphs of the cell protection assay of ⁇ -D-2′-CH 3 -riboG, ⁇ -D-2′-CH 3 -riboC, ⁇ -D-2′-CH 3 -riboU, ⁇ -D-2′-CH 3 -riboA and ribavirin.
- FIG. 7 are line graphs of the results of the plaque reduction assay for ⁇ -D-2′-CH 3 -riboU, ⁇ -D-2′-CH 3 -riboC and ⁇ -D-2′-CH 3 -riboG.
- FIG. 8 is an illustration of plaque reduction based on increasing concentrations of ⁇ -D-2′-CH 3 -riboU.
- FIG. 9 is a line graph of the results of the yield reduction assay for ⁇ -D-2′-CH 3 -riboG, depicting a 4 log reduction at 9 ⁇ M.
- FIG. 10 is an illustration of the yield reduction based on increasing concentrations of ⁇ -D-2′-CH 3 -riboC.
- the invention as disclosed herein is a compound, method and composition for the treatment of pestiviruses and flaviviruses in humans and other host animals, that includes the administration of an effective flavivirus or pestivirus treatment amount of an ⁇ -D- or ⁇ -L-nucleoside as described herein or a pharmaceutically acceptable salt or prodrug thereof, optionally in a pharmaceutically acceptable carrier.
- the compounds of this invention either possess antiviral (i.e., anti-flavivirus or pestivirus) activity, or are metabolized to a compound that exhibits such activity.
- the present invention includes the following features:
- Flaviviruses included within the scope of this invention are discussed generally in Fields Virology , Editors: Fields, B. N., Knipe, D. M., and Howley, P. M., Lippincott-Raven Publishers, Philadelphia, Pa., Chapter 31, 1996.
- flaviviruses include, without limitation: Absettarov, Alfuy, AIN, Aroa, Bagaza, Banzi, Bouboui, Bussuquara, Cacipacore, Carey Island, Dakar bat, Dengue 1, Dengue 2, Dengue 3, Dengue 4, Edge Hill, Entebbe bat, Gadgets Gully, Hanzalova, Hypr, Ilheus, Israel turkey meningoencephalitis, Japanese encephalitis, Jugra, Jutiapa, Kadam, Karshi, Kedougou, Kokobera, Koutango, Kumlinge, Kunjin, Kyasanur Forest disease, Langat, Louping ill, Meaban, Modoc, Montana myotis leukoencephalitis, Murray valley encephalitis, Naranjal, Negishi, Ntaya, Omsk hemorrhagic fever, Phnom-Penh bat, Powassan, Rio Bravo, Rocio, Royal Farm, Russian spring-summer encephalitis, Saboya
- Pestiviruses included within the scope of this invention are discussed generally in Fields Virology , Editors: Fields, B. N., Knipe, D. M., and Howley, P. M., Lippincott-Raven Publishers, Philadelphia, Pa., Chapter 33, 1996.
- Specific pestiviruses include, without limitation: bovine viral diarrhea virus (“BVDV”), classical swine fever virus (“CSFV,” also called hog cholera virus), and border disease virus (“BDV”).
- BVDV bovine viral diarrhea virus
- CSFV classical swine fever virus
- BDV border disease virus
- a compound of Formula I or a pharmaceutically acceptable salt or prodrug thereof, is provided:
- a compound of Formula IV or a pharmaceutically acceptable salt or prodrug thereof, is provided:
- a compound selected from Formulas VII, VIII and IX, or a pharmaceutically acceptable salt or prodrug thereof, is provided:
- Base is a purine or pyrimidine base as defined herein;
- a compound of Formula X, XI or XII, or a pharmaceutically acceptable salt or prodrug thereof is provided:
- Base is a purine or pyrimidine base as defined herein;
- the invention provides a compound of Formula XVI, or a pharmaceutically acceptable salt or prodrug thereof:
- a compound of Formula XVI is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R 1 is independently H or phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R 1 is independently H or phosphate; (3) R 6 is independently H or phosphate;
- a compound of Formula XVI is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R 1 is independently H or phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R 1 is independently H or phosphate; (3) R 6 is independently H or phosphate;
- a compound of Formula XVI is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R 1 is independently H or phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R 1 is independently H or phosphate; (3) R 6 is independently H or phosphate;
- a compound of Formula XVI, or its pharmaceutically acceptable salt or prodrug is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R 1 is independently H or phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R 1 is independently H or phosphate; (3) R 6 is independently H or phosphate;
- a compound of Formula XVI is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R 1 is independently H or phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R 1 is independently H or phosphate; (3) R 6 is independently H or phosphate;
- a compound of Formula XVI, or its pharmaceutically acceptable salt or prodrug is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R 1 is independently H or phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R 1 is independently H or phosphate; (3) R 6 is independently H or phosphate;
- a compound of Formula XVI is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R 1 is independently H or phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R 1 is independently H or phosphate; (3) R 6 is independently H or phosphate;
- a compound of Formula XVI, or its pharmaceutically acceptable salt or prodrug is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R 1 is independently H or phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R 1 is independently H or phosphate; (3) R 6 is independently H or phosphate;
- a compound of Formula XVI, or its pharmaceutically acceptable salt or prodrug is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R 1 is independently H or phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R 1 is independently H or phosphate; (3) R 6 is independently H or phosphate;
- a compound of Formula XVI is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R 1 is independently H or phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R 1 is independently H or phosphate; (3) R 1 is independently H or phosphate; (3) R 1 is independently H or phosphate; (3) R 1 is independently
- a compound of Formula XVI, or its pharmaceutically acceptable salt or prodrug is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R 1 is independently H or phosphate; (3) R 6 is alkyl (including lower alkyl), alkenyl, alkynyl, Br-vinyl, hydroxy, O-alkyl, O-alkenyl, chloro, bromo, fluoro, iodo, NO 2 , amino, lower alkylamino or di(lower alkyl)amino; (4) R 7 and R 9 are independently OR 2 ; (5) R 8 and R 10 are hydrogen; and (6) X is O, S, SO 2 or CH 2 .
- a compound of Formula XVI, or its pharmaceutically acceptable salt or prodrug is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R 1 is independently H or phosphate; (3) R 6 is alkyl; (4) R 7 and R 9 are independently OR 2 ; (5) R 8 and R 10 are hydrogen; and (6) X is O, S, SO 2 , or CH 2 .
- a compound of Formula XVI, or its pharmaceutically acceptable salt or prodrug is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R 1 is independently H or phosphate; (3) R 6 is alkyl; (4) R 7 and R 9 are independently OR 2 ; (5) R 8 and R 10 are independently H, alkyl (including lower alkyl), chlorine, bromine, or iodine; and (6) X is O.
- a compound of Formula XVI, or its pharmaceutically acceptable salt or prodrug is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R 1 is independently H or phosphate; (3) R 6 is alkyl; (4) R 7 and R 9 are independently OR 2 , alkyl (including lower alkyl), alkenyl, alkynyl, Br-vinyl, O-alkenyl, chlorine, bromine, iodine, NO 2 , amino, lower alkylamino or di(lower alkyl)amino;
- R 8 and R 10 are hydrogen; and (6) X is O.
- Base is adenine; (2) R 1 is hydrogen; (3) R 6 is methyl; (4) R 7 and R 9 are hydroxyl; (5) R 8 and R 10 are hydrogen; and (6) X is O;
- Base is guanine; (2) R 1 is hydrogen; (3) R 6 is methyl; (4) R 7 and R 9 are hydroxyl; (5) R 8 and R 10 are hydrogen; and (6) X is O;
- Base is cytosine; (2) R 1 is hydrogen; (3) R 6 is methyl; (4) R 7 and R 9 are hydroxyl; (5) R 8 and R 10 are hydrogen; and (6) X is O;
- Base is thymine; (2) R 1 is hydrogen; (3) R 6 is methyl; (4) R 7 and R 9 are hydroxyl; (5) R 8 and R 10 are hydrogen; and (6) X is O;
- Base is uracil; (2) R 1 is hydrogen; (3) R 6 is methyl; (4) R 7 and R 9 are hydroxyl; (5) R 8 and R 10 are hydrogen; and (6) X is O;
- Base is adenine; (2) R 1 is phosphate; (3) R 6 is methyl; (4) R 7 and R 9 are hydroxyl; (5) R 8 and R 10 are hydrogen; and (6) X is O;
- Base is adenine; (2) R 1 is hydrogen; (3) R 6 is ethyl; (4) R 7 and R 9 are hydroxyl; (5) R 8 and R 10 are hydrogen; and (6) X is O;
- Base is adenine; (2) R 1 is hydrogen; (3) R 6 is propyl; (4) R 7 and R 9 are hydroxyl; (5) R 8 and R 10 are hydrogen; and (6) X is O;
- Base is adenine; (2) R 1 is hydrogen; (3) R 6 is butyl; (4) R 7 and R 9 are hydroxyl; (5) R 8 and R 10 are hydrogen; and (6) X is O;
- Base is adenine; (2) R 1 is hydrogen; (3) R 6 is methyl; (4) R 7 is hydrogen and R 9 is hydroxyl; (5) R 8 and R 10 are hydrogen; and (6) X is O;
- Base is adenine; (2) R 1 is hydrogen; (3) R 6 is methyl; (4) R 7 and R 9 are hydroxyl; (5) R 8 and R 10 are hydrogen; and (6) X is S;
- Base is adenine; (2) R 1 is hydrogen; (3) R 6 is methyl; (4) R 7 and R 9 are hydroxyl; (5) R 8 and R 10 are hydrogen; and (6) X is SO 2 ;
- Base is adenine; (2) R 1 is hydrogen; (3) R 6 is methyl; (4) R 7 and R 9 are hydroxyl; (5) R 8 and R 10 are hydrogen; and (6) X is CH 2 ;
- the invention provides a compound of Formula XVII, or a pharmaceutically acceptable salt or prodrug thereof:
- a compound of Formula XVII, or its pharmaceutically acceptable salt or prodrug is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R 1 is independently H; phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R 1 is independently H or phosphate; (3) R 6
- a compound of Formula XVII, or its pharmaceutically acceptable salt or prodrug is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R 1 is independently H; phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R 1 is independently H or phosphate; (3) R 6
- a compound of Formula XVII, or its pharmaceutically acceptable salt or prodrug is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R 1 is independently H; phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R 1 is independently H or phosphate; (3) R 6
- a compound of Formula XVII, or its pharmaceutically acceptable salt or prodrug is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R 1 is independently H; phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R 1 is independently H or phosphate; (3) R 6
- a compound of Formula XVII, or its pharmaceutically acceptable salt or prodrug is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R 1 is independently H; phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R 1 is independently H or phosphate; (3) R 6
- a compound of Formula XVII, or its pharmaceutically acceptable salt or prodrug is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R 1 is independently H; phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R 1 is independently H or phosphate; (3) R 6
- a compound of Formula XVII, or its pharmaceutically acceptable salt or prodrug is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R 1 is independently H; phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R 1 is independently H or phosphate; (3) R 6
- a compound of Formula XVII, or its pharmaceutically acceptable salt or prodrug is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R 1 is independently H or phosphate; (3) R 6 is alkyl; (4) R 7 and R 9 are independently hydrogen, OR 2 , alkyl (including lower alkyl), alkenyl, alkynyl, Br-vinyl, O-alkenyl, chlorine, bromine, iodine, NO 2 , amino, lower alkylamino or di(lower alkyl)-amino; (5) R 10 is H, alkyl (including lower alkyl), chlorine, bromine or iodine; and (6) X is O, S, SO 2 , or CH 2 .
- a compound of Formula XVII, or its pharmaceutically acceptable salt or prodrug is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R 1 is independently H or phosphate; (3) R 6 is alkyl (including lower alkyl), alkenyl, alkynyl, Br-vinyl, hydroxy, O-alkyl, O-alkenyl, chloro, bromo, fluoro, iodo, NO 2 , amino, lower alkylamino, or di(lower alkyl)amino; (4) R 7 and R 9 are independently OR 2 ; (5) R 10 is H; and (6) X is O, S, SO 2 , or CH 2 .
- a compound of Formula XVII, or its pharmaceutically acceptable salt or prodrug is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R 1 is independently H or phosphate; (3) R 6 is alkyl; (4) R 7 and R 9 are independently OR 2 ; (5) R 10 is H; and (6) X is O, S, SO 2 , or CH 2 .
- Base is adenine; (2) R 1 is hydrogen; (3) R 6 is methyl; (4) R 7 and R 9 are hydroxyl; (5) R 10 is hydrogen; and (6) X is O;
- Base is guanine; (2) R 1 is hydrogen; (3) R 6 is methyl; (4) R 7 and R 9 are hydroxyl; (5) R 10 is hydrogen; and (6) X is O;
- Base is cytosine; (2) R 1 is hydrogen; (3) R 6 is methyl; (4) R 7 and R 9 are hydroxyl; (5) R 10 is hydrogen; and (6) X is O;
- Base is thymine; (2) R 1 is hydrogen; (3) R 6 is methyl; (4) R 7 and R 9 are hydroxyl; (5) R 10 is hydrogen; and (6) X is O;
- Base is uracil; (2) R 1 is hydrogen; (3) R 6 is methyl; (4) R 7 and R 9 are hydroxyl; (5) R 10 is hydrogen; and (6) X is O;
- Base is adenine; (2) R 1 is phosphate; (3) R 6 is methyl; (4) R 7 and R 9 are hydroxyl; (5) R 10 is hydrogen; and (6) X is O;
- Base is adenine; (2) R 1 is hydrogen; (3) R 6 is ethyl; (4) R 7 and R 9 are hydroxyl; (5) R 10 is hydrogen; and (6) X is O;
- Base is adenine; (2) R 1 is hydrogen; (3) R 6 is propyl; (4) R 7 and R 9 are hydroxyl; (5) R 10 is hydrogen; and (6) X is O;
- Base is adenine; (2) R 1 is hydrogen; (3) R 6 is butyl; (4) R 7 and R 9 are hydroxyl; (5) R 10 is hydrogen; and (6) X is O;
- Base is adenine; (2) R 1 is hydrogen; (3) R 6 is methyl; (4) R 7 and R 9 are hydroxyl; (5) R 10 is hydrogen; and (6) X is S;
- Base is adenine; (2) R 1 is hydrogen; (3) R 6 is methyl; (4) R 7 and R 9 are hydroxyl; (5) R 10 is hydrogen; and (6) X is SO 2 ; or
- Base is adenine; (2) R 1 is hydrogen; (3) R 6 is methyl; (4) R 7 and R 9 are hydroxyl; (5) R 10 is hydrogen; and (6) X is CH 2 .
- the invention provides a compound of Formula XVIII, or a pharmaceutically acceptable salt or prodrug thereof:
- a compound of Formula XVIII, or its pharmaceutically acceptable salt or prodrug is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R 1 is independently H; phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R 1 is independently H or phosphate; (3) R 6
- a compound of Formula XVIII, or its pharmaceutically acceptable salt or prodrug is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R 1 is independently H; phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R 1 is independently H or phosphate; (3) R 6
- a compound of Formula XVIII, or its pharmaceutically acceptable salt or prodrug is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R 1 is independently H; phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R 1 is independently H or phosphate; (3) R 6
- a compound of Formula XVIII, or its pharmaceutically acceptable salt or prodrug is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R 1 is independently H; phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R 1 is independently H or phosphate; (3) R 6
- a compound of Formula XVIII, or its pharmaceutically acceptable salt or prodrug is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R 1 is independently H; phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R 1 is independently H or phosphate; (3) R 6
- a compound of Formula XVIII, or its pharmaceutically acceptable salt or prodrug is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R 1 is independently H; phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R 1 is independently H or phosphate; (3) R 6
- a compound of Formula XVIII, or its pharmaceutically acceptable salt or prodrug is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R 1 is independently H; phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R 1 is independently H or phosphate; (3) R 6
- a compound of Formula XVIII, or its pharmaceutically acceptable salt or prodrug is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R 1 is independently H or phosphate; (3) R 6 is alkyl (including lower alkyl), alkenyl, alkynyl, Br-vinyl, hydroxy, O-alkyl, O-alkenyl, chloro, bromo, fluoro, iodo, NO 2 , amino, lower alkylamino or di(lower alkyl)amino; (4) R 7 and R 9 are independently OR 2 ; (5) R 8 is H; and (6) X is O, S, SO 2 or CH 2 .
- a compound of Formula XVIII, or its pharmaceutically acceptable salt or prodrug is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R 1 is independently H or phosphate; (3) R 6 is alkyl; (4) R 7 and R 9 are independently OR 2 ; (5) R 8 is H; and (6) X is O, S, SO 2 , or CH 2 .
- a compound of Formula XVIII, or its pharmaceutically acceptable salt or prodrug is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R 1 is independently H or phosphate; (3) R 6 is alkyl; (4) R 7 and R 9 are independently OR 2 ; (5) R 8 is H; and (6) X is O.
- Base is adenine; (2) R 1 is hydrogen; (3) R 6 is methyl; (4) R 7 and R 9 are hydroxyl; (5) R 1 is hydrogen; and (6) X is O;
- Base is guanine; (2) R 1 is hydrogen; (3) R 6 is methyl; (4) R 7 and R 9 are hydroxyl; (5) R 8 is hydrogen; and (6) X is O;
- Base is cytosine; (2) R 1 is hydrogen; (3) R 6 is methyl; (4) R 7 and R 9 are hydroxyl; (5) R 8 is hydrogen; and (6) X is O;
- Base is thymine; (2) R 1 is hydrogen; (3) R 6 is methyl; (4) R 7 and R 9 are hydroxyl; (5) R 8 is hydrogen; and (6) X is O;
- Base is uracil; (2) R 1 is hydrogen; (3) R 6 is methyl; (4) R 7 and R 9 are hydroxyl; (5) R 8 is hydrogen; and (6) X is O;
- Base is adenine; (2) R 1 is phosphate; (3) R 6 is methyl; (4) R 7 and R 9 are hydroxyl; (5) R 8 is hydrogen; and (6) X is O;
- Base is adenine; (2) R 1 is hydrogen; (3) R 6 is ethyl; (4) R 7 and R 9 are hydroxyl; (5) R 8 is hydrogen; and (6) X is O;
- Base is adenine; (2) R 1 is hydrogen; (3) R 6 is propyl; (4) R 7 and R 9 are hydroxyl; (5) R 8 is hydrogen; and (6) X is O;
- Base is adenine; (2) R 1 is hydrogen; (3) R 6 is butyl; (4) R 7 and R 9 are hydroxyl; (5) R 1 is hydrogen; and (6) X is O;
- Base is adenine; (2) R 1 is hydrogen; (3) R 6 is methyl; (4) R 7 and R 9 are hydroxyl; (5) R 8 is hydrogen; and (6) X is S;
- Base is adenine; (2) R 1 is hydrogen; (3) R 6 is methyl; (4) R 7 and R 9 are hydroxyl; (5) R 8 is hydrogen; and (6) X is SO 2 ; or
- Base is adenine; (2) R 1 is hydrogen; (3) R 6 is methyl; (4) R 7 and R 9 are hydroxyl; (5) R 8 is hydrogen; and (6) X is CH 2 .
- the ⁇ -D- and ⁇ -L-nucleosides of this invention belong to a class of anti-flavivirus or pestivirus agents that may inhibit flavivirus or pestivirus polymerase activity.
- Nucleosides can be screened for their ability to inhibit flavivirus or pestivirus polymerase activity in vitro according to screening methods set forth more particularly herein. One can readily determine the spectrum of activity by evaluating the compound in the assays described herein or with another confirmatory assay.
- the efficacy of the anti-flavivirus or pestivirus compound is measured according to the concentration of compound necessary to reduce the plaque number of the virus in vitro, according to methods set forth more particularly herein, by 50% (i.e. the compound's EC 50 ). In preferred embodiments the compound exhibits an EC 50 of less than 15 or 10 micromolar.
- HCV is a member of the Flaviviridae family; however, now, HCV has been placed in a new monotypic genus, hepacivirus. Therefore, in one embodiment, the flavivirus or pestivirus is not HCV.
- the active compound can be administered as any salt or prodrug that upon administration to the recipient is capable of providing directly or indirectly the parent compound, or that exhibits activity itself.
- Nonlimiting examples are the pharmaceutically acceptable salts (alternatively referred to as “physiologically acceptable salts”), and a compound, which has been alkylated or acylated at the 5′-position, or on the purine or pyrimidine base (a type of “pharmaceutically acceptable prodrug”).
- physiologically acceptable salts alternatively referred to as “physiologically acceptable salts”
- the modifications can affect the biological activity of the compound, in some cases increasing the activity over the parent compound. This can easily be assessed by preparing the salt or prodrug and testing its antiviral activity according to the methods described herein, or other methods known to those skilled in the art.
- alkyl refers to a saturated straight, branched, or cyclic, primary, secondary, or tertiary hydrocarbon of typically C 1 to C 10 , and specifically includes methyl, trifluoromethyl, ethyl, propyl, isopropyl, cyclopropyl, butyl, isobutyl, t-butyl, pentyl, cyclopentyl, isopentyl, neopentyl, hexyl, isohexyl, cyclohexyl, cyclohexylmethyl, 3-methylpentyl, 2,2-dimethylbutyl, and 2,3-dimethylbutyl.
- the term includes both substituted and unsubstituted alkyl groups.
- Moieties with which the alkyl group can be substituted are selected from the group consisting of hydroxyl, amino, alkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, sulfonic acid, sulfate, phosphonic acid, phosphate, or phosphonate, either unprotected, or protected as necessary, as known to those skilled in the art, for example, as taught in Greene, et al., Protective Groups in Organic Synthesis , John Wiley and Sons, Second Edition, 1991, hereby incorporated by reference.
- lower alkyl refers to a C 1 to C 4 saturated straight, branched, or if appropriate, a cyclic (for example, cyclopropyl) alkyl group, including both substituted and unsubstituted forms. Unless otherwise specifically stated in this application, when alkyl is a suitable moiety, lower alkyl is preferred. Similarly, when alkyl or lower alkyl is a suitable moiety, unsubstituted alkyl or lower alkyl is preferred.
- alkylamino or arylamino refers to an amino group that has one or two alkyl or aryl substituents, respectively.
- protected refers to a group that is added to an oxygen, nitrogen, or phosphorus atom to prevent its further reaction or for other purposes.
- oxygen and nitrogen protecting groups are known to those skilled in the art of organic synthesis.
- aryl refers to phenyl, biphenyl, or naphthyl, and preferably phenyl.
- the term includes both substituted and unsubstituted moieties.
- the aryl group can be substituted with one or more moieties selected from the group consisting of hydroxyl, amino, alkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, sulfonic acid, sulfate, phosphonic acid, phosphate, or phosphonate, either unprotected, or protected as necessary, as known to those skilled in the art, for example, as taught in Greene, et al., Protective Groups in Organic Synthesis , John Wiley and Sons, Second Edition, 1991.
- alkaryl or alkylaryl refers to an alkyl group with an aryl substituent.
- aralkyl or arylalkyl refers to an aryl group with an alkyl substituent.
- halo includes chloro, bromo, iodo, and fluoro.
- purine or pyrimidine base includes, but is not limited to, adenine, N 6 -alkylpurines, N 6 -acylpurines (wherein acyl is C(O)(alkyl, aryl, alkylaryl, or arylalkyl), N 6 -benzylpurine, N 6 -halopurine, N 6 -vinylpurine, N 6 -acetylenic purine, N 6 -acyl purine, N 6 -hydroxyalkyl purine, N 6 -thioalkyl purine, N 2 -alkylpurines, N 2 -alkyl-6-thiopurines, thymine, cytosine, 5-fluorocytosine, 5-methylcytosine, 6-azapyrimidine, including 6-azacytosine, 2- and/or 4-mercaptopyrmidine, uracil, 5-halouracil, including 5-fluorouracil, C 5 -alkylpyrimidines, C 5 -
- Purine bases include, but are not limited to, guanine, adenine, hypoxanthine, 2,6-diaminopurine, and 6-chloropurine. Functional oxygen and nitrogen groups on the base can be protected as necessary or desired. Suitable protecting groups are well known to those skilled in the art, and include trimethylsilyl, dimethylhexylsilyl, t-butyldimethylsilyl and t-butyldiphenylsilyl, trityl, alkyl groups, and acyl groups such as acetyl and propionyl, methanesulfonyl, and p-toluenesulfonyl.
- the purine or pyrimidine base can optionally substituted such that it forms a viable prodrug, which can be cleaved in vivo.
- appropriate substituents include acyl moiety, an amine or cyclopropyl (e.g., 2-amino, 2,6-diamino or cyclopropyl guanosine).
- acyl refers to a carboxylic acid ester in which the non-carbonyl moiety of the ester group is selected from straight, branched, or cyclic alkyl or lower alkyl, alkoxyalkyl including methoxymethyl, aralkyl including benzyl, aryloxyalkyl such as phenoxymethyl, aryl including phenyl optionally substituted with halogen, C 1 to C 4 alkyl or C 1 to C 4 alkoxy, sulfonate esters such as alkyl or aralkyl sulphonyl including methanesulfonyl, the mono, di or triphosphate ester, trityl or monomethoxytrityl, substituted benzyl, trialkylsilyl (e.g.
- esters dimethyl-t-butylsilyl or diphenylmethylsilyl.
- Aryl groups in the esters optimally comprise a phenyl group.
- lower acyl refers to an acyl group in which the non-carbonyl moiety is lower alkyl.
- the term “substantially free of” or “substantially in the absence of” refers to a nucleoside composition that includes at least 85 or 90% by weight, preferably 95% to 98% by weight, and even more preferably 99% to 100% by weight, of the designated enantiomer of that nucleoside. In a preferred embodiment, in the methods and compounds of this invention, the compounds are substantially free of enantiomers.
- isolated refers to a nucleoside composition that includes at least 85 or 90% by weight, preferably 95% to 98% by weight, and even more preferably 99% to 100% by weight, of the nucleoside, the remainder comprising other chemical species or enantiomers.
- both R′′ can be carbon, both R′′ can be nitrogen, or one R′′ can be carbon and the other R′′ nitrogen.
- host refers to an unicellular or multicellular organism in which the virus can replicate, including cell lines and animals, and preferably a human. Alternatively, the host can be carrying a part of the flavivirus or pestivirus genome, whose replication or function can be altered by the compounds of the present invention.
- the term host specifically refers to infected cells, cells transfected with all or part of the flavivirus or pestivirus genome and animals, in particular, primates (including chimpanzees) and humans. In most animal applications of the present invention, the host is a human patient. Veterinary applications, in certain indications, however, are clearly anticipated by the present invention (such as chimpanzees).
- pharmaceutically acceptable salt or prodrug is used throughout the specification to describe any pharmaceutically acceptable form (such as an ester, phosphate ester, salt of an ester or a related group) of a nucleoside compound which, upon administration to a patient, provides the nucleoside compound.
- Pharmaceutically acceptable salts include those derived from pharmaceutically acceptable inorganic or organic bases and acids. Suitable salts include those derived from alkali metals such as potassium and sodium, alkaline earth metals such as calcium and magnesium, among numerous other acids well known in the pharmaceutical art.
- Pharmaceutically acceptable prodrugs refer to a compound that is metabolized, for example hydrolyzed or oxidized, in the host to form the compound of the present invention.
- prodrugs include compounds that have biologically labile protecting groups on a functional moiety of the active compound.
- Prodrugs include compounds that can be oxidized, reduced, aminated, deaminated, hydroxylated, dehydroxylated, hydrolyzed, dehydrolyzed, alkylated, dealkylated, acylated, deacylated, phosphorylated, dephosphorylated to produce the active compound.
- the compounds of this invention possess antiviral activity against flavivirus or pestivirus, or are metabolized to a compound that exhibits such activity.
- pharmaceutically acceptable salts are organic acid addition salts formed with acids, which form a physiological acceptable anion, for example, tosylate, methanesulfonate, acetate, citrate, malonate, tartarate, succinate, benzoate, ascorbate, ⁇ -ketoglutarate, and ⁇ -glycerophosphate.
- Suitable inorganic salts may also be formed, including, sulfate, nitrate, bicarbonate, and carbonate salts.
- salts may be obtained using standard procedures well known in the art, for example by reacting a sufficiently basic compound such as an amine with a suitable acid affording a physiologically acceptable anion.
- a sufficiently basic compound such as an amine
- a suitable acid affording a physiologically acceptable anion.
- Alkali metal (for example, sodium, potassium or lithium) or alkaline earth metal (for example calcium) salts of carboxylic acids can also be made.
- nucleosides described herein can be administered as a nucleotide prodrug to increase the activity, bioavailability, stability or otherwise alter the properties of the nucleoside.
- a number of nucleotide prodrug ligands are known.
- alkylation, acylation or other lipophilic modification of the mono, di or triphosphate of the nucleoside will increase the stability of the nucleotide.
- substituent groups that can replace one or more hydrogens on the phosphate moiety are alkyl, aryl, steroids, carbohydrates, including sugars, 1,2-diacylglycerol and alcohols. Many are described in R. Jones and N. Bischofberger, Antiviral Research, 27 (1995) 1-17. Any of these can be used in combination with the disclosed nucleosides to achieve a desired effect.
- the active nucleoside can also be provided as a 5′-phosphoether lipid or a 5′-ether lipid, as disclosed in the following references, which are incorporated by reference herein: Kucera, L. S., N. Iyer, E. Leake, A. Raben, Modest E. K., D. L. W., and C. Piantadosi, “Novel membrane-interactive ether lipid analogs that inhibit infectious HIV-1 production and induce defective virus formation,” AIDS Res. Hum. Retro Viruses, 1990, 6, 491-501; Piantadosi, C., J. Marasco C. J., S. L. Morris-Natschke, K. L. Meyer, F. Gumus, J. R. Surles, K. S.
- Nonlimiting examples of U.S. patents that disclose suitable lipophilic substituents that can be covalently incorporated into the nucleoside, preferably at the 5′-OH position of the nucleoside or lipophilic preparations include U.S. Pat. No. 5,149,794 (Sep. 22, 1992, Yatvin et al.); U.S. Pat. No. 5,194,654 (Mar. 16, 1993, Hostetler et al., U.S. Pat. No. 5,223,263 (Jun. 29, 1993, Hostetler et al.); U.S. Pat. No. 5,256,641 (Oct. 26, 1993, Yatvin et al.); U.S. Pat. No.
- Drug resistance most typically occurs by mutation of a gene that encodes for an enzyme used in viral replication.
- the efficacy of a drug against flavivirus or pestivirus infection can be prolonged, augmented, or restored by administering the compound in combination or alternation with a second, and perhaps third, antiviral compound that induces a different mutation from that caused by the principle drug.
- the pharmacokinetics, biodistribution or other parameter of the drug can be altered by such combination or alternation therapy.
- combination therapy is typically preferred over alternation therapy because it induces multiple simultaneous stresses on the virus.
- antiviral agents that can be used in combination or alternation with the compounds disclosed herein include:
- Inhibitors of serine proteases particularly hepatitis C virus NS3 protease, PCT WO 98/17679), including alphaketoamides and hydrazinoureas, and inhibitors that terminate in an electrophile such as a boronic acid or phosphonate.
- Llinas-Brunet et al Hepatitis C inhibitor peptide analogues, PCT WO 99/07734.
- Non-substrate-based inhibitors such as 2,4,6-trihydroxy-3-nitro-benzamide derivatives (Sudo K. et al., Biochemical and Biophysical Research Communications, 238:643-647, 1997; Sudo K. et al. Antiviral Chemistry and Chemotherapy 9:186, 1998), including RD3-4082 and RD3-4078, the former substituted on the amide with a 14 carbon chain and the latter processing a para-phenoxyphenyl group;
- Helicase inhibitors (Diana G. D. et al., Compounds, compositions and methods for treatment of hepatitis C, U.S. Pat. No. 5,633,358; Diana G. D. et al., Piperidine derivatives, pharmaceutical compositions thereof and their use in the treatment of hepatitis C, PCT WO 97/36554);
- S-ODN Antisense phosphorothioate oligodeoxynucleotides (S-ODN) complementary to sequence stretches in the 5′ non-coding region (NCR) of the virus (Alt M. et al., Hepatology 22:707-717, 1995), or nucleotides 326-348 comprising the 3′ end of the NCR and nucleotides 371-388 located in the core coding region of the IICV RNA (Alt M. et al., Archives of Virology 142:589-599, 1997; Galderisi U. et al., Journal of Cellular Physiology 181:251-257, 1999);
- Inhibitors of IRES-dependent translation (Ikeda N et al., Agent for the prevention and treatment of hepatitis C, Japanese Patent Publication JP-08268890; Kai Y. et al. Prevention and treatment of viral diseases, Japanese Patent Publication JP-10101591);
- miscellaneous compounds including 1-amino-alkylcyclohexanes (U.S. Pat. No. 6,034,134 to Gold et al.), alkyl lipids (U.S. Pat. No. 5,922,757 to Chojkier et al.), vitamin E and other antioxidants (U.S. Pat. No. 5,922,757 to Chojkier et al,), squalene, amantadine, bile acids (U.S. Pat. No. 5,846,964 to Ozeki et al.), N-(phophonoacetyl)-L-aspartic acid, (U.S. Pat. No.
- Host including humans, infected with flavivirus or pestivirus, or a gene fragment thereof can be treated by administering to the patient an effective amount of the active compound or a pharamceutically acceptable prodrug or salt thyereof in the presence of a pharamceutically acceptable carrier or diluent.
- the active materials can be admistered by any appropriate route, for example, orally, parenterally, intravenously, intradermally, subcutaneously, or topically, in liquid or solid form.
- a preferred dose of the compound for flavivirus or pestivirus infection will be in the range from about 1 to 50 mg/kg, preferably 1 to 20 mg/kg, of body weight per day, more generally 0.1 to about 100 mg per kilogram body weight of the recipient per day.
- the effective dosage range of the pharmaceutically acceptable salts and prodrugs can be calculated based on the weight of the parent nucleoside to be delivered. If the salt or prodrug exhibits activity in itself, the effective doseage can be estimated as above using the weight of the salt or prodrug, or by other means known to those skilled in the art.
- the compound is conveniently administered in unit any suitable dosage form, including but not limited to one containing 7 to 3000 mg, preferably 70 to 1400 mg of active ingredient per unit dosage form.
- a oral dosage of 50-1000 mg is usually convenient,
- the active ingredient should be administered to achieve peak plasma concentrations of the active compound of form about 0.2 to 70 ⁇ M, preferably about 1.0 to 10 ⁇ M. This may be achieved, for example, by the intravenous injection of a 0.1 to 5% solution of the active ingredient, optionally in saline, or administered as a bolus of the active ingredient.
- the concentration of active compound in the drug composition will depend on absorption, inactivation, and excretion rates of the drug as well as other factors known to those of skill in the art. It is to be noted that dosage values will also vary with the severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions, and that the concentration ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed composition.
- the active ingredient may be administered at once, or may be divided into a number of smaller doses to be administered at varying intervals of time.
- Oral compositions will generally include an inert diluent or an edible carrier. They may be enclosed in gelatin capsules or compressed into tablets.
- the active compound can be incorporated with excipients and used in the form of tablets, troches or capsules. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition.
- the tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.
- a binder such as microcrystalline cellulose, gum tragacanth or gelatin
- an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch
- a lubricant such as magnesium stearate or Sterotes
- a glidant such as colloidal silicon dioxide
- the compound can be administered as a component of an elixir, suspension, syrup, wafer, chewing gum or the like.
- a syrup may contain, in addition to the active compounds, sucrose as a sweetening agent and certain preservatives, dyes and colorings and flavors.
- the compound or a pharmaceutically acceptable prodrug or salts thereof can also be mixed with other active materials that do not impair the desired action, or with materials that supplement the desired action, such as antibiotics, antifungals, anti-inflammatories, or other antivirals, including other nucleoside compounds.
- Solutions or suspensions used for parenteral, intradermal, subcutaneous, or topical application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose.
- the parental preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
- preferred carriers are physiological saline or phosphate buffered saline-(PBS).
- the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems.
- a controlled release formulation including implants and microencapsulated delivery systems.
- Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be obtained commercially from Alza Corporation.
- Liposomal suspensions are also preferred as pharmaceutically acceptable carriers. These may be prepared according to methods known to those skilled in the art, for example, as described in U.S. Pat. No. 4,522,811 (which is incorporated herein by reference in its entirety). For example, liposome formulations may be prepared by dissolving appropriate lipid(s) (such as stearoyl phosphatidyl ethanolamine, stearoyl phosphatidyl choline, arachadoyl phosphatidyl choline, and cholesterol) in an inorganic solvent that is then evaporated, leaving behind a thin film of dried lipid on the surface of the container.
- appropriate lipid(s) such as stearoyl phosphatidyl ethanolamine, stearoyl phosphatidyl choline, arachadoyl phosphatidyl choline, and cholesterol
- aqueous solution of the active compound or its monophosphate, diphosphate, and/or triphosphate derivatives is then introduced into the container.
- the container is then swirled by hand to free lipid material from the sides of the container and to disperse lipid aggregates, thereby forming the liposomal suspension.
- nucleosides of the present invention can be synthesized by any means known in the art.
- the synthesis of the present nucleosides can be achieved by either alkylating the appropriately modified sugar, followed by glycosylation or glycosylation followed by alkylation of the nucleoside.
- the following non-limiting embodiments illustrate some general methodology to obtain the nucleosides of the present invention.
- the key starting material for this process is an appropriately substituted lactone.
- the lactone can be purchased or can be prepared by any known means including standard epimerization, substitution and cyclization techniques.
- the lactone can be optionally protected with a suitable protecting group, preferably with an acyl or silyl group, by methods well known to those skilled in the art, as taught by Greene et al. Protective Groups in Organic Synthesis , John Wiley and Sons, Second Edition, 1991.
- the protected lactone can then be coupled with a suitable coupling agent, such as an organometallic carbon nucleophile, such as a Grignard reagent, an organolithium, lithium dialkyl copper or R 6 —SiMe 3 in TBAF with the appropriate non-protic solvent at a suitable temperature, to give the 1′-alkylated sugar.
- a suitable coupling agent such as an organometallic carbon nucleophile, such as a Grignard reagent, an organolithium, lithium dialkyl copper or R 6 —SiMe 3 in TBAF with the appropriate non-protic solvent at a suitable temperature, to give the 1′-alkylated sugar.
- the optionally activated sugar can then be coupled to the BASE by methods well known to those skilled in the art, as taught by Townsend Chemistry of Nucleosides and Nucleotides , Plenum Press, 1994.
- an acylated sugar can be coupled to a silylated base with a lewis acid, such as tin tetrachloride, titanium tetrachloride or trimethylsilyltriflate in the appropriate solvent at a suitable temperature.
- nucleoside can be deprotected by methods well known to those skilled in the art, as taught by Greene et al. Protective Groups in Organic Synthesis , John Wiley and Sons, Second Edition, 1991.
- the 1′-C-branched ribonucleoside is desired.
- the synthesis of a ribonucleoside is shown in Scheme 1.
- deoxyribo-nucleoside is desired.
- the formed ribonucleoside can optionally be protected by methods well known to those skilled in the art, as taught by Greene et al. Protective Groups in Organic Synthesis , John Wiley and Sons, Second Edition, 1991, and then the 2′-OH can be reduced with a suitable reducing agent.
- the 2′-hydroxyl can be activated to facilitate reduction; i.e. via the Barton reduction.
- the key starting material for this process is an appropriately substituted hexose.
- the hexose can be purchased or can be prepared by any known means including standard epimerization (e.g. via alkaline treatment), substitution and coupling techniques.
- the hexose can be selectively protected to give the appropriate hexa-furanose, as taught by Townsend Chemistry of Nucleosides and Nucleotides , Plenum Press, 1994.
- the 1′-hydroxyl can be optionally activated to a suitable leaving group such as an acyl group or a halogen via acylation or halogenation, respectively.
- the optionally activated sugar can then be coupled to the BASE by methods well known to those skilled in the art, as taught by Townsend Chemistry of Nucleosides and Nucleotides , Plenum Press, 1994.
- an acylated sugar can be coupled to a silylated base with a lewis acid, such as tin tetrachloride, titanium tetrachloride or trimethylsilyltriflate in the appropriate solvent at a suitable temperature.
- a halo-sugar can be coupled to a silylated base with the presence of trimethylsilyltriflate.
- the 1′-CH 2 —OH if protected, can be selectively deprotected by methods well known in the art.
- the resultant primary hydroxyl can be functionalized to yield various C-branched nucleosides.
- the primary hydroxyl can be reduced to give the methyl, using a suitable reducing agent.
- the hydroxyl can be activated prior to reduction to facilitate the reaction; i.e. via the Barton reduction.
- the primary hydroxyl can be oxidized to the aldehyde, then coupled with a carbon nucleophile, such as a Grignard reagent, an organolithium, lithium dialkyl copper or R 6 —SiMe 3 in TBAF with the appropriate non-protic solvent at a suitable temperature.
- a carbon nucleophile such as a Grignard reagent, an organolithium, lithium dialkyl copper or R 6 —SiMe 3 in TBAF with the appropriate non-protic solvent at a suitable temperature.
- the 1′-C-branched ribonucleoside is desired.
- the synthesis of a ribonucleoside is shown in Scheme 2.
- deoxyribo-nucleoside is desired.
- the formed ribonucleoside can optionally be protected by methods well known to those skilled in the art, as taught by Greene et al. Protective Groups in Organic Synthesis , John Wiley and Sons, Second Edition, 1991, and then the 2′-OH can be reduced with a suitable reducing agent.
- the 2′-hydroxyl can be activated to facilitate reduction; i.e. via the Barton reduction.
- L-enantiomers corresponding to the compounds of the invention can be prepared following the same general methods (1 or 2), beginning with the corresponding L-sugar or nucleoside L-enantiomer as starting material.
- BASE is a purine or pyrimidine base as defined herein;
- the key starting material for this process is an appropriately substituted sugar with a 2′-OH and 2′-H, with the appropriate leaving group (LG), for example an acyl group or a halogen.
- the sugar can be purchased or can be prepared by any known means including standard epimerization, substitution, oxidation and reduction techniques.
- the substituted sugar can then be oxidized with the appropriate oxidizing agent in a compatible solvent at a suitable temperature to yield the 2′-modified sugar.
- Possible oxidizing agents are Jones reagent (a mixture of chromic acid and sulfuric acid), Collins's reagent (dipyridine Cr(VI) oxide, Corey's reagent (pyridinium chlorochromate), pyridinium dichromate, acid dichromate, potassium permanganate, MnO 2 , ruthenium tetroxide, phase transfer catalysts such as chromic acid or permanganate supported on a polymer, Cl 2 -pyridine, H 2 O 2 -ammonium molybdate, NaBrO 2 —CAN, NaOCl in HOAc, copper chromite, copper oxide, Raney nickel, palladium acetate, Meerwin-Pondorf-Verley reagent (aluminum t-butoxide with another ketone) and N-bromosuccinimide.
- Jones reagent a mixture of chromic acid and sulfuric acid
- Collins's reagent dipyridine Cr(VI) oxide
- an organometallic carbon nucleophile such as a Grignard reagent, an organolithium, lithium dialkyl copper or R 6 —SiMe 3 in TBAF with the ketone with the appropriate non-protic solvent at a suitable temperature, yields the 2′-alkylated sugar.
- the alkylated sugar can be optionally protected with a suitable protecting group, preferably with an acyl or silyl group, by methods well known to those skilled in the art, as taught by Greene et al. Protective Groups in Organic Synthesis , John Wiley and Sons, Second Edition, 1991.
- the optionally protected sugar can then be coupled to the BASE by methods well known to those skilled in the art, as taught by Townsend Chemistry of Nucleosides and Nucleotides , Plenum Press, 1994.
- an acylated sugar can be coupled to a silylated base with a lewis acid, such as tin tetrachloride, titanium tetrachloride or trimethylsilyltriflate in the appropriate solvent at a suitable temperature.
- a halo-sugar can be coupled to a silylated base with the presence of trimethylsilyltriflate.
- nucleoside can be deprotected by methods well known to those skilled in the art, as taught by Greene et al. Protective Groups in Organic Synthesis , John Wiley and Sons, Second Edition, 1991.
- the 2′-C-branched ribonucleoside is desired.
- the synthesis of a ribonucleoside is shown in Scheme 3.
- deoxyribo-nucleoside is desired.
- the formed ribonucleoside can optionally be protected by methods well known to those skilled in the art, as taught by Greene et al. Protective Groups in Organic Synthesis , John Wiley and Sons, Second Edition, 1991, and then the 2′-OH can be reduced with a suitable reducing agent.
- the 2′-hydroxyl can be activated to facilitate reduction; i.e. via the Barton reduction.
- the key starting material for this process is an appropriately substituted nucleoside with a 2′-OH and 2′-H.
- the nucleoside can be purchased or can be prepared by any known means including standard coupling techniques.
- the nucleoside can be optionally protected with suitable protecting groups, preferably with acyl or silyl groups, by methods well known to those skilled in the art, as taught by Greene et al. Protective Groups in Organic Synthesis , John Wiley and Sons, Second Edition, 1991.
- the appropriately protected nucleoside can then be oxidized with the appropriate oxidizing agent in a compatible solvent at a suitable temperature to yield the 2′-modified sugar.
- Possible oxidizing agents are Jones reagent (a mixture of chromic acid and sulfuric acid), Collins's reagent (dipyridine Cr(VI) oxide, Corey's reagent (pyridinium chlorochromate), pyridinium dichromate, acid dichromate, potassium permanganate, MnO 2 , ruthenium tetroxide, phase transfer catalysts such as chromic acid or permanganate supported on a polymer, Cl 2 -pyridine, H 2 O 2 -ammonium molybdate, NaBrO 2 —CAN, NaOCl in HOAc, copper chromite, copper oxide, Raney nickel, palladium acetate, Meerwin-Pondorf-Verley reagent (aluminum t-butoxide with another ketone) and N-bromosuccinimide.
- nucleoside can be deprotected by methods well known to those skilled in the art, as taught by Greene Greene et al. Protective Groups in Organic Synthesis , John Wiley and Sons, Second Edition, 1991.
- the 2′-C-branched ribonucleoside is desired.
- the synthesis of a ribonucleoside is shown in Scheme 4.
- deoxyribo-nucleoside is desired.
- the formed ribonucleoside can optionally be protected by methods well known to those skilled in the art, as taught by Greene et al. Protective Groups in Organic Synthesis , John Wiley and Sons, Second Edition, 1991, and then the 2′-OH can be reduced with a suitable reducing agent.
- the 2′-hydroxyl can be activated to facilitate reduction; i.e. via the Barton reduction.
- the L-enantiomers are desired. Therefore, the L-enantiomers can be corresponding to the compounds of the invention can be prepared following the same foregoing general methods, beginning with the corresponding L-sugar or nucleoside L-enantiomer as starting material.
- BASE is a purine or pyrimidine base as defined herein;
- the key starting material for this process is an appropriately substituted sugar with a 3′-OH and 3′-H, with the appropriate leaving group (LG), for example an acyl group or a halogen.
- LG leaving group
- the sugar can be purchased or can be prepared by any known means including standard epimerization, substitution, oxidation and reduction techniques.
- the substituted sugar can then be oxidized with the appropriate oxidizing agent in a compatible solvent at a suitable temperature to yield the 3′-modified sugar.
- Possible oxidizing agents are Jones reagent (a mixture of chromic acid and sulfuric acid), Collins's reagent (dipyridine Cr(VI) oxide, Corey's reagent (pyridinium chlorochromate), pyridinium dichromate, acid dichromate, potassium permanganate, MnO 2 , ruthenium tetroxide, phase transfer catalysts such as chromic acid or permanganate supported on a polymer, Cl 2 -pyridine, H 2 O 2 -ammonium molybdate, NaBrO 2 —CAN, NaOCl in HOAc, copper chromite, copper oxide, Raney nickel, palladium acetate, Meerwin-Pondorf-Verley reagent (aluminum t-butoxide with another ketone) and N-bromosuccinimide.
- Jones reagent a mixture of chromic acid and sulfuric acid
- Collins's reagent dipyridine Cr(VI) oxide
- an organometallic carbon nucleophile such as a Grignard reagent, an organolithium, lithium dialkyl copper or R 6 —SiMe 3 in TBAF with the ketone with the appropriate non-protic solvent at a suitable temperature, yields the 3′-C-branched sugar.
- the 3′-C-branched sugar can be optionally protected with a suitable protecting group, preferably with an acyl or silyl group, by methods well known to those skilled in the art, as taught by Greene-et al. Protective Groups in Organic Synthesis , John Wiley and Sons, Second Edition, 1991.
- the optionally protected sugar can then be coupled to the BASE by methods well known to those skilled in the art, as taught by Townsend Chemistry of Nucleosides and Nucleotides , Plenum Press; 1994.
- an acylated sugar can be coupled to a silylated base with a lewis acid, such as tin tetrachloride, titanium tetrachloride or trimethylsilyltriflate in the appropriate solvent at a suitable temperature.
- a halo-sugar can be coupled to a silylated base with the presence of trimethylsilyltriflate.
- nucleoside can be deprotected by methods well known to those skilled in the art, as taught by Greene et al. Protective Groups in Organic Synthesis , John Wiley and Sons, Second Edition, 1991.
- the 3′-C-branched ribonucleoside is desired.
- the synthesis of a ribonucleoside is shown in Scheme 5.
- deoxyribo-nucleoside is desired.
- the formed ribonucleoside can optionally be protected by methods well known to those skilled in the art, as taught by Greene et al. Protective Groups in Organic Synthesis , John Wiley and Sons, Second Edition, 1991, and then the 2′-OH can be reduced with a suitable reducing agent.
- the 2′-hydroxyl can be activated to facilitate reduction; i.e. via the Barton reduction.
- the key starting material for this process is an appropriately substituted nucleoside with a 3′-OH and 3′-H.
- the nucleoside can be purchased or can be prepared by any known means including standard coupling techniques.
- the nucleoside can be optionally protected with suitable protecting groups, preferably with acyl or silyl groups, by methods well known to those skilled in the art, as taught by Greene et al. Protective Groups in Organic Synthesis , John Wiley and Sons, Second Edition, 1991.
- the appropriately protected nucleoside can then be oxidized with the appropriate oxidizing agent in a compatible solvent at a suitable temperature to yield the 2′-modified sugar.
- Possible oxidizing agents are Jones reagent (a mixture of chromic acid and sulfuric acid), Collins's reagent (dipyridine Cr(VI) oxide, Corey's reagent (pyridinium chlorochromate), pyridinium dichromate, acid dichromate, potassium permanganate, MnO 2 , ruthenium tetroxide, phase transfer catalysts such as chromic acid or permanganate supported on a polymer, Cl 2 -pyridine, H 2 O 2 -ammonium molybdate, NaBrO 2 —CAN, NaOCl in HOAc, copper chromite, copper oxide, Raney nickel, palladium acetate, Meerwin-Pondorf-Verley reagent (aluminum t-butoxide with another ketone) and N-bromosuccinimide.
- nucleoside can be deprotected by methods well known to those skilled in the art, as taught by Greene et al. Protective Groups in Organic Synthesis , John Wiley and Sons, Second Edition, 1991.
- the 3′-C-branched ribonucleoside is desired.
- the synthesis of a ribonucleoside is shown in Scheme 6.
- deoxyribo-nucleoside is desired.
- the formed ribonucleoside can optionally be protected by methods well known to those skilled in the art, as taught by Greene et al. Protective Groups in Organic Synthesis , John Wiley and Sons, Second Edition, 1991, and then the 2′-OH can be reduced with a suitable reducing agent.
- the 2′-hydroxyl can be activated to facilitate reduction; i.e. via the Barton reduction.
- the L-enantiomers are desired. Therefore, the L-enantiomers can be corresponding to the compounds of the invention can be prepared following the same foregoing general methods, beginning with the corresponding L-sugar or nucleoside L-enantiomer as starting material.
- nucleosides of Formula I are prepared.
- nucleosides of Formula IV are prepared, using the appropriate sugar and pyrimidine or purine bases.
- nucleosides of Formula VII are prepared, using the appropriate sugar and pyrimidine or purine bases.
- nucleosides of Formula VIII are prepared, using the appropriate sugar and pyrimidine or purine bases.
- nucleosides of Formula IX are prepared, using the appropriate sugar and pyrimidine or purine bases.
- nucleosides of Formula XVI are prepared, using the appropriate sugar and pyrimidine or purine bases.
- nucleosides of Formula II are prepared.
- nucleosides of Formula V are prepared, using the appropriate sugar and pyrimidine or purine bases.
- nucleosides of Formula X are prepared, using the appropriate sugar and pyrimidine or purine bases.
- nucleosides of Formula XI are prepared, using the appropriate sugar and pyrimidine or purine bases.
- nucleosides of Formula XII are prepared, using the appropriate sugar and pyrimidine or purine bases.
- R 1 R 6 X Base H CH 3 O 2,4-O-Diacetyluracil H CH 3 O Hyoxanthine H CH 3 O 2,4-O-Diacetyithymine H CH 3 O Thymine H CH 3 O Cytosine H CH 3 O 4-(N-mono-acetyl)cytosine H CH 3 O 4-(N,N-diacetyl)cytosine H CH 3 O Uracil H CH 3 O 5-Fluorouracil H CH 3 S 2,4-O-Diacetyluracil H CH 3 S Hypoxanthine H CH 3 S 2,4-O-Diacetylthymine H CH 3 S Thymine H CH 3 S Cytosine H CH 3 S 4-(N-mono-acetyl)cytosine H CH 3 S 4-(N,N-diacetyl)cytosine H CH 3 S Uracil H CH 3 S 5-Fluorouracil monophosphate CH 3 O 2,4-O-
- nucleosides of Formula XVII are prepared, using the appropriate sugar and pyrimidine or purine bases.
- nucleosides of Formula III are prepared.
- nucleosides of Formula VI are prepared, using the appropriate sugar and pyrimidine or purine bases.
- nucleosides of Formula XIII are prepared, using the appropriate sugar and pyrimidine or purine bases.
- nucleosides of Formula XIV are prepared, using the appropriate sugar and pyrimidine or purine bases.
- nucleosides of Formula XV are prepared, using the appropriate sugar and pyrimidine or purine bases.
- nucleosides of Formula XVIII are prepared, using the appropriate sugar and pyrimidine or purine bases.
- Compounds can exhibit anti-flavivirus or pestivirus activity by inhibiting flavivirus or pestivirus polymerase, by inhibiting other enzymes needed in the replication cycle, or by other pathways.
- test compounds were dissolved in DMSO at an initial concentration of 200 ⁇ M and then were serially diluted in culture medium.
- BHK-21 baby hamster kidney (ATCC CCL-10) and Bos Taurus (BT) (ATCC CRL 1390) cells were grown at 37° C. in a humidified CO 2 (5%) atmosphere.
- FBS fetal bovine serum
- BT cells were passaged in Dulbecco's modified Eagle's medium with 4 mM L-glutamine and 10% horse serum (HS, Gibco), adjusted to contain 1.5 g/L sodium bicarbonate, 4.5 g/L glucose and 1.0 mM sodium pyruvate.
- the vaccine strain 17D (YFV-17D) (Stamaril®, Pasteur Merieux) and Bovine Viral Diarrhea virus (BVDV) (ATCC VR-534) were used to infect BHK and BT cells, respectively, in 75 cm 2 bottles. After a 3 day incubation period at 37° C., extensive cytopathic effect was observed.
- HepG2 cells were obtained from the American Type Culture Collection (Rockville, Md.), and were grown in 225 cm 2 tissue culture flasks in minimal essential medium supplemented with non-essential amino acids, 1% penicillin-streptomycin. The medium was renewed every three days, and the cells were subcultured once a week.
- confluent HepG2 cells were seeded at a density of 2.5 ⁇ 10 6 cells per well in a 6-well plate and exposed to 10 ⁇ M of [ 3 H] labeled active compound (500 dpm/pmol) for the specified time periods.
- the cells were maintained at 37° C. under a 5% CO 2 atmosphere.
- the cells were washed three times with ice-cold phosphate-buffered saline (PBS). Intracellular active compound and its respective metabolites were extracted by incubating the cell pellet overnight at ⁇ 20° C.
- PBS ice-cold phosphate-buffered saline
- the cynomolgus monkey was surgically implanted with a chronic venous catheter and subcutaneous venous access port (VAP) to facilitate blood collection and underwent a physical examination including hematology and serum chemistry evaluations and the body weight was recorded.
- VAP chronic venous catheter and subcutaneous venous access port
- Each monkey (six total), received approximately 250 uCi of 3 H activity with each dose of active compound, namely ⁇ -D-2′-CH 3 -riboG at a dose level of 10 mg/kg at a dose concentration of 5 mg/mL, either via an intravenous bolus (3 monkeys, IV), or via oral gavage (3 monkeys, PO).
- Each dosing syringe was weighed before dosing to gravimetrically determine the quantity of formulation administered.
- Urine samples were collected via pan catch at the designated intervals (approximately 18-0 hours pre-dose, 0-4, 4-8 and 8-12 hours post-dosage) and processed. Blood samples were collected as well (pre-dose, 0.25, 0.5, 1, 2, 3, 6, 8, 12 and 24 hours post-dosage) via the chronic venous catheter and VAP or from a peripheral vessel if the chronic venous catheter procedure should not be possible.
- C max maximum concentration
- T max time when the maximum concentration was achieved
- AUC area under the curve
- T 1/2 half life of the dosage concentration
- CL clearance
- V ss steady state volume and distribution
- F bioavailability
- Human bone marrow cells were collected from normal healthy volunteers and the mononuclear population was separated by Ficoll-Hypaque gradient centrifugation as described previously by Sommadossi J-P, Carlisle R. “Toxicity of 3′-azido-3′-deoxythymidine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine for normal human hematopoietic progenitor cells in vitro” Antimicrobial Agents and Chemotherapy 1987; 31:452-454; and Sommadossi J-P, Schinazi R F, Chu C K, Xie M-Y.
- HepG2 cells were cultured in 12-well plates as described above and exposed to various concentrations of drugs as taught by Pan-Zhou X-R, Cui L, Zhou X-J, Sommadossi J-P, Darley-Usmer V M. “Differential effects of antiretroviral nucleoside analogs on mitochondrial function in HepG2 cells” Antimicrob Agents Chemother 2000; 44:496-503. Lactic acid levels in the culture medium after 4 day drug exposure was measured using a boehringer lactic acid assay kit. Lactic acid levels were normalized by cell number as measured by hemocytometer count. The preliminary results from this assay are tabulated in Table 5
- the assay was performed essentially as described by Baginski, S. G.; Pevear, D. C.; Seipel, M.; Sun, S. C. C.; Benetatos, C. A.; Chunduru, S. K.; Rice, C. M. and M. S. Collett “Mechanism of action of a pestivirus antiviral compound” PNAS USA 2000, 97(14), 7981-7986.
- MDBK cells ATCC were seeded onto 96-well culture plates (4,000 cells per well) 24 hours before use.
- test compounds were added to both infected and uninfected cells in a final concentration of 0.5% DMSO in growth medium. Each dilution was tested in quadruplicate. Cell densities and virus inocula were adjusted to ensure continuous cell growth throughout the experiment and to achieve more than 90% virus-induced cell destruction in the untreated controls after four days post-infection. After four days, plates were fixed with 50% TCA and stained with sulforhodamine B. The optical density of the wells was read in a microplate reader at 550 nm.
- FIGS. 4 and 5 provide a graphical illustration of the methodology used to arrive at the 50% effective concentration (EC 50 ) values for ⁇ -D-2′-CH 3 -riboG and ribavirin.
- FIG. 6 compares the results of the CPA for ⁇ -D-2′-CH 3 -riboG, ⁇ -D-2′-CH 3 -riboC, ⁇ -D-2′-CH 3 -riboU, ⁇ -D-2′-CH 3 -riboA and ribavirin
- FIG. 7 is a graphical illustration of the results from the Plaque Reduction Assay.
- FIG. 8 is an image of BVDV plaque formation in the presence of increasing concentrations of ⁇ -D-2′-CH 3 -riboU.
- MDBK cells were seeded onto 24-well plates (2 ⁇ 105 cells per well) 24 hours before infection with BVDV (NADL strain) at a multiplicity of infection (MOI) of 0.1 PFU per cell.
- Serial dilutions of test compounds were added to cells in a final concentration of 0.5% DMSO in growth medium. Each dilution as tested in triplicate.
- cell cultures cell monolayers and supernatants were lysed by three freeze-thaw cycles, and virus yield was quantified by plaque assay.
- MDBK cells were seeded onto 6-well plates (5 ⁇ 105 cells per well) 24 h before use.
- FIG. 9 is a graphical illustration of the results from the Yield Reduction Assay.
- FIG. 8 is an image of BVDV yield reduction in the presence of increasing concentrations of ⁇ -D-2′-CH 3 -riboC.
- Table 10 summarizes the cytoxicity of two compounds of this invention, ⁇ -D-1′-CH 3 -riboA and ⁇ -D-2′-CH 3 -riboA, in comparison to RBV (“ribavirin”), in various cell systems.
- Table 11 summarizes the antiviral activity of ⁇ -D-1′-CH 3 -riboA and ⁇ -D-2′-CH 3 -riboA against several viruses within the flavivirus and pestivirus genuses.
- Table 12 summarizes the antiviral activity and toxicity of ⁇ -D-2′-methyl-riboG, ⁇ -D-2′-methyl-riboC and ⁇ -D-2′-methyl-riboU, against a couple of viruses within the flavivirus and pestivirus genuses.
- Table 13 summarizes the anti-viral activity of several compounds of this invention against BVDV in three different assays.
Abstract
A method and composition for treating a host infected with flavivirus or pestivirus comprising administering an effective flavivirus or pestivirus treatment amount of a described 1′, 2′ or 3′-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided.
Description
This invention is in the area of pharmaceutical chemistry, and in particular, is a compound, method and composition for the treatment of flaviviruses and pestiviruses. This application is a continuation of U.S. application Ser. No. 10/602,135, filed on Jun. 20, 2003, now U.S. Pat. No. 7,163,929, which is a continuation of U.S. application Ser. No. 09/863,816, filed on May 23, 2001, now U.S. Pat. No. 6,812,219, which claims priority to U.S. provisional application No. 60/207,674, filed on May 26, 2000 and U.S. provisional application No. 60/283,276, filed on Apr. 11, 2001, the disclosures of which are incorporated herein by reference.
The subject matter of this application arises in part from a joint research agreement between Idenix Pharmaceuticals, Inc., Universita Degli Studi di Cagliari, Centre National de la Recherche Scientifique, and L' Université Montpellier II.
Pestiviruses and flaviviruses belong to the Flaviviridae family of viruses along with hepatitis C virus. The pestivirus genus includes bovine viral diarrhea virus (BVDV), classical swine fever virus (CSFV, also called hog cholera virus) and border disease virus (BDV) of sheep (Moennig, V. et al. Adv. Vir. Res. 1992, 41, 53-98). Pestivirus infections of domesticated livestock (cattle, pigs and sheep) cause significant economic losses worldwide. BVDV causes mucosal disease in cattle and is of significant economic importance to the livestock industry (Meyers, G. and Thiel, H.-J., Advances in Virus Research, 1996, 47, 53-118; Moennig V., et al, Adv. Vir. Res. 1992, 41, 53-98).
Human pestiviruses have not been as extensively characterized as the animal pestiviruses. However, serological surveys indicate considerable pestivirus exposure in humans. Pestivirus infections in man have been implicated in several diseases including congenital brain injury, infantile gastroenteritis and chronic diarrhea in human immunodeficiency virus (HIV) positive patients. M. Giangaspero et al., Arch. Virol. Suppl., 1993, 7, 53-62; M. Giangaspero et al., Int. J. Std. Aids, 1993, 4 (5): 300-302.
The flavivirus genus includes more than 68 members separated into groups on the basis of serological relatedness (Calisher et al., J. Gen. Virol, 1993, 70, 37-43). Clinical symptoms vary and include fever, encephalitis and hemorrhagic fever. Fields Virology, Editors: Fields, B. N., Knipe, D. M., and Howley, P. M., Lippincott-Raven Publishers, Philadelphia, Pa., 1996, Chapter 31, 931-959. Flaviviruses of global concern that are associated with human disease include the dengue hemorrhagic fever viruses (DHF), yellow fever virus, shock syndrome and Japanese encephalitis virus. Halstead, S. B., Rev. Infect. Dis., 1984, 6, 251-264; Halstead, S. B., Science, 239:476-481, 1988; Monath, T. P., New Eng. J. Med., 1988, 319, 641-643.
Examples of antiviral agents that have been identified as active against the flavivirus or pestiviruses include:
-
- (1) interferon and ribavirin (Battaglia, A. M. et al., Ann. Pharmacother, 2000, 34, 487-494); Berenguer, M. et al. Antivir. Ther., 1998, 3 (Suppl. 3), 125-136);
- (2) Substrate-based NS3 protease inhibitors (Attwood et al., Antiviral peptide derivatives, PCT WO 98/22496, 1998; Attwood et al., Antiviral Chemistry and Chemotherapy 1999, 10, 259-273; Attwood et al., Preparation and use of amino acid derivatives as anti-viral agents, German Patent Pub. DE 19914474; Tung et al. Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease, PCT WO 98/17679), including alphaketoamides and hydrazinoureas, and inhibitors that terminate in an electrophile such as a boronic acid or phosphonate (Llinas-Brunet et al, Hepatitis C inhibitor peptide analogues, PCT WO 99/07734).
- (3) Non-substrate-based inhibitors such as 2,4,6-trihydroxy-3-nitro-benzamide derivatives (Sudo K. et al., Biochemical and Biophysical Research Communications, 1997, 238, 643-647; Sudo K. et al. Antiviral Chemistry and Chemotherapy, 1998, 9, 186), including RD3-4082 and RD3-4078, the former substituted on the amide with a 14 carbon chain and the latter processing a para-phenoxyphenyl group;
- (4) Thiazolidine derivatives which show relevant inhibition in a reverse-phase HPLC assay with an NS3/4A fusion protein and NS5A/5B substrate (Sudo K. et al., Antiviral Research, 1996, 32, 9-18), especially compound RD-1-6250, possessing a fused cinnamoyl moiety substituted with a long alkyl chain, RD4 6205 and RD4 6193;
- (5) Thiazolidines and benzanilides identified in Kakiuchi N. et al. J. EBS Letters 421, 217-220; Takeshita N. et al. Analytical Biochemistry, 1997, 247, 242-246;
- (6) A phenan-threnequinone possessing activity against protease in a SDS-PAGE and autoradiography assay isolated from the fermentation culture broth of Streptomyces sp., Sch 68631 (Chu M. et al., Tetrahedron Letters, 1996, 37, 7229-7232), and Sch 351633, isolated from the fungus Penicillium griscofuluum, which demonstrates activity in a scintillation proximity assay (Chu M. et al., Bioorganic and Medicinal Chemistry Letters 9, 1949-1952);
- (7) Selective NS3 inhibitors based on the macromolecule elgin c, isolated from leech (Qasim M. A. et al., Biochemistry, 1997, 36, 1598-1607);
- (8) Helicase inhibitors (Diana G. D. et al., Compounds, compositions and methods for treatment of hepatitis C, U.S. Pat. No. 5,633,358; Diana G. D. et al., Piperidine derivatives, pharmaceutical compositions thereof and their use in the treatment of hepatitis C, PCT WO 97/36554);
- (9) Polymerase inhibitors such as nucleotide analogues, gliotoxin (Ferrari R. et al. Journal of Virology, 1999, 73, 1649-1654), and the natural product cerulenin (Lohmann V. et al., Virology, 1998, 249, 108-118);
- (10) Antisense phosphorothioate oligodeoxynucleotides (S-ODN) complementary to sequence stretches in the 5′ non-coding region (NCR) of the virus (Alt M. et al., Hepatology, 1995, 22, 707-717), or nucleotides 326-348 comprising the 3′ end of the NCR and nucleotides 371-388 located in the core coding region of the IICV RNA (Alt M. et al., Archives of Virology, 1997, 142, 589-599; Galderisi U. et al., Journal of Cellular Physiology, 1999, 181, 251-257);
- (11) Inhibitors of IRES-dependent translation (Ikeda N et al., Agent for the prevention and treatment of hepatitis C, Japanese Patent Pub. JP-08268890; Kai Y. et al. Prevention and treatment of viral diseases, Japanese Patent Pub. JP-10101591);
- (12) Nuclease-resistant ribozymes (Maccjak, D. J. et al., Hepatology 1999, 30, abstract 995); and
- (13) Other miscellaneous compounds including 1-amino-alkylcyclohexanes (U.S. Pat. No. 6,034,134 to Gold et al.), alkyl lipids (U.S. Pat. No. 5,922,757 to Chojkier et al.), vitamin E and other antioxidants (U.S. Pat. No. 5,922,757 to Chojkier et al.), squalene, amantadine, bile acids (U.S. Pat. No. 5,846,964 to Ozeki et al.), N-(phosphonoacetyl)-L-aspartic acid, (U.S. Pat. No. 5,830,905 to Diana et al.), benzenedicarboxamides (U.S. Pat. No. 5,633,388 to Diana et al.), polyadenylic acid derivatives (U.S. Pat. No. 5,496,546 to Wang et al.), 2′,3′-dideoxyinosine (U.S. Pat. No. 5,026,687 to Yarchoan et al.), and benzimidazoles (U.S. Pat. No. 5,891,874 to Colacino et al.).
In view of the severity of diseases associated with pestiviruses and flaviviruses, and their pervasiveness in animal and man, it is an object of the present invention to provide a compound, method and composition for the treatment of a host infected with flavivirus or pestivirus.
Compounds, methods and compositions for the treatment of a host infected with a flavivirus or pestivirus infection are described that includes an effective treatment amount of a β-D- or β-L-nucleoside of the Formulas (I)-(XVIII), or a pharmaceutically acceptable salt or prodrug thereof.
In a first principal embodiment, a compound of Formula I, or a pharmaceutically acceptable salt or prodrug thereof, is provided:
- R1, R2 and R3 are independently H, phosphate (including mono-, di- or triphosphate and a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1, R2 or R3 is independently H or phosphate;
- Y is hydrogen, bromo, chloro, fluoro, iodo, OR4, NR4R5 or SR4;
- X1 and X2 are independently selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, chloro, bromo, fluoro, iodo, OR4, NR4NR5 or SR5; and
- R4 and R5 are independently hydrogen, acyl (including lower acyl), or alkyl (including but not limited to methyl, ethyl, propyl and cyclopropyl).
In a second principal embodiment, a compound of Formula II, or a pharmaceutically acceptable salt or prodrug thereof, is provided:
- R1, R2 and R3 are independently H; phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1, R2 or R3 is independently H or phosphate; and
- Y is hydrogen, bromo, chloro, fluoro, iodo, OR4, NR4R5 or SR4;
- X1 and X2 are independently selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, chloro, bromo, fluoro, iodo, OR4, NR4NR5 or SR5; and
- R4 and R5 are independently hydrogen, acyl (including lower acyl), or alkyl (including but not limited to methyl, ethyl, propyl and cyclopropyl).
In a third principal embodiment, a compound of Formula III, or a pharmaceutically acceptable salt or prodrug thereof, is provided:
- R1, R2 and R3 are independently H; phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1, R2 or R3 is independently H or phosphate; and
- Y is hydrogen, bromo, chloro, fluoro, iodo, OR4, NR4R5 or SR4;
- X1 and X2 are independently selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, chloro, bromo, fluoro, iodo, OR4, NR4NR5 or SR5; and
- R4 and R5 are independently hydrogen, acyl (including lower acyl), or alkyl (including but not limited to methyl, ethyl, propyl and cyclopropyl).
In a fourth principal embodiment, a compound of Formula IV, or a pharmaceutically acceptable salt or prodrug thereof, is provided:
- R1, R2 and R3 are independently H, phosphate (including mono-, di- or triphosphate and a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1, R2 or R3 is independently H or phosphate;
- Y is hydrogen, bromo, chloro, fluoro, iodo, OR4, NR4R5 or SR4;
- X1 is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, chloro, bromo, fluoro, iodo, OR4, NR4NR5 or SR5; and
- R4 and R5 are independently hydrogen, acyl (including lower acyl), or alkyl (including but not limited to methyl, ethyl, propyl and cyclopropyl).
In a fifth principal embodiment, a compound of Formula V, or a pharmaceutically acceptable salt or prodrug thereof, is provided:
- R1, R2 and R3 are independently H; phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1, R2 or R3 is independently H or phosphate; and
- Y is hydrogen, bromo, chloro, fluoro, iodo, OR4, NR4R5 or SR4;
- X1 is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, chloro, bromo, fluoro, iodo, OR4, NR4NR5 or SR5; and
- R4 and R5 are independently hydrogen, acyl (including lower acyl), or alkyl (including but not limited to methyl, ethyl, propyl and cyclopropyl).
In a sixth principal embodiment, a compound of Formula VI, or a pharmaceutically acceptable salt or prodrug thereof, is provided:
- R1, R2 and R3 are independently H; phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1, R2 or R3 is independently H or phosphate; and
- Y is hydrogen, bromo, chloro, fluoro, iodo, OR4, NR4R5 or SR4;
- X1 is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, chloro, bromo, fluoro, iodo, OR4, NR4NR5 or SR5; and
- R4 and R5 are independently hydrogen, acyl (including lower acyl), or alkyl (including but not limited to methyl, ethyl, propyl and cyclopropyl).
In a seventh principal embodiment, a compound selected from Formulas VII, VIII and IX, or a pharmaceutically acceptable salt or prodrug thereof, is provided:
- Base is a purine or pyrimidine base as defined herein;
- R1, R2 and R3 are independently H; phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1, R2 or R3 is independently H or phosphate;
- R6 is hydrogen, hydroxy, alkyl (including lower alkyl), azido, cyano, alkenyl, alkynyl, Br-vinyl, 2-Br-ethyl, —C(O)O(alkyl), —C(O)O(lower alkyl), —O(acyl), —O(lower acyl), —O(alkyl), —O(lower alkyl), —O(alkenyl), CF3, chloro, bromo, fluoro, iodo, NO2, NH2, —NH(lower alkyl), —NH(acyl), —N(lower alkyl)2, —N(acyl)2; and
- X is O, S, SO2 or CH2.
In a eighth principal embodiment, a compound of Formulas X, XI and XII, or a pharmaceutically acceptable salt or prodrug thereof, is provided:
- Base is a purine or pyrimidine base as defined herein;
R1, R2 and R3 are independently H; phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1, R2 or R3 is independently H or phosphate; - R6 is hydrogen, hydroxy, alkyl (including lower alkyl), azido, cyano, alkenyl, alkynyl, Br-vinyl, —C(O)O(alkyl), —C(O)O(lower alkyl), —O(acyl), —O(lower acyl), —O(alkyl), —O(lower alkyl), —O(alkenyl), chloro, bromo, fluoro, iodo, NO2, NH2, —NH(lower alkyl), —NH(acyl), —N(lower alkyl)2, —N(acyl)2;
- R7 is hydrogen, OR3, hydroxy, alkyl (including lower alkyl), azido, cyano, alkenyl, alkynyl, Br-vinyl, —C(O)O(alkyl), —C(O)O(lower alkyl), —O(acyl), —O(lower acyl), —O(alkyl), —O(lower alkyl), —O(alkenyl), chlorine, bromine, iodine, NO2, NH2, —NH(lower alkyl), —NH(acyl), —N(lower alkyl)2, —N(acyl)2; and
- X is O, S, SO2 or CH2.
In a ninth principal embodiment a compound selected from Formulas XIII, XIV and XV, or a pharmaceutically acceptable salt or prodrug thereof, is provided:
- Base is a purine or pyrimidine base as defined herein;
- R1, R2 and R3 are independently H; phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1, R2 or R3 is independently H or phosphate;
- R6 is hydrogen, hydroxy, alkyl (including lower alkyl), azido, cyano, alkenyl, alkynyl, Br-vinyl, —C(O)O(alkyl), —C(O)O(lower alkyl), —O(acyl), —O(lower acyl), —O(alkyl), —O(lower alkyl), —O(alkenyl), chloro, bromo, fluoro, iodo, NO2, NH2, —NH(lower alkyl), —NH(acyl), —N(lower alkyl)2, —N(acyl)2; and
- X is O, S, SO2, or CH2.
In a tenth principal embodiment the invention provides a compound of Formula XVI, or a pharmaceutically acceptable salt or prodrug thereof:
- Base is a purine or pyrimidine base as defined herein;
- R1 and R2 are independently H; phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1 or R2 is independently H or phosphate;
- R6 is hydrogen, hydroxy, alkyl (including lower alkyl), azido, cyano, alkenyl, alkynyl, Br-vinyl, —C(O)O(alkyl), —C(O)O(lower alkyl), —O(acyl), —O(lower acyl), —O(alkyl), —O(lower alkyl), —O(alkenyl), chloro, bromo, fluoro, iodo, NO2, NH2, —NH(lower alkyl), —NH(acyl), —N(lower alkyl)2, —N(acyl)2;
- R7 and R9 are independently hydrogen, OR2, hydroxy, alkyl (including lower alkyl), azido, cyano, alkenyl, alkynyl, Br-vinyl, —C(O)O(alkyl), —C(O)O(lower alkyl), —O(acyl), —O(lower acyl), —O(alkyl), —O(lower alkyl), —O(alkenyl), chlorine, bromine, iodine, NO2, NH2, —NH(lower alkyl), —NH(acyl), —N(lower alkyl)2, —N(acyl)2;
- R8 and R10 are independently H, alkyl (including lower alkyl), chlorine, bromine or iodine; alternatively, R7 and R9, R7 and R10, R8 and R9, or R8 and R10 can come together to form a pi bond; and
- X is O, S, SO2 or CH2.
In a eleventh principal embodiment the invention provides a compound of Formula XVII, or a pharmaceutically acceptable salt or prodrug thereof:
- Base is a purine or pyrimidine base as defined herein;
- R1 and R2 are independently H; phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1 or R2 is independently H or phosphate;
- R6 is hydrogen, hydroxy, alkyl (including lower alkyl), azido, cyano, alkenyl, alkynyl, Br-vinyl, —C(O)O(alkyl), —C(O)O(lower alkyl), —O(acyl), —O(lower acyl), —O(alkyl), —O(lower alkyl), —O(alkenyl), chloro, bromo, fluoro, iodo, NO2, NH2, —NH(lower alkyl), —NH(acyl), —N(lower alkyl)2, —N(acyl)2;
- R7 and R9 are independently hydrogen, OR2, hydroxy, alkyl (including lower alkyl), azido, cyano, alkenyl, alkynyl, Br-vinyl, —C(O)O(alkyl), —C(O)O(lower alkyl), —O(acyl), —O(lower acyl), —O(alkyl), —O(lower alkyl), —O(alkenyl), chlorine, bromine, iodine, NO2, NH2, —NH(lower alkyl), —NH(acyl), —N(lower alkyl)2, —N(acyl)2;
- R10 is H, alkyl (including lower alkyl), chlorine, bromine or iodine;
- alternatively, R7 and R9, or R7 and R10 can come together to form a pi bond; and
- X is O, S, SO2 or CH2.
In an twelfth principal embodiment, the invention provides a compound of Formula XVIII, or a pharmaceutically acceptable salt or prodrug thereof:
- Base is a purine or pyrimidine base as defined herein;
- R1 and R2 independently H; phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1 or R2 is independently H or phosphate;
- R6 is hydrogen, hydroxy, alkyl (including lower alkyl), azido, cyano, alkenyl, alkynyl, Br-vinyl, —C(O)O(alkyl), —C(O)O(lower alkyl), —O(acyl), —O(lower acyl), —O(alkyl), —O(lower alkyl), —O(alkenyl), chloro, bromo, fluoro, iodo, NO2, NH2, —NH(lower alkyl), —NH(acyl), —N(lower alkyl)2, —N(acyl)2;
- R7 and R9 are independently hydrogen, OR2, alkyl (including lower alkyl), alkenyl, alkynyl, Br-vinyl, O-alkenyl, chlorine, bromine, iodine, NO2, amino, lower alkylamino or di(lower-alkyl)amino;
- R8 is H, alkyl (including lower alkyl), chlorine, bromine or iodine;
- alternatively, R7 and R9, or R8 and R9 can come together to form a pi bond;
- X is O, S, SO2 or CH2.
The β-D- and β-L-nucleosides of this invention may inhibit flavivirus or pestivirus polymerase activity. These nucleosides can be assessed for their ability to inhibit flavivirus or pestivirus polymerase activity in vitro according to standard screening methods.
In one embodiment the efficacy of the anti-flavivirus or pestivirus compound is measured according to the concentration of compound necessary to reduce the plaque number of the virus in vitro, according to methods set forth more particularly herein, by 50% (i.e. the compound's EC50). In preferred embodiments the compound exhibits an EC50 of less than 15 or preferably, less than 10 micromolar in vitro.
In another embodiment, the active compound can be administered in combination or alternation with another anti-flavivirus or pestivirus agent. In combination therapy, effective dosages of two or more agents are administered together, whereas during alternation therapy an effective dosage of each agent is administered serially. The dosages will depend on absorption, inactivation and excretion rates of the drug as well as other factors known to those of skill in the art. It is to be noted that dosage values will also vary with the severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens and schedules should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions.
HCV is a member of the Flaviviridae family; however, now, HCV has been placed in a new monotypic genus, hepacivirus. Therefore, in one embodiment, the flavivirus or pestivirus is not HCV.
Nonlimiting examples of antiviral agents that can be used in combination with the compounds disclosed herein include:
(1) an interferon and/or ribavirin (Battaglia, A. M. et al., Ann. Pharmacother. 34:487-494, 2000); Berenguer, M. et al. Antivir. Ther. 3(Suppl. 3):125-136, 1998);
(2) Substrate-based NS3 protease inhibitors (Attwood et al., Antiviral peptide derivatives, PCT WO 98/22496, 1998; Attwood et al., Antiviral Chemistry and Chemotherapy 10.259-273, 1999; Attwood et al., Preparation and use of amino acid derivatives as anti-viral agents, German Patent Publication DE 19914474; Tung et al. Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease, PCT WO 98/17679), including alphaketoamides and hydrazinoureas, and inhibitors that terminate in an electrophile such as a boronic acid or phosphonate. Llinas-Brunet et al, Hepatitis C inhibitor peptide analogues, PCT WO 99/07734.
(3) Non-substrate-based inhibitors such as 2,4,6-trihydroxy-3-nitro-benzamide derivatives (Sudo K. et al., Biochemical and Biophysical Research Communications, 238:643-647, 1997; Sudo K. et al. Antiviral Chemistry and Chemotherapy 9:186, 1998), including RD3-4082 and RD3-4078, the former substituted on the amide with a 14 carbon chain and the latter processing a para-phenoxyphenyl group;
(4) Thiazolidine derivatives which show relevant inhibition in a reverse-phase HPLC assay with an NS3/4A fusion protein and NS5A/5B substrate (Sudo K. et al., Antiviral Research 32:9-18, 1996), especially compound RD-1-6250, possessing a fused cinnamoyl moiety substituted with a long alkyl chain, RD4 6205 and RD4 6193;
(5) Thiazolidines and benzanilides identified in Kakiuchi N. et al. J. EBS Letters 421:217-220; Takeshita N. et al. Analytical Biochemistry 247:242-246, 1997;
(6) A phenan-threnequinone possessing activity against protease in a SDS-PAGE and autoradiography assay isolated from the fermentation culture broth of Streptomyces sp., Sch 68631 (Chu M. et al., Tetrahedron Letters 37:7229-7232, 1996), and Sch 351633, isolated from the fungus Penicillium griscofuluum, which demonstrates activity in a scintillation proximity assay (Chu M. et al., Bioorganic and Medicinal Chemistry Letters 9:1949-1952);
(7) Selective NS3 inhibitors based on the macromolecule elgin c, isolated from leech (Qasim M. A. et al., Biochemistry 36:1598-1607, 1997);
(8) Helicase inhibitors (Diana G. D. et al., Compounds, compositions and methods for treatment of hepatitis C, U.S. Pat. No. 5,633,358; Diana G. D. et al., Piperidine derivatives, pharmaceutical compositions thereof and their use in the treatment of hepatitis C, PCT WO 97/36554);
(9) Polymerase inhibitors such as nucleotide analogues, gliotoxin (Ferrari R. et al. Journal of Virology 73:1649-1654, 1999), and the natural product cerulenin (Lohmann V. et al., Virology 249:108-118, 1998);
(10) Antisense phosphorothioate oligodeoxynucleotides (S-ODN) complementary to sequence stretches in the 5′ non-coding region (NCR) of the virus (Alt M. et al., Hepatology 22:707-717, 1995), or nucleotides 326-348 comprising the 3′ end of the NCR and nucleotides 371-388 located in the core coding region of the IICV RNA (Alt M. et al., Archives of Virology 142:589-599, 1997; Galderisi U. et al., Journal of Cellular Physiology 181:251-257, 1999);
(11) Inhibitors of IRES-dependent translation (Ikeda N et al., Agent for the prevention and treatment of hepatitis C, Japanese Patent Publication JP-08268890; Kai Y. et al. Prevention and treatment of viral diseases, Japanese Patent Publication JP-10101591);
(12) Nuclease-resistant ribozymes. (Maccjak D. J. et al., Hepatology 30 abstract 995, 1999); and
(13) Other miscellaneous compounds including 1-amino-alkylcyclohexanes (U.S. Pat. No. 6,034,134 to Gold et al.), alkyl lipids (U.S. Pat. No. 5,922,757 to Chojkier et al.), vitamin E and other antioxidants (U.S. Pat. No. 5,922,757 to Chojkier et al.), squalene, amantadine, bile acids (U.S. Pat. No. 5,846,964 to Ozeki et al.), N-(phosphonoacetyl)-L-aspartic acid, (U.S. Pat. No. 5,830,905 to Diana et al.), benzenedicarboxamides (U.S. Pat. No. 5,633,388 to Diana et al.), polyadenylic acid derivatives (U.S. Pat. No. 5,496,546 to Wang et al.), 2′,3′-dideoxyinosine (U.S. Pat. No. 5,026,687 to Yarchoan et al.), and benzimidazoles (U.S. Pat. No. 5,891,874 to Colacino et al.).
The invention as disclosed herein is a compound, method and composition for the treatment of pestiviruses and flaviviruses in humans and other host animals, that includes the administration of an effective flavivirus or pestivirus treatment amount of an β-D- or β-L-nucleoside as described herein or a pharmaceutically acceptable salt or prodrug thereof, optionally in a pharmaceutically acceptable carrier. The compounds of this invention either possess antiviral (i.e., anti-flavivirus or pestivirus) activity, or are metabolized to a compound that exhibits such activity.
In summary, the present invention includes the following features:
-
- (a) β-D- and β-L-nucleosides, as described herein, and pharmaceutically acceptable salts and prodrugs thereof;
- (b) β-D- and β-L-nucleosides as described herein, and pharmaceutically acceptable salts and prodrugs thereof for use in the treatment or prophylaxis of a flavivirus or pestivirus infection, especially in individuals diagnosed as having a flavivirus or pestivirus infection or being at risk for becoming infected by flavivirus or pestivirus;
- (c) use of these β-D- and β-L-nucleosides, and pharmaceutically acceptable salts and prodrugs thereof in the manufacture of a medicament for treatment of a flavivirus or pestivirus infection;
- (d) pharmaceutical formulations comprising the β-D- and β-L-nucleosides or pharmaceutically acceptable salts or prodrugs thereof together with a pharmaceutically acceptable carrier or diluent;
- (e) β-D- and β-L-nucleosides as described herein substantially in the absence of enantiomers of the described nucleoside, or substantially isolated from other chemical entities;
- (f) processes for the preparation of β-D- and β-L-nucleosides, as described in more detail below; and
- (g) processes for the preparation of β-D- and β-L-nucleosides substantially in the absence of enantiomers of the described nucleoside, or substantially isolated from other chemical entities.
Flaviviruses included within the scope of this invention are discussed generally in Fields Virology, Editors: Fields, B. N., Knipe, D. M., and Howley, P. M., Lippincott-Raven Publishers, Philadelphia, Pa., Chapter 31, 1996. Specific flaviviruses include, without limitation: Absettarov, Alfuy, Apoi, Aroa, Bagaza, Banzi, Bouboui, Bussuquara, Cacipacore, Carey Island, Dakar bat, Dengue 1, Dengue 2, Dengue 3, Dengue 4, Edge Hill, Entebbe bat, Gadgets Gully, Hanzalova, Hypr, Ilheus, Israel turkey meningoencephalitis, Japanese encephalitis, Jugra, Jutiapa, Kadam, Karshi, Kedougou, Kokobera, Koutango, Kumlinge, Kunjin, Kyasanur Forest disease, Langat, Louping ill, Meaban, Modoc, Montana myotis leukoencephalitis, Murray valley encephalitis, Naranjal, Negishi, Ntaya, Omsk hemorrhagic fever, Phnom-Penh bat, Powassan, Rio Bravo, Rocio, Royal Farm, Russian spring-summer encephalitis, Saboya, St. Louis encephalitis, Sal Vieja, San Perlita, Saumarez Reef, Sepik, Sokuluk, Spondweni, Stratford, Tembusu, Tyuleniy, Uganda S, Usutu, Wesselsbron, West Nile, Yaounde, Yellow fever, and Zika.
Pestiviruses included within the scope of this invention are discussed generally in Fields Virology, Editors: Fields, B. N., Knipe, D. M., and Howley, P. M., Lippincott-Raven Publishers, Philadelphia, Pa., Chapter 33, 1996. Specific pestiviruses include, without limitation: bovine viral diarrhea virus (“BVDV”), classical swine fever virus (“CSFV,” also called hog cholera virus), and border disease virus (“BDV”).
I. Active Compound, and Physiologically Acceptable Salts and Prodrugs Thereof
In a first principal embodiment, a compound of Formula I, or a pharmaceutically acceptable salt or prodrug thereof, is provided:
- R1, R2 and R3 are independently H, phosphate (including mono-, di- or triphosphate and a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1, R2 or R3 is independently H or phosphate;
- Y is hydrogen, bromo, chloro, fluoro, iodo, OR4, NR4R5 or SR4;
- X1 and X2 are independently selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, chloro, bromo, fluoro, iodo, OR4, NR4NR5 or SR5; and
- R4 and R5 are independently hydrogen, acyl (including lower acyl), or alkyl (including but not limited to methyl, ethyl, propyl and cyclopropyl).
In a preferred subembodiment, a compound of Formula I, or a pharmaceutically acceptable salt or prodrug thereof, is provided wherein:
- R1, R2 and R3 are independently H or phosphate (preferably H);
- X1 is H;
- X2 is H or NH2; and
- Y is hydrogen, bromo, chloro, fluoro, iodo, NH2 or OH.
In a second principal embodiment, a compound of Formula II, or a pharmaceutically acceptable salt or prodrug thereof, is provided:
- R1, R2 and R3 are independently H; phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1, R2 or R3 is independently H or phosphate; and
- Y is hydrogen, bromo, chloro, fluoro, iodo, OR4, NR4R5 or SR4;
- X1 and X2 are independently selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, chloro, bromo, fluoro, iodo, OR4, NR4NR5 or SR5; and
- R4 and R5 are independently hydrogen, acyl (including lower acyl), or alkyl (including but not limited to methyl, ethyl, propyl and cyclopropyl).
In a preferred subembodiment, a compound of Formula II, or a pharmaceutically acceptable salt or prodrug thereof, is provided wherein:
- R1, R2 and R3 are independently H or phosphate (preferably H);
- X1 is H;
- X2 is H or NH2; and
- Y is hydrogen, bromo, chloro, fluoro, iodo, NH2 or OH.
In a third principal embodiment, a compound of Formula III, or a pharmaceutically acceptable salt or prodrug thereof, is provided:
- R1, R2 and R3 are independently H; phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1, R2 or R3 is independently H or phosphate; and
- Y is hydrogen, bromo, chloro, fluoro, iodo, OR4, NR4R5 or SR4;
- X1 and X2 are independently selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, chloro, bromo, fluoro, iodo, OR4, NR4NR5 or SR5; and
- R4 and R5 are independently hydrogen, acyl (including lower acyl), or alkyl (including but not limited to methyl, ethyl, propyl and cyclopropyl).
In a preferred sub embodiment, a compound of Formula II, or a pharmaceutically acceptable salt or prodrug thereof, is provided wherein:
- R1, R2 and R3 are independently H or phosphate (preferably H);
- X1 is H;
- X2 is H or NH2; and
- Y is hydrogen, bromo, chloro, fluoro, iodo, NH2 or OH.
In a fourth principal embodiment, a compound of Formula IV, or a pharmaceutically acceptable salt or prodrug thereof, is provided:
- R1, R2 and R3 are independently H, phosphate (including mono-, di- or triphosphate and a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1, R2 or R3 is independently H or phosphate;
- Y is hydrogen, bromo, chloro, fluoro, iodo, OR4, NR4R1 or SR4;
- X1 is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, chloro, bromo, fluoro, iodo, OR4, NR4NR5 or SR4; and
- R4 and R5 are independently hydrogen, acyl (including lower acyl), or alkyl (including but not limited to methyl, ethyl, propyl and cyclopropyl).
In a preferred subembodiment, a compound of Formula IV, or a pharmaceutically acceptable salt or prodrug thereof, is provided wherein:
- R1, R2 and R3 are independently H or phosphate (preferably H);
- X1 is H or CH3; and
- Y is hydrogen, bromo, chloro, fluoro, iodo, NH2 or OH.
In a fifth principal embodiment, a compound of Formula V, or a pharmaceutically acceptable salt or prodrug thereof, is provided:
- R1, R2 and R3 are independently H; phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1, R2 or R3 is independently H or phosphate; and
- Y is hydrogen, bromo, chloro, fluoro, iodo, OR4, NR4R5 or SR4;
- X1 is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, chloro, bromo, fluoro, iodo, OR4, NR4NR5 or SR5; and
- R4 and R5 are independently hydrogen, acyl (including lower acyl), or alkyl (including but not limited to methyl, ethyl, propyl and cyclopropyl).
In a preferred subembodiment, a compound of Formula V, or a pharmaceutically acceptable salt or prodrug thereof, is provided wherein:
- R1, R2 and R3 are independently H or phosphate (preferably H);
- X1 is H or CH3; and
- Y is hydrogen, bromo, chloro, fluoro, iodo, NH2 or OH.
In a sixth principal embodiment, a compound of Formula VI, or a pharmaceutically acceptable salt or prodrug thereof, is provided:
- R1, R2 and R3 are independently H; phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1, R2 or R3 is independently H or phosphate; and
- Y is hydrogen, bromo, chloro, fluoro, iodo, OR4, NR4R5 or SR4;
- X1 is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, chloro, bromo, fluoro, iodo, OR4, NR4NR5 or SR5; and
- R4 and R5 are independently hydrogen, acyl (including lower acyl), or alkyl (including but not limited to methyl, ethyl, propyl and cyclopropyl).
In a preferred subembodiment, a compound of Formula VI, or a pharmaceutically acceptable salt or prodrug thereof, is provided wherein:
- R1, R2 and R3 are independently H or phosphate (preferably H);
- X1 is H or CH3; and
- Y is hydrogen, bromo, chloro, fluoro, iodo, NH2 or OH.
In a seventh principal embodiment, a compound selected from Formulas VII, VIII and IX, or a pharmaceutically acceptable salt or prodrug thereof, is provided:
- Base is a purine or pyrimidine base as defined herein;
- R1, R2 and R3 are independently H; phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1, R2 or R3 is independently H or phosphate;
- R6 is hydrogen, hydroxy, alkyl (including lower alkyl), azido, cyano, alkenyl, alkynyl, Br-vinyl, 2-Br-ethyl, —C(O)O(alkyl), —C(O)O(lower alkyl), —O(acyl), —O(lower acyl), —O(alkyl), —O(lower alkyl), —O(alkenyl), CF3, chloro, bromo, fluoro, iodo, NO2, NH2, —NH(lower alkyl), —NH(acyl), —N(lower alkyl)2, —N(acyl)2; and
- X is O, S, SO2, or CH2.
In a first preferred subembodiment, a compound of Formula VII, VIII or IX, or a pharmaceutically acceptable salt or prodrug thereof, is provided wherein:
- Base is a purine or pyrimidine base as defined herein;
- R1, R2 and R3 are independently hydrogen or phosphate;
- R6 is alkyl; and
- X is O, S, SO2 or CH2.
In a second preferred subembodiment, a compound of Formula VII, VIII or IX, or a pharmaceutically acceptable salt or prodrug thereof, is provided wherein:
- Base is a purine or pyrimidine base as defined herein;
- R1, R2 and R3 are hydrogens;
- R6 is alkyl; and
- X is O, S, SO2 or CH2.
In a third preferred subembodiment, a compound of Formula VII, VIII or IX, or a pharmaceutically acceptable salt or prodrug thereof, is provided wherein: Base is a purine or pyrimidine base as defined herein;
- R1, R2 and R3 are independently hydrogen or phosphate;
- R6 is alkyl; and
- X is O.
In a eighth principal embodiment, a compound of Formula X, XI or XII, or a pharmaceutically acceptable salt or prodrug thereof, is provided:
- Base is a purine or pyrimidine base as defined herein;
- R1, R2 and R3 are independently H; phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1, R2 or R3 is independently H or phosphate;
- R6 is hydrogen, hydroxy, alkyl (including lower alkyl), azido, cyano, alkenyl, alkynyl, Br-vinyl, —C(O)O(alkyl), —C(O)O(lower alkyl), —O(acyl), —O(lower acyl), —O(alkyl), —O(lower alkyl), —O(alkenyl), chloro, bromo, fluoro, iodo, NO2, NH2, —NH(lower alkyl), —NH(acyl), —N(lower alkyl)2, —N(acyl)2;
- R7 is hydrogen, OR3, hydroxy, alkyl (including lower alkyl), azido, cyano, alkenyl, alkynyl, Br-vinyl, —C(O)O(alkyl), —C(O)O(lower alkyl), —O(acyl), —O(lower acyl), —O(alkyl), —O(lower alkyl), —O(alkenyl), chlorine, bromine, iodine, NO2, NH2, —NH(lower alkyl), —NH(acyl), N(lower alkyl)2, —N(acyl)2; and
- X is O, S, SO2 or CH2.
In a first preferred subembodiment, a compound of Formula X, XI or XII, or a pharmaceutically acceptable salt or prodrug thereof, is provided wherein:
- Base is a purine or pyrimidine base as defined herein;
- R1, R2 and R3 are independently hydrogen or phosphate;
- R6 is alkyl; and
- X is O, S, SO2 or CH2
In a second preferred subembodiment, a compound of Formula X, XI or XII, or a pharmaceutically acceptable salt or prodrug thereof, is provided wherein:
- Base is a purine or pyrimidine base as defined herein;
- R1, R2 and R3 are hydrogens;
- R6 is alkyl; and
- X is O, S, SO2 or CH2.
In a third preferred subembodiment, a compound of Formula X, XI or XII, or a pharmaceutically acceptable salt or prodrug thereof, is provided wherein:
- Base is a purine or pyrimidine base as defined herein;
- R1, R2 and R3 are independently H or phosphate;
- R6 is alkyl; and
- X is O.
In even more preferred subembodiments, a compound of Formula XI, or its pharmaceutically acceptable salt or prodrug, is provided:
- Base is a purine or pyrimidine base as defined herein; optionally substituted with an amine or cyclopropyl (e.g., 2-amino, 2,6-diamino or cyclopropyl guanosine); and
- R1 and R2 are independently H; phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1 or R2 is independently H or phosphate.
In a ninth principal embodiment a compound selected from Formula XIII, XIV or XV, or a pharmaceutically acceptable salt or prodrug thereof, is provided:
- Base is a purine or pyrimidine base as defined herein;
- R1, R2 and R3 are independently H; phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1, R2 or R3 is independently H or phosphate;
- R6 is hydrogen, hydroxy, alkyl (including lower alkyl), azido, cyano, alkenyl, alkynyl, Br-vinyl, —C(O)O(alkyl), —C(O)O(lower alkyl), —O(acyl), —O(lower acyl), —O(alkyl), —O(lower alkyl), —O(alkenyl), chloro, bromo, fluoro, iodo, NO2, NH2, —NH(lower alkyl), —NH(acyl), —N(lower alkyl)2, —N(acyl)2; and
- X is O, S, SO2 or CH2.
In a first preferred subembodiment, a compound of Formula XIII, XIV or XV, or a pharmaceutically acceptable salt or prodrug thereof, is provided wherein:
- Base is a purine or pyrimidine base as defined herein;
- R1, R2 and R3 are independently hydrogen or phosphate;
- R6 is alkyl; and
- X is O, S, SO2 or CH2.
In a second preferred subembodiment, a compound of Formula XIII, XIV or XV, or a pharmaceutically acceptable salt or prodrug thereof, is provided wherein:
- Base is a purine or pyrimidine base as defined herein;
- R1, R2 and R3 are hydrogens;
- R6 is alkyl; and
- X is O, S, SO2 or CH2.
In a third preferred subembodiment, a compound of Formula XIII, XIV or XV, or a pharmaceutically acceptable salt or prodrug thereof, is provided wherein: Base is a purine or pyrimidine base as defined herein;
- R1, R2 and R3 are independently hydrogen or phosphate;
- R6 is alkyl; and
- X is O.
In a tenth principal embodiment the invention provides a compound of Formula XVI, or a pharmaceutically acceptable salt or prodrug thereof:
- Base is a purine or pyrimidine base as defined herein;
- R1 and R2 are independently H; phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1 and R2 are independently H or phosphate;
- R6 is hydrogen, hydroxy, alkyl (including lower alkyl), azido, cyano, alkenyl, alkynyl, Br-vinyl, —C(O)O(alkyl), —C(O)O(lower alkyl), —O(acyl), —O(lower acyl), —O(alkyl), —O(lower alkyl), —O(alkenyl), chloro, bromo, fluoro, iodo, NO2, NH2, —NH(lower alkyl), —NH(acyl), —N(lower alkyl)2, —N(acyl)2;
- R7 and R9 are independently hydrogen, OR2, hydroxy, alkyl (including lower alkyl), azido, cyano, alkenyl, alkynyl, Br-vinyl, —C(O)O(alkyl), —C(O)O(lower alkyl), —O(acyl), —O(lower acyl), —O(alkyl), —O(lower alkyl), —O(alkenyl), chlorine, bromine, iodine, NO2, NH2, —NH(lower alkyl), —NH(acyl), —N(lower alkyl)2, —N(acyl)2;
- R8 and R10 are independently H, alkyl (including lower alkyl), chlorine, bromine or iodine;
- alternatively, R7 and R9, R7 and R10, R1 and R9, or R8 and R10 can come together to form a pi bond; and
- X is O, S, SO2 or CH2.
In a first preferred subembodiment, a compound of Formula XVI, or its pharmaceutically acceptable salt or prodrug, is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R1 is independently H or phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1 is independently H or phosphate; (3) R6 is alkyl; (4) R7 and R9 are independently OR2, alkyl, alkenyl, alkynyl, Br-vinyl, O-alkenyl, chlorine, bromine, iodine, NO2, amino, lower alkylamino or di(lower alkyl)amino; (5) R8 and R10 are independently H, alkyl (including lower alkyl), chlorine, bromine, or iodine; and (6) X is O, S, SO2 or CH2.
In a second preferred subembodiment, a compound of Formula XVI, or its pharmaceutically acceptable salt or prodrug, is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R1 is independently H or phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1 is independently H or phosphate; (3) R6 is alkyl, alkenyl, alkynyl, Br-vinyl, hydroxy, O-alkyl, O-alkenyl, chloro, bromo, fluoro, iodo, NO2, amino, lower alkylamino, or di(lower alkyl)amino; (4) R7 and R9 are independently OR2; (5) R8 and R10 are independently H, alkyl (including lower alkyl), chlorine, bromine, or iodine; and (6) X is O, S, SO2 or CH2.
In a third preferred subembodiment, a compound of Formula XVI, or its pharmaceutically acceptable salt or prodrug, is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R1 is independently H or phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1 is independently H or phosphate; (3) R6 is alkyl, alkenyl, alkynyl, Br-vinyl, hydroxy, O-alkyl, O-alkenyl, chloro, bromo, fluoro, iodo, NO2, amino, lower alkylamino or di(lower alkyl)amino; (4) R7 and R9 are independently OR2, alkyl, alkenyl, alkynyl, Br-vinyl, O-alkenyl, chlorine, bromine, iodine, NO2, amino, lower alkylamino or di(lower alkyl)amino; (5) R8 and R10 are H; and (6) X is O, S, SO2 or CH2.
In a fourth preferred subembodiment, a compound of Formula XVI, or its pharmaceutically acceptable salt or prodrug, is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R1 is independently H or phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1 is independently H or phosphate; (3) R6 is alkyl, alkenyl, alkynyl, Br-vinyl, hydroxy, O-alkyl, O-alkenyl, chloro, bromo, fluoro, iodo, NO2, amino, lower alkylamino, or di(lower alkyl)amino; (4) R7 and R9 are independently OR2, alkyl, alkenyl, alkynyl, Br-vinyl, O-alkenyl, chlorine, bromine, iodine, NO2, amino, lower alkylamino, or di(lower alkyl)amino; (5) R8 and R10 are independently H, alkyl (including lower alkyl), chlorine, bromine, or iodine; and (6) X is O.
In a fifth preferred subembodiment, a compound of Formula XVI, or its pharmaceutically acceptable salt or prodrug, is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R1 is independently H or phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1 is independently H or phosphate; (3) R6 is alkyl; (4) R7 and R9 are independently OR1; (5) R8 and R10 are independently H, alkyl (including lower alkyl), chlorine, bromine or iodine; and (6) X is O, S, SO2 or CH2.
In a sixth preferred subembodiment, a compound of Formula XVI, or its pharmaceutically acceptable salt or prodrug, is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R1 is independently H or phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1 is independently H or phosphate; (3) R6 is alkyl; (4) R7 and R9 are independently OR2, alkyl (including lower alkyl), alkenyl, alkynyl, Br-vinyl, O-alkenyl, chlorine, bromine, iodine, NO2, amino, lower alkylamino, or di(lower alkyl)amino; (5) R8 and R10 are H; and (6) X is O, S, SO2, or CH2.
In a seventh preferred subembodiment, a compound of Formula XVI, or its pharmaceutically acceptable salt or prodrug, is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R1 is independently H or phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1 is independently H or phosphate; (3) R6 is alkyl; (4) R7 and R9 are independently OR2, alkyl (including lower alkyl), alkenyl, alkynyl, Br-vinyl, O-alkenyl, chlorine, bromine, iodine, NO2, amino, lower alkylamino or di(lower alkyl)amino; (5) R8 and R10 are independently H, alkyl (including lower alkyl), chlorine, bromine or iodine; and (6) X is O.
In a eighth preferred subembodiment, a compound of Formula XVI, or its pharmaceutically acceptable salt or prodrug, is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R1 is independently H or phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1 is independently H or phosphate; (3) R6 is alkyl (including lower alkyl), alkenyl, alkynyl, Br-vinyl, hydroxy, O-alkyl, O-alkenyl, chloro, bromo, fluoro, iodo, NO2, amino, lower alkylamino or di(lower alkyl)amino; (4) R7 and R9 are in dependently OR2; (5) R8 and R10 are hydrogen; and (6) X is O, S, SO2 or CH2.
In a ninth preferred subembodiment, a compound of Formula XVI, or its pharmaceutically acceptable salt or prodrug, is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R1 is independently H or phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1 is independently H or phosphate; (3) R6 is alkyl (including lower alkyl), alkenyl, alkynyl, Br-vinyl, hydroxy, O-alkyl, O-alkenyl, chloro, bromo, fluoro, iodo, NO2, amino, lower alkylamino or di(lower alkyl)amino; (4) R7 and R9 are independently OR2; (5) R8 and R10 are independently H, alkyl (including lower alkyl), chlorine, bromine or iodine; and (6) X is O.
In a tenth preferred subembodiment, a compound of Formula XVI, or its pharmaceutically acceptable salt or prodrug, is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R1 is independently H or phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1 is independently H or phosphate; (3) R6 is alkyl (including lower alkyl), alkenyl, alkynyl, Br-vinyl, hydroxy, O-alkyl, O-alkenyl, chloro, bromo, fluoro, iodo, NO2, amino, lower alkylamino or di(lower alkyl)amino; (4) R7 and R9 are independently OR2, alkyl (including lower alkyl), alkenyl, alkynyl, Br-vinyl, O-alkenyl, chlorine, bromine, iodine, NO2, amino, lower alkylamino, or di(lower alkyl)amino; (5) R8 and R10 are hydrogen; and (6) X is O.
In an eleventh preferred subembodiment, a compound of Formula XVI, or its pharmaceutically acceptable salt or prodrug, is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R1 is independently H or phosphate; (3) R6 is alkyl (including lower alkyl), alkenyl, alkynyl, Br-vinyl, hydroxy, O-alkyl, O-alkenyl, chloro, bromo, fluoro, iodo, NO2, amino, lower alkylamino or di(lower alkyl)amino; (4) R7 and R9 are independently OR2; (5) R8 and R10 are hydrogen; and (6) X is O, S, SO2 or CH2.
In a twelfth preferred subembodiment, a compound of Formula XVI, or its pharmaceutically acceptable salt or prodrug, is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R1 is independently H or phosphate; (3) R6 is alkyl; (4) R7 and R9 are independently OR2; (5) R8 and R10 are hydrogen; and (6) X is O, S, SO2, or CH2.
In a thirteenth preferred subembodiment, a compound of Formula XVI, or its pharmaceutically acceptable salt or prodrug, is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R1 is independently H or phosphate; (3) R6 is alkyl; (4) R7 and R9 are independently OR2; (5) R8 and R10 are independently H, alkyl (including lower alkyl), chlorine, bromine, or iodine; and (6) X is O.
In a fourteenth preferred subembodiment, a compound of Formula XVI, or its pharmaceutically acceptable salt or prodrug, is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R1 is independently H or phosphate; (3) R6 is alkyl; (4) R7 and R9 are independently OR2, alkyl (including lower alkyl), alkenyl, alkynyl, Br-vinyl, O-alkenyl, chlorine, bromine, iodine, NO2, amino, lower alkylamino or di(lower alkyl)amino;
(5) R8 and R10 are hydrogen; and (6) X is O.
In even more preferred subembodiments, a compound of Formula XVI, or its pharmaceutically acceptable salt or prodrug, is provided in which:
(1) Base is adenine; (2) R1 is hydrogen; (3) R6 is methyl; (4) R7 and R9 are hydroxyl; (5) R8 and R10 are hydrogen; and (6) X is O;
(1) Base is guanine; (2) R1 is hydrogen; (3) R6 is methyl; (4) R7 and R9 are hydroxyl; (5) R8 and R10 are hydrogen; and (6) X is O;
(1) Base is cytosine; (2) R1 is hydrogen; (3) R6 is methyl; (4) R7 and R9 are hydroxyl; (5) R8 and R10 are hydrogen; and (6) X is O;
(1) Base is thymine; (2) R1 is hydrogen; (3) R6 is methyl; (4) R7 and R9 are hydroxyl; (5) R8 and R10 are hydrogen; and (6) X is O;
(1) Base is uracil; (2) R1 is hydrogen; (3) R6 is methyl; (4) R7 and R9 are hydroxyl; (5) R8 and R10 are hydrogen; and (6) X is O;
(1) Base is adenine; (2) R1 is phosphate; (3) R6 is methyl; (4) R7 and R9 are hydroxyl; (5) R8 and R10 are hydrogen; and (6) X is O;
(1) Base is adenine; (2) R1 is hydrogen; (3) R6 is ethyl; (4) R7 and R9 are hydroxyl; (5) R8 and R10 are hydrogen; and (6) X is O;
(1) Base is adenine; (2) R1 is hydrogen; (3) R6 is propyl; (4) R7 and R9 are hydroxyl; (5) R8 and R10 are hydrogen; and (6) X is O;
(1) Base is adenine; (2) R1 is hydrogen; (3) R6 is butyl; (4) R7 and R9 are hydroxyl; (5) R8 and R10 are hydrogen; and (6) X is O;
(1) Base is adenine; (2) R1 is hydrogen; (3) R6 is methyl; (4) R7 is hydrogen and R9 is hydroxyl; (5) R8 and R10 are hydrogen; and (6) X is O;
(1) Base is adenine; (2) R1 is hydrogen; (3) R6 is methyl; (4) R7 and R9 are hydroxyl; (5) R8 and R10 are hydrogen; and (6) X is S;
(1) Base is adenine; (2) R1 is hydrogen; (3) R6 is methyl; (4) R7 and R9 are hydroxyl; (5) R8 and R10 are hydrogen; and (6) X is SO2;
(1) Base is adenine; (2) R1 is hydrogen; (3) R6 is methyl; (4) R7 and R9 are hydroxyl; (5) R8 and R10 are hydrogen; and (6) X is CH2;
In a eleventh principal embodiment the invention provides a compound of Formula XVII, or a pharmaceutically acceptable salt or prodrug thereof:
- Base is a purine or pyrimidine base as defined herein;
- R1 is H; phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1 is independently H or phosphate;
- R6 is hydrogen, hydroxy, alkyl (including lower alkyl), azido, cyano, alkenyl, alkynyl, Br-vinyl, —C(O)O(alkyl), —C(O)O(lower alkyl), —O(acyl), —O(lower acyl), —O(alkyl), —O(lower alkyl), —O(alkenyl), chloro, bromo, fluoro, iodo, NO2, NH2, —NH(lower alkyl), —NH(acyl), —N(lower alkyl)2, —N(acyl)2;
- R7 and R9 are independently hydrogen, OR2, hydroxy, alkyl (including lower alkyl), azido, cyano, alkenyl, alkynyl, Br-vinyl, —C(O)O(alkyl), —C(O)O(lower alkyl), —O(acyl), —O(lower acyl), —O(alkyl), —O(lower alkyl), —O(alkenyl), chlorine, bromine, iodine, NO2, NH2, —NH(lower alkyl), —NH(acyl), —N(lower alkyl)2, —N(acyl)2;
- R10 is H, alkyl (including lower alkyl), chlorine, bromine, or iodine; alternatively, R7 and R9, or R7 and R10 can come together to form a pi bond; and
- X is O, S, SO2 or CH2.
In a first preferred subembodiment, a compound of Formula XVII, or its pharmaceutically acceptable salt or prodrug, is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R1 is independently H; phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1 is independently H or phosphate; (3) R6 is alkyl (including lower alkyl), alkenyl, alkynyl, Br-vinyl, hydroxy, O-alkyl, O-alkenyl, chloro, bromo, fluoro, iodo, NO2, amino, lower alkylamino, or di(lower alkyl)amino; (4) R7 and R9 are independently hydrogen, OR2, alkyl (including lower alkyl), alkenyl, alkynyl, Br-vinyl, O-alkenyl, chlorine, bromine, iodine, NO2, amino, lower alkylamino or di(lower alkyl)amino; (5) R10 is H; and (6) X is O, S, SO2, or CH2.
In a second preferred subembodiment, a compound of Formula XVII, or its pharmaceutically acceptable salt or prodrug, is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R1 is independently H; phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1 is independently H or phosphate; (3) R6 is alkyl (including lower alkyl), alkenyl, alkynyl, Br-vinyl, hydroxy, O-alkyl, O-alkenyl, chloro, bromo, fluoro, iodo, NO2, amino, lower alkylamino or di(lower alkyl)amino; (4) R7 and R9 are independently OR2; (5) R10 is H, alkyl (including lower alkyl), chlorine, bromine, or iodine; and (6) X is O, S, SO2 or CH2.
In a third preferred subembodiment, a compound of Formula XVII, or its pharmaceutically acceptable salt or prodrug, is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R1 is independently H; phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1 is independently H or phosphate; (3) R6 is alkyl (including lower alkyl), alkenyl, alkynyl, Br-vinyl, hydroxy, O-alkyl, O-alkenyl, chloro, bromo, fluoro, iodo, NO2, amino, lower alkylamino, or di(lower alkyl)amino; (4) R7 and R9 are independently hydrogen, OR2, alkyl (including lower alkyl), alkenyl, alkynyl, Br-vinyl, O-alkenyl, chlorine, bromine, iodine, NO2, amino, lower alkylamino or di(lower alkyl)amino; (5) R10 is H, alkyl (including lower alkyl), chlorine, bromine or iodine; and (6) X is O.
In a fourth preferred subembodiment, a compound of Formula XVII, or its pharmaceutically acceptable salt or prodrug, is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R1 is independently H; phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1 is independently H or phosphate; (3) R6 is alkyl (including lower alkyl), alkenyl, alkynyl, Br-vinyl, hydroxy, O-alkyl, O-alkenyl, chloro, bromo, fluoro, iodo, NO2, amino, lower alkylamino or di(lower alkyl)amino; (4) R7 and R9 are independently OR2; (5) R10 is H; and (6) X is O, S, SO2 or CH2.
In a fifth preferred subembodiment, a compound of Formula XVII, or its pharmaceutically acceptable salt or prodrug, is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R1 is independently H; phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1 is independently H or phosphate; (3) R6 is alkyl (including lower alkyl), alkenyl, alkynyl, Br-vinyl, hydroxy, O-alkyl, O-alkenyl, chloro, bromo, fluoro, iodo, NO2, amino, lower alkylamino or di(lower alkyl)amino; (4) R7 and R9 are independently OR2; (5) R10 is H, alkyl (including lower alkyl), chlorine, bromine or iodine; and (6) X is O.
In a sixth preferred subembodiment, a compound of Formula XVII, or its pharmaceutically acceptable salt or prodrug, is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R1 is independently H; phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1 is independently H or phosphate; (3) R6 is alkyl (including lower alkyl), alkenyl, alkynyl, Br-vinyl, hydroxy, O-alkyl, O-alkenyl, chloro, bromo, fluoro, iodo, NO2, amino, lower alkylamino, or di(lower alkyl)amino; (4) R7 and R9, are independently hydrogen, OR2, alkyl (including lower alkyl), alkenyl, alkynyl, Br-vinyl, O-alkenyl, chlorine, bromine, iodine, NO2, amino, lower alkylamino, or di(lower alkyl)amino; (5) R10 is H; and (6) X is O.
In a seventh preferred subembodiment, a compound of Formula XVII, or its pharmaceutically acceptable salt or prodrug, is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R1 is independently H; phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1 is independently H or phosphate; (3) R6 is alkyl (including lower alkyl), alkenyl, alkynyl, Br-vinyl, hydroxy, O-alkyl, O-alkenyl, chloro, bromo, fluoro, iodo, NO2, amino, lower alkylamino, or di(lower alkyl)amino; (4) R7 and R9 are independently OR2; (5) R10 is H; and (6) X is O.
In an eighth preferred subembodiment, a compound of Formula XVII, or its pharmaceutically acceptable salt or prodrug, is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R1 is independently H or phosphate; (3) R6 is alkyl; (4) R7 and R9 are independently hydrogen, OR2, alkyl (including lower alkyl), alkenyl, alkynyl, Br-vinyl, O-alkenyl, chlorine, bromine, iodine, NO2, amino, lower alkylamino or di(lower alkyl)-amino; (5) R10 is H, alkyl (including lower alkyl), chlorine, bromine or iodine; and (6) X is O, S, SO2, or CH2.
In a ninth preferred subembodiment, a compound of Formula XVII, or its pharmaceutically acceptable salt or prodrug, is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R1 is independently H or phosphate; (3) R6 is alkyl (including lower alkyl), alkenyl, alkynyl, Br-vinyl, hydroxy, O-alkyl, O-alkenyl, chloro, bromo, fluoro, iodo, NO2, amino, lower alkylamino, or di(lower alkyl)amino; (4) R7 and R9 are independently OR2; (5) R10 is H; and (6) X is O, S, SO2, or CH2.
In a tenth preferred subembodiment, a compound of Formula XVII, or its pharmaceutically acceptable salt or prodrug, is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R1 is independently H or phosphate; (3) R6 is alkyl; (4) R7 and R9 are independently OR2; (5) R10 is H; and (6) X is O, S, SO2, or CH2.
In even more preferred subembodiments, a compound of Formula XVII, or its pharmaceutically acceptable salt or prodrug, is provided in which:
(1) Base is adenine; (2) R1 is hydrogen; (3) R6 is methyl; (4) R7 and R9 are hydroxyl; (5) R10 is hydrogen; and (6) X is O;
(1) Base is guanine; (2) R1 is hydrogen; (3) R6 is methyl; (4) R7 and R9 are hydroxyl; (5) R10 is hydrogen; and (6) X is O;
(1) Base is cytosine; (2) R1 is hydrogen; (3) R6 is methyl; (4) R7 and R9 are hydroxyl; (5) R10 is hydrogen; and (6) X is O;
(1) Base is thymine; (2) R1 is hydrogen; (3) R6 is methyl; (4) R7 and R9 are hydroxyl; (5) R10 is hydrogen; and (6) X is O;
(1) Base is uracil; (2) R1 is hydrogen; (3) R6 is methyl; (4) R7 and R9 are hydroxyl; (5) R10 is hydrogen; and (6) X is O;
(1) Base is adenine; (2) R1 is phosphate; (3) R6 is methyl; (4) R7 and R9 are hydroxyl; (5) R10 is hydrogen; and (6) X is O;
(1) Base is adenine; (2) R1 is hydrogen; (3) R6 is ethyl; (4) R7 and R9 are hydroxyl; (5) R10 is hydrogen; and (6) X is O;
(1) Base is adenine; (2) R1 is hydrogen; (3) R6 is propyl; (4) R7 and R9 are hydroxyl; (5) R10 is hydrogen; and (6) X is O;
(1) Base is adenine; (2) R1 is hydrogen; (3) R6 is butyl; (4) R7 and R9 are hydroxyl; (5) R10 is hydrogen; and (6) X is O;
(1) Base is adenine; (2) R1 is hydrogen; (3) R6 is methyl; (4) R7 and R9 are hydroxyl; (5) R10 is hydrogen; and (6) X is S;
(1) Base is adenine; (2) R1 is hydrogen; (3) R6 is methyl; (4) R7 and R9 are hydroxyl; (5) R10 is hydrogen; and (6) X is SO2; or
(1) Base is adenine; (2) R1 is hydrogen; (3) R6 is methyl; (4) R7 and R9 are hydroxyl; (5) R10 is hydrogen; and (6) X is CH2.
In an twelfth principal embodiment the invention provides a compound of Formula XVIII, or a pharmaceutically acceptable salt or prodrug thereof:
- Base is a purine or pyrimidine base as defined herein;
- R1 is independently H; phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1 is independently H or phosphate;
- R6 is hydrogen, hydroxy, alkyl (including lower alkyl), azido, cyano, alkenyl, alkynyl, Br-vinyl, —C(O)O(alkyl), —C(O)O(lower alkyl), —O(acyl), —O(lower acyl), —O(alkyl), —O(lower alkyl), —O(alkenyl), chloro, bromo, fluoro, iodo, NO2, NH2, —NH(lower alkyl), —NH(acyl), —N(lower alkyl)2, —N(acyl)2;
- R7 and R9 are independently hydrogen, OR2, alkyl (including lower alkyl), alkenyl, alkynyl, Br-vinyl, O-alkenyl, chlorine, bromine, iodine, NO2, amino, lower alkylamino, or di(lower alkyl)amino;
- R8 is H, alkyl (including lower alkyl), chlorine, bromine or iodine;
- alternatively, R7 and R9, or R8 and R9 can come together to form a pi bond;
- X is O, S, SO2 or CH2.
In a first preferred subembodiment, a compound of Formula XVIII, or its pharmaceutically acceptable salt or prodrug, is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R1 is independently H; phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1 is independently H or phosphate; (3) R6 is alkyl; (4) R7 and R9 are independently hydrogen, OR2, alkyl (including lower alkyl), alkenyl, alkynyl, Br-vinyl, O-alkenyl, chlorine, bromine, iodine, NO2, amino, lower alkylamino or di(lower alkyl)amino; (5) R8 is H, alkyl (including lower alkyl), chlorine, bromine or iodine; and (6) X is O, S, SO2 or CH2.
In a second preferred subembodiment, a compound of Formula XVIII, or its pharmaceutically acceptable salt or prodrug, is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R1 is independently H; phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1 is independently H or phosphate; (3) R6 is alkyl (including lower alkyl), alkenyl, alkynyl, Br-vinyl, hydroxy, O-alkyl, O-alkenyl, chloro, bromo, fluoro, iodo, NO2, amino, lower alkylamino or di-(lower alkyl)amino; (4) R1 and R9 are independently OR2; (5) R8 is H, alkyl (including lower alkyl), chlorine, bromine, or iodine; and (6) X is O, S, SO2 or CH2.
In a third preferred subembodiment, a compound of Formula XVIII, or its pharmaceutically acceptable salt or prodrug, is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R1 is independently H; phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1 is independently H or phosphate; (3) R6 is alkyl (including lower alkyl), alkenyl, alkynyl, Br-vinyl, hydroxy, O-alkyl, O-alkenyl, chloro, bromo, fluoro, iodo, NO2, amino, lower alkylamino, or di(lower-alkyl)amino; (4) R7 and R9 are independently hydrogen, OR2, alkyl (including lower alkyl), alkenyl, alkynyl, Br-vinyl, O-alkenyl, chlorine, bromine, iodine, NO2, amino, lower alkylamino, or di(lower alkyl)amino; (5) R8 is H; and (6) X is O, S, SO2 or CH2.
In a fourth preferred subembodiment, a compound of Formula XVIII, or its pharmaceutically acceptable salt or prodrug, is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R1 is independently H; phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1 is independently H or phosphate; (3) R6 is alkyl (including lower alkyl), alkenyl, alkynyl, Br-vinyl, hydroxy, O-alkyl, O-alkenyl, chloro, bromo, fluoro, iodo, NO2, amino, lower alkylamino, or di(lower alkyl)amino; (4) R7 and R9 are independently hydrogen, OR2, alkyl (including lower alkyl), alkenyl, alkynyl, Br-vinyl, O-alkenyl, chlorine, bromine, iodine, NO2, amino, lower alkylamino, or di(lower alkyl)amino; (5) R8 is H, alkyl (including lower alkyl), chlorine, bromine, or iodine; and (6) X is O.
In a fifth preferred subembodiment, a compound of Formula XVIII, or its pharmaceutically acceptable salt or prodrug, is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R1 is independently H; phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1 is independently H or phosphate; (3) R6 is alkyl (including lower alkyl), alkenyl, alkynyl, Br-vinyl, hydroxy, O-alkyl, O-alkenyl, chloro, bromo, fluoro, iodo, NO2, amino, lower alkylamino, or di(lower alkyl)amino; (4) R7 and R9 are independently OR2; (5) R8 is H; and (6) X is O, S, SO2, or CH2.
In a sixth preferred subembodiment, a compound of Formula XVIII, or its pharmaceutically acceptable salt or prodrug, is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R1 is independently H; phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1 is independently H or phosphate; (3) R6 is alkyl (including lower alkyl), alkenyl, alkynyl, Br-vinyl, hydroxy, O-alkyl, O-alkenyl, chloro, bromo, fluoro, iodo, NO2, amino, lower alkylamino, or di(lower alkyl)amino; (4) R7 and R9 are independently OR2; (5) R8 is H, alkyl (including lower alkyl), chlorine, bromine, or iodine; and (6) X is O.
In a seventh preferred subembodiment, a compound of Formula XVIII, or its pharmaceutically acceptable salt or prodrug, is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R1 is independently H; phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1 is independently H or phosphate; (3) R6 is alkyl (including lower alkyl), alkenyl, alkynyl, Br-vinyl, hydroxy, Q-alkyl, O-alkenyl, chloro, bromo, fluoro, iodo, NO2, amino, lower alkylamino, or di(lower alkyl)amino; (4) R7 and R9 are independently hydrogen, OR2, alkyl (including lower alkyl), alkenyl, alkynyl, Br-vinyl, O-alkenyl, chlorine, bromine, iodine, NO2, amino, lower alkylamino, or di(lower alkyl)amino; (5) R8 is H; and (6) X is O.
In an eighth preferred subembodiment, a compound of Formula XVIII, or its pharmaceutically acceptable salt or prodrug, is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R1 is independently H or phosphate; (3) R6 is alkyl (including lower alkyl), alkenyl, alkynyl, Br-vinyl, hydroxy, O-alkyl, O-alkenyl, chloro, bromo, fluoro, iodo, NO2, amino, lower alkylamino or di(lower alkyl)amino; (4) R7 and R9 are independently OR2; (5) R8 is H; and (6) X is O, S, SO2 or CH2.
In a ninth preferred subembodiment, a compound of Formula XVIII, or its pharmaceutically acceptable salt or prodrug, is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R1 is independently H or phosphate; (3) R6 is alkyl; (4) R7 and R9 are independently OR2; (5) R8 is H; and (6) X is O, S, SO2, or CH2.
In a tenth preferred subembodiment, a compound of Formula XVIII, or its pharmaceutically acceptable salt or prodrug, is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R1 is independently H or phosphate; (3) R6 is alkyl; (4) R7 and R9 are independently OR2; (5) R8 is H; and (6) X is O.
In even more preferred subembodiments, a compound of Formula XVIII, or its pharmaceutically acceptable salt or prodrug, is provided in which:
(1) Base is adenine; (2) R1 is hydrogen; (3) R6 is methyl; (4) R7 and R9 are hydroxyl; (5) R1 is hydrogen; and (6) X is O;
(1) Base is guanine; (2) R1 is hydrogen; (3) R6 is methyl; (4) R7 and R9 are hydroxyl; (5) R8 is hydrogen; and (6) X is O;
(1) Base is cytosine; (2) R1 is hydrogen; (3) R6 is methyl; (4) R7 and R9 are hydroxyl; (5) R8 is hydrogen; and (6) X is O;
(1) Base is thymine; (2) R1 is hydrogen; (3) R6 is methyl; (4) R7 and R9 are hydroxyl; (5) R8 is hydrogen; and (6) X is O;
(1) Base is uracil; (2) R1 is hydrogen; (3) R6 is methyl; (4) R7 and R9 are hydroxyl; (5) R8 is hydrogen; and (6) X is O;
(1) Base is adenine; (2) R1 is phosphate; (3) R6 is methyl; (4) R7 and R9 are hydroxyl; (5) R8 is hydrogen; and (6) X is O;
(1) Base is adenine; (2) R1 is hydrogen; (3) R6 is ethyl; (4) R7 and R9 are hydroxyl; (5) R8 is hydrogen; and (6) X is O;
(1) Base is adenine; (2) R1 is hydrogen; (3) R6 is propyl; (4) R7 and R9 are hydroxyl; (5) R8 is hydrogen; and (6) X is O;
(1) Base is adenine; (2) R1 is hydrogen; (3) R6 is butyl; (4) R7 and R9 are hydroxyl; (5) R1 is hydrogen; and (6) X is O;
(1) Base is adenine; (2) R1 is hydrogen; (3) R6 is methyl; (4) R7 and R9 are hydroxyl; (5) R8 is hydrogen; and (6) X is S;
(1) Base is adenine; (2) R1 is hydrogen; (3) R6 is methyl; (4) R7 and R9 are hydroxyl; (5) R8 is hydrogen; and (6) X is SO2; or
(1) Base is adenine; (2) R1 is hydrogen; (3) R6 is methyl; (4) R7 and R9 are hydroxyl; (5) R8 is hydrogen; and (6) X is CH2.
The β-D- and β-L-nucleosides of this invention belong to a class of anti-flavivirus or pestivirus agents that may inhibit flavivirus or pestivirus polymerase activity. Nucleosides can be screened for their ability to inhibit flavivirus or pestivirus polymerase activity in vitro according to screening methods set forth more particularly herein. One can readily determine the spectrum of activity by evaluating the compound in the assays described herein or with another confirmatory assay.
In one embodiment the efficacy of the anti-flavivirus or pestivirus compound is measured according to the concentration of compound necessary to reduce the plaque number of the virus in vitro, according to methods set forth more particularly herein, by 50% (i.e. the compound's EC50). In preferred embodiments the compound exhibits an EC50 of less than 15 or 10 micromolar.
HCV is a member of the Flaviviridae family; however, now, HCV has been placed in a new monotypic genus, hepacivirus. Therefore, in one embodiment, the flavivirus or pestivirus is not HCV.
The active compound can be administered as any salt or prodrug that upon administration to the recipient is capable of providing directly or indirectly the parent compound, or that exhibits activity itself. Nonlimiting examples are the pharmaceutically acceptable salts (alternatively referred to as “physiologically acceptable salts”), and a compound, which has been alkylated or acylated at the 5′-position, or on the purine or pyrimidine base (a type of “pharmaceutically acceptable prodrug”). Further, the modifications can affect the biological activity of the compound, in some cases increasing the activity over the parent compound. This can easily be assessed by preparing the salt or prodrug and testing its antiviral activity according to the methods described herein, or other methods known to those skilled in the art.
II. Definitions
The term alkyl, as used herein, unless otherwise specified, refers to a saturated straight, branched, or cyclic, primary, secondary, or tertiary hydrocarbon of typically C1 to C10, and specifically includes methyl, trifluoromethyl, ethyl, propyl, isopropyl, cyclopropyl, butyl, isobutyl, t-butyl, pentyl, cyclopentyl, isopentyl, neopentyl, hexyl, isohexyl, cyclohexyl, cyclohexylmethyl, 3-methylpentyl, 2,2-dimethylbutyl, and 2,3-dimethylbutyl. The term includes both substituted and unsubstituted alkyl groups. Moieties with which the alkyl group can be substituted are selected from the group consisting of hydroxyl, amino, alkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, sulfonic acid, sulfate, phosphonic acid, phosphate, or phosphonate, either unprotected, or protected as necessary, as known to those skilled in the art, for example, as taught in Greene, et al., Protective Groups in Organic Synthesis, John Wiley and Sons, Second Edition, 1991, hereby incorporated by reference.
The term lower alkyl, as used herein, and unless otherwise specified, refers to a C1 to C4 saturated straight, branched, or if appropriate, a cyclic (for example, cyclopropyl) alkyl group, including both substituted and unsubstituted forms. Unless otherwise specifically stated in this application, when alkyl is a suitable moiety, lower alkyl is preferred. Similarly, when alkyl or lower alkyl is a suitable moiety, unsubstituted alkyl or lower alkyl is preferred.
The term alkylamino or arylamino refers to an amino group that has one or two alkyl or aryl substituents, respectively.
The term “protected” as used herein and unless otherwise defined refers to a group that is added to an oxygen, nitrogen, or phosphorus atom to prevent its further reaction or for other purposes. A wide variety of oxygen and nitrogen protecting groups are known to those skilled in the art of organic synthesis.
The term aryl, as used herein, and unless otherwise specified, refers to phenyl, biphenyl, or naphthyl, and preferably phenyl. The term includes both substituted and unsubstituted moieties. The aryl group can be substituted with one or more moieties selected from the group consisting of hydroxyl, amino, alkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, sulfonic acid, sulfate, phosphonic acid, phosphate, or phosphonate, either unprotected, or protected as necessary, as known to those skilled in the art, for example, as taught in Greene, et al., Protective Groups in Organic Synthesis, John Wiley and Sons, Second Edition, 1991.
The term alkaryl or alkylaryl refers to an alkyl group with an aryl substituent. The term aralkyl or arylalkyl refers to an aryl group with an alkyl substituent.
The term halo, as used herein, includes chloro, bromo, iodo, and fluoro.
The term purine or pyrimidine base includes, but is not limited to, adenine, N6-alkylpurines, N6-acylpurines (wherein acyl is C(O)(alkyl, aryl, alkylaryl, or arylalkyl), N6-benzylpurine, N6-halopurine, N6-vinylpurine, N6-acetylenic purine, N6-acyl purine, N6-hydroxyalkyl purine, N6-thioalkyl purine, N2-alkylpurines, N2-alkyl-6-thiopurines, thymine, cytosine, 5-fluorocytosine, 5-methylcytosine, 6-azapyrimidine, including 6-azacytosine, 2- and/or 4-mercaptopyrmidine, uracil, 5-halouracil, including 5-fluorouracil, C5-alkylpyrimidines, C5-benzylpyrimidines, C5-halopyrimidines, C5-vinylpyrimidine, C5-acetylenic pyrimidine, C5-acyl pyrimidine, C5-hydroxyalkyl purine, C5-amidopyrimidine, C5-cyanopyrimidine, C5-nitropyrimidine, C5-aminopyrimidine, N2-alkylpurines, N2-alkyl-6-thiopurines, 5-azacytidinyl, 5-azauracilyl, triazolopyridinyl, imidazolopyridinyl, pyrrolopyrimidinyl, and pyrazolo-pyrimidinyl. Purine bases include, but are not limited to, guanine, adenine, hypoxanthine, 2,6-diaminopurine, and 6-chloropurine. Functional oxygen and nitrogen groups on the base can be protected as necessary or desired. Suitable protecting groups are well known to those skilled in the art, and include trimethylsilyl, dimethylhexylsilyl, t-butyldimethylsilyl and t-butyldiphenylsilyl, trityl, alkyl groups, and acyl groups such as acetyl and propionyl, methanesulfonyl, and p-toluenesulfonyl. Alternatively, the purine or pyrimidine base can optionally substituted such that it forms a viable prodrug, which can be cleaved in vivo. Examples of appropriate substituents include acyl moiety, an amine or cyclopropyl (e.g., 2-amino, 2,6-diamino or cyclopropyl guanosine).
The term acyl refers to a carboxylic acid ester in which the non-carbonyl moiety of the ester group is selected from straight, branched, or cyclic alkyl or lower alkyl, alkoxyalkyl including methoxymethyl, aralkyl including benzyl, aryloxyalkyl such as phenoxymethyl, aryl including phenyl optionally substituted with halogen, C1 to C4 alkyl or C1 to C4 alkoxy, sulfonate esters such as alkyl or aralkyl sulphonyl including methanesulfonyl, the mono, di or triphosphate ester, trityl or monomethoxytrityl, substituted benzyl, trialkylsilyl (e.g. dimethyl-t-butylsilyl) or diphenylmethylsilyl. Aryl groups in the esters optimally comprise a phenyl group. The term “lower acyl” refers to an acyl group in which the non-carbonyl moiety is lower alkyl.
As used herein, the term “substantially free of” or “substantially in the absence of” refers to a nucleoside composition that includes at least 85 or 90% by weight, preferably 95% to 98% by weight, and even more preferably 99% to 100% by weight, of the designated enantiomer of that nucleoside. In a preferred embodiment, in the methods and compounds of this invention, the compounds are substantially free of enantiomers.
Similarly, the term “isolated” refers to a nucleoside composition that includes at least 85 or 90% by weight, preferably 95% to 98% by weight, and even more preferably 99% to 100% by weight, of the nucleoside, the remainder comprising other chemical species or enantiomers.
The term “independently” is used herein to indicate that the variable, which is independently applied, varies independently from application to application. Thus, in a compound such as R″XYR″, wherein R″ is “independently carbon or nitrogen,” both R″ can be carbon, both R″ can be nitrogen, or one R″ can be carbon and the other R″ nitrogen.
The term host, as used herein, refers to an unicellular or multicellular organism in which the virus can replicate, including cell lines and animals, and preferably a human. Alternatively, the host can be carrying a part of the flavivirus or pestivirus genome, whose replication or function can be altered by the compounds of the present invention. The term host specifically refers to infected cells, cells transfected with all or part of the flavivirus or pestivirus genome and animals, in particular, primates (including chimpanzees) and humans. In most animal applications of the present invention, the host is a human patient. Veterinary applications, in certain indications, however, are clearly anticipated by the present invention (such as chimpanzees).
The term “pharmaceutically acceptable salt or prodrug” is used throughout the specification to describe any pharmaceutically acceptable form (such as an ester, phosphate ester, salt of an ester or a related group) of a nucleoside compound which, upon administration to a patient, provides the nucleoside compound. Pharmaceutically acceptable salts include those derived from pharmaceutically acceptable inorganic or organic bases and acids. Suitable salts include those derived from alkali metals such as potassium and sodium, alkaline earth metals such as calcium and magnesium, among numerous other acids well known in the pharmaceutical art. Pharmaceutically acceptable prodrugs refer to a compound that is metabolized, for example hydrolyzed or oxidized, in the host to form the compound of the present invention. Typical examples of prodrugs include compounds that have biologically labile protecting groups on a functional moiety of the active compound. Prodrugs include compounds that can be oxidized, reduced, aminated, deaminated, hydroxylated, dehydroxylated, hydrolyzed, dehydrolyzed, alkylated, dealkylated, acylated, deacylated, phosphorylated, dephosphorylated to produce the active compound. The compounds of this invention possess antiviral activity against flavivirus or pestivirus, or are metabolized to a compound that exhibits such activity.
III. Nucleotide Salt or Prodrug Formulations
In cases where compounds are sufficiently basic or acidic to form stable nontoxic acid or base salts, administration of the compound as a pharmaceutically acceptable salt may be appropriate. Examples of pharmaceutically acceptable salts are organic acid addition salts formed with acids, which form a physiological acceptable anion, for example, tosylate, methanesulfonate, acetate, citrate, malonate, tartarate, succinate, benzoate, ascorbate, α-ketoglutarate, and α-glycerophosphate. Suitable inorganic salts may also be formed, including, sulfate, nitrate, bicarbonate, and carbonate salts.
Pharmaceutically acceptable salts may be obtained using standard procedures well known in the art, for example by reacting a sufficiently basic compound such as an amine with a suitable acid affording a physiologically acceptable anion. Alkali metal (for example, sodium, potassium or lithium) or alkaline earth metal (for example calcium) salts of carboxylic acids can also be made.
Any of the nucleosides described herein can be administered as a nucleotide prodrug to increase the activity, bioavailability, stability or otherwise alter the properties of the nucleoside. A number of nucleotide prodrug ligands are known. In general, alkylation, acylation or other lipophilic modification of the mono, di or triphosphate of the nucleoside will increase the stability of the nucleotide. Examples of substituent groups that can replace one or more hydrogens on the phosphate moiety are alkyl, aryl, steroids, carbohydrates, including sugars, 1,2-diacylglycerol and alcohols. Many are described in R. Jones and N. Bischofberger, Antiviral Research, 27 (1995) 1-17. Any of these can be used in combination with the disclosed nucleosides to achieve a desired effect.
The active nucleoside can also be provided as a 5′-phosphoether lipid or a 5′-ether lipid, as disclosed in the following references, which are incorporated by reference herein: Kucera, L. S., N. Iyer, E. Leake, A. Raben, Modest E. K., D. L. W., and C. Piantadosi, “Novel membrane-interactive ether lipid analogs that inhibit infectious HIV-1 production and induce defective virus formation,” AIDS Res. Hum. Retro Viruses, 1990, 6, 491-501; Piantadosi, C., J. Marasco C. J., S. L. Morris-Natschke, K. L. Meyer, F. Gumus, J. R. Surles, K. S. Ishaq, L. S. Kucera, N. Iyer, C. A. Wallen, S. Piantadosi, and E. J. Modest, “Synthesis and evaluation of novel ether lipid nucleoside conjugates for anti-HIV activity,” J. Med. Chem., 1991, 34, 1408-1414; Hosteller, K. Y., D. D. Richman, D. A. Carson, L. M. Stuhmiller, G. M. T. van Wijk, and H. van den Bosch, “Greatly enhanced inhibition of human immunodeficiency virus type I replication in CEM and HT4-6C cells by 3′-deoxythymidine diphosphate dimyristoylglycerol, a lipid prodrug of 3-deoxythymidine,” Antimicrob. Agents Chemother., 1992, 36, 2025-2029; Hosetler, K. Y., L. M. Stuhmiller, H. B. Lenting, H. van den Bosch, and D. D. Richman, “Synthesis and antiretroviral activity of phospholipid analogs of azidothymidine and other antiviral nucleosides.” J. Biol. Chem., 1990, 265, 61127.
Nonlimiting examples of U.S. patents that disclose suitable lipophilic substituents that can be covalently incorporated into the nucleoside, preferably at the 5′-OH position of the nucleoside or lipophilic preparations, include U.S. Pat. No. 5,149,794 (Sep. 22, 1992, Yatvin et al.); U.S. Pat. No. 5,194,654 (Mar. 16, 1993, Hostetler et al., U.S. Pat. No. 5,223,263 (Jun. 29, 1993, Hostetler et al.); U.S. Pat. No. 5,256,641 (Oct. 26, 1993, Yatvin et al.); U.S. Pat. No. 5,411,947 (May 2, 1995, Hostetler et al.); U.S. Pat. No. 5,463,092 (Oct. 31, 1995, Hostetler et al.); U.S. Pat. No. 5,543,389 (Aug. 6, 1996, Yatvin et al.); U.S. Pat. No. 5,543,390 (Aug. 6, 1996, Yatvin et al.); U.S. Pat. No. 5,543,391 (Aug. 6, 1996, Yatvin et al.); and U.S. Pat. No. 5,554,728 (Sep. 10, 1996; Basava et al.), all of which are incorporated herein by reference. Foreign patent applications that disclose lipophilic substituents that can be attached to the nucleosides of the present invention, or lipophilic preparations, include WO 89/02733, WO 90/00555, WO 91/16920, WO 91/18914, WO 93/00910, WO 94/26273, WO 96/15132, EP 0 350 287, EP 93917054.4, and WO 91/19721.
IV. Combination and Alternation Therapy
It has been recognized that drug-resistant variants of viruses can emerge after prolonged treatment with an antiviral agent. Drug resistance most typically occurs by mutation of a gene that encodes for an enzyme used in viral replication. The efficacy of a drug against flavivirus or pestivirus infection can be prolonged, augmented, or restored by administering the compound in combination or alternation with a second, and perhaps third, antiviral compound that induces a different mutation from that caused by the principle drug. Alternatively, the pharmacokinetics, biodistribution or other parameter of the drug can be altered by such combination or alternation therapy. In general, combination therapy is typically preferred over alternation therapy because it induces multiple simultaneous stresses on the virus.
Nonlimiting examples of antiviral agents that can be used in combination or alternation with the compounds disclosed herein include:
(1) an interferon and/or ribavirin (Battaglia, A. M. et al., Ann. Pharmacother. 34:487-494, 2000); Berenguer, M. et al. Antivir. Ther. 3(Suppl. 3):125-136, 1998);
(2) Substrate-based NS3 protease inhibitors (Attwood et al., Antiviral peptide derivatives, PCT WO 98/22496, 1998; Attwood et al., Antiviral Chemistry and Chemotherapy 10.259-273, 1999; Attwood et al., Preparation and use of amino acid derivatives as anti-viral agents, German Patent Publication DE 19914474; Tung et al. Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease, PCT WO 98/17679), including alphaketoamides and hydrazinoureas, and inhibitors that terminate in an electrophile such as a boronic acid or phosphonate. Llinas-Brunet et al, Hepatitis C inhibitor peptide analogues, PCT WO 99/07734.
(3) Non-substrate-based inhibitors such as 2,4,6-trihydroxy-3-nitro-benzamide derivatives (Sudo K. et al., Biochemical and Biophysical Research Communications, 238:643-647, 1997; Sudo K. et al. Antiviral Chemistry and Chemotherapy 9:186, 1998), including RD3-4082 and RD3-4078, the former substituted on the amide with a 14 carbon chain and the latter processing a para-phenoxyphenyl group;
(4) Thiazolidine derivatives which show relevant inhibition in a reverse-phase HPLC assay with an NS3/4A fusion protein and NS5A/5B substrate (Sudo K. et al., Antiviral Research 32:9-18, 1996), especially compound RD-1-6250, possessing a fused cinnamoyl moiety substituted with a long alkyl chain, RD4 6205 and RD4 6193;
(5) Thiazolidines and benzanilides identified in Kakiuchi N. et al. J. EBS Letters 421:217-220; Takeshita N. et al. Analytical Biochemistry 247:242-246, 1997;
(6) A phenan-threnequinone possessing activity against protease in a SDS-PAGE and autoradiography assay isolated from the fermentation culture broth of Streptomyces sp., Sch 68631 (Chu M. et al., Tetrahedron Letters 37:7229-7232, 1996), and Sch 351633, isolated from the fungus Penicillium griscofuluum, which demonstrates activity in a scintillation proximity assay (Chu M. et al., Bioorganic and Medicinal Chemistry Letters 9:1949-1952);
(7) Selective NS3 inhibitors based on the macromolecule elgin c, isolated from leech (Qasim M. A. et al., Biochemistry 36:1598-1607, 1997);
(8) Helicase inhibitors (Diana G. D. et al., Compounds, compositions and methods for treatment of hepatitis C, U.S. Pat. No. 5,633,358; Diana G. D. et al., Piperidine derivatives, pharmaceutical compositions thereof and their use in the treatment of hepatitis C, PCT WO 97/36554);
(9) Polymerase inhibitors such as nucleotide analogues, gliotoxin (Ferrari R. et al. Journal of Virology 73:1649-1654, 1999), and the natural product cerulenin (Lohmann V. et al., Virology 249:108-118, 1998);
(10) Antisense phosphorothioate oligodeoxynucleotides (S-ODN) complementary to sequence stretches in the 5′ non-coding region (NCR) of the virus (Alt M. et al., Hepatology 22:707-717, 1995), or nucleotides 326-348 comprising the 3′ end of the NCR and nucleotides 371-388 located in the core coding region of the IICV RNA (Alt M. et al., Archives of Virology 142:589-599, 1997; Galderisi U. et al., Journal of Cellular Physiology 181:251-257, 1999);
(11) Inhibitors of IRES-dependent translation (Ikeda N et al., Agent for the prevention and treatment of hepatitis C, Japanese Patent Publication JP-08268890; Kai Y. et al. Prevention and treatment of viral diseases, Japanese Patent Publication JP-10101591);
(12) Nuclease-resistant ribozymes. (Maccjak D. J. et al., Hepatology 30 abstract 995, 1999); and
(13) Other miscellaneous compounds including 1-amino-alkylcyclohexanes (U.S. Pat. No. 6,034,134 to Gold et al.), alkyl lipids (U.S. Pat. No. 5,922,757 to Chojkier et al.), vitamin E and other antioxidants (U.S. Pat. No. 5,922,757 to Chojkier et al,), squalene, amantadine, bile acids (U.S. Pat. No. 5,846,964 to Ozeki et al.), N-(phophonoacetyl)-L-aspartic acid, (U.S. Pat. No. 5,830,905 to Diana et al.), benzendicarboxamides (U.S. Pat. No. 5,633,388 to Diana et al.), polyadenylic acid derivatives (U.S. Pat. No. 5,496,546 to Wang et al.), 2′,3′-dideoxyinosine (U.S. Pat. No. 5,026,687 to Yarchoan et al.), and benzimidazoles (U.S. Pat. No. 5,891,874 to Colacino et al.).
V. Pharamaceutical Compositons
Host, including humans, infected with flavivirus or pestivirus, or a gene fragment thereof can be treated by administering to the patient an effective amount of the active compound or a pharamceutically acceptable prodrug or salt thyereof in the presence of a pharamceutically acceptable carrier or diluent. The active materials can be admistered by any appropriate route, for example, orally, parenterally, intravenously, intradermally, subcutaneously, or topically, in liquid or solid form.
A preferred dose of the compound for flavivirus or pestivirus infection will be in the range from about 1 to 50 mg/kg, preferably 1 to 20 mg/kg, of body weight per day, more generally 0.1 to about 100 mg per kilogram body weight of the recipient per day. The effective dosage range of the pharmaceutically acceptable salts and prodrugs can be calculated based on the weight of the parent nucleoside to be delivered. If the salt or prodrug exhibits activity in itself, the effective doseage can be estimated as above using the weight of the salt or prodrug, or by other means known to those skilled in the art.
The compound is conveniently administered in unit any suitable dosage form, including but not limited to one containing 7 to 3000 mg, preferably 70 to 1400 mg of active ingredient per unit dosage form. A oral dosage of 50-1000 mg is usually convenient,
Ideally the active ingredient should be administered to achieve peak plasma concentrations of the active compound of form about 0.2 to 70 μM, preferably about 1.0 to 10 μM. This may be achieved, for example, by the intravenous injection of a 0.1 to 5% solution of the active ingredient, optionally in saline, or administered as a bolus of the active ingredient.
The concentration of active compound in the drug composition will depend on absorption, inactivation, and excretion rates of the drug as well as other factors known to those of skill in the art. It is to be noted that dosage values will also vary with the severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions, and that the concentration ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed composition. The active ingredient may be administered at once, or may be divided into a number of smaller doses to be administered at varying intervals of time.
A preferred mode of administration of the active compound is oral. Oral compositions will generally include an inert diluent or an edible carrier. They may be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches or capsules. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition.
The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring. When the dosage unit form is a capsule, it can contain, in addition to material of the above type, a liquid carrier such as a fatty oil. In addition, dosage unit forms can contain various other materials which modify the physical form of the dosage unit, for example, coatings of sugar, shellac, or other enteric agents.
The compound can be administered as a component of an elixir, suspension, syrup, wafer, chewing gum or the like. A syrup may contain, in addition to the active compounds, sucrose as a sweetening agent and certain preservatives, dyes and colorings and flavors.
The compound or a pharmaceutically acceptable prodrug or salts thereof can also be mixed with other active materials that do not impair the desired action, or with materials that supplement the desired action, such as antibiotics, antifungals, anti-inflammatories, or other antivirals, including other nucleoside compounds. Solutions or suspensions used for parenteral, intradermal, subcutaneous, or topical application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. The parental preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
If administered intravenously, preferred carriers are physiological saline or phosphate buffered saline-(PBS).
In a preferred embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be obtained commercially from Alza Corporation.
Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) are also preferred as pharmaceutically acceptable carriers. These may be prepared according to methods known to those skilled in the art, for example, as described in U.S. Pat. No. 4,522,811 (which is incorporated herein by reference in its entirety). For example, liposome formulations may be prepared by dissolving appropriate lipid(s) (such as stearoyl phosphatidyl ethanolamine, stearoyl phosphatidyl choline, arachadoyl phosphatidyl choline, and cholesterol) in an inorganic solvent that is then evaporated, leaving behind a thin film of dried lipid on the surface of the container. An aqueous solution of the active compound or its monophosphate, diphosphate, and/or triphosphate derivatives is then introduced into the container. The container is then swirled by hand to free lipid material from the sides of the container and to disperse lipid aggregates, thereby forming the liposomal suspension.
VI. Processes for the Preparation of Active Compounds
The nucleosides of the present invention can be synthesized by any means known in the art. In particular, the synthesis of the present nucleosides can be achieved by either alkylating the appropriately modified sugar, followed by glycosylation or glycosylation followed by alkylation of the nucleoside. The following non-limiting embodiments illustrate some general methodology to obtain the nucleosides of the present invention.
A. General Synthesis of 1′-C-Branched Nucleosides
1′-C-Branched ribonucleosides of the following structure:
- wherein BASE is a purine or pyrimidine base as defined herein;
- R7 and R9 are independently hydrogen, OR2, hydroxy, alkyl (including lower alkyl), azido, cyano, alkenyl, alkynyl, Br-vinyl, —C(O)O(alkyl), —C(O)O(lower alkyl), —O(acyl), —O(lower acyl), —O(alkyl), —O(lower alkyl), —O(alkenyl), chlorine, bromine, iodine, NO2, NH2, —NH(lower alkyl), —NH(acyl), —N(lower alkyl)2, —N(acyl)2;
- R8 and R10 are independently H, alkyl (including lower alkyl), chlorine, bromine or iodine; alternatively, R7 and R9, R7 and R10, R8 and R9, or R8 and R10 can come together to form a pi bond;
- R1 and R2 are independently H; phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1 is independently H or phosphate;
- R6 is an alkyl, halogeno-alkyl (i.e. CF3), alkenyl, or alkynyl (i.e. allyl); and
- X is O, S, SO2 or CH2
- can be prepared by one of the following general methods.
1) Modification from the Lactone
The key starting material for this process is an appropriately substituted lactone. The lactone can be purchased or can be prepared by any known means including standard epimerization, substitution and cyclization techniques. The lactone can be optionally protected with a suitable protecting group, preferably with an acyl or silyl group, by methods well known to those skilled in the art, as taught by Greene et al. Protective Groups in Organic Synthesis, John Wiley and Sons, Second Edition, 1991. The protected lactone can then be coupled with a suitable coupling agent, such as an organometallic carbon nucleophile, such as a Grignard reagent, an organolithium, lithium dialkyl copper or R6—SiMe3 in TBAF with the appropriate non-protic solvent at a suitable temperature, to give the 1′-alkylated sugar.
The optionally activated sugar can then be coupled to the BASE by methods well known to those skilled in the art, as taught by Townsend Chemistry of Nucleosides and Nucleotides, Plenum Press, 1994. For example, an acylated sugar can be coupled to a silylated base with a lewis acid, such as tin tetrachloride, titanium tetrachloride or trimethylsilyltriflate in the appropriate solvent at a suitable temperature.
Subsequently, the nucleoside can be deprotected by methods well known to those skilled in the art, as taught by Greene et al. Protective Groups in Organic Synthesis, John Wiley and Sons, Second Edition, 1991.
In a particular embodiment, the 1′-C-branched ribonucleoside is desired. The synthesis of a ribonucleoside is shown in Scheme 1. Alternatively, deoxyribo-nucleoside is desired. To obtain these nucleosides, the formed ribonucleoside can optionally be protected by methods well known to those skilled in the art, as taught by Greene et al. Protective Groups in Organic Synthesis, John Wiley and Sons, Second Edition, 1991, and then the 2′-OH can be reduced with a suitable reducing agent. Optionally, the 2′-hydroxyl can be activated to facilitate reduction; i.e. via the Barton reduction.
The key starting material for this process is an appropriately substituted hexose. The hexose can be purchased or can be prepared by any known means including standard epimerization (e.g. via alkaline treatment), substitution and coupling techniques. The hexose can be selectively protected to give the appropriate hexa-furanose, as taught by Townsend Chemistry of Nucleosides and Nucleotides, Plenum Press, 1994.
The 1′-hydroxyl can be optionally activated to a suitable leaving group such as an acyl group or a halogen via acylation or halogenation, respectively. The optionally activated sugar can then be coupled to the BASE by methods well known to those skilled in the art, as taught by Townsend Chemistry of Nucleosides and Nucleotides, Plenum Press, 1994. For example, an acylated sugar can be coupled to a silylated base with a lewis acid, such as tin tetrachloride, titanium tetrachloride or trimethylsilyltriflate in the appropriate solvent at a suitable temperature. Alternatively, a halo-sugar can be coupled to a silylated base with the presence of trimethylsilyltriflate.
The 1′-CH2—OH, if protected, can be selectively deprotected by methods well known in the art. The resultant primary hydroxyl can be functionalized to yield various C-branched nucleosides. For example, the primary hydroxyl can be reduced to give the methyl, using a suitable reducing agent. Alternatively, the hydroxyl can be activated prior to reduction to facilitate the reaction; i.e. via the Barton reduction. In an alternate embodiment, the primary hydroxyl can be oxidized to the aldehyde, then coupled with a carbon nucleophile, such as a Grignard reagent, an organolithium, lithium dialkyl copper or R6—SiMe3 in TBAF with the appropriate non-protic solvent at a suitable temperature.
In a particular embodiment, the 1′-C-branched ribonucleoside is desired. The synthesis of a ribonucleoside is shown in Scheme 2. Alternatively, deoxyribo-nucleoside is desired. To obtain these nucleosides, the formed ribonucleoside can optionally be protected by methods well known to those skilled in the art, as taught by Greene et al. Protective Groups in Organic Synthesis, John Wiley and Sons, Second Edition, 1991, and then the 2′-OH can be reduced with a suitable reducing agent. Optionally, the 2′-hydroxyl can be activated to facilitate reduction; i.e. via the Barton reduction.
In addition, the L-enantiomers corresponding to the compounds of the invention can be prepared following the same general methods (1 or 2), beginning with the corresponding L-sugar or nucleoside L-enantiomer as starting material.
B. General Synthesis of 2′-C-Branched Nucleosides
2′-C-Branched ribonucleosides of the following structure:
- R7 and R9 are independently hydrogen, OR2, hydroxy, alkyl (including lower alkyl), azido, cyano, alkenyl, alkynyl, Br-vinyl, —C(O)O(alkyl), —C(O)O(lower alkyl), —O(acyl), —O(lower acyl), —O(alkyl), —O(lower alkyl), —O(alkenyl), chlorine, bromine, iodine, NO2, NH2, —NH(lower alkyl), —NH(acyl), —N(lower alkyl)2, —N(acyl)2;
- R10 is H, alkyl (including lower alkyl), chlorine, bromine or iodine;
- alternatively, R7 and R9, or R7 and R10 can come together to form a pi bond;
- R1 and R2 are independently H; phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1 is independently H or phosphate;
- R6 is an alkyl, halogeno-alkyl (i.e. CF3), alkenyl, or alkynyl (i.e. allyl); and
- X is OS, SO2 or CH2
- can be prepared by one of the following general methods.
1. Glycosylation of the Nucleobase with an Appropriately Modified Sugar
The key starting material for this process is an appropriately substituted sugar with a 2′-OH and 2′-H, with the appropriate leaving group (LG), for example an acyl group or a halogen. The sugar can be purchased or can be prepared by any known means including standard epimerization, substitution, oxidation and reduction techniques. The substituted sugar can then be oxidized with the appropriate oxidizing agent in a compatible solvent at a suitable temperature to yield the 2′-modified sugar. Possible oxidizing agents are Jones reagent (a mixture of chromic acid and sulfuric acid), Collins's reagent (dipyridine Cr(VI) oxide, Corey's reagent (pyridinium chlorochromate), pyridinium dichromate, acid dichromate, potassium permanganate, MnO2, ruthenium tetroxide, phase transfer catalysts such as chromic acid or permanganate supported on a polymer, Cl2-pyridine, H2O2-ammonium molybdate, NaBrO2—CAN, NaOCl in HOAc, copper chromite, copper oxide, Raney nickel, palladium acetate, Meerwin-Pondorf-Verley reagent (aluminum t-butoxide with another ketone) and N-bromosuccinimide.
Then coupling of an organometallic carbon nucleophile, such as a Grignard reagent, an organolithium, lithium dialkyl copper or R6—SiMe3 in TBAF with the ketone with the appropriate non-protic solvent at a suitable temperature, yields the 2′-alkylated sugar. The alkylated sugar can be optionally protected with a suitable protecting group, preferably with an acyl or silyl group, by methods well known to those skilled in the art, as taught by Greene et al. Protective Groups in Organic Synthesis, John Wiley and Sons, Second Edition, 1991.
The optionally protected sugar can then be coupled to the BASE by methods well known to those skilled in the art, as taught by Townsend Chemistry of Nucleosides and Nucleotides, Plenum Press, 1994. For example, an acylated sugar can be coupled to a silylated base with a lewis acid, such as tin tetrachloride, titanium tetrachloride or trimethylsilyltriflate in the appropriate solvent at a suitable temperature. Alternatively, a halo-sugar can be coupled to a silylated base with the presence of trimethylsilyltriflate.
Subsequently, the nucleoside can be deprotected by methods well known to those skilled in the art, as taught by Greene et al. Protective Groups in Organic Synthesis, John Wiley and Sons, Second Edition, 1991.
In a particular embodiment, the 2′-C-branched ribonucleoside is desired. The synthesis of a ribonucleoside is shown in Scheme 3. Alternatively, deoxyribo-nucleoside is desired. To obtain these nucleosides, the formed ribonucleoside can optionally be protected by methods well known to those skilled in the art, as taught by Greene et al. Protective Groups in Organic Synthesis, John Wiley and Sons, Second Edition, 1991, and then the 2′-OH can be reduced with a suitable reducing agent. Optionally, the 2′-hydroxyl can be activated to facilitate reduction; i.e. via the Barton reduction.
The key starting material for this process is an appropriately substituted nucleoside with a 2′-OH and 2′-H. The nucleoside can be purchased or can be prepared by any known means including standard coupling techniques. The nucleoside can be optionally protected with suitable protecting groups, preferably with acyl or silyl groups, by methods well known to those skilled in the art, as taught by Greene et al. Protective Groups in Organic Synthesis, John Wiley and Sons, Second Edition, 1991.
The appropriately protected nucleoside can then be oxidized with the appropriate oxidizing agent in a compatible solvent at a suitable temperature to yield the 2′-modified sugar. Possible oxidizing agents are Jones reagent (a mixture of chromic acid and sulfuric acid), Collins's reagent (dipyridine Cr(VI) oxide, Corey's reagent (pyridinium chlorochromate), pyridinium dichromate, acid dichromate, potassium permanganate, MnO2, ruthenium tetroxide, phase transfer catalysts such as chromic acid or permanganate supported on a polymer, Cl2-pyridine, H2O2-ammonium molybdate, NaBrO2—CAN, NaOCl in HOAc, copper chromite, copper oxide, Raney nickel, palladium acetate, Meerwin-Pondorf-Verley reagent (aluminum t-butoxide with another ketone) and N-bromosuccinimide.
Subsequently, the nucleoside can be deprotected by methods well known to those skilled in the art, as taught by Greene Greene et al. Protective Groups in Organic Synthesis, John Wiley and Sons, Second Edition, 1991.
In a particular embodiment, the 2′-C-branched ribonucleoside is desired. The synthesis of a ribonucleoside is shown in Scheme 4. Alternatively, deoxyribo-nucleoside is desired. To obtain these nucleosides, the formed ribonucleoside can optionally be protected by methods well known to those skilled in the art, as taught by Greene et al. Protective Groups in Organic Synthesis, John Wiley and Sons, Second Edition, 1991, and then the 2′-OH can be reduced with a suitable reducing agent. Optionally, the 2′-hydroxyl can be activated to facilitate reduction; i.e. via the Barton reduction.
In another embodiment of the invention, the L-enantiomers are desired. Therefore, the L-enantiomers can be corresponding to the compounds of the invention can be prepared following the same foregoing general methods, beginning with the corresponding L-sugar or nucleoside L-enantiomer as starting material.
C. General Synthesis of 3′-C-Branched Nucleosides
3′-C-Branched ribonucleosides of the following structure:
- R7 and R9 are independently hydrogen, OR2, hydroxy, alkyl (including lower alkyl), azido, cyano, alkenyl, alkynyl, Br-vinyl, —C(O)O(alkyl), —C(O)O(lower alkyl), —O(acyl), —O(lower acyl), —O(alkyl), —O(lower alkyl), —O(alkenyl), chlorine, bromine, iodine, NO2, NH2, —NH(lower alkyl), —NH(acyl), —N(lower alkyl)2, —N(acyl)2;
- R8 is H, alkyl (including lower alkyl), chlorine, bromine or iodine;
- alternatively, R7 and R9, or R8 and R9 can come together to form a pi bond;
- R1 and R2 are independently H; phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1 is independently H or phosphate;
- R6 is an alkyl, halogeno-alkyl (i.e. CF3), alkenyl, or alkynyl (i.e. allyl); and
- X is O, S, SO2 or CH2
- can be prepared by one of the following general methods.
1 Glycosylation of the Nucleobase with an Appropriately Modified Sugar
The key starting material for this process is an appropriately substituted sugar with a 3′-OH and 3′-H, with the appropriate leaving group (LG), for example an acyl group or a halogen. The sugar can be purchased or can be prepared by any known means including standard epimerization, substitution, oxidation and reduction techniques. The substituted sugar can then be oxidized with the appropriate oxidizing agent in a compatible solvent at a suitable temperature to yield the 3′-modified sugar. Possible oxidizing agents are Jones reagent (a mixture of chromic acid and sulfuric acid), Collins's reagent (dipyridine Cr(VI) oxide, Corey's reagent (pyridinium chlorochromate), pyridinium dichromate, acid dichromate, potassium permanganate, MnO2, ruthenium tetroxide, phase transfer catalysts such as chromic acid or permanganate supported on a polymer, Cl2-pyridine, H2O2-ammonium molybdate, NaBrO2—CAN, NaOCl in HOAc, copper chromite, copper oxide, Raney nickel, palladium acetate, Meerwin-Pondorf-Verley reagent (aluminum t-butoxide with another ketone) and N-bromosuccinimide.
Then coupling of an organometallic carbon nucleophile, such as a Grignard reagent, an organolithium, lithium dialkyl copper or R6—SiMe3 in TBAF with the ketone with the appropriate non-protic solvent at a suitable temperature, yields the 3′-C-branched sugar. The 3′-C-branched sugar can be optionally protected with a suitable protecting group, preferably with an acyl or silyl group, by methods well known to those skilled in the art, as taught by Greene-et al. Protective Groups in Organic Synthesis, John Wiley and Sons, Second Edition, 1991.
The optionally protected sugar can then be coupled to the BASE by methods well known to those skilled in the art, as taught by Townsend Chemistry of Nucleosides and Nucleotides, Plenum Press; 1994. For example, an acylated sugar can be coupled to a silylated base with a lewis acid, such as tin tetrachloride, titanium tetrachloride or trimethylsilyltriflate in the appropriate solvent at a suitable temperature. Alternatively, a halo-sugar can be coupled to a silylated base with the presence of trimethylsilyltriflate.
Subsequently, the nucleoside can be deprotected by methods well known to those skilled in the art, as taught by Greene et al. Protective Groups in Organic Synthesis, John Wiley and Sons, Second Edition, 1991.
In a particular embodiment, the 3′-C-branched ribonucleoside is desired. The synthesis of a ribonucleoside is shown in Scheme 5. Alternatively, deoxyribo-nucleoside is desired. To obtain these nucleosides, the formed ribonucleoside can optionally be protected by methods well known to those skilled in the art, as taught by Greene et al. Protective Groups in Organic Synthesis, John Wiley and Sons, Second Edition, 1991, and then the 2′-OH can be reduced with a suitable reducing agent. Optionally, the 2′-hydroxyl can be activated to facilitate reduction; i.e. via the Barton reduction.
The key starting material for this process is an appropriately substituted nucleoside with a 3′-OH and 3′-H. The nucleoside can be purchased or can be prepared by any known means including standard coupling techniques. The nucleoside can be optionally protected with suitable protecting groups, preferably with acyl or silyl groups, by methods well known to those skilled in the art, as taught by Greene et al. Protective Groups in Organic Synthesis, John Wiley and Sons, Second Edition, 1991.
The appropriately protected nucleoside can then be oxidized with the appropriate oxidizing agent in a compatible solvent at a suitable temperature to yield the 2′-modified sugar. Possible oxidizing agents are Jones reagent (a mixture of chromic acid and sulfuric acid), Collins's reagent (dipyridine Cr(VI) oxide, Corey's reagent (pyridinium chlorochromate), pyridinium dichromate, acid dichromate, potassium permanganate, MnO2, ruthenium tetroxide, phase transfer catalysts such as chromic acid or permanganate supported on a polymer, Cl2-pyridine, H2O2-ammonium molybdate, NaBrO2—CAN, NaOCl in HOAc, copper chromite, copper oxide, Raney nickel, palladium acetate, Meerwin-Pondorf-Verley reagent (aluminum t-butoxide with another ketone) and N-bromosuccinimide.
Subsequently, the nucleoside can be deprotected by methods well known to those skilled in the art, as taught by Greene et al. Protective Groups in Organic Synthesis, John Wiley and Sons, Second Edition, 1991.
In a particular embodiment, the 3′-C-branched ribonucleoside is desired. The synthesis of a ribonucleoside is shown in Scheme 6. Alternatively, deoxyribo-nucleoside is desired. To obtain these nucleosides, the formed ribonucleoside can optionally be protected by methods well known to those skilled in the art, as taught by Greene et al. Protective Groups in Organic Synthesis, John Wiley and Sons, Second Edition, 1991, and then the 2′-OH can be reduced with a suitable reducing agent. Optionally, the 2′-hydroxyl can be activated to facilitate reduction; i.e. via the Barton reduction.
In another embodiment of the invention, the L-enantiomers are desired. Therefore, the L-enantiomers can be corresponding to the compounds of the invention can be prepared following the same foregoing general methods, beginning with the corresponding L-sugar or nucleoside L-enantiomer as starting material.
The title compound could also be prepared according to a published procedure (J. Farkas, and F. Sorm, “nucleic acid components and their analogues. XCIV. Synthesis of 6-amino-9-(1-deoxy-β-D-psicofuranosyl)purine” Collect. Czech. Chem. Commun. 1967, 32 2663-2667; J. Farkas”, Collect. Czech. Chem. Commun. 1966, 31, 1535) (Scheme 7).
In a similar manner, but using the appropriate sugar and pyrimidine or purine bases, the following nucleosides of Formula I are prepared.
(I) | |
|
|
wherein: | |||||
R1 | R2 | R3 | X1 | X2 | Y |
H | H | H | H | H | H |
H | H | H | H | H | NH2 |
H | H | H | H | H | NH-cyclopropyl |
H | H | H | H | H | NH-methyl |
H | H | H | H | H | NH-ethyl |
H | H | H | H | H | NH-acetyl |
H | H | H | H | H | OH |
H | H | H | H | H | OMe |
H | H | H | H | H | OEt |
H | H | H | H | H | O-cyclopropyl |
H | H | H | H | H | O-acetyl |
H | H | H | H | H | SH |
H | H | H | H | H | SMe |
H | H | H | H | H | SEt |
H | H | H | H | H | S-cyclopropyl |
H | H | H | H | H | F |
H | H | H | H | H | Cl |
H | H | H | H | H | Br |
H | H | H | H | H | I |
monophosphate | H | H | H | H | NH2 |
monophosphate | H | H | H | H | NH-acetyl |
monophosphate | H | H | H | H | NH-cyclopropyl |
monophosphate | H | H | H | H | NH-methyl |
monophosphate | H | H | H | H | NH-ethyl |
monophosphate | H | H | H | H | OH |
monophosphate | H | H | H | H | O-acetyl |
monophosphate | H | H | H | H | OMe |
monophosphate | H | H | H | H | OEt |
monophosphate | H | H | H | H | O-cyclopropyl |
monophosphate | H | H | H | H | SH |
monophosphate | H | H | H | H | SMe |
monophosphate | H | H | H | H | SEt |
monophosphate | H | H | H | H | S-cyclopropyl |
monophosphate | H | H | H | H | F |
monophosphate | H | H | H | H | Cl |
monophosphate | H | H | H | H | Br |
monophosphate | H | H | H | H | I |
diphosphate | H | H | H | H | NH2 |
diphosphate | H | H | H | H | NH-acetyl |
diphosphate | H | H | H | H | NH-cyclopropyl |
diphosphate | H | H | H | H | NH-methyl |
diphosphate | H | H | H | H | NH-ethyl |
diphosphate | H | H | H | H | OH |
diphosphate | H | H | H | H | O-acetyl |
diphosphate | H | H | H | H | OMe |
diphosphate | H | H | H | H | OEt |
diphosphate | H | H | H | H | O-cyclopropyl |
diphosphate | H | H | H | H | SH |
diphosphate | H | H | H | H | SMe |
diphosphate | H | H | H | H | SEt |
diphosphate | H | H | H | H | S-cyclopropyl |
diphosphate | H | H | H | H | F |
diphosphate | H | H | H | H | Cl |
diphosphate | H | H | H | H | Br |
diphosphate | H | H | H | H | I |
triphosphate | H | H | H | H | NH2 |
triphosphate | H | H | H | H | NH-acetyl |
triphosphate | H | H | H | H | NH-cyclopropyl |
triphosphate | H | H | H | H | NH-methyl |
triphosphate | H | H | H | H | NH-ethyl |
triphosphate | H | H | H | H | OH |
triphosphate | H | H | H | H | OMe |
triphosphate | H | H | H | H | OEt |
triphosphate | H | H | H | H | O-cyclopropyl |
triphosphate | H | H | H | H | O-acetyl |
triphosphate | H | H | H | H | SH |
triphosphate | H | H | H | H | SMe |
triphosphate | H | H | H | H | SEt |
triphosphate | H | H | H | H | S-cyclopropyl |
triphosphate | H | H | H | H | F |
triphosphate | H | H | H | H | Cl |
triphosphate | H | H | H | H | Br |
triphosphate | H | H | H | H | I |
monophosphate | monophosphate | monophosphate | H | H | NH2 |
monophosphate | monophosphate | monophosphate | H | H | NH-cyclopropyl |
monophosphate | monophosphate | monophosphate | H | H | OH |
monophosphate | monophosphate | monophosphate | H | H | F |
monophosphate | monophosphate | monophosphate | H | H | Cl |
diphosphate | diphosphate | diphosphate | H | H | NH2 |
diphosphate | diphosphate | diphosphate | H | H | NH-cyclopropyl |
diphosphate | diphosphate | diphosphate | H | H | OH |
diphosphate | diphosphate | diphosphate | H | H | F |
diphosphate | diphosphate | diphosphate | H | H | Cl |
triphosphate | triphosphate | triphosphate | H | H | NH2 |
triphosphate | triphosphate | triphosphate | H | H | NH-cyclopropyl |
triphosphate | triphosphate | triphosphate | H | H | OH |
triphosphate | triphosphate | triphosphate | H | H | F |
triphosphate | triphosphate | triphosphate | H | H | Cl |
H | H | H | F | H | NH2 |
H | H | H | F | H | NH-cyclopropyl |
H | H | H | F | H | OH |
H | H | H | F | H | F |
H | H | H | F | H | Cl |
H | H | H | Cl | H | NH2 |
H | H | H | Cl | H | NH-cyclopropyl |
H | H | H | Cl | H | OH |
H | H | H | Cl | H | F |
H | H | H | Cl | H | Cl |
H | H | H | Br | H | NH2 |
H | H | H | Br | H | NH-cyclopropyl |
H | H | H | Br | H | OH |
H | H | H | Br | H | F |
H | H | H | Br | H | Cl |
H | H | H | NH2 | H | NH2 |
H | H | H | NH2 | H | NH-cyclopropyl |
H | H | H | NH2 | H | OH |
H | H | H | NH2 | H | F |
H | H | H | NH2 | H | Cl |
H | H | H | SH | H | NH2 |
H | H | H | SH | H | NH-cyclopropyl |
H | H | H | SH | H | OH |
H | H | H | SH | H | F |
H | H | H | SH | H | Cl |
acetyl | H | H | H | H | NH2 |
acetyl | H | H | H | H | NH-cyclopropyl |
acetyl | H | H | H | H | OH |
acetyl | H | H | H | H | F |
acetyl | H | H | H | H | Cl |
acetyl | H | H | F | H | NH2 |
acetyl | H | H | F | H | NH-cyclopropyl |
acetyl | H | H | F | H | OH |
acetyl | H | H | F | H | F |
acetyl | H | H | F | H | Cl |
H | acetyl | acetyl | H | H | NH2 |
H | acetyl | acetyl | H | H | NH-cyclopropyl |
H | acetyl | acetyl | H | H | OH |
H | acetyl | acetyl | H | H | F |
H | acetyl | acetyl | H | H | Cl |
acetyl | acetyl | acetyl | H | H | NH2 |
acetyl | acetyl | acetyl | H | H | NH-cyclopropyl |
acetyl | acetyl | acetyl | H | H | OH |
acetyl | acetyl | acetyl | H | H | F |
acetyl | acetyl | acetyl | H | H | Cl |
monophosphate | acetyl | acetyl | H | H | NH2 |
monophosphate | acetyl | acetyl | H | H | NH-cyclopropyl |
monophosphate | acetyl | acetyl | H | H | OH |
monophosphate | acetyl | acetyl | H | H | F |
monophosphate | acetyl | acetyl | H | H | Cl |
diphosphate | acetyl | acetyl | H | H | NH2 |
diphosphate | acetyl | acetyl | H | H | NH-cyclopropyl |
diphosphate | acetyl | acetyl | H | H | OH |
diphosphate | acetyl | acetyl | H | H | F |
diphosphate | acetyl | acetyl | H | H | Cl |
triphosphate | acetyl | acetyl | H | H | NH2 |
triphosphate | acetyl | acetyl | H | H | NH-cyclopropyl |
triphosphate | acetyl | acetyl | H | H | OH |
triphosphate | acetyl | acetyl | H | H | F |
triphosphate | acetyl | acetyl | H | H | Cl |
H | H | H | H | NH2 | H |
H | H | H | H | NH2 | NH2 |
H | H | H | H | NH2 | NH-cyclopropyl |
H | H | H | H | NH2 | NH-methyl |
H | H | H | H | NH2 | NH-ethyl |
H | H | H | H | NH2 | NH-acetyl |
H | H | H | H | NH2 | OH |
H | H | H | H | NH2 | OMe |
H | H | H | H | NH2 | OEt |
H | H | H | H | NH2 | O-cyclopropyl |
H | H | H | H | NH2 | O-acetyl |
H | H | H | H | NH2 | SH |
H | H | H | H | NH2 | SMe |
H | H | H | H | NH2 | SEt |
H | H | H | H | NH2 | S-cyclopropyl |
H | H | H | H | NH2 | F |
H | H | H | H | NH2 | Cl |
H | H | H | H | NH2 | Br |
H | H | H | H | NH2 | I |
monophosphate | H | H | H | NH2 | NH2 |
monophosphate | H | H | H | NH2 | NH-acetyl |
monophosphate | H | H | H | NH2 | NH-cyclopropyl |
monophosphate | H | H | H | NH2 | NH-methyl |
monophosphate | H | H | H | NH2 | NH-ethyl |
monophosphate | H | H | H | NH2 | OH |
monophosphate | H | H | H | NH2 | O-acetyl |
monophosphate | H | H | H | NH2 | OMe |
monophosphate | H | H | H | NH2 | OEt |
monophosphate | H | H | H | NH2 | O-cyclopropyl |
monophosphate | H | H | H | NH2 | SH |
monophosphate | H | H | H | NH2 | SMe |
monophosphate | H | H | H | NH2 | SEt |
monophosphate | H | H | H | NH2 | S-cyclopropyl |
monophosphate | H | H | H | NH2 | F |
monophosphate | H | H | H | NH2 | Cl |
monophosphate | H | H | H | NH2 | Br |
monophosphate | H | H | H | NH2 | I |
diphosphate | H | H | H | NH2 | NH2 |
diphosphate | H | H | H | NH2 | NH-acetyl |
diphosphate | H | H | H | NH2 | NH-cyclopropyl |
diphosphate | H | H | H | NH2 | NH-methyl |
diphosphate | H | H | H | NH2 | NH-ethyl |
diphosphate | H | H | H | NH2 | OH |
diphosphate | H | H | H | NH2 | O-acetyl |
diphosphate | H | H | H | NH2 | OMe |
diphosphate | H | H | H | NH2 | OEt |
diphosphate | H | H | H | NH2 | O-cyclopropyl |
diphosphate | H | H | H | NH2 | SH |
diphosphate | H | H | H | NH2 | SMe |
diphosphate | H | H | H | NH2 | SEt |
diphosphate | H | H | H | NH2 | S-cyclopropyl |
diphosphate | H | H | H | NH2 | F |
diphosphate | H | H | H | NH2 | Cl |
diphosphate | H | H | H | NH2 | Br |
diphosphate | H | H | H | NH2 | I |
triphosphate | H | H | H | NH2 | NH2 |
triphosphate | H | H | H | NH2 | NH-acetyl |
triphosphate | H | H | H | NH2 | NH-cyclopropyl |
triphosphate | H | H | H | NH2 | NH-methyl |
triphosphate | H | H | H | NH2 | NH-ethyl |
triphosphate | H | H | H | NH2 | OH |
triphosphate | H | H | H | NH2 | OMe |
triphosphate | H | H | H | NH2 | OEt |
triphosphate | H | H | H | NH2 | O-cyclopropyl |
triphosphate | H | H | H | NH2 | O-acetyl |
triphosphate | H | H | H | NH2 | SH |
triphosphate | H | H | H | NH2 | SMe |
triphosphate | H | H | H | NH2 | SEt |
triphosphate | H | H | H | NH2 | S-cyclopropyl |
triphosphate | H | H | H | NH2 | F |
triphosphate | H | H | H | NH2 | Cl |
triphosphate | H | H | H | NH2 | Br |
triphosphate | H | H | H | NH2 | I |
monophosphate | monophosphate | monophosphate | H | NH2 | NH2 |
monophosphate | monophosphate | monophosphate | H | NH2 | NH-cyclopropyl |
monophosphate | monophosphate | monophosphate | H | NH2 | OH |
monophosphate | monophosphate | monophosphate | H | NH2 | F |
monophosphate | monophosphate | monophosphate | H | NH2 | Cl |
diphosphate | diphosphate | diphosphate | H | NH2 | NH2 |
diphosphate | diphosphate | diphosphate | H | NH2 | NH-cyclopropyl |
diphosphate | diphosphate | diphosphate | H | NH2 | OH |
diphosphate | diphosphate | diphosphate | H | NH2 | F |
diphosphate | diphosphate | diphosphate | H | NH2 | Cl |
triphosphate | triphosphate | triphosphate | H | NH2 | NH2 |
triphosphate | triphosphate | triphosphate | H | NH2 | NH-cyclopropyl |
triphosphate | triphosphate | triphosphate | H | NH2 | OH |
triphosphate | triphosphate | triphosphate | H | NH2 | F |
triphosphate | triphosphate | triphosphate | H | NH2 | Cl |
H | H | H | F | NH2 | NH2 |
H | H | H | F | NH2 | NH-cyclopropyl |
H | H | H | F | NH2 | OH |
H | H | H | F | NH2 | F |
H | H | H | F | NH2 | Cl |
H | H | H | Cl | NH2 | NH2 |
H | H | H | Cl | NH2 | NH-cyclopropyl |
H | H | H | Cl | NH2 | OH |
H | H | H | Cl | NH2 | F |
H | H | H | Cl | NH2 | Cl |
H | H | H | Br | NH2 | NH2 |
H | H | H | Br | NH2 | NH-cyclopropyl |
H | H | H | Br | NH2 | OH |
H | H | H | Br | NH2 | F |
H | H | H | Br | NH2 | Cl |
H | H | H | NH2 | NH2 | NH2 |
H | H | H | NH2 | NH2 | NH-cyclopropyl |
H | H | H | NH2 | NH2 | OH |
H | H | H | NH2 | NH2 | F |
H | H | H | NH2 | NH2 | Cl |
H | H | H | SH | NH2 | NH2 |
H | H | H | SH | NH2 | NH-cyclopropyl |
H | H | H | SH | NH2 | OH |
H | H | H | SH | NH2 | F |
H | H | H | SH | NH2 | Cl |
acetyl | H | H | H | NH2 | NH2 |
acetyl | H | H | H | NH2 | NH-cyclopropyl |
acetyl | H | H | H | NH2 | OH |
acetyl | H | H | H | NH2 | F |
acetyl | H | H | H | NH2 | Cl |
acetyl | H | H | F | NH2 | NH2 |
acetyl | H | H | F | NH2 | NH-cyclopropyl |
acetyl | H | H | F | NH2 | OH |
acetyl | H | H | F | NH2 | F |
acetyl | H | H | F | NH2 | Cl |
H | H | H | H | Cl | NH-acetyl |
H | H | H | H | Cl | OH |
H | H | H | H | Cl | OMe |
H | H | H | H | Cl | OEt |
H | H | H | H | Cl | O-cyclopropyl |
H | H | H | H | Cl | O-acetyl |
H | H | H | H | Cl | SH |
H | H | H | H | Cl | SMe |
H | H | H | H | Cl | SEt |
H | H | H | H | Cl | S-cyclopropyl |
monophosphate | H | H | H | Cl | NH2 |
monophosphate | H | H | H | Cl | NH-acetyl |
monophosphate | H | H | H | Cl | NH-cyclopropyl |
monophosphate | H | H | H | Cl | NH-methyl |
monophosphate | H | H | H | Cl | NH-ethyl |
monophosphate | H | H | H | Cl | OH |
monophosphate | H | H | H | Cl | O-acetyl |
monophosphate | H | H | H | Cl | OMe |
monophosphate | H | H | H | Cl | OEt |
monophosphate | H | H | H | Cl | O-cyclopropyl |
monophosphate | H | H | H | Cl | SH |
monophosphate | H | H | H | Cl | SMe |
monophosphate | H | H | H | Cl | SEt |
monophosphate | H | H | H | Cl | S-cyclopropyl |
diphosphate | H | H | H | Cl | NH2 |
diphosphate | H | H | H | Cl | NH-acetyl |
diphosphate | H | H | H | Cl | NH-cyclopropyl |
diphosphate | H | H | H | Cl | NH-methyl |
diphosphate | H | H | H | Cl | NH-ethyl |
diphosphate | H | H | H | Cl | OH |
diphosphate | H | H | H | Cl | O-acetyl |
H | acetyl | acetyl | H | NH2 | NH2 |
H | acetyl | acetyl | H | NH2 | NH-cyclopropyl |
H | acetyl | acetyl | H | NH2 | OH |
H | acetyl | acetyl | H | NH2 | F |
H | acetyl | acetyl | H | NH2 | Cl |
acetyl | acetyl | acetyl | H | NH2 | NH2 |
acetyl | acetyl | acetyl | H | NH2 | NH-cyclopropyl |
acetyl | acetyl | acetyl | H | NH2 | OH |
acetyl | acetyl | acetyl | H | NH2 | F |
acetyl | acetyl | acetyl | H | NH2 | Cl |
monophosphate | acetyl | acetyl | H | NH2 | NH2 |
monophosphate | acetyl | acetyl | H | NH2 | NH-cyclopropyl |
monophosphate | acetyl | acetyl | H | NH2 | OH |
monophosphate | acetyl | acetyl | H | NH2 | F |
monophosphate | acetyl | acetyl | H | NH2 | Cl |
diphosphate | acetyl | acetyl | H | NH2 | NH2 |
diphosphate | acetyl | acetyl | H | NH2 | NH-cyclopropyl |
diphosphate | acetyl | acetyl | H | NH2 | OH |
diphosphate | acetyl | acetyl | H | NH2 | F |
diphosphate | acetyl | acetyl | H | NH2 | Cl |
triphosphate | acetyl | acetyl | H | NH2 | NH2 |
triphosphate | acetyl | acetyl | H | NH2 | NH-cyclopropyl |
triphosphate | acetyl | acetyl | H | NH2 | OH |
triphosphate | acetyl | acetyl | H | NH2 | F |
triphosphate | acetyl | acetyl | H | NH2 | Cl |
H | H | H | H | Cl | H |
H | H | H | H | Cl | H |
H | H | H | H | Cl | NH2 |
H | H | H | H | Cl | NH-cyclopropyl |
H | H | H | H | Cl | NH-methyl |
H | H | H | H | Cl | NH-ethyl |
diphosphate | H | H | H | Cl | OMe |
diphosphate | H | H | H | Cl | OEt |
diphosphate | H | H | H | Cl | O-cyclopropyl |
diphosphate | H | H | H | Cl | SH |
diphosphate | H | H | H | Cl | SMe |
diphosphate | H | H | H | Cl | SEt |
diphosphate | H | H | H | Cl | S-cyclopropyl |
triphosphate | H | H | H | Cl | NH2 |
triphosphate | H | H | H | Cl | NiI-acetyl |
triphosphate | H | H | H | Cl | NH-cyclopropyl |
triphosphate | H | H | H | Cl | NH-methyl |
triphosphate | H | H | H | Cl | NH-ethyl |
triphosphate | H | H | H | Cl | OH |
triphosphate | H | H | H | Cl | OMe |
triphosphate | H | H | H | Cl | OEt |
triphosphate | H | H | H | Cl | O-cyclopropyl |
triphosphate | H | H | H | Cl | O-acetyl |
triphosphate | H | H | H | Cl | SH |
triphosphate | H | H | H | Cl | SMe |
triphosphate | H | H | H | Cl | SEt |
triphosphate | H | H | H | Cl | S-cyclopropyl |
monophosphate | monophosphate | monophosphate | H | Cl | NH2 |
monophosphate | monophosphate | monophosphate | H | Cl | NH-cyclopropyl |
monophosphate | monophosphate | monophosphate | H | Cl | OH |
diphosphate | diphosphate | diphosphate | H | Cl | NH2 |
diphosphate | diphosphate | diphosphate | H | Cl | NH-cyclopropyl |
diphosphate | diphosphate | diphosphate | H | Cl | OH |
triphosphate | triphosphate | triphosphate | H | Cl | NH2 |
triphosphate | triphosphate | triphosphate | H | Cl | NH-cyclopropyl |
triphosphate | triphosphate | triphosphate | H | Cl | OH |
H | H | H | F | Cl | NH2 |
H | H | H | F | Cl | NH-cyclopropyl |
H | H | H | F | Cl | OH |
H | H | H | Cl | Cl | NH2 |
H | H | H | Cl | Cl | NH-cyclopropyl |
H | H | H | Cl | Cl | OH |
H | H | H | Br | Cl | NH2 |
H | H | H | Br | Cl | NH-cyclopropyl |
H | H | H | Br | Cl | OH |
H | H | H | NH2 | Cl | NH2 |
H | H | H | NH2 | Cl | NH-cyclopropyl |
H | H | H | NH2 | Cl | OH |
H | H | H | SH | Cl | NH2 |
H | H | H | SH | Cl | NH-cyclopropyl |
H | H | H | SH | Cl | OH |
acetyl | H | H | H | Cl | NH2 |
acetyl | H | H | H | Cl | NH-cyclopropyl |
acetyl | H | H | H | Cl | OH |
acetyl | H | H | F | Cl | NH2 |
acetyl | H | H | F | Cl | NH-cyclopropyl |
acetyl | H | H | F | Cl | OH |
H | acetyl | acetyl | H | Cl | NH2 |
H | acetyl | acetyl | H | Cl | NH-cyclopropyl |
H | acetyl | acetyl | H | Cl | OH |
acetyl | acetyl | acetyl | H | Cl | NH2 |
acetyl | acetyl | acetyl | H | Cl | NH-cyclopropyl |
acetyl | acetyl | acetyl | H | Cl | OH |
monophosphate | acetyl | acetyl | H | Cl | NH2 |
monophosphate | acetyl | acetyl | H | Cl | NH-cyclopropyl |
monophosphate | acetyl | acetyl | H | Cl | OH |
diphosphate | acetyl | acetyl | H | Cl | NH2 |
diphosphate | acetyl | acetyl | H | Cl | NH-cyclopropyl |
diphosphate | acetyl | acetyl | H | Cl | OH |
triphosphate | acetyl | acetyl | H | Cl | NH2 |
triphosphate | acetyl | acetyl | H | Cl | NEl-cyclopropyl |
triphosphate | acetyl | acetyl | H | Cl | OH |
H | H | H | H | Cl | NH2 |
H | H | H | H | Cl | NH-cyclopropyl |
H | H | H | H | Cl | OH |
H | H | H | H | Br | NH2 |
H | H | H | H | Br | NH-cyclopropyl |
H | H | H | H | Br | OH |
Alternatively, the following nucleosides of Formula IV are prepared, using the appropriate sugar and pyrimidine or purine bases.
(IV) | |
|
|
wherein: | ||||
R1 | R2 | R3 | X1 | Y |
H | H | H | H | H |
H | H | H | H | NH2 |
H | H | H | H | NH- |
cyclopropyl | ||||
H | H | H | H | NH-methyl |
H | H | H | H | NH-ethyl |
H | H | H | H | NH-acetyl |
H | H | H | H | OH |
H | H | H | H | OMe |
H | H | H | H | OEt |
H | H | H | H | O-cyclopropyl |
H | H | H | H | O-acetyl |
H | H | H | H | SH |
H | H | H | H | SMe |
H | H | H | H | SEt |
H | H | H | H | S-cyclopropyl |
monophosphate | H | H | H | NH2 |
monophosphate | H | H | H | NH-acetyl |
monophosphate | H | H | H | NH- |
cyclopropyl | ||||
monophosphate | H | H | H | NH-methyl |
monophosphate | H | H | H | NH-ethyl |
monophosphate | H | H | H | OH |
monophosphate | H | H | H | O-acetyl |
monophosphate | H | H | H | OMe |
monophosphate | H | H | H | OEt |
monophosphate | H | H | H | O-cyclopropyl |
monophosphate | H | H | H | SH |
monophosphate | H | H | H | SMe |
monophosphate | H | H | H | SEt |
monophosphate | H | H | H | S-cyclopropyl |
diphosphate | H | H | H | NH2 |
diphosphate | H | H | H | NH-acetyl |
diphosphate | H | H | H | NH- |
cyclopropyl | ||||
diphosphate | H | H | H | NH-methyl |
diphosphate | H | H | H | NH-ethyl |
diphosphate | H | H | H | OH |
diphosphate | H | H | H | O-acetyl |
diphosphate | H | H | H | OMe |
diphosphate | H | H | H | OEt |
diphosphate | H | H | H | O-cyclopropyl |
diphosphate | H | H | H | SH |
diphosphate | H | H | H | SMe |
diphosphate | H | H | H | SEt |
diphosphate | H | H | H | S-cyclopropyl |
triphosphate | H | H | H | NH2 |
triphosphate | H | H | H | NH-acetyl |
triphosphate | H | H | H | NH- |
cyclopropyl | ||||
triphosphate | H | H | H | NH-methyl |
triphosphate | H | H | H | NH-ethyl |
triphosphate | H | H | H | OH |
triphosphate | H | H | H | OMe |
triphosphate | H | H | H | OEt |
triphosphate | H | H | H | O-cyclopropyl |
tnphosphate | H | H | H | O-acetyl |
triphosphate | H | H | H | SH |
triphosphate | H | H | H | SMe |
triphosphate | H | H | H | SEt |
triphosphate | H | H | H | S-cyclopropyl |
monophosphate | monophosphate | monophosphate | H | NH2 |
monophosphate | monophosphate | monophosphate | H | NH- |
cyclopropyl | ||||
monophosphate | monophosphate | monophosphate | H | OH |
diphosphate | diphosphate | diphosphate | H | NH2 |
diphosphate | diphosphate | diphosphate | H | NH- |
cyclopropyl | ||||
diphosphate | diphosphate | diphosphate | H | OH |
triphosphate | triphosphate | triphosphate | H | NH2 |
triphosphate | triphosphate | triphosphate | H | NH- |
cyclopropyl | ||||
triphosphate | triphosphate | triphosphate | H | OH |
H | H | H | F | NH2 |
H | H | H | F | NH- |
cyclopropyl | ||||
H | H | H | F | OH |
H | H | H | Cl | NH2 |
H | H | H | Cl | NH- |
cyclopropyl | ||||
H | H | H | Cl | OH |
H | H | H | Br | NH2 |
H | H | H | Br | NH- |
cyclopropyl | ||||
H | H | H | Br | OH |
H | H | H | NH2 | NH2 |
H | H | H | NH2 | NH- |
cyclopropyl | ||||
H | H | H | NH2 | OH |
H | H | H | SH | NH2 |
H | H | H | SH | NH- |
cyclopropyl | ||||
H | H | H | SH | OH |
acetyl | H | H | H | NH2 |
acetyl | H | H | H | NH- |
cyclopropyl | ||||
acetyl | H | H | H | OH |
acetyl | H | H | F | NH2 |
acetyl | H | H | F | NH- |
cyclopropyl | ||||
acetyl | H | H | F | OH |
H | acetyl | acetyl | H | NH2 |
H | acetyl | acetyl | H | NH- |
cyclopropyl | ||||
H | acetyl | acetyl | H | OH |
acetyl | acetyl | acetyl | H | NH2 |
acetyl | acetyl | acetyl | H | NH- |
cyclopropyl | ||||
acetyl | acetyl | acetyl | H | OH |
monophosphate | acetyl | acetyl | H | NH2 |
monophosphate | acetyl | acetyl | H | NH- |
cyclopropyl | ||||
monophosphate | acetyl | acetyl | H | OH |
diphosphate | acetyl | acetyl | H | NH2 |
diphosphate | acetyl | acetyl | H | NH- |
cyclopropyl | ||||
diphosphate | acetyl | acetyl | H | OH |
triphosphate | acetyl | acetyl | H | NH2 |
triphosphate | acetyl | acetyl | H | NH- |
cyclopropyl | ||||
triphosphate | acetyl | acetyl | H | OH |
Alternatively, the following nucleosides of Formula VII are prepared, using the appropriate sugar and pyrimidine or purine bases.
(VII) | |
|
|
wherein: | |||||
R1 | R2 | R3 | R6 | X | Base |
H | H | H | CH3 | O | 2,4-O-Diacetyluracil |
H | H | H | CH3 | O | Hypoxanthine |
H | H | H | CH3 | O | 2,4-O-Diacetyluracil |
H | H | H | CH3 | O | Thymine |
H | H | H | CH3 | O | Cytosine |
H | H | H | CH3 | O | 4-(N-monoacetyl)cytosine |
H | H | H | CH3 | O | 4-(N,N-diacetyl)cytosine |
H | H | H | CH3 | O | Uracil |
H | H | H | CH3 | O | 5-Fluorouracil |
H | H | H | CH3 | S | 2,4-O-Diacetyluracil |
H | H | H | CH3 | S | Hypoxanthine |
H | H | H | CH3 | S | 2,4-O-Diacetyluracil |
H | H | H | CH3 | S | Thymine |
H | H | H | CH3 | S | Cytosine |
H | H | H | CH3 | S | 4-(N-monoacetyl)cytosine |
H | H | H | CH3 | S | 4-(N,N-diacetyl)cytosine |
H | H | H | CH3 | S | Uracil |
H | H | H | CH3 | S | 5-Fluorouracil |
monophosphate | H | H | CH3 | O | 2,4-O-Diacetyluracil |
monophosphate | H | H | CH3 | O | Hypoxanthine |
monophosphate | H | H | CH3 | O | 2,4-O-Diacetylthym |
monophosphate | H | H | CH3 | O | Thymine |
monophosphate | H | H | CH3 | O | Cytosine |
monophosphate | H | H | CH3 | O | 4-(N-monoacetyl)cytosine |
monophosphate | H | H | CH3 | O | 4-(N,N-diacetyl)cytosine |
monophosphate | H | H | CH3 | O | Uracil |
monophosphate | H | H | CH3 | O | 5-Fluorouracil |
monophosphate | H | H | CH3 | S | 2,4-O-Diacetyluracil |
monophosphate | H | H | CH3 | S | Hypoxanthine |
monophosphate | H | H | CH3 | 5 | 2,4-O-Diacetylthym |
monophosphate | H | H | CH3 | S | Thymine |
monophosphate | H | H | CH3 | S | Cytosine |
monophosphate | H | H | CH3 | S | 4-(N-monoacetyl)cytosine |
monophosphate | H | H | CH3 | S | 4-(N,N-diacetyl)cytosine |
monophosphate | H | H | CH3 | S | Uracil |
monophosphate | H | H | CH3 | S | 5-Fluorouracil |
diphosphate | H | H | CH3 | O | 2,4-O-Diacetyluracil |
diphosphate | H | H | CH3 | O | Hypoxanthine |
diphosphate | H | H | CH3 | O | 2,4-O-Diacetylthymine |
diphosphate | H | H | CH3 | O | Thymine |
diphosphate | H | H | CH3 | O | Cytosine |
diphosphate | H | H | CH3 | O | 4-(N-monoacetyl)cytosine |
diphosphate | H | H | CH3 | O | 4-(N,N-diacetyl)cytosine |
diphosphate | H | H | CH3 | O | Uracil |
diphosphate | H | H | CH3 | O | 5-Fluorouracil |
diphosphate | H | H | CH3 | S | 2,4-O-Diacetyluracil |
diphosphate | H | H | CH3 | S | Hypoxanthine |
diphosphate | H | H | CH3 | S | 2,4-O-Diacetylthym |
diphosphate | H | H | CH3 | S | Thymine |
diphosphate | H | H | CH3 | S | Cytosine |
triphosphate | H | H | CH3 | O | 2,4-O-Diacetyluracil |
triphosphate | H | H | CH3 | O | Hypoxanthine |
triphosphate | H | H | CH3 | O | 2,4-O-Diacetylthymine |
triphosphate | H | H | CH3 | O | Thymine |
triphosphate | H | H | CH3 | O | Cytosine |
triphosphate | H | H | CH3 | O | 4-(N-monoacetyl)cytosine |
triphosphate | H | H | CH3 | O | 4-(N,N-diacetyl)cytosine |
triphosphate | H | H | CH3 | O | Uracil |
triphosphate | H | H | CH3 | O | 5-Fluorouracil |
triphosphate | H | H | CH3 | S | 2,4-O-Diacetyluracil |
triphosphate | H | H | CH3 | S | Hypoxanthine |
triphosphate | H | H | CH3 | S | 2,4-O-Diacetylthymine |
triphosphate | H | H | CH3 | S | Thymine |
triphosphate | H | H | CH3 | S | Cytosine |
monophosphate | monophosphate | monophosphate | CF3 | O | 2,4-O-Diacetyluracil |
monophosphate | monophosphate | monophosphate | CF3 | O | Hypoxanthine |
monophosphate | monophosphate | monophosphate | CF3 | O | 2,4-O-Diacetylthymine |
monophosphate | monophosphate | monophosphate | CF3 | O | Thymine |
monophosphate | monophosphate | monophosphate | CF3 | O | Cytosine |
monophosphate | monophosphate | monophosphate | CF3 | O | 4-(N-monoacetyl)cytosine |
monophosphate | monophosphate | monophosphate | CF3 | O | 4-(N,N-diacetyl)cytosine |
monophosphate | monophosphate | monophosphate | CF3 | O | Uracil |
monophosphate | monophosphate | monophosphate | CF3 | O | 5-Fluorouracil |
monophosphate | monophosphate | monophosphate | CF3 | S | 2,4-O-Diacetyluracil |
monophosphate | monophosphate | monophosphate | CF3 | S | Hypoxanthine |
monophosphate | monophosphate | monophosphate | CF3 | S | 2,4-O-Diacetylthymine |
monophosphate | monophosphate | monophosphate | CF3 | S | Thymine |
monophosphate | monophosphate | monophosphate | CF3 | S | Cytosine |
monophosphate | monophosphate | monophosphate | CF3 | S | 4-(N-monoacetyl)cytosine |
monophosphate | monophosphate | monophosphate | CF3 | S | 4-(N,N-diacetyl)cytosine |
monophosphate | monophosphate | monophosphate | CF3 | S | Uracil |
monophosphate | monophosphate | monophosphate | CF3 | S | 5-Fluorouracil |
acetyl | acetyl | acetyl | CF3 | O | 4-(N,N-diacetyl)cytosine |
acetyl | acetyl | acetyl | CF3 | S | 4-(N,N-diacetyl)cytosine |
acetyl | acetyl | acetyl | 2-bromo- | O | 4-(N,N-diacetyl)cytosine |
vinyl | |||||
acetyl | acetyl | acetyl | 2-bromo- | S | 4-(N,N-diacetyl)cytosine |
vinyl | |||||
H | H | H | CH3 | O | 2-(N,N-diacetyl)guanine |
H | H | H | CH3 | O | 6-O-acetylguanine |
H | H | H | CH3 | O | 8-fluoroguanine |
H | H | H | CH3 | O | guanine |
H | H | H | CH3 | O | 6-(N,N-diacetyl)adenine |
H | H | H | CH3 | O | 2-fluoroadenine |
H | H | H | CH3 | O | 8-fluoroadenine |
H | H | H | CH3 | O | 2,8-difluoroadenine |
H | H | H | CH3 | O | adenine |
H | H | H | CH3 | S | 2-(N,N-diacetyl)guanine |
H | H | H | CH3 | S | 6-O-acetylguanine |
H | H | H | CH3 | S | 8-fluoroguanine |
H | H | H | CH3 | S | guanine |
H | H | H | CH3 | S | 6-(N,N-diacetyl)- |
adenine | |||||
H | H | H | CH3 | S | 2-fluoroadenine |
H | H | H | CH3 | S | 8-fluoroadenine |
H | H | H | CH3 | S | 2,8-difluoroadenine |
H | H | H | CH3 | S | adenine |
monophosphate | H | H | CH3 | O | 2-(N,N-diacetyl)guanine |
monophosphate | H | H | CH3 | O | 6-O-acetylguanine |
monophosphate | H | H | CH3 | O | 8-fluoroguanine |
monophosphate | H | H | CH3 | O | guanine |
monophosphate | H | H | CH3 | O | 6-(N,N-diacetyl)adenine |
monophosphate | H | H | CH3 | O | 2-fluoroadenine |
monophosphate | H | H | CH3 | O | 8-fluoroadenine |
monophosphate | H | H | CH3 | O | 2,8-difluoroadenine |
monophosphate | H | H | CH3 | O | adenine |
monophosphate | H | H | CH3 | S | 2-(N,N-diacetyl)guanine |
monophosphate | H | H | CH3 | S | 6-O-acetylguanine |
monophosphate | H | H | CH3 | S | 8-fluoroguanine |
monophosphate | H | H | CH3 | S | guanine |
monophosphate | H | H | CH3 | S | 6-(N,N-diacetyl)adenine |
monophosphate | H | H | CH3 | S | 2-fluoroadenine |
monophosphate | H | H | CH3 | S | 8-fluoroadenine |
monophosphate | H | H | CH3 | S | 2,8-difluoroadenine |
monophosphate | H | H | CH3 | S | adenine |
diphosphate | H | H | CH3 | O | 2-(N,N-diacetyl)guanine |
diphosphate | H | H | CH3 | O | 6-O-acetylguanine |
diphosphate | H | H | CH3 | O | 8-fluoroguanine |
diphosphate | H | H | CH3 | O | guanine |
diphosphate | H | H | CH3 | O | 6-(N,N-diacetyl)adenine |
diphosphate | H | H | CH3 | O | 2-fluoroadenine |
diphosphate | H | H | CH3 | O | 8-fluoroadenine |
diphosphate | H | H | CH3 | O | 2,8-difluoroadenine |
diphosphate | H | H | CH3 | O | adenine |
diphosphate | H | H | CH3 | S | 2-(N,N-diacetyl)guanine |
diphosphate | H | H | CH3 | S | 6-O-acetylguanine |
diphosphate | H | H | CH3 | S | 8-fluoroguanine |
diphosphate | H | H | CH3 | S | guanine |
diphosphate | H | H | CH3 | S | 6-(N,N-diacetyl)adenine |
diphosphate | H | H | CH3 | S | 2-fluoroadenine |
diphosphate | H | H | CH3 | S | 8-fluoroadenine |
diphosphate | H | H | CH3 | S | 2,8-difluoroadenine |
diphosphate | H | H | CH3 | S | adenine |
triphosphate | H | H | CH3 | O | 2-(N,N-diacetyl)guanine |
triphosphate | H | H | CH3 | O | 6-O-acetylguanine |
triphosphate | H | H | CH3 | O | 8-fluoroguanine |
triphosphate | H | H | CH3 | O | guanine |
triphosphate | H | H | CH3 | O | 6-(N,N-diacetyl)adenine |
triphosphate | H | H | CH3 | O | 2-fluoroadenine |
triphosphate | H | H | CH3 | O | 8-fluoroadenine |
triphosphate | H | H | CH3 | O | 2,8-difluoroadenine |
triphosphate | H | H | CH3 | O | 2-(N,N-diacetyl)guanine |
triphosphate | H | H | CH3 | S | 6-O-acetylguanine |
triphosphate | H | H | CH3 | S | 8-fluoroguanine |
triphosphate | H | H | CH3 | S | guanine |
triphosphate | H | H | CH3 | S | 6-(N,N-diacetyl)adenine |
triphosphate | H | H | CH3 | S | 2-fluoroadenine |
triphosphate | H | H | CH3 | S | 8-fluoroadenine |
triphosphate | H | H | CH3 | S | 2,8-difluoroadenine |
triphosphate | H | H | CH3 | S | adenine |
monophosphate | monophosphate | monophosphate | CF3 | O | 2-(N,N-diacetyl)guanine |
monophosphate | monophosphate | monophosphate | CF3 | O | 6-O-acetylguanine |
monophosphate | monophosphate | monophosphate | CF3 | O | 8-fluoroguanine |
monophosphate | monophosphate | monophosphate | CF3 | O | guanine |
monophosphate | monophosphate | monophosphate | CF3 | O | 6-(N,N-diacetyl)adenine |
monophosphate | monophosphate | monophosphate | CF3 | O | 2-fluoroadenine |
monophosphate | monophosphate | monophosphate | CF3 | O | 8-fluoroadenine |
monophosphate | monophosphate | monophosphate | CF3 | O | 2,8-difluoroadenine |
monophosphate | monophosphate | monophosphate | CF3 | O | adenine |
monophosphate | monophosphate | monophosphate | CF3 | S | 2-(N,N-diacetyl)guanine |
monophosphate | monophosphate | monophosphate | CF3 | S | 6-O-acetylguanine |
monophosphate | monophosphate | monophosphate | CF3 | S | 8-fluoroguanine |
monophosphate | monophosphate | monophosphate | CF3 | S | guanine |
monophosphate | monophosphate | monophosphate | CF3 | S | 6-(N,N-diacetyl)adenine |
monophosphate | monophosphate | monophosphate | CF3 | S | 2-fluoroadenine |
monophosphate | monophosphate | monophosphate | CF3 | S | 8-fluoroadenine |
monophosphate | monophosphate | monophosphate | CF3 | S | 2,8-difluoroadenine |
monophosphate | monophosphate | monophosphate | CF3 | S | adenine |
acetyl | acetyl | acetyl | CF3 | O | guanine |
acetyl | acetyl | acetyl | CF3 | S | guanine |
acetyl | acetyl | acetyl | 2-bromo- | O | guanine |
vinyl | |||||
acetyl | acetyl | acetyl | 2-bromo- | S | guanine |
vinyl | |||||
Alternatively, the following nucleosides of Formula VIII are prepared, using the appropriate sugar and pyrimidine or purine bases.
(VIII) | |
|
|
wherein |
R1 | R2 | R6 | X | Base |
H | H | CH3 | O | 2,4-O-Diacetyluracil |
H | H | CH3 | O | Hypoxanthine |
H | H | CH3 | O | 2,4-O-Diacetylthymine |
H | H | CH3 | O | Thymine |
H | H | CH3 | O | Cytosine |
H | H | CH3 | O | 4-(N-mono-acetyl)cytosine |
H | H | CH3 | O | 4-(N,N-diacetyl)cytosine |
H | H | CH3 | O | Uracil |
H | H | CH3 | O | 5-Fluorouracil |
H | H | CH3 | S | 2,4-O-Diacetyluracil |
H | H | CH3 | S | Hypoxanthine |
H | H | CH3 | S | 2,4-O-Diacetylthylnine |
H | H | CH3 | S | Thymine |
H | H | CH3 | S | Cytosine |
H | H | CH3 | S | 4-(N-mono-acetyl)cytosine |
H | H | CH3 | S | 4-(N,N-diacetyl)cytosine |
H | H | CH3 | S | Uracil |
H | H | CH3 | S | 5-Fluorouracil |
monophosphate | H | CH3 | O | 2,4-O-Diacetyluracil |
monophosphate | H | CH3 | O | Hypoxanthine |
monophosphate | H | CH3 | O | 2,4-O-Diacetylthymine |
monophosphate | H | CH3 | O | Thymine |
monophosphate | H | CH3 | O | Cytosine |
monophosphate | H | CH3 | O | 4-(N-mono-acetyl)cytosine |
monophosphate | H | CH3 | O | 4-(N,N-diacetyl)cytosine |
monophosphate | H | CH3 | O | Uracil |
monophosphate | H | CH3 | O | 5-Fluorouracil |
monophosphate | H | CH3 | S | 2,4-O-Diacetyluracil |
monophosphate | H | CH3 | S | Hypoxanthine |
monophosphate | H | CH3 | S | 2,4-O-Diacetylthymine |
monophosphate | H | CH3 | S | Thymine |
monophosphate | H | CH3 | S | Cytosine |
monophosphate | H | CH3 | S | 4-(N-mono-acetyl)cytosine |
monophosphate | H | CH3 | S | 4-(N,N-diacetyl)cytosine |
monophosphate | H | CH3 | S | Uracil |
monophosphate | H | CH3 | S | 5-Fluorouracil |
diphosphate | H | CH3 | O | 2,4-O-Diacetyluracil |
diphosphate | H | CH3 | O | Hypoxanthine |
diphosphate | H | CH3 | O | 2,4-O-Diacetylthymine |
diphosphate | H | CH3 | O | Thymine |
diphosphate | H | CH3 | O | Cytosine |
diphosphate | H | CH3 | O | 4-(N-mono-acetyl)cytosine |
diphosphate | H | CH3 | O | 4-(N,N-diacetyl)cytosine |
diphosphate | H | CH3 | O | Uracil |
diphosphate | H | CH3 | O | 5-Fluorouracil |
diphosphate | H | CH3 | S | 2,4-O-Diacetyluracil |
diphosphate | H | CH3 | S | Hypoxanthine |
diphosphate | H | CH3 | S | 2,4-O-Diacetylthymine |
diphosphate | H | CH3 | S | Thymine |
diphosphate | H | CH3 | S | Cytosine |
diphosphate | H | CH3 | S | 4-(N-mono-acetyl)cytosine |
diphosphate | H | CH3 | S | 4-(N,N-diacetyl)cytosine |
diphosphate | H | CH3 | S | Uracil |
diphosphate | H | CH3 | S | 5-Fluorouracil |
triphosphate | H | CH3 | O | 2,4-O-Diacetyluracil |
triphosphate | H | CH3 | O | Hypoxanthine |
triphosphate | H | CH3 | O | 2,4-O-diacethylthymine |
triphosphate | H | CH3 | O | Thymine |
triphosphate | H | CH3 | O | Cytosine |
triphosphate | H | CH3 | O | 4-(N-mono-acetyl)cytosine |
triphosphate | H | CH3 | O | 4-(N,N-diacetyl)cytosine |
triphosphate | H | CH3 | O | Uracil |
triphosphate | H | CH3 | O | 5-Fluorouracil |
triphosphate | H | CH3 | S | 2,4-O-Diacetyluracil |
triphosphate | H | CH3 | S | Hypoxanthine |
triphosphate | H | CH3 | S | 2,4-O-Diacetylthymine |
triphosphate | H | CH3 | S | Thymine |
triphosphate | H | CH3 | S | Cytosine |
triphosphate | H | CH3 | S | 4-(N-mono-acetyl)cytosine |
triphosphate | H | CH3 | S | 4-(N,N-diacetyl)cytosine |
triphosphate | H | CH3 | S | Uracil |
triphosphate | H | CH3 | S | 5-Fluorouracil |
monophosphate | monophosphate | CF3 | O | 2,4-O-Diacetyluracil |
monophosphate | monophosphate | CF3 | O | Hypoxanthine |
monophosphate | monophosphate | CF3 | O | 2,4-O-Diacetylthymine |
monophosphate | monophosphate | CF3 | O | Thymine |
monophosphate | monophosphate | CF3 | O | Cytosine |
monophosphate | monophosphate | CF3 | O | 4-(N-mono-acetyl)cytosine |
monophosphate | monophosphate | CF3 | O | 4-(N,N-diacetyl)cytosine |
monophosphate | monophosphate | CF3 | O | Uracil |
monophosphate | monophosphate | CF3 | O | 5-Fluorouracil |
monophosphate | monophosphate | CF3 | S | 2,4-O-Diacetyluracil |
monophosphate | monophosphate | CF3 | S | Hypoxanthine |
monophosphate | monophosphate | CF3 | S | 2,4-O-Diacetylthymine |
monophosphate | monophosphate | CF3 | S | Thymine |
monophosphate | monophosphate | CF3 | S | Cytosine |
monophosphate | monophosphate | CF3 | S | 4-(N-mono-acetyl)cytosine |
monophosphate | monophosphate | CF3 | S | 4-(N,N-diacetyl)cytosine |
monophosphate | monophosphate | CF3 | S | Uracil |
monophosphate | monophosphate | CF3 | S | 5-Fluorouracil |
acetyl | acetyl | CF3 | O | 4-(N,N-diacetyl)cytosine |
acetyl | acetyl | CF3 | S | 4-(N,N-diacetyl)cytosine |
acetyl | acetyl | 2-bromo- | O | 4-(N,N-diacetyl)cytosine |
vinyl | ||||
acetyl | acetyl | 2-bromo- | S | 4-(N,N-diacetyl)cytosine |
vinyl | ||||
H | H | CH3 | O | 2-(N,N-diacetyl)-guanine |
H | H | CH3 | O | 6-O-acetyl guanine |
H | H | CH3 | O | 8-fluoroguanine |
H | H | CH3 | O | guanine |
H | H | CH3 | O | 6-(N,N-diacetyl)-adenine |
H | H | CH3 | O | 2-fluoroadenine |
H | H | CH3 | O | 8-fluoroadenine |
H | H | CH3 | O | 2,8-difluoro-adenine |
H | H | CH3 | O | adenine |
H | H | CH3 | S | 2-(N,N-diacetyl)-guanine |
H | H | CH3 | S | 6-O-acetyl guanine |
H | H | CH3 | S | 8-fluoroguanine |
H | H | CH3 | S | guanine |
H | H | CH3 | S | 6-(N,N-diacetyl)-adenine |
H | H | CH3 | S | 2-fluoroadenine |
H | H | CH3 | S | 8-fluoroadenine |
H | H | CH3 | S | 2,8-difluoro-adenine |
H | H | CH3 | S | adenine |
monophosphate | H | CH3 | O | 2-(N,N-diacetyl)-guanine |
monophosphate | H | CH3 | O | 6-O-acetyl guanine |
monophosphate | H | CH3 | O | 8-fluoroguanine |
monophosphate | H | CH3 | O | guanine |
monophosphate | H | CH3 | O | 6-(N,N-diacetyl)-adenine |
monophosphate | H | CH3 | O | 2-fluoroadenine |
monophosphate | H | CH3 | O | 8-fluoroadenine |
monophosphate | H | CH3 | O | 2,8-difluoro-adenine |
monophosphate | H | CH3 | O | adenine |
monophosphate | H | CH3 | S | 2-(N,N-diacetyl)-guanine |
monophosphate | H | CH3 | S | 6-O-acetyl guanine |
monophosphate | H | CH3 | S | 8-fluoroguanine |
monophosphate | H | CH3 | S | guanine |
monophosphate | H | CH3 | S | 6-(N,N-diacetyl)-adenine |
monophosphate | H | CH3 | S | 2-fluoroadenine |
monophosphate | H | CH3 | S | 8-fluoroadenine |
monophosphate | H | CH3 | S | 2,8-difluoro-adenine |
monophosphate | H | CH3 | S | adenine |
diphosphate | H | CH3 | O | 2-(N,N-diacetyl)-guanine |
diphosphate | H | CH3 | O | 6-O-acetyl guanine |
diphosphate | H | CH3 | O | 8-fluoroguanine |
diphosphate | H | CH3 | O | guanine |
diphosphate | H | CH3 | O | 6-(N,N-diacetyl)-adenine |
diphosphate | H | CH3 | O | 2-fluoroadenine |
diphosphate | H | CH3 | O | 8-fluoroadenine |
diphosphate | H | CH3 | O | 2,8-difluoro-adenine |
diphosphate | H | CH3 | O | adenine |
diphosphate | H | CH3 | S | 2-(N,N-diacetyl)-guanine |
diphosphate | H | CH3 | S | 6-O-acetyl guanine |
diphosphate | H | CH3 | S | 8-fluoroguanine |
diphosphate | H | CH3 | S | guanine |
diphosphate | H | CH3 | S | 6-(N,N-diacetyl)-adenine |
diphosphate | H | CH3 | S | 2-fluoroadenine |
diphosphate | H | CH3 | S | 8-fluoroadenine |
diphosphate | H | CH3 | S | 2,8-difluoro-adenine |
diphosphate | H | CH3 | S | adenine |
triphosphate | H | CH3 | O | 2-(N,N-diacetyl)-guanine |
triphosphate | H | CH3 | O | 6-O-acetyl guanine |
triphosphate | H | CH3 | O | 8-fluoroguanine |
triphosphate | H | CH3 | O | guanine |
triphosphate | H | CH3 | O | 6-(N,N-diacetyl)-adenine |
triphosphate | H | CH3 | O | 2-fluoroadenine |
triphosphate | H | CH3 | O | 8-fluoroadenine |
triphosphate | H | CH3 | O | 2,8-difluoro-adenine |
triphosphate | H | CH3 | O | adenine |
triphosphate | H | CH3 | S | 2-(N,N-diacetyl)-guanine |
triphosphate | H | CH3 | S | 6-O-acetyl guanine |
triphosphate | H | CH3 | S | 8-fluoroguanine |
triphosphate | H | CH3 | S | guanine |
triphosphate | H | CH3 | S | 6-(N,N-diacetyl)-adenine |
triphosphate | H | CH3 | S | 2-fluoroadenine |
triphosphate | H | CH3 | S | 8-fluoroadenine |
triphosphate | H | CH3 | S | 2,8-difluoro-adenine |
triphosphate | H | CH3 | S | adenine |
monophosphate | monophosphate | CF3 | O | 2-(N,N-diacetyl)-guanine |
monophosphate | monophosphate | CF3 | O | 6-O-acetyl guanine |
monophosphate | monophosphate | CF3 | O | 8-fluoroguanine |
monophosphate | monophosphate | CF3 | O | guanine |
monophosphate | monophosphate | CF3 | O | 6-(N,N-diacetyl)-adenine |
monophosphate | monophosphate | CF3 | O | 2-fluoroadenine |
monophosphate | monophosphate | CF3 | O | 8-fluoroadenine |
monophosphate | monophosphate | CF3 | O | 2,8-difluoro-adenine |
monophosphate | monophosphate | CF3 | O | adenine |
monophosphate | monophosphate | CF3 | S | 2-(N,N-diacetyl)-guanine |
monophosphate | monophosphate | CF3 | S | 6-O-acetyl guanine |
monophosphate | monophosphate | CF3 | S | 8-fluoroguanine |
monophosphate | monophosphate | CF3 | S | guanine |
monophosphate | monophosphate | CF3 | S | 6-(N,N-diacetyl)-adenine |
monophosphate | monophosphate | CF3 | S | 2-fluoroadenine |
monophosphate | monophosphate | CF3 | S | 8-fluoroadenine |
monophosphate | monophosphate | CF3 | S | 2,8-difluoro-adenine |
monophosphate | monophosphate | CF3 | S | adenine |
acetyl | acetyl | CF3 | O | guanine |
acetyl | acetyl | CF3 | S | guanine |
acetyl | acetyl | 2-bromo- | O | guanine |
vinyl | ||||
acetyl | acetyl | 2-bromo- | S | guanine |
vinyl | ||||
Alternatively, the following nucleosides of Formula IX are prepared, using the appropriate sugar and pyrimidine or purine bases.
(IX) | |
|
|
wherein: |
R1 | R6 | X | Base |
H | CH3 | O | 2,4-O-Diacetyluracil |
H | CH3 | O | Hypoxanthine |
H | CH3 | O | 2,4-O-Diacetylthymine |
H | CH3 | O | Thymine |
H | CH3 | O | Cytosine |
H | CH3 | O | 4-(N-mono-acetyl)cytosine |
H | CH3 | O | 4-(N,N-diacetyl)cytosine |
H | CH3 | O | Uracil |
H | CH3 | O | 5-Fluorouracil |
H | CH3 | S | 2,4-O-Diacetyluracil |
H | CH3 | S | Hypoxanthine |
H | CH3 | S | 2,4-O-Diacetylthymine |
H | CH3 | S | Thymine |
H | CH3 | S | Cytosine |
H | CH3 | S | 4-(N-mono-acetyl)cytosine |
H | CH3 | S | 4-(N,N-diacetyl)cytosine |
H | CH3 | S | Uracil |
H | CH3 | S | 5-Fluorouracil |
monophosphate | CH3 | O | 2,4-O-Diacetyluracil |
monophosphate | CH3 | O | Hypoxanthine |
monophosphate | CH3 | O | 2,4-O-Diacetylthymine |
monophosphate | CH3 | O | Thymine |
monophosphate | CH3 | O | Cytosine |
monophosphate | CH3 | O | 4-(N-mono-acetyl)cytosine |
monophosphate | CH3 | O | 4-(N,N-diacetyl)cytosine |
monophosphate | CH3 | O | Uracil |
monophosphate | CH3 | O | 5-Fluorouracil |
monophosphate | CH3 | S | 2,4-O-Diacetyluracil |
monophosphate | CH3 | S | Hypoxanthine |
monophosphate | CH3 | S | 2,4-O-Diacetylthymine |
monophosphate | CH3 | S | Thymine |
monophosphate | CH3 | S | Cytosine |
monophosphate | CH3 | S | 4-(N-mono-acetyl)cytosine |
monophosphate | CH3 | S | 4-(N,N-diacetyl)cytos |
monophosphate | CH3 | S | Uracil |
monophosphate | CH3 | S | 5-Fluorouracil |
diphosphate | CH3 | O | 2,4-O-Diacetyluracil |
diphosphate | CH3 | O | Hypoxanthine |
diphosphate | CH3 | O | 2,4-O-Diacetylthymine |
diphosphate | CH3 | O | Thymine |
diphosphate | CH3 | O | Cytosine |
diphosphate | CH3 | O | 4-(N-mono-acetyl)cytosine |
diphosphate | CH3 | O | 4-(N,N-diacetyl)cytosine |
diphosphate | CH3 | O | Uracil |
diphosphate | CH3 | O | 5-Fluorouracil |
diphosphate | CH3 | S | 2,4-O-Diacetyluracil |
diphosphate | CH3 | S | Hypoxanthine |
diphosphate | CH3 | S | 2,4-O-Diacetylthymine |
diphosphate | CH3 | S | Thymine |
diphosphate | CH3 | S | Cytosine |
triphosphate | CH3 | O | 2,4-O-Diacetyluracil |
triphosphate | CH3 | O | Hypoxanthine |
triphosphate | CH3 | O | 2,4-O-Diacetylthymine |
triphosphate | CH3 | O | Thymine |
triphosphate | CH3 | O | Cytosine |
triphosphate | CH3 | O | 4-(N-mono-acetyl)cytosine |
triphosphate | CH3 | O | 4-(N,N-diacetyl)cytosine |
triphosphate | CH3 | O | Uracil |
triphosphate | CH3 | O | 5-Fluorouracil |
triphosphate | CH3 | S | 2,4-O-Diacetyluracil |
triphosphate | CH3 | S | Hypoxanthine |
triphospahate | CH3 | S | 2,4-O-Diacetylthymine |
triphospahate | CH3 | S | Thymine |
triphospahate | CH3 | S | Cytosine |
monophosphate | CF3 | O | 2,4-O-Diacetyluracil |
monophosphate | CF3 | O | Hypoxanthine |
monophosphate | CF3 | O | 2,4-O-Diacetylthymine |
monophosphate | CF3 | O | Thymine |
monophosphate | CF3 | O | Cytosine |
monophosphate | CF3 | O | 4-(N-mono-acetyl)cytosine |
monophosphate | CF3 | O | 4-(N,N-diacetyl)cytos |
monophosphate | CF3 | O | Uracil |
monophosphate | CF3 | O | 5-Fluorouracil |
monophosphate | CF3 | S | 2,4-O-Diacetyluracil |
monophosphate | CF3 | S | Hypoxanthine |
monophosphate | CF3 | S | 2,4-O-Diacetylthymine |
monophosphate | CF3 | S | Thymine |
monophosphate | CF3 | S | Cytosine |
monophosphate | CF3 | S | 4-(N-mono-acetyl)cytosine |
monophosphate | CF3 | S | 4-(N,N-diacetyl)cytosine |
monophosphate | CF3 | S | Uracil |
monophosphate | CF3 | S | 5-Fluorouracil |
acetyl | CF3 | O | 4-(N,N-diacetyl)cytosine |
acetyl | CF3 | S | 4-(N,N-diacetyl)cytosine |
acetyl | 2-bromo-vinyl | O | 4-(N,N-diacetyl)cytosine |
acetyl | 2-bromo-vinyl | S | 4-(N,N-diacetyl)cytosine |
Alternatively, the following nucleosides of Formula XVI are prepared, using the appropriate sugar and pyrimidine or purine bases.
(XVI) | |
|
|
wherein: |
R1 | R6 | R7 | R8 | X | Base | R10 | R9 |
H | CH3 | H | H | O | 2,4-O-Diacetyluracil | OH | Me |
H | CH3 | H | H | O | Hypoxanthine | OH | Me |
H | CH3 | H | H | O | 2,4-O-Diacetylthymine | OH | Me |
H | CH3 | H | H | O | Thymine | OH | Me |
H | CH3 | H | H | O | Cytosine | OH | Me |
H | CH3 | H | H | O | 4-(N-mono-acetyl)cytosine | OH | Me |
H | CH3 | H | H | O | 4-(N,N-diacetyl)cytosine | OH | Me |
H | CH3 | H | H | O | Uracil | OH | Me |
H | CH3 | H | H | O | 5-Fluorouracil | OH | Me |
H | CH3 | H | H | S | 2,4-O-Diacetyluracil | OH | Me |
H | CH3 | H | H | S | Hypoxanthine | OH | Me |
H | CH3 | H | H | S | 2,4-O-Diacetylthymine | OH | Me |
H | CH3 | H | H | S | Thymine | OH | Me |
H | CH3 | H | H | S | Cytosine | OH | Me |
H | CH3 | H | H | S | 4-(N-mono-acetyl)cytosine | OH | Me |
H | CH3 | H | H | S | 4-(N,N-diacetyl)cytosine | OH | Me |
H | CH3 | H | H | S | Uracil | OH | Me |
H | CH3 | H | H | S | 5-Fluorouracil | OH | Me |
monophosphate | CH3 | H | H | O | 2,4-O-Diacetyluracil | OH | Me |
monophosphate | CH3 | H | H | O | Hypoxanthine | OH | Me |
monophosphate | CH3 | H | H | O | 2,4-O-Diacetylthymine | OH | Me |
monophosphate | CH3 | H | H | O | Thymine | OH | Me |
monophosphate | CH3 | H | H | O | Cytosine | OH | Me |
monophosphate | CH3 | H | H | O | 4-(N-mono-acetyl)cytosine | OH | Me |
monophosphate | CH3 | H | H | O | 4-(N,N-diacetyl)cytosine | OH | Me |
monophosphate | CH3 | H | H | O | Uracil | OH | Me |
monophosphate | CH3 | H | H | O | 5-Fluorouracil | OH | Me |
monophosphate | CH3 | H | H | S | 2,4-O-Diacetyluracil | OH | Me |
monophosphate | CH3 | H | H | S | Hypoxanthine | OH | Me |
monophosphate | CH3 | H | H | S | 2,4-O-Diacetylthymine | OH | Me |
monophosphate | CH3 | H | H | S | Thymine | OH | Me |
monophosphate | CH3 | H | H | S | Cytosine | OH | Me |
monophosphate | CH3 | H | H | S | 4-(N-mono-acetyl)cytosine | OH | Me |
monophosphate | CH3 | H | H | S | 4-(N,N-diacetyl)cytosine | OH | Me |
monophosphate | CH3 | H | H | S | Uracil | OH | Me |
monophosphate | CH3 | H | H | S | 5-Fluorouracil | OH | Me |
diphosphate | CH3 | H | H | O | 2,4-O-Diacetyluracil | OH | Me |
diphosphate | CH3 | H | H | O | Hypoxanthine | OH | Me |
diphosphate | CH3 | H | H | O | 2,4-O-Diacetylthymine | OH | Me |
diphosphate | CH3 | H | H | O | Thymine | OH | Me |
diphosphate | CH3 | H | H | O | Cytosine | OH | Me |
diphosphate | CH3 | H | H | O | 4-(N-mono-acetyl)cytosine | OH | Me |
diphosphate | CH3 | H | H | O | 4-(N,N-diacetyl)cytosine | OH | Me |
diphosphate | CH3 | H | H | O | Uracil | OH | Me |
diphosphate | CH3 | H | H | O | 5-Fluorouracil | OH | Me |
diphosphate | CH3 | H | H | S | 2,4-O-Diacetyluracil | OH | Me |
diphosphate | CH3 | H | H | S | Hypoxanthine | OH | Me |
diphosphate | CH3 | H | H | S | 2,4-O-Diacetylthymine | OH | Me |
diphosphate | CH3 | H | H | S | Thymine | OH | Me |
diphosphate | CH3 | H | H | S | Cytosine | OH | Me |
triphosphate | CH3 | H | H | O | 2,4-O-Diacetyluracil | OH | Me |
triphosphate | CH3 | H | H | O | Hypoxanthine | OH | Me |
triphosphate | CH3 | H | H | O | 2,4-O-Diacetylthymine | OH | Me |
triphosphate | CH3 | H | H | O | Thymine | OH | Me |
triphosphate | CH3 | H | H | O | Cytosine | OH | Me |
triphosphate | CH3 | H | H | O | 4-(N-mono-acetyl)cytosine | OH | Me |
triphosphate | CH3 | H | H | O | 4-(N,N-diacetyl)cytosine | OH | Me |
triphosphate | CH3 | H | H | O | Uracil | OH | Me |
triphosphate | CH3 | H | H | O | 5-Fluorouracil | OH | Me |
triphosphate | CH3 | H | H | S | 2,4-O-Diacetyluracil | OH | Me |
triphosphate | CH3 | H | H | S | Hypoxanthine | OH | Me |
triphosphate | CH3 | H | H | S | 2,4-O-Diacetylthymine | OH | Me |
triphosphate | CH3 | H | H | S | Thymine | OH | Me |
triphosphate | CH3 | H | H | S | Cytosine | OH | Me |
monophosphate | CF3 | H | H | O | 2,4-O-Diacetyluracil | OH | Me |
monophosphate | CF3 | H | H | O | Hypoxanthine | OH | Me |
monophosphate | CF3 | H | H | O | 2,4-O-Diacetylthymine | OH | Me |
monophosphate | CF3 | H | H | O | Thymine | OH | Me |
monophosphate | CF3 | H | H | O | Cytosine | OH | Me |
monophosphate | CF3 | H | H | O | 4-(N-mono-acetyl)cytosine | OH | Me |
monophosphate | CF3 | H | H | O | 4-(N,N-diacetyl)cytosine | OH | Me |
monophosphate | CF3 | H | H | O | Uracil | OH | Me |
monophosphate | CF3 | H | H | O | 5-Fluorouracil | OH | Me |
monophosphate | CF3 | H | H | S | 2,4-O-Diacetyluracil | OH | Me |
monophosphate | CF3 | H | H | S | Hypoxanthine | OH | Me |
monophosphate | CF3 | H | H | S | 2,4-O-Diacetylthymine | OH | Me |
monophosphate | CF3 | H | H | S | Thymine | OH | Me |
monophosphate | CF3 | H | H | S | Cytosine | OH | Me |
monophosphate | CF3 | H | H | S | 4-(N-mono-acetyl)cytosine | OH | Me |
monophosphate | CF3 | H | H | S | 4-(N,N-diacetyl)cytosine | OH | Me |
monophosphate | CF3 | H | H | S | Uracil | OH | Me |
monophosphate | CF3 | H | H | S | 5-Fluorouracil | OH | Me |
acetyl | CH3 | H | H | O | 4-(N,N-diacetyl)cytosine | H | Br |
acetyl | CH3 | H | H | S | 4-(N,N-diacetyl)cytosine | H | Br |
acetyl | CH3 | OH | H | O | 4-(N,N-diacetyl)cytosine | H | Br |
acetyl | CH3 | OH | H | S | 4-(N,N-diacetyl)cytosine | H | Br |
The title compound was prepared according to a published procedure (R. E. Harry-O'kuru, J. M. Smith, and M. S. Wolfe, “A short, flexible route toward 2′-C-branched ribonucleosides”, J. Org. Chem. 1997, 62, 1754-1759) (Scheme 8).
In a similar manner, but using the appropriate sugar and pyrimidine or purine bases, the following nucleosides of Formula II are prepared.
(II) | |
|
|
wherein: |
R1 | R2 | R3 | X1 | X2 | Y |
H | H | H | H | H | H |
H | H | H | H | H | NH2 |
H | H | H | H | H | NH-cyclopropyl |
H | H | H | H | H | NH-methyl |
H | H | H | H | H | NH-ethyl |
H | H | H | H | H | NH-acetyl |
H | H | H | H | H | OH |
H | H | H | H | H | OMe |
H | H | H | H | H | OEt |
H | H | H | H | H | O-cyclopropyl |
H | H | H | H | H | O-acetyl |
H | H | H | H | H | SH |
H | H | H | H | H | SMe |
H | H | H | H | H | SEt |
H | H | H | H | H | S-cyclopropyl |
H | H | H | H | H | F |
H | H | H | H | H | Cl |
H | H | H | H | H | Br |
H | H | H | H | H | I |
monophosphate | H | H | H | H | NH2 |
monophosphate | H | H | H | H | NH-acetyl |
monophosphate | H | H | H | H | NH-cyclopropyl |
monophosphate | H | H | H | H | NH-methyl |
monophosphate | H | H | H | H | NH-ethyl |
monophosphate | H | H | H | H | OH |
monophosphate | H | H | H | H | O-acetyl |
monophosphate | H | H | H | H | OMe |
monophosphate | H | H | H | H | OEt |
monophosphate | H | H | H | H | O-cyclopropyl |
monophosphate | H | H | H | H | SH |
monophosphate | H | H | H | H | SMe |
monophosphate | H | H | H | H | SEt |
monophosphate | H | H | H | H | S-cyclopropyl |
monophosphate | H | H | H | H | F |
monophosphate | H | H | H | H | Cl |
monophosphate | H | H | H | H | Br |
monophosphate | H | H | H | H | I |
diphosphate | H | H | H | H | NH2 |
diphosphate | H | H | H | H | NH-acetyl |
diphosphate | H | H | H | H | NH-cyclopropyl |
diphosphate | H | H | H | H | NH-methyl |
diphosphate | H | H | H | H | NH-ethyl |
diphosphate | H | H | H | H | OH |
diphosphate | H | H | H | H | O-acetyl |
diphosphate | H | H | H | H | OMe |
diphosphate | H | H | H | H | OEt |
diphosphate | H | H | H | H | O-cyclopropyl |
diphosphate | H | H | H | H | SH |
diphosphate | H | H | H | H | SMe |
diphosphate | H | H | H | H | SEt |
diphosphate | H | H | H | H | S-cyclopropyl |
diphosphate | H | H | H | H | F |
diphosphate | H | H | H | H | Cl |
diphosphate | H | H | H | H | Br |
diphosphate | H | H | H | H | I |
triphosphate | H | H | H | H | NH2 |
triphosphate | H | H | H | H | NH-acetyl |
triphosphate | H | H | H | H | NH-cyclopropyl |
triphosphate | H | H | H | H | NH-methyl |
triphosphate | H | H | H | H | NH-ethyl |
triphosphate | H | H | H | H | OH |
triphosphate | H | H | H | H | OMe |
triphosphate | H | H | H | H | OEt |
triphosphate | H | H | H | H | O-cyclopropyl |
triphosphate | H | H | H | H | O-acetyl |
triphosphate | H | H | H | H | SH |
triphosphate | H | H | H | H | SMe |
triphosphate | H | H | H | H | SEt |
triphosphate | H | H | H | H | S-cyclopropyl |
triphosphate | H | H | H | H | F |
triphosphate | H | H | H | H | Cl |
triphosphate | H | H | H | H | Br |
triphosphate | H | H | H | H | I |
monophosphate | monophosphate | monophosphate | H | H | NH2 |
monophosphate | monophosphate | monophosphate | H | H | NH-cyclopropyl |
monophosphate | monophosphate | monophosphate | H | H | OH |
monophosphate | monophosphate | monophosphate | H | H | F |
monophosphate | monophosphate | monophosphate | H | H | Cl |
diphosphate | diphosphate | diphosphate | H | H | NH2 |
diphosphate | diphosphate | diphosphate | H | H | NH-cyclopropyl |
diphosphate | diphosphate | diphosphate | H | H | OH |
diphosphate | diphosphate | diphosphate | H | H | F |
diphosphate | diphosphate | diphosphate | H | H | Cl |
triphosphate | triphosphate | triphosphate | H | H | NH2 |
triphosphate | triphosphate | triphosphate | H | H | NH-cyclopropyl |
triphosphate | triphosphate | triphosphate | H | H | OH |
triphosphate | triphosphate | triphosphate | H | H | F |
triphosphate | triphosphate | triphosphate | H | H | Cl |
H | H | H | F | H | NH2 |
H | H | H | F | H | NH-cyclopropyl |
H | H | H | F | H | OH |
H | H | H | F | H | F |
H | H | H | F | H | Cl |
H | H | H | Cl | H | NH2 |
H | H | H | Cl | H | NH-cyclopropyl |
H | H | H | Cl | H | OH |
H | H | H | Cl | H | F |
H | H | H | Cl | H | Cl |
H | H | H | Br | H | NH2 |
H | H | H | Br | H | NH-cyclopropyl |
H | H | H | Br | H | OH |
H | H | H | Br | H | F |
H | H | H | Br | H | Cl |
H | H | H | NH2 | H | NH2 |
H | H | H | NH2 | H | NH-cyclopropyl |
H | H | H | NH2 | H | OH |
H | H | H | NH2 | H | F |
H | H | H | NH2 | H | Cl |
H | H | H | SH | H | NH2 |
H | H | H | SH | H | NH-cyclopropyl |
H | H | H | SH | H | OH |
H | H | H | SH | H | F |
H | H | H | SH | H | Cl |
acetyl | H | H | H | H | NH2 |
acetyl | H | H | H | H | NH-cyclopropyl |
acetyl | H | H | H | H | OH |
acetyl | H | H | H | H | F |
acetyl | H | H | H | H | Cl |
acetyl | H | H | F | H | NH2 |
acetyl | H | H | F | H | NH-cyclopropyl |
acetyl | H | H | F | H | OH |
acetyl | H | H | F | H | F |
acetyl | H | H | F | H | Cl |
H | acetyl | acetyl | H | H | NH2 |
H | acetyl | acetyl | H | H | NH-cyclopropyl |
H | acetyl | acetyl | H | H | OH |
H | acetyl | acetyl | H | H | F |
H | acetyl | acetyl | H | H | Cl |
acetyl | acetyl | acetyl | H | H | NH2 |
acetyl | acetyl | acetyl | H | H | NH-cyclopropyl |
acetyl | acetyl | acetyl | H | H | OH |
acetyl | acetyl | acetyl | H | H | F |
acetyl | acetyl | acetyl | H | H | Cl |
monophosphate | acetyl | acetyl | H | H | NH2 |
monophosphate | acetyl | acetyl | H | H | NH-cyclopropyl |
monophosphate | acetyl | acetyl | H | H | OH |
monophosphate | acetyl | acetyl | H | H | F |
monophosphate | acetyl | acetyl | H | H | Cl |
diphosphate | acetyl | acetyl | H | H | NH2 |
diphosphate | acetyl | acetyl | H | H | NH-cyclopropyl |
diphosphate | acetyl | acetyl | H | H | OH |
diphosphate | acetyl | acetyl | H | H | F |
diphosphate | acetyl | acetyl | H | H | Cl |
triphosphate | acetyl | acetyl | H | H | NH2 |
triphosphate | acetyl | acetyl | H | H | NH-cyclopropyl |
triphosphate | acetyl | acetyl | H | H | OH |
triphosphate | acetyl | acetyl | H | H | F |
triphosphate | acetyl | acetyl | H | H | Cl |
H | H | H | H | NH2 | H |
H | H | H | H | NH2 | NH2 |
H | H | H | H | NH2 | NH-cyclopropyl |
H | H | H | H | NH2 | NH-methyl |
H | H | H | H | NH2 | NH-ethyl |
H | H | H | H | NH2 | NH-acetyl |
H | H | H | H | NH2 | OH |
H | H | H | H | NH2 | OMe |
H | H | H | H | NH2 | OEt |
H | H | H | H | NH2 | O-cyclopropyl |
H | H | H | H | NH2 | O-acetyl |
H | H | H | H | NH2 | SH |
H | H | H | H | NH2 | SMe |
H | H | H | H | NH2 | SEt |
H | H | H | H | NH2 | S-cyclopropyl |
H | H | H | H | NH2 | F |
H | H | H | H | NH2 | Cl |
H | H | H | H | NH2 | Br |
H | H | H | H | NH2 | I |
monophosphate | H | H | H | NH2 | NH2 |
monophosphate | H | H | H | NH2 | NH-acetyl |
monophosphate | H | H | H | NH2 | NH-cyclopropyl |
monophosphate | H | H | H | NH2 | NH-methyl |
monophosphate | H | H | H | NH2 | NH-ethyl |
monophosphate | H | H | H | NH2 | OH |
monophosphate | H | H | H | NH2 | O-acetyl |
monophosphate | H | H | H | NH2 | OMe |
monophosphate | H | H | H | NH2 | OEt |
monophosphate | H | H | H | NH2 | O-cyclopropyl |
monophosphate | H | H | H | NH2 | SH |
monophosphate | H | H | H | NH2 | SMe |
monophosphate | H | H | H | NH2 | SEt |
monophosphate | H | H | H | NH2 | S-cyclopropyl |
monophosphate | H | H | H | NH2 | F |
monophosphate | H | H | H | NH2 | Cl |
monophosphate | H | H | H | NH2 | Br |
monophosphate | H | H | H | NH2 | I |
diphosphate | H | H | H | NH2 | NH2 |
diphosphate | H | H | H | NH2 | NH-acetyl |
diphosphate | H | H | H | NH2 | NH-cyclopropyl |
diphosphate | H | H | H | NH2 | NH-methyl |
diphosphate | H | H | H | NH2 | NH-ethyl |
diphosphate | H | H | H | NH2 | OH |
diphosphate | H | H | H | NH2 | O-acetyl |
diphosphate | H | H | H | NH2 | OMe |
diphosphate | H | H | H | NH2 | OEt |
diphosphate | H | H | H | NH2 | O-cyclopropyl |
diphosphate | H | H | H | NH2 | SH |
diphosphate | H | H | H | NH2 | SMe |
diphosphate | H | H | H | NH2 | SEt |
diphosphate | H | H | H | NH2 | S-cyclopropyl |
diphosphate | H | H | H | NH2 | F |
diphosphate | H | H | H | NH2 | Cl |
diphosphate | H | H | H | NH2 | Br |
diphosphate | H | H | H | NH2 | I |
triphosphate | H | H | H | NH2 | NH2 |
triphosphate | H | H | H | NH2 | NH-acetyl |
triphosphate | H | H | H | NH2 | NH-cyclopropyl |
triphosphate | H | H | H | NH2 | NH-methyl |
triphosphate | H | H | H | NH2 | NH-ethyl |
triphosphate | H | H | H | NH2 | OH |
triphosphate | H | H | H | NH2 | OMe |
triphosphate | H | H | H | NH2 | OEt |
triphosphate | H | H | H | NH2 | O-cyclopropyl |
triphosphate | H | H | H | NH2 | O-acetyl |
triphosphate | H | H | H | NH2 | SH |
triphosphate | H | H | H | NH2 | SMe |
triphosphate | H | H | H | NH2 | SEt |
triphosphate | H | H | H | NH2 | S-cyclopropyl |
triphosphate | H | H | H | NH2 | F |
triphosphate | H | H | H | NH2 | Cl |
triphosphate | H | H | H | NH2 | Br |
triphosphate | H | H | H | NH2 | I |
monophosphate | monophosphate | monophosphate | H | NH2 | NH2 |
monophosphate | monophosphate | monophosphate | H | NH2 | NH-cyclopropyl |
monophosphate | monophosphate | monophosphate | H | NH2 | OH |
monophosphate | monophosphate | monophosphate | H | NH2 | F |
monophosphate | monophosphate | monophosphate | H | NH2 | Cl |
diphosphate | diphosphate | diphosphate | H | NH2 | NH2 |
diphosphate | diphosphate | diphosphate | H | NH2 | NH-cyclopropyl |
diphosphate | diphosphate | diphosphate | H | NH2 | OH |
diphosphate | diphosphate | diphosphate | H | NH2 | F |
diphosphate | diphosphate | diphosphate | H | NH2 | Cl |
triphosphate | triphosphate | triphosphate | H | NH2 | NH2 |
triphosphate | triphosphate | triphosphate | H | NH2 | NH-cyclopropyl |
triphosphate | triphosphate | triphosphate | H | NH2 | OH |
triphosphate | triphosphate | triphosphate | H | NH2 | F |
triphosphate | triphosphate | triphosphate | H | NH2 | Cl |
H | H | H | F | NH2 | NH2 |
H | H | H | F | NH2 | NH-cyclopropyl |
H | H | H | F | NH2 | OH |
H | H | H | F | NH2 | F |
H | H | H | F | NH2 | Cl |
H | H | H | Cl | NH2 | NH2 |
H | H | H | Cl | NH2 | NH-cyclopropyl |
H | H | H | Cl | NH2 | OH |
H | H | H | Cl | NH2 | F |
H | H | H | Cl | NH2 | Cl |
H | H | H | Br | NH2 | NH2 |
H | H | H | Br | NH2 | NH-cyclopropyl |
H | H | H | Br | NH2 | OH |
H | H | H | Br | NH2 | F |
H | H | H | Br | NH2 | Cl |
H | H | H | NH2 | NH2 | NH2 |
H | H | H | NH2 | NH2 | NH-cyclopropyl |
H | H | H | NH2 | NH2 | OH |
H | H | H | NH2 | NH2 | F |
H | H | H | NH2 | NH2 | Cl |
H | H | H | SH | NH2 | NH2 |
H | H | H | SH | NH2 | NH-cyclopropyl |
H | H | H | SH | NH2 | OH |
H | H | H | SH | NH2 | F |
H | H | H | SH | NH2 | Cl |
acetyl | H | H | H | NH2 | NH2 |
acetyl | H | H | H | NH2 | NH-cyclopropyl |
acetyl | H | H | H | NH2 | OH |
acetyl | H | H | H | NH2 | F |
acetyl | H | H | H | NH2 | Cl |
acetyl | H | H | F | NH2 | NH2 |
acetyl | H | H | F | NH2 | NH-cyclopropyl |
acetyl | H | H | F | NH2 | OH |
acetyl | H | H | F | NH2 | F |
acetyl | H | H | F | NH2 | Cl |
H | acetyl | acetyl | H | NH2 | NH2 |
H | acetyl | acetyl | H | NH2 | NH-cyclopropyl |
H | acetyl | acetyl | H | NH2 | OH |
H | acetyl | acetyl | H | NH2 | F |
H | acetyl | acetyl | H | NH2 | Cl |
acetyl | acetyl | acetyl | H | NH2 | NH2 |
acetyl | acetyl | acetyl | H | NH2 | NH-cyclopropyl |
acetyl | acetyl | acetyl | H | NH2 | OH |
acetyl | acetyl | acetyl | H | NH2 | F |
acetyl | acetyl | acetyl | H | NH2 | Cl |
monophosphate | acetyl | acetyl | H | NH2 | NH2 |
monophosphate | acetyl | acetyl | H | NH2 | NH-cyclopropyl |
monophosphate | acetyl | acetyl | H | NH2 | OH |
monophosphate | acetyl | acetyl | H | NH2 | F |
monophosphate | acetyl | acetyl | H | NH2 | Cl |
diphosphate | acetyl | acetyl | H | NH2 | NH2 |
diphosphate | acetyl | acetyl | H | NH2 | NH-cyclopropyl |
diphosphate | acetyl | acetyl | H | NH2 | OH |
diphosphate | acetyl | acetyl | H | NH2 | F |
diphosphate | acetyl | acetyl | H | NH2 | Cl |
triphosphate | acetyl | acetyl | H | NH2 | NH2 |
triphosphate | acetyl | acetyl | H | NH2 | NH-cyclopropyl |
triphosphate | acetyl | acetyl | H | NH2 | OH |
triphosphate | acetyl | acetyl | H | NH2 | F |
triphosphate | acetyl | acetyl | H | NH2 | Cl |
H | H | H | H | Cl | H |
H | H | H | H | Cl | H |
H | H | H | H | Cl | NH2 |
H | H | H | H | Cl | NH-cyclopropyl |
H | H | H | H | Cl | NH-methyl |
H | H | H | H | Cl | NH-ethyl |
H | H | H | H | Cl | NH-acetyl |
H | H | H | H | Cl | OH |
H | H | H | H | Cl | OMe |
H | H | H | H | Cl | OEt |
H | H | H | H | Cl | O-cyclopropyl |
H | H | H | H | Cl | O-acetyl |
H | H | H | H | Cl | SH |
H | H | H | H | Cl | SMe |
H | H | H | H | Cl | SEt |
H | H | H | H | Cl | S-cyclopropyl |
monophosphate | H | H | H | Cl | NH2 |
monophosphate | H | H | H | Cl | NH-acetyl |
monophosphate | H | H | H | Cl | NH-cyclopropyl |
monophosphate | H | H | H | Cl | NH-methyl |
monophosphate | H | H | H | Cl | NH-ethyl |
monophosphate | H | H | H | Cl | OH |
monophosphate | H | H | H | Cl | O-acetyl |
monophosphate | H | H | H | Cl | OMe |
monophosphate | H | H | H | Cl | OEt |
monophosphate | H | H | H | Cl | O-cyclopropyl |
monophosphate | H | H | H | Cl | SH |
monophosphate | H | H | H | Cl | SMe |
monophosphate | H | H | H | Cl | SEt |
monophosphate | H | H | H | Cl | S-cyclopropyl |
diphosphate | H | H | H | Cl | NH2 |
diphosphate | H | H | H | Cl | NH-acetyl |
diphosphate | H | H | H | Cl | NH-cyclopropyl |
diphosphate | H | H | H | Cl | NH-methyl |
diphosphate | H | H | H | Cl | NH-ethyl |
diphosphate | H | H | H | Cl | OH |
diphosphate | H | H | H | Cl | O-acetyl |
diphosphate | H | H | H | Cl | OMe |
diphosphate | H | H | H | Cl | OEt |
diphosphate | H | H | H | Cl | O-cyclopropyl |
diphosphate | H | H | H | Cl | SH |
diphosphate | H | H | H | Cl | SMe |
diphosphate | H | H | H | Cl | SEt |
diphosphate | H | H | H | Cl | S-cyclopropyl |
triphosphate | H | H | H | Cl | NH2 |
triphosphate | H | H | H | Cl | NH-acetyl |
triphosphate | H | H | H | Cl | NH-cyclopropyl |
triphosphate | H | H | H | Cl | NH-methyl |
triphosphate | H | H | H | Cl | NH-ethyl |
triphosphate | H | H | H | Cl | OH |
triphosphate | H | H | H | Cl | OMe |
triphosphate | H | H | H | Cl | OEt |
triphosphate | H | H | H | Cl | O-cyclopropyl |
triphosphate | H | H | H | Cl | O-acetyl |
triphosphate | H | H | H | Cl | SH |
triphosphate | H | H | H | Cl | SMe |
triphosphate | H | H | H | Cl | SEt |
triphosphate | H | H | H | Cl | S-cyclopropyl |
monophosphate | monophosphate | monophosphate | H | Cl | NH2 |
monophosphate | monophosphate | monophosphate | H | Cl | NH-cyclopropyl |
monophosphate | monophosphate | monophosphate | H | Cl | OH |
diphosphate | diphosphate | diphosphate | H | Cl | NH2 |
diphosphate | diphosphate | diphosphate | H | Cl | NH-cyclopropyl |
diphosphate | diphosphate | diphosphate | H | Cl | OH |
triphosphate | triphosphate | triphosphate | H | Cl | NH2 |
triphosphate | triphosphate | triphosphate | H | Cl | NH-cyclopropyl |
triphosphate | triphosphate | triphosphate | H | Cl | OH |
H | H | H | F | Cl | NH2 |
H | H | H | F | Cl | NH-cyclopropyl |
H | H | H | F | Cl | OH |
H | H | H | Cl | Cl | NH2 |
H | H | H | Cl | Cl | NH-cyclopropyl |
H | H | H | Cl | Cl | OH |
H | H | H | Br | Cl | NH2 |
H | H | H | Br | Cl | NH-cyclopropyl |
H | H | H | Br | Cl | OH |
H | H | H | NH2 | Cl | NH2 |
H | H | H | NH2 | Cl | NH-cyclopropyl |
H | H | H | NH2 | Cl | OH |
H | H | H | SH | Cl | NH2 |
H | H | H | SH | Cl | NH-cyclopropyl |
H | H | H | SH | Cl | OH |
acetyl | H | H | H | Cl | NH2 |
acetyl | H | H | H | Cl | NH-cyclopropyl |
acetyl | H | H | H | Cl | OH |
acetyl | H | H | F | Cl | NH2 |
acetyl | H | H | F | Cl | NH-cyclopropyl |
acetyl | H | H | F | Cl | OH |
H | acetyl | acetyl | H | Cl | NH2 |
H | acetyl | acetyl | H | Cl | NH-cyclopropyl |
H | acetyl | acetyl | H | Cl | OH |
acetyl | acetyl | acetyl | H | Cl | NH2 |
acetyl | acetyl | acetyl | H | Cl | NH-cyclopropyl |
acetyl | acetyl | acetyl | H | Cl | OH |
monophosphate | acetyl | acetyl | H | Cl | NH2 |
monophosphate | acetyl | acetyl | H | Cl | NH-cyclopropyl |
monophosphate | acetyl | acetyl | H | Cl | OH |
diphosphate | acetyl | acetyl | H | Cl | NH2 |
diphosphate | acetyl | acetyl | H | Cl | NH-cyclopropyl |
diphosphate | acetyl | acetyl | H | Cl | OH |
triphosphate | acetyl | acetyl | H | Cl | NH2 |
triphosphate | acetyl | acetyl | H | Cl | NH-cyclopropyl |
triphosphate | acetyl | acetyl | H | Cl | OH |
H | H | H | H | Cl | NH2 |
H | H | H | H | Cl | NH-cyclopropyl |
H | H | H | H | Cl | OH |
H | H | H | H | Br | NH2 |
H | H | H | H | Br | NH-cyclopropyl |
H | H | H | H | Br | OH |
Alternatively, the following nucleosides of Formula V are prepared, using the appropriate sugar and pyrimidine or purine bases.
(V) | |
|
|
wherein: |
R1 | R2 | R3 | X1 | Y |
H | H | H | H | H |
H | H | H | H | NH2 |
H | H | H | H | NH-cyclopropyl |
H | H | H | H | NH-methyl |
H | H | H | H | NH-ethyl |
H | H | H | H | NH-acetyl |
H | H | H | H | OH |
H | H | H | H | OMe |
H | H | H | H | OEt |
H | H | H | H | O-cyclopropyl |
H | H | H | H | O-acetyl |
H | H | H | H | SH |
H | H | H | H | SMe |
H | H | H | H | SEt |
H | H | H | H | S-cyclopropyl |
monophosphate | H | H | H | NH2 |
monophosphate | H | H | H | NH-acetyl |
monophosphate | H | H | H | NH-cyclopropyl |
monophosphate | H | H | H | NH-methyl |
monophosphate | H | H | H | NH-ethyl |
monophosphate | H | H | H | OH |
monophosphate | H | H | H | O-acetyl |
monophosphate | H | H | H | OMe |
monophosphate | H | H | H | OEt |
monophosphate | H | H | H | O-cyclopropyl |
monophosphate | H | H | H | SH |
monophosphate | H | H | H | SMe |
monophosphate | H | H | H | SEt |
monophosphate | H | H | H | S-cyclopropyl |
diphosphate | H | H | H | NH2 |
diphosphate | H | H | H | NH-acetyl |
diphosphate | H | H | H | NH-cyclopropyl |
diphosphate | H | H | H | NH-methyl |
diphosphate | H | H | H | NH-ethyl |
diphosphate | H | H | H | OH |
diphosphate | H | H | H | O-acetyl |
diphosphate | H | H | H | OMe |
diphosphate | H | H | H | OEt |
diphosphate | H | H | H | O-cyclopropyl |
diphosphate | H | H | H | SH |
diphosphate | H | H | H | SMe |
diphosphate | H | H | H | SEt |
diphosphate | H | H | H | S-cyclopropyl |
triphosphate | H | H | H | NH2 |
triphosphate | H | H | H | NH-acetyl |
triphosphate | H | H | H | NH-cyclopropyl |
triphosphate | H | H | H | NH-methyl |
triphosphate | H | H | H | NH-ethyl |
triphosphate | H | H | H | OH |
triphosphate | H | H | H | OMe |
triphosphate | H | H | H | OEt |
triphosphate | H | H | H | O-cyclopropyl |
triphosphate | H | H | H | O-acetyl |
triphosphate | H | H | H | SH |
triphosphate | H | H | H | SMe |
triphosphate | H | H | H | SEt |
triphosphate | H | H | H | S-cyclopropyl |
monophosphate | monophosphate | monophosphate | H | NH2 |
monophosphate | monophosphate | monophosphate | H | NH-cyclopropyl |
monophosphate | monophosphate | monophosphate | H | OH |
diphosphate | diphosphate | diphosphate | H | NH2 |
diphosphate | diphosphate | diphosphate | H | NH-cyclopropyl |
diphosphate | diphosphate | diphosphate | H | OH |
triphosphate | triphosphate | triphosphate | H | NH2 |
triphosphate | triphosphate | triphosphate | H | NH-cyclopropyl |
triphosphate | triphosphate | triphosphate | H | OH |
H | H | H | F | NH2 |
H | H | H | F | NH-cyclopropyl |
H | H | H | F | OH |
H | H | H | Cl | NH2 |
H | H | H | Cl | NH-cyclopropyl |
H | H | H | Cl | OH |
H | H | H | Br | NH2 |
H | H | H | Br | NH-cyclopropyl |
H | H | H | Br | OH |
H | H | H | NH2 | NH2 |
H | H | H | NH2 | NH-cyclopropyl |
H | H | H | NH2 | OH |
H | H | H | SH | NH2 |
H | H | H | SH | NH-cyclopropyl |
H | H | H | SH | OH |
acetyl | H | H | H | NH2 |
acetyl | H | H | H | NH-cyclopropyl |
acetyl | H | H | H | OH |
acetyl | H | H | F | NH2 |
acetyl | H | H | F | NH-cyclopropyl |
acetyl | H | H | F | OH |
H | acetyl | acetyl | H | NH2 |
H | acetyl | acetyl | H | NH-cyclopropyl |
H | acetyl | acetyl | H | OH |
acetyl | acetyl | acetyl | H | NH2 |
acetyl | acetyl | acetyl | H | NH-cyclopropyl |
acetyl | acetyl | acetyl | H | OH |
monophosphate | acetyl | acetyl | H | NH2 |
monophosphate | acetyl | acetyl | H | NH-cyclopropyl |
monophosphate | acetyl | acetyl | H | OH |
diphosphate | acetyl | acetyl | H | NH2 |
diphosphate | acetyl | acetyl | H | NH-cyclopropyl |
diphosphate | acetyl | acetyl | H | OH |
triphosphate | acetyl | acetyl | H | NH2 |
triphosphate | acetyl | acetyl | H | NH-cyclopropyl |
triphosphate | acetyl | acetyl | H | OH |
Alternatively, the following nucleosides of Formula X are prepared, using the appropriate sugar and pyrimidine or purine bases.
(X) | |
|
|
wherein: |
R1 | R2 | R3 | R6 | X | Base |
H | H | H | CH3 | O | 2,4-O- |
Diacetyluracil | |||||
H | H | H | CH3 | O | Hypoxanthine |
H | H | H | CH3 | O | 2,4-O- |
Diacetylthymine | |||||
H | H | H | CH3 | O | Thymine |
H | H | H | CH3 | O | Cytosme |
H | H | H | CH3 | O | 4-(N-mono- |
acetyl)cytosine | |||||
H | H | H | CH3 | O | 4-(N,N- |
diacetyl)cytosine | |||||
H | H | H | CH3 | O | Uracil |
H | H | H | CH3 | O | 5-Fluorouracil |
H | H | H | CH3 | |
2,4-O- |
Diacetyluraci | |||||
H | H | H | CH3 | S | Hypoxanthine |
H | H | H | CH3 | |
2,4-O- |
Diacetylthymine | |||||
H | H | H | CH3 | S | Thymine |
H | H | H | CH3 | S | Cytosine |
H | H | H | CH3 | S | 4-(N-mono- |
acetyl)cytosine | |||||
H | H | H | CH3 | S | 4-(N,N- |
diacetyl)cytosine | |||||
H | H | H | CH3 | S | Uracil |
H | H | H | CH3 | S | 5-Fluorouracil |
monophosphate | H | H | CH3 | |
2,4-O- |
Diacetyluracil | |||||
monophosphate | H | H | CH3 | O | Hypoxanthine |
monophosphate | H | H | CH3 | |
2,4-O- |
Diacetylthym | |||||
monophosphate | H | H | CH3 | O | Thymine |
monophosphate | H | H | CH3 | O | Cytosine |
monophosphate | H | H | CH3 | O | 4-(N-mono- |
acetyl)cytosine | |||||
monophosphate | H | H | CH3 | O | 4-(N,N- |
diacetyl)cytosine | |||||
monophosphate | H | H | CH3 | O | Uracil |
monophosphate | H | H | CH3 | O | 5-Fluorouracil |
monophosphate | H | H | CH3 | S | 2,4-O- |
Diacetyluracil | |||||
monophosphate | H | H | CH3 | S | Hypoxanthine |
monophosphate | H | H | CH3 | S | 2,4-O- |
Diacetylthym | |||||
monophosphate | H | H | CH3 | S | Thymine |
monophosphate | H | H | CH3 | S | Cytosine |
monophosphate | H | H | CH3 | S | 4-(N-mono- |
acetyl)cytosine | |||||
monophosphate | H | H | CH3 | S | 4-(N,N- |
diacetyl)cytosine | |||||
monophosphate | H | H | CH3 | S | Uracil |
monophosphate | H | H | CH3 | S | 5-Fluorouracil |
diphosphate | H | H | CH3 | O | 2,4-O- |
Diacetyluracil | |||||
diphosphate | H | H | CH3 | O | Hypoxanthine |
diphosphate | H | H | CH3 | O | 2,4-O- |
Diacetylthymine | |||||
diphosphate | H | H | CH3 | O | Thymine |
diphosphate | H | H | CH3 | O | Cytosine |
diphosphate | H | H | CH3 | O | 4-(N-niono- |
acetyl)cytosine | |||||
diphosphate | H | H | CH3 | O | 4-(N,N- |
diacetyl)cytosine | |||||
diphosphate | H | H | CH3 | O | Uracil |
diphosphate | H | H | CH3 | O | 5-Fluorouracil |
diphosphate | H | H | CH3 | S | 2,4-O- |
Diacetyluracil | |||||
diphosphate | H | H | CH3 | S | Hypoxanthine |
diphosphate | H | H | CH3 | S | 2,4-O- |
Diacetylthym | |||||
diphosphate | H | H | CH3 | S | Thymine |
diphosphate | H | H | CH3 | S | Cytosine |
triphosphate | H | H | CH3 | O | 2,4-O- |
Diacetyluracil | |||||
triphosphate | H | H | CH3 | O | Hypoxanthine |
triphosphate | H | H | CH3 | O | 2,4-O- |
Diacetylthymine | |||||
triphosphate | H | H | CH3 | O | Thymine |
triphosphate | H | H | CH3 | O | Cytosine |
triphosphate | H | H | CH3 | O | 4-(N-mono- |
acetyl)cytosine | |||||
triphosphate | H | H | CH3 | O | 4-(N,N- |
diacetyl)cytosine | |||||
triphosphate | H | H | CH3 | O | Uracil |
triphosphate | H | H | CH3 | O | 5-Fluorouracil |
triphosphate | H | H | CH3 | |
2,4-O- |
Diacetyluracil | |||||
triphosphate | H | H | CH3 | S | Hypoxanthine |
triphosphate | H | H | CH3 | |
2,4-O- |
Diacetylthymine | |||||
triphosphate | H | H | CH3 | S | Thymine |
triphosphate | H | H | CH3 | S | Cytosine |
monophosphate | monophosphate | monophosphate | CF3 | O | 2,4-O- |
Diacetyluracil | |||||
monophosphate | monophosphate | monophosphate | CF3 | O | Hypoxanthine |
monophosphate | monophosphate | monophosphate | CF3 | O | 2,4-O- |
Diacetylthymine | |||||
monophosphate | monophosphate | monophosphate | CF3 | O | Thymine |
monophosphate | monophosphate | monophosphate | CF3 | O | Cytosine |
monophosphate | monophosphate | monophosphate | CF3 | O | 4-(N-mono- |
acetyl)cytosine | |||||
monophosphate | monophosphate | monophosphate | CF3 | O | 4-(N,N- |
diacetyl)cytosine | |||||
monophosphate | monophosphate | monophosphate | CF3 | O | Uracil |
monophosphate | monophosphate | monophosphate | CF3 | O | 5-Fluorouracil |
monophosphate | monophosphate | monophosphate | CF3 | S | 2,4-O- |
Diacetyluracil | |||||
monophosphate | monophosphate | monophosphate | CF3 | S | Hypoxanthine |
monophosphate | monophosphate | monophosphate | CF3 | S | 2,4-O- |
Diacetylthymine | |||||
monophosphate | monophosphate | monophosphate | CF3 | S | Thymine |
monophosphate | monophosphate | monophosphate | CF3 | S | Cytosine |
monophosphate | monophosphate | monophosphate | CF3 | S | 4-(N-mono- |
acetyl)cytosine | |||||
monophosphate | monophosphate | monophosphate | CF3 | S | 4-(N,N- |
diacetyl)cytosine | |||||
monophosphate | monophosphate | monophosphate | CF3 | S | Uracil |
monophosphate | monophosphate | monophosphate | CF3 | S | 5-Fluorouracil |
acetyl | acetyl | acetyl | CF3 | O | 4-(N,N- |
diacetyl)cytosine | |||||
acetyl | acetyl | acetyl | CF3 | S | 4-(N,N- |
diacetyl)cytosine | |||||
acetyl | acetyl | acetyl | 2-bromo- | O | 4-(N,N- |
vinyl | diacetyl)cytosine | ||||
acetyl | acetyl | acetyl | 2-bromo- | S | 4-(N,N- |
vinyl | diacetyl)cytosine | ||||
H | H | H | CH3 | O | 2-(N,N-diacetyl)- |
guanine | |||||
H | H | H | CH3 | O | 6-O-acetyl |
guanine | |||||
H | H | H | CH3 | O | 8-fluoroguanine |
H | H | H | CH3 | O | guanine |
H | H | H | CH3 | O | 6-(N,N-diacetyl)- |
adenine | |||||
H | H | H | CH3 | O | 2-fluoroadenine |
H | H | H | CH3 | O | 8-fluoroadenine |
H | H | H | CH3 | O | 2,8-difluoro- |
adenine | |||||
H | H | H | CH3 | O | adenine |
H | H | H | CH3 | S | 2-(N,N-diacetyl)- |
guanine | |||||
H | H | H | CH3 | S | 6-O-acetyl |
guanine | |||||
H | H | H | CH3 | S | 8-fluoroguanine |
H | H | H | CH3 | S | guanine |
H | H | H | CH3 | S | 6-(N,N-diacetyl)- |
adenine | |||||
H | H | H | CH3 | S | 2-fluoroadenine |
H | H | H | CH3 | S | 8-fluoroadenine |
H | H | H | CH3 | |
2,8-difluoro- |
adenine | |||||
H | H | H | CH3 | S | adenine |
monophosphate | H | H | CH3 | O | 2-(N,N-diacetyl)- |
guanine | |||||
monophosphate | H | H | CH3 | O | 6-O-acetyl |
guanine | |||||
monophosphate | H | H | CH3 | O | 8-fluoroguanine |
monophosphate | H | H | CH3 | O | guanine |
monophosphate | H | H | CH3 | O | 6-(N,N-diacetyl)- |
adenine | |||||
monophosphate | H | H | CH3 | O | 2-fluoroadenine |
monophosphate | H | H | CH3 | O | 8-fluoroadenine |
monophosphate | H | H | CH3 | O | 2,8-difluoro- |
adenine | |||||
monophosphate | H | H | CH3 | O | adenine |
monophosphate | H | H | CH3 | S | 2-(N,N-diacetyl)- |
guanine | |||||
monophosphate | H | H | CH3 | S | 6-O-acetyl |
guanine | |||||
monophosphate | H | H | CH3 | S | 8-fluoroguanine |
monophosphate | H | H | CH3 | S | guanine |
monophosphate | H | H | CH3 | S | 6-(N,N-diacetyl)- |
adenine | |||||
monophosphate | H | H | CH3 | S | 2-fluoroademne |
monophosphate | H | H | CH3 | S | 8-fluoroadenine |
monophosphate | H | H | CH3 | S | 2,8-difluoro- |
adenine | |||||
monophosphate | H | H | CH3 | S | adenine |
diphosphate | H | H | CH3 | O | 2-(N,N-diacetyl)- |
guanine | |||||
diphosphate | H | H | CH3 | O | 6-O-acetyl |
guanine | |||||
diphosphate | H | H | CH3 | O | 8-fluoroguanine |
diphosphate | H | H | CH3 | O | guanine |
diphosphate | H | H | CH3 | O | 6-(N,N-diacetyl)- |
adenine | |||||
diphosphate | H | H | CH3 | O | 2-fluoroadenine |
diphosphate | H | H | CH3 | O | 8-fluoroadenine |
diphosphate | H | H | CH3 | O | 2,8-difluoro- |
adenine | |||||
diphosphate | H | H | CH3 | O | adenine |
diphosphate | H | H | CH3 | S | 2-(N,N-diacetyl)- |
guanine | |||||
diphosphate | H | H | CH3 | S | 6-O-acetyl |
guanine | |||||
diphosphate | H | H | CH3 | S | 8-fluoroguanine |
diphosphate | H | H | CH3 | S | guanine |
diphosphate | H | H | CH3 | S | 6-(N,N-diacetyl)- |
adenine | |||||
diphosphate | H | H | CH3 | S | 2-fluoroadenine |
diphosphate | H | H | CH3 | S | 8-fluoroadenine |
diphosphate | H | H | CH3 | S | 2,8-difluoro- |
adenine | |||||
diphosphate | H | H | CH3 | S | adenine |
triphosphate | H | H | CH3 | O | 2-(N,N-diacetyl)- |
guanine | |||||
triphosphate | H | H | CH3 | O | 6-O-acetyl |
guanine | |||||
triphosphate | H | H | CH3 | O | 8-fluoroguanine |
triphosphate | H | H | CH3 | O | guanine |
triphosphate | H | H | CH3 | O | 6-(N,N-diacetyl)- |
adenine | |||||
triphosphate | H | H | CH3 | O | 2-fluoroadenine |
triphosphate | H | H | CH3 | O | 8-fluoroadenine |
triphosphate | H | H | CH3 | O | 2,8-difluoro- |
adenine | |||||
triphosphate | H | H | CH3 | O | 2-(N,N-diacetyl)- |
guanine | |||||
triphosphate | H | H | CH3 | S | 6-O-acetyl |
guanine | |||||
triphosphate | H | H | CH3 | S | 8-fluoroguanine |
triphosphate | H | H | CH3 | S | guanine |
triphosphate | H | H | CH3 | S | 6-(N,N-diacetyl)- |
adenine | |||||
triphosphate | H | H | CH3 | S | 2-fluoroadenine |
triphosphate | H | H | CH3 | S | 8-fluoroadenine |
triphosphate | H | H | CH3 | |
2,8-difluoro- |
adenine | |||||
triphosphate | H | H | CH3 | S | adenine |
monophosphate | monophosphate | monophosphate | CF3 | O | 2-(N,N-diacetyl)- |
guanine | |||||
monophosphate | monophosphate | monophosphate | CF3 | O | 6-O-acetyl |
guanine | |||||
monophosphate | monophosphate | monophosphate | CF3 | O | 8-fluoroguanine |
monophosphate | monophosphate | monophosphate | CF3 | O | guanine |
monophosphate | monophosphate | monophosphate | CF3 | O | 6-(N,N-diacetyl)- |
adenine | |||||
monophosphate | monophosphate | monophosphate | CF3 | O | 2-fluoroadenine |
monophosphate | monophosphate | monophosphate | CF3 | O | 8-fluoroadenine |
monophosphate | monophosphate | monophosphate | CF3 | O | 2,8-difluoro- |
adenine | |||||
monophosphate | monophosphate | monophosphate | CF3 | O | adenine |
monophosphate | monophosphate | monophosphate | CF3 | S | 2-(N,N-diacetyl)- |
guanine | |||||
monophosphate | monophosphate | monophosphate | CF3 | S | 6-O-acetyl |
guanine | |||||
monophosphate | monophosphate | monophosphate | CF3 | S | 8-fluoroguanine |
monophosphate | monophosphate | monophosphate | CF3 | S | guanine |
monophosphate | monophosphate | monophosphate | CF3 | S | 6-(N,N-diacetyl)- |
adenine | |||||
monophosphate | monophosphate | monophosphate | CF3 | S | 2-fluoroadenine |
monophosphate | monophosphate | monophosphate | CF3 | S | 8-fluoroadenine |
monophosphate | monophosphate | monophosphate | CF3 | S | 2,8-difluoro- |
adenine | |||||
monophosphate | monophosphate | monophosphate | CF3 | S | adenine |
acetyl | acetyl | acetyl | CF3 | O | guanine |
acetyl | acetyl | acetyl | CF3 | S | guanine |
acetyl | acetyl | acetyl | 2-bromo- | O | guanine |
vinyl | |||||
acetyl | acetyl | acetyl | 2-bromo- | S | guanine |
vinyl | |||||
Alternatively, the following nucleosides of Formula XI are prepared, using the appropriate sugar and pyrimidine or purine bases.
(XI) | |
|
|
wherein: |
R1 | R2 | R7 | R6 | X | Base |
H | H | H | CH3 | O | 2,4-O-Diacetyluracil |
H | H | H | CH3 | O | Hypoxanthine |
H | H | H | CH3 | O | 2,4-O-Diacetyithymine |
H | H | H | CH3 | O | Thymine |
H | H | H | CH3 | O | Cytosine |
H | H | H | CH3 | O | 4-(N-mono- |
acetyl)cytosine | |||||
H | H | H | CH3 | O | 4-(N,N-diacetyl)cytosine |
H | H | H | CH3 | O | Uracil |
H | H | H | CH3 | O | 5-Fluorouracil |
H | H | H | CH3 | S | 2,4-O-Diacetyluracil |
H | H | H | CH3 | S | Hypoxanthine |
H | H | H | CH3 | S | 2,4-O-Diacetyithymine |
H | H | H | CH3 | S | Thymine |
H | H | H | CH3 | S | Cytosine |
H | H | H | CH3 | S | 4-(N-mono-acetyl)cytosin |
H | H | H | CH3 | S | 4-(N,N-diacetyl)cytosine |
H | H | H | CH3 | S | Uracil |
H | H | H | CH3 | S | 5-Fluorouracil |
CH3 | |||||
monophosphate | H | H | CH3 | O | 2,4-O-Diacetyluracil |
monophosphate | H | H | CH3 | O | Hypoxanthine |
monophosphate | H | H | CH3 | O | 2,4-O-Diacetylthymine |
monophosphate | H | H | CH3 | O | Thymine |
monophosphate | H | H | CH3 | O | Cytosine |
monophosphate | H | H | CH3 | O | 4-(N-mono- |
acetyl)cytosine | |||||
monophosphate | H | H | CH3 | O | 4-(N,N-diacetyl)cytosine |
monophosphate | H | H | CH3 | O | Uracil |
monophosphate | H | H | CH3 | O | 5-Fluorouracil |
monophosphate | H | H | CH3 | S | 2,4-O-Diacetyluracil |
monophosphate | H | H | CH3 | S | Hypoxanthine |
monophosphate | H | H | CH3 | S | 2,4-O-Diacetylthymine |
monophosphate | H | H | CH3 | S | Thymine |
monophosphate | H | H | CH3 | S | Cytosine |
monophosphate | H | H | CH3 | S | 4-(N-mono- |
acetyl)cytosine | |||||
monophosphate | H | H | CH3 | S | 4-(N,N-diacetyl)cytosine |
monophosphate | H | H | CH3 | S | Uracil |
monophosphate | H | H | CH3 | S | 5-Fluorouracil |
diphosphate | H | H | CH3 | O | 2,4-O-Diacetylurac |
diphosphate | H | H | CH3 | O | Hypoxanthine |
diphosphate | H | H | CH3 | O | 2,4-O-Diacetylthymine |
diphosphate | H | H | CH3 | O | Thymine |
diphosphate | H | H | CH3 | O | Cytosine |
diphosphate | H | H | CH3 | O | 4-(N-mono- |
acetyl)cytosine | |||||
diphosphate | H | H | CH3 | O | 4-(N,N-diacetyl)cytosine |
diphosphate | H | H | CH3 | O | Uracil |
diphosphate | H | H | CH3 | O | 5-Fluorouracil |
diphosphate | H | H | CH3 | S | 2,4-O-Diacetyluracil |
diphosphate | H | H | CH3 | S | Hypoxanthine |
diphosphate | H | H | CH3 | S | 2,4-O-Diacetylthym |
diphosphate | H | H | CH3 | S | Thymine |
diphosphate | H | H | CH3 | S | Cytosine |
triphosphate | H | H | CH3 | O | 2,4-O-Diacetyluracil |
triphosphate | H | H | CH3 | O | Hypoxanthine |
triphosphate | H | H | CH3 | O | 2,4-O-Diacetylthymine |
triphosphate | H | H | CH3 | O | Thymine |
triphosphate | H | H | CH3 | O | Cytosine |
triphosphate | H | H | CH3 | O | 4-(N-mono- |
acetyl)cytosine | |||||
triphosphate | H | H | CH3 | O | 4-(N,N-diacetyl)cytos |
triphosphate | H | H | CH3 | O | Uracil |
triphosphate | H | H | CH3 | O | 5-Fluorouracil |
triphosphate | H | H | CH3 | S | 2,4-O-Diacetyluracil |
triphosphate | H | H | CH3 | S | Hypoxanthine |
triphosphate | H | H | CH3 | S | 2,4-O-Diacetylthym |
triphosphate | H | H | CH3 | S | Thymine |
triphosphate | H | H | CH3 | S | Cytosine |
monophosphate | monophosphate | Br | CF3 | O | 2,4-O-Diacetyluracil |
monophosphate | monophosphate | Br | CF3 | O | Hypoxanthine |
monophosphate | monophosphate | Br | CF3 | O | 2,4-O-Diacetylthymine |
monophosphate | monophosphate | Br | CF3 | O | Thymine |
monophosphate | monophosphate | Br | CF3 | O | Cytosine |
monophosphate | monophosphate | Br | CF3 | O | 4-(N-mono- |
acetyl)cytosine | |||||
monophosphate | monophosphate | Br | CF3 | O | 4-(N,N-diacetyl)cytosine |
monophosphate | monophosphate | Br | CF3 | O | Uracil |
monophosphate | monophosphate | Br | CF3 | O | 5-Fluorouracil |
monophosphate | monophosphate | Br | CF3 | S | 2,4-O-Diacetyluracil |
monophosphate | monophosphate | Br | CF3 | S | Hypoxanthine |
monophosphate | monophosphate | Br | CF3 | S | 2,4-O-Diacetylthymine |
monophosphate | monophosphate | Br | CF3 | S | Thymine |
monophosphate | monophosphate | Br | CF3 | S | Cytosine |
monophosphate | monophosphate | Br | CF3 | S | 4-(N-mono- |
acetyl)cytosine | |||||
monophosphate | monophosphate | Br | CF3 | S | 4-(N,N-diacetyl)cytos |
monophosphate | monophosphate | Br | CF3 | S | Uracil |
monophosphate | monophosphate | Br | CF3 | S | 5-Fluorouracil |
acetyl | acetyl | NO2 | CF3 | O | 4-(N,N-diacetyl)cytosine |
acetyl | acetyl | NO2 | CF3 | S | 4-(N,N-diacetyl)cytosine |
acetyl | acetyl | NO2 | CF3 | O | 4-(N,N-diacetyl)cytosine |
acetyl | acetyl | NO2 | 2-bromo- | S | 4-(N,N-diacetyl)cytosine |
vinyl | |||||
Alternatively, the following nucleosides of Formula XII are prepared, using the appropriate sugar and pyrimidine or purine bases.
(XII) | |
|
|
wherein: |
R1 | R6 | X | Base |
H | CH3 | O | 2,4-O-Diacetyluracil |
H | CH3 | O | Hyoxanthine |
H | CH3 | O | 2,4-O-Diacetyithymine |
H | CH3 | O | Thymine |
H | CH3 | O | Cytosine |
H | CH3 | O | 4-(N-mono-acetyl)cytosine |
H | CH3 | O | 4-(N,N-diacetyl)cytosine |
H | CH3 | O | Uracil |
H | CH3 | O | 5-Fluorouracil |
H | CH3 | S | 2,4-O-Diacetyluracil |
H | CH3 | S | Hypoxanthine |
H | CH3 | S | 2,4-O-Diacetylthymine |
H | CH3 | S | Thymine |
H | CH3 | S | Cytosine |
H | CH3 | S | 4-(N-mono-acetyl)cytosine |
H | CH3 | S | 4-(N,N-diacetyl)cytosine |
H | CH3 | S | Uracil |
H | CH3 | S | 5-Fluorouracil |
monophosphate | CH3 | O | 2,4-O-Diacetyluracil |
monophosphate | CH3 | O | Hypoxanthine |
monophosphate | CH3 | O | 2,4-O-Diacetylthymine |
monophosphate | CH3 | O | Thymine |
monophosphate | CH3 | O | Cytosine |
monophosphate | CH3 | O | 4-(N-mono-acetyl)cytosine |
monophosphate | CH3 | O | 4-(N,N-diacetyl)cytosine |
monophosphate | CH3 | O | Uracil |
monophosphate | CH3 | O | 5-Fluorouracil |
monophosphate | CH3 | S | 2,4-O-Diacetyluracil |
monophosphate | CH3 | S | Hypoxanthine |
monophosphate | CH3 | S | 2,4-O-Diacetylthymine |
monophosphate | CH3 | S | Thymine |
monophosphate | CH3 | S | Cytosine |
monophosphate | CH3 | S | 4-(N-mono-acetyl)cytosine |
monophosphate | CH3 | S | 4-(N,N-diacetyl)cytosine |
monophosphate | CH3 | S | Uracil |
monophosphate | CH3 | S | 5-Fluorouracil |
diphosphate | CH3 | O | 2,4-O-Diacetyluracil |
diphosphate | CH3 | O | Hypoxanthine |
diphosphate | CH3 | O | 2,4-O-Diacetylthymine |
diphosphate | CH3 | O | Thymine |
diphosphate | CH3 | O | Cytosine |
diphosphate | CH3 | O | 4-(N-mono-acetyl)cytosine |
diphosphate | CH3 | O | 4-(N,N-diacetyl)cytosine |
diphosphate | CH3 | O | Uracil |
diphosphate | CH3 | O | 5-Fluorouracil |
diphosphate | CH3 | S | 2,4-O-Diacetyluracil |
diphosphate | CH3 | S | Hypoxanthine |
diphosphate | CH3 | S | 2,4-O-Diacetylthymine |
diphosphate | CH3 | S | Thymine |
diphosphate | CH3 | S | Cytosine |
triphosphate | CH3 | O | 2,4-O-Diacetyluracil |
triphosphate | CH3 | O | Hypoxanthine |
triphosphate | CH3 | O | 2,4-O-Diacetylthymine |
triphosphate | CH3 | O | Thymine |
triphosphate | CH3 | O | Cytosine |
triphosphate | CH3 | O | 4-(N-mono-acetyl)cytosine |
triphosphate | CH3 | O | 4-(N,N-diacetyl)cytosine |
triphosphate | CH3 | O | Uracil |
triphosphate | CH3 | O | 5-Fluorouracil |
triphosphate | CH3 | S | 2,4-O-Diacetyluracil |
triphosphate | CH3 | S | Hypoxanthine |
triphosphate | CH3 | S | 2,4-O-Diacetylthymine |
triphosphate | CH3 | S | Thymine |
triphosphate | CH3 | S | Cytosine |
monophosphate | CF3 | O | 2,4-O-Diacetyluracil |
monophosphate | CF3 | O | Hypoxanthine |
monophosphate | CF3 | O | 2,4-O-Diacetylthymine |
monophosphate | CF3 | O | Thymine |
monophosphate | CF3 | O | Cytosine |
monophosphate | CF3 | O | 4-(N-mono-acetyl)cytosine |
monophosphate | CF3 | O | 4-(N,N-diacetyl)cytosine |
monophosphate | CF3 | O | Uracil |
monophosphate | CF3 | O | 5-Fluorouracil |
monophosphate | CF3 | S | 2,4-O-Diacetyluracil |
monophosphate | CF3 | S | Hypoxanthine |
monophosphate | CF3 | S | 2,4-O-Diacetylthymine |
monophosphate | CF3 | S | Thymine |
monophosphate | CF3 | S | Cytosine |
monophosphate | CF3 | S | 4-(N-mono-acetyl)cytosine |
monophosphate | CF3 | S | 4-(N,N-diacetyl)cytosine |
monophosphate | CF3 | S | Uracil |
monophosphate | CF3 | S | 5-Fluorouracil |
acetyl | CF3 | O | 4-(N,N-diacetyl)cytosine |
acetyl | CF3 | S | 4-(N,N-diacetyl)cytosine |
acetyl | 2-bromo-vinyl | O | 4-(N,N-diacetyl)cytosine |
acetyl | 2-bromo-vinyl | S | 4-(N,N-diacetyl)cytosine |
Alternatively, the following nucleosides of Formula XVII are prepared, using the appropriate sugar and pyrimidine or purine bases.
(XVII) | |
|
|
wherein: |
R1 | R6 | R7 | X | Base | R9 | R10 | |
H | CH3 | H | O | 2,4-O-Diacetyluracil | NHAc | Me | |
H | CH3 | H | O | Hypoxanthine | NH2 | Me | |
H | CH3 | H | O | 2,4-O-Diacetylthymine | NHAc | Me | |
H | CH3 | H | O | Thymine | NH2 | Me | |
H | CH3 | H | O | Cytosine | NH2 | Me | |
H | CH3 | H | O | 4-(N-mono-acetyl)cytosine | NHAc | Me | |
H | CH3 | H | O | 4-(N,N-diacetyl)cytosine | NHAc | Me | |
H | CH3 | H | O | Uracil | NH2 | Me | |
H | CH3 | H | O | 5-Fluorouracil | NH2 | Me | |
H | CH3 | H | S | 2,4-O-Diacetyluracil | NHAc | Me | |
H | CH3 | H | S | Hypoxanthine | NH2 | Me | |
H | CH3 | H | S | 2,4-O-Diacetylthymine | NHAc | Me | |
H | CH3 | H | S | Thymine | NH2 | Me | |
H | CH3 | H | S | Cytosine | NH2 | Me | |
H | CH3 | H | S | 4-(N-mono-acetyl)cytosine | NHAc | Me | |
H | CH3 | H | S | 4-(N,N-diacetyl)cytosine | NHAc | Me | |
H | CH3 | H | S | Uracil | NH2 | Me | |
H | CH3 | H | S | 5-Fluorouracil | NH2 | Me | |
monophosphate | CH3 | H | O | 2,4-O-Diacetyluracil | NHAc | Me | |
monophosphate | CH3 | H | O | Hypoxanthine | NH2 | Me | |
monophosphate | CH3 | | O | 2,4-O-Diacetylthymine | NHAc | Me | |
monophosphate | CH3 | H | O | Thymine | NH2 | Me | |
monophosphate | CH3 | H | O | Cytosine | NH2 | Me | |
monophosphate | CH3 | H | O | 4-(N-mono-acetyl)cytosine | NHAC | Me | |
monophosphate | CH3 | H | O | 4-(N,N-diacetyl)cytosine | NHAc | Me | |
monophosphate | CH3 | H | O | Uracil | NH2 | Me | |
monophosphate | CH3 | H | O | 5-Fluorouracil | NH2 | Me | |
monophosphate | CH3 | H | S | 2,4-O-Diacetyluracil | NHAc | Me | |
monophosphate | CH3 | H | S | Hypoxanthine | NH2 | Me | |
monophosphate | CH3 | H | S | 2,4-O-Diacetylthymine | NHAc | Me | |
monophosphate | CH3 | H | S | Thymine | NH2 | Me | |
monophosphate | CH3 | H | S | Cytosine | NH2 | Me | |
monophosphate | CH3 | H | S | 4-(N-mono-acetyl)cytosine | NHAc | Me | |
monophosphate | CH3 | H | S | 4-(N,N-diacetyl)cytosine | NHAc | Me | |
monophosphate | CH3 | H | S | Uracil | NH2 | Me | |
monophosphate | CH3 | H | S | 5-Fluorouracil | NH2 | Me | |
diphosphate | CH3 | H | O | 2,4-O-Diacetyluracil | NHAc | Me | |
diphosphate | CH3 | H | O | Hypoxanthine | NH2 | Me | |
diphosphate | CH3 | | O | 2,4-O-Diacetylthymine | NH2 | Me | |
diphosphate | CH3 | H | O | Thymine | NH2 | Me | |
diphosphate | CH3 | H | O | Cytosine | NH2 | Me | |
diphosphate | CH3 | H | O | 4-(N-mono-acetyl)cytosine | NHAc | Me | |
diphosphate | CH3 | H | O | 4-(N,N-diacetyl)cytos | NHAc | Me | |
diphosphate | CH3 | H | O | Uracil | NH2 | Me | |
diphosphate | CH3 | H | O | 5-Fluorouracil | NH2 | Me | |
diphosphate | CH3 | H | S | 2,4-O-Diacetyluracil | NH2 | Me | |
diphosphate | CH3 | H | S | Hypoxanthine | NH2 | Me | |
diphosphate | CH3 | H | S | 2,4-O-Diacetylthymine | NHAc | Me | |
diphosphate | CH3 | H | S | Thymine | NH2 | Me | |
diphosphate | CH3 | H | S | Cytosine | NH2 | Me | |
triphosphate | CH3 | H | O | 2,4-O-Diacetyluracil | NHAc | Me | |
triphosphate | CH3 | H | O | Hypoxanthine | NHAc | Me | |
triphosphate | CH3 | H | O | 2,4-O-Diacetylthymine | NHAc | Me | |
triphosphate | CH3 | H | O | Thymine | NH2 | Me | |
triphosphate | CH3 | H | O | Cytosine | NH2 | Me | |
triphosphate | CH3 | H | O | 4-(N-mono-acetyl)cytosine | NHAc | Me | |
triphosphate | CH3 | H | O | 4-(N,N-diacetyl)cytosine | NH2 | Me | |
triphosphate | CH3 | H | O | Uracil | NH2 | Me | |
triphosphate | CH3 | H | O | 5-Fluorouracil | NH2 | Me | |
triphosphate | CH3 | H | S | 2,4-O-Diacetyluracil | NH2 | Me | |
triphosphate | CH3 | H | S | Hypoxanthine | NH2 | Me | |
triphosphate | CH3 | H | S | 2,4-O-Diacetylthymine | NH2 | Me | |
triphosphate | CH3 | H | S | Thymine | NH2 | Me | |
triphosphate | CH3 | H | S | Cytosine | NH2 | Me | |
monophosphate | CF3 | H | O | 2,4-O-Diacetyluracil | NH2 | Me | |
monophosphate | CF3 | H | O | Hypoxanthine | NH2 | Me | |
monophosphate | CF3 | H | O | 2,4-O-Diacetylthymine | NH2 | Me | |
monophosphate | CF3 | H | O | Thymine | NH2 | Me | |
monophosphate | CF3 | H | O | Cytosine | NH2 | Me | |
monophosphate | CF3 | H | O | 4-(N-mono-acetyl)cytosine | NH2 | Me | |
monophosphate | CF3 | H | O | 4-(N,N-diacetyl)cytosine | NH2 | Me | |
monophosphate | CF3 | H | O | Uracil | NH2 | Me | |
monophosphate | CF3 | H | O | 5-Fluorouracil | NH2 | Me | |
monophosphate | CF3 | H | S | 2,4-O-Diacetyluracil | NH2 | Me | |
monophosphate | CF3 | H | S | Hypoxanthine | NH2 | Me | |
monophosphate | CF3 | H | S | 2,4-O-Diacetylthymine | NH2 | Me | |
monophosphate | CF3 | H | S | Thymine | NH2 | Me | |
monophosphate | CF3 | H | S | Cytosine | NH2 | Me | |
monophosphate | CF3 | H | S | 4-(N-mono-acetyl)cytosine | NH2 | Me | |
monophosphate | CF3 | H | S | 4-(N,N-diacetyl)cytosine | NH2 | Me | |
monophosphate | CF3 | H | S | Uracil | NH2 | Me | |
monophosphate | CF3 | H | S | 5-Fluorouracil | NH2 | Me | |
acetyl | CH3 | H | O | 4-(N,N-diacetyl)cytosine | H | Br | |
acetyl | CH3 | H | S | 4-(N,N-diacetyl)cytosine | H | Br | |
acetyl | CH3 | OH | O | 4-(N,N-diacetyl)cytosine | H | Br | |
acetyl | CH3 | OH | S | 4-(N,N-diacetyl)cytosine | H | Br | |
The title compound can be prepared according to a published procedure (R. F. Nutt, M. J. Dickinson, F. W. Holly, and E. Walton, “Branched-chain sugar nucleosides. III. 3′-C-methyladenine”, J. Org. Chem. 1968, 33, 1789-1795) (Scheme 9).
In a similar manner, but using the appropriate sugar and pyrimidine or purine bases, the following nucleosides of Formula III are prepared.
(III) | |
|
|
wherein: |
R1 | R2 | R3 | X1 | X2 | Y |
H | H | H | H | H | H |
H | H | H | H | H | NH2 |
H | H | H | H | H | NH-cyclopropyl |
H | H | H | H | H | NH-methyl |
H | H | H | H | H | NH-ethyl |
H | H | H | H | H | NH-acetyl |
H | H | H | H | H | OH |
H | H | H | H | H | OMe |
H | H | H | H | H | OEt |
H | H | H | H | H | O-cyclopropyl |
H | H | H | H | H | O-acetyl |
H | H | H | H | H | SH |
H | H | H | H | H | SMe |
H | H | H | H | H | SEt |
H | H | H | H | H | S-cyclopropyl |
H | H | H | H | H | F |
H | H | H | H | H | Cl |
H | H | H | H | H | Br |
H | H | H | H | H | I |
monophosphate | H | H | H | H | NH2 |
monophosphate | H | H | H | H | NH-acetyl |
monophosphate | H | H | H | H | NH-cyclopropyl |
monophosphate | H | H | H | H | NH-methyl |
monophosphate | H | H | H | H | NH-ethyl |
monophosphate | H | H | H | H | OH |
monophosphate | H | H | H | H | O-acetyl |
monophosphate | H | H | H | H | OMe |
monophosphate | H | H | H | H | OEt |
monophosphate | H | H | H | H | O-cyclopropyl |
monophosphate | H | H | H | H | SH |
monophosphate | H | H | H | H | SMe |
monophosphate | H | H | H | H | SEt |
monophosphate | H | H | H | H | S-cyclopropyl |
monophosphate | H | H | H | H | F |
monophosphate | H | H | H | H | Cl |
monophosphate | H | H | H | H | Br |
monophosphate | H | H | H | H | I |
diphosphate | H | H | H | H | NH2 |
diphosphate | H | H | H | H | NH-acetyl |
diphosphate | H | H | H | H | NH-cyclopropyl |
diphosphate | H | H | H | H | NH-methyl |
diphosphate | H | H | H | H | NH-ethyl |
diphosphate | H | H | H | H | OH |
diphosphate | H | H | H | H | O-acetyl |
diphosphate | H | H | H | H | OMe |
diphosphate | H | H | H | H | OEt |
diphosphate | H | H | H | H | O-cyclopropyl |
diphosphate | H | H | H | H | SH |
diphosphate | H | H | H | H | SMe |
diphosphate | H | H | H | H | SEt |
diphosphate | H | H | H | H | S-cyclopropyl |
diphosphate | H | H | H | H | F |
diphosphate | H | H | H | H | Cl |
diphosphate | H | H | H | H | Br |
diphosphate | H | H | H | H | I |
triphosphate | H | H | H | H | NH2 |
triphosphate | H | H | H | H | NH-acetyl |
triphosphate | H | H | H | H | NH-cyclopropyl |
triphosphate | H | H | H | H | NH-methyl |
triphosphate | H | H | H | H | NH-ethyl |
triphosphate | H | H | H | H | OH |
triphosphate | H | H | H | H | OMe |
triphosphate | H | H | H | H | OEt |
triphosphate | H | H | H | H | O-cyclopropyl |
triphosphate | H | H | H | H | O-acetyl |
triphosphate | H | H | H | H | SH |
triphosphate | H | H | H | H | SMe |
triphosphate | H | H | H | H | SEt |
triphosphate | H | H | H | H | S-cyclopropyl |
triphosphate | H | H | H | H | F |
triphosphate | H | H | H | H | Cl |
triphosphate | H | H | H | H | Br |
triphosphate | H | H | H | H | I |
monophosphate | monophosphate | monophosphate | H | H | NH2 |
monophosphate | monophosphate | monophosphate | H | H | NH-cyclopropyl |
monophosphate | monophosphate | monophosphate | H | H | OH |
monophosphate | monophosphate | monophosphate | H | H | F |
monophosphate | monophosphate | monophosphate | H | H | Cl |
diphosphate | diphosphate | diphosphate | H | H | NH2 |
diphosphate | diphosphate | diphosphate | H | H | NH-cyclopropyl |
diphosphate | diphosphate | diphosphate | H | H | OH |
diphosphate | diphosphate | diphosphate | H | H | F |
diphosphate | diphosphate | diphosphate | H | H | Cl |
triphosphate | triphosphate | triphosphate | H | H | NH2 |
triphosphate | triphosphate | triphosphate | H | H | NH-cyclopropyl |
triphosphate | triphosphate | triphosphate | H | H | OH |
triphosphate | triphosphate | triphosphate | H | H | F |
triphosphate | triphosphate | triphosphate | H | H | Cl |
H | H | H | F | H | NH2 |
H | H | H | F | H | NH-cyclopropyl |
H | H | H | F | H | OH |
H | H | H | F | H | F |
H | H | H | F | H | Cl |
H | H | H | Cl | H | NH2 |
H | H | H | Cl | H | NH-cyclopropyl |
H | H | H | Cl | H | OH |
H | H | H | Cl | H | F |
H | H | H | Cl | H | Cl |
H | H | H | Br | H | NH2 |
H | H | H | Br | H | NH-cyclopropyl |
H | H | H | Br | H | OH |
H | H | H | Br | H | F |
H | H | H | Br | H | Cl |
H | H | H | NH2 | H | NH2 |
H | H | H | NH2 | H | NH-cyclopropyl |
H | H | H | NH2 | H | OH |
H | H | H | NH2 | H | F |
H | H | H | NH2 | H | Cl |
H | H | H | SH | H | NH2 |
H | H | H | SH | H | NH-cyclopropyl |
H | H | H | SH | H | OH |
H | H | H | SH | H | F |
H | H | H | SH | H | Cl |
acetyl | H | H | H | H | NH2 |
acetyl | H | H | H | H | NH-cyclopropyl |
acetyl | H | H | H | H | OH |
acetyl | H | H | H | H | F |
acetyl | H | H | H | H | Cl |
acetyl | H | H | F | H | NH2 |
acetyl | H | H | F | H | NH-cyclopropyl |
acetyl | H | H | F | H | OH |
acetyl | H | H | F | H | F |
acetyl | H | H | F | H | Cl |
H | acetyl | acetyl | H | H | NH2 |
H | acetyl | acetyl | H | H | NH-cyclopropyl |
H | acetyl | acetyl | H | H | OH |
H | acetyl | acetyl | H | H | F |
H | acetyl | acetyl | H | H | Cl |
acetyl | acetyl | acetyl | H | H | NH2 |
acetyl | acetyl | acetyl | H | H | NH-cyclopropyl |
acetyl | acetyl | acetyl | H | H | OH |
acetyl | acetyl | acetyl | H | H | F |
acetyl | acetyl | acetyl | H | H | Cl |
monophosphate | acetyl | acetyl | H | H | NH2 |
monophosphate | acetyl | acetyl | H | H | NH-cyclopropyl |
monophosphate | acetyl | acetyl | H | H | OH |
monophosphate | acetyl | acetyl | H | H | F |
monophosphate | acetyl | acetyl | H | H | Cl |
diphosphate | acetyl | acetyl | H | H | NH2 |
diphosphate | acetyl | acetyl | H | H | NH-cyclopropyl |
diphosphate | acetyl | acetyl | H | H | OH |
diphosphate | acetyl | acetyl | H | H | F |
diphosphate | acetyl | acetyl | H | H | Cl |
triphosphate | acetyl | acetyl | H | H | NH2 |
triphosphate | acetyl | acetyl | H | H | NH-cyclopropyl |
triphosphate | acetyl | acetyl | H | H | OH |
triphosphate | acetyl | acetyl | H | H | F |
triphosphate | acetyl | acetyl | H | H | Cl |
H | H | H | H | NH2 | H |
H | H | H | H | NH2 | NH2 |
H | H | H | H | NH2 | NH-cyclopropyl |
H | H | H | H | NH2 | NH-methyl |
H | H | H | H | NH2 | NH-ethyl |
H | H | H | H | NH2 | NH-acetyl |
H | H | H | H | NH2 | OH |
H | H | H | H | NH2 | OMe |
H | H | H | H | NH2 | OEt |
H | H | H | H | NH2 | O-cyclopropyl |
H | H | H | H | NH2 | O-acetyl |
H | H | H | H | NH2 | SH |
H | H | H | H | NH2 | SMe |
H | H | H | H | NH2 | SEt |
H | H | H | H | NH2 | S-cyclopropyl |
H | H | H | H | NH2 | F |
H | H | H | H | NH2 | Cl |
H | H | H | H | NH2 | Br |
H | H | H | H | NH2 | I |
monophosphate | H | H | H | NH2 | NH2 |
monophosphate | H | H | H | NH2 | NH-acetyl |
monophosphate | H | H | H | NH2 | NH-cyclopropyl |
monophosphate | H | H | H | NH2 | NH-methyl |
monophosphate | H | H | H | NH2 | NH-ethyl |
monophosphate | H | H | H | NH2 | OH |
monophosphate | H | H | H | NH2 | O-acetyl |
monophosphate | H | H | H | NH2 | OMe |
monophosphate | H | H | H | NH2 | OEt |
monophosphate | H | H | H | NH2 | O-cyclopropyl |
monophosphate | H | H | H | NH2 | SH |
monophosphate | H | H | H | NH2 | SMe |
monophosphate | H | H | H | NH2 | SEt |
monophosphate | H | H | H | NH2 | S-cyclopropyl |
monophosphate | H | H | H | NH2 | F |
monophosphate | H | H | H | NH2 | Cl |
monophosphate | H | H | H | NH2 | Br |
monophosphate | H | H | H | NH2 | I |
diphosphate | H | H | H | NH2 | NH2 |
diphosphate | H | H | H | NH2 | NH-acetyl |
diphosphate | H | H | H | NH2 | NH-cyclopropyl |
diphosphate | H | H | H | NH2 | NH-methyl |
diphosphate | H | H | H | NH2 | NH-ethyl |
diphosphate | H | H | H | NH2 | OH |
diphosphate | H | H | H | NH2 | O-acetyl |
diphosphate | H | H | H | NH2 | OMe |
diphosphate | H | H | H | NH2 | OEt |
diphosphate | H | H | H | NH2 | O-cyclopropyl |
diphosphate | H | H | H | NH2 | SH |
diphosphate | H | H | H | NH2 | SMe |
diphosphate | H | H | H | NH2 | SEt |
diphosphate | H | H | H | NH2 | S-cyclopropyl |
diphosphate | H | H | H | NH2 | F |
diphosphate | H | H | H | NH2 | Cl |
diphosphate | H | H | H | NH2 | Br |
diphosphate | H | H | H | NH2 | I |
triphosphate | H | H | H | NH2 | NH2 |
triphosphate | H | H | H | NH2 | NH-acetyl |
triphosphate | H | H | H | NH2 | NH-cyclopropyl |
triphosphate | H | H | H | NH2 | NH-methyl |
triphosphate | H | H | H | NH2 | NH-ethyl |
triphosphate | H | H | H | NH2 | OH |
triphosphate | H | H | H | NH2 | OMe |
triphosphate | H | H | H | NH2 | OEt |
triphosphate | H | H | H | NH2 | O-cyclopropyl |
triphosphate | H | H | H | NH2 | O-acetyl |
triphosphate | H | H | H | NH2 | SH |
triphosphate | H | H | H | NH2 | SMe |
triphosphate | H | H | H | NH2 | SEt |
triphosphate | H | H | H | NH2 | S-cyclopropyl |
triphosphate | H | H | H | NH2 | F |
triphosphate | H | H | H | NH2 | Cl |
triphosphate | H | H | H | NH2 | Br |
triphosphate | H | H | H | NH2 | I |
monophosphate | monophosphate | monophosphate | H | NH2 | NH2 |
monophosphate | monophosphate | monophosphate | H | NH2 | NH-cyclopropyl |
monophosphate | monophosphate | monophosphate | H | NH2 | OH |
monophosphate | monophosphate | monophosphate | H | NH2 | F |
monophosphate | monophosphate | monophosphate | H | NH2 | Cl |
diphosphate | diphosphate | diphosphate | H | NH2 | NH2 |
diphosphate | diphosphate | diphosphate | H | NH2 | NH-cyclopropyl |
diphosphate | diphosphate | diphosphate | H | NH2 | OH |
diphosphate | diphosphate | diphosphate | H | NH2 | F |
diphosphate | diphosphate | diphosphate | H | NH2 | Cl |
triphosphate | triphosphate | triphosphate | H | NH2 | NH2 |
triphosphate | triphosphate | triphosphate | H | NH2 | NH-cyclopropyl |
triphosphate | triphosphate | triphosphate | H | NH2 | OH |
triphosphate | triphosphate | triphosphate | H | NH2 | F |
triphosphate | triphosphate | triphosphate | H | NH2 | Cl |
H | H | H | F | NH2 | NH2 |
H | H | H | F | NH2 | NH-cyclopropyl |
H | H | H | F | NH2 | OH |
H | H | H | F | NH2 | F |
H | H | H | F | NH2 | Cl |
H | H | H | Cl | NH2 | NH2 |
H | H | H | Cl | NH2 | NH-cyclopropyl |
H | H | H | Cl | NH2 | OH |
H | H | H | Cl | NH2 | F |
H | H | H | Cl | NH2 | Cl |
H | H | H | Br | NH2 | NH2 |
H | H | H | Br | NH2 | NH-cyclopropyl |
H | H | H | Br | NH2 | OH |
H | H | H | Br | NH2 | F |
H | H | H | Br | NH2 | Cl |
H | H | H | NH2 | NH2 | NH2 |
H | H | H | NH2 | NH2 | NH-cyclopropyl |
H | H | H | NH2 | NH2 | OH |
H | H | H | NH2 | NH2 | F |
H | H | H | NH2 | NH2 | Cl |
H | H | H | SH | NH2 | NH2 |
H | H | H | SH | NH2 | NH-cyclopropyl |
H | H | H | SH | NH2 | OH |
H | H | H | SH | NH2 | F |
H | H | H | SH | NH2 | Cl |
acetyl | H | H | H | NH2 | NH2 |
acetyl | H | H | H | NH2 | NH-cyclopropyl |
acetyl | H | H | H | NH2 | OH |
acetyl | H | H | H | NH2 | F |
acetyl | H | H | H | NH2 | Cl |
acetyl | H | H | F | NH2 | NH2 |
acetyl | H | H | F | NH2 | NH-cyclopropyl |
acetyl | H | H | F | NH2 | OH |
acetyl | H | H | F | NH2 | F |
acetyl | H | H | F | NH2 | Cl |
H | acetyl | acetyl | H | NH2 | NH2 |
H | acetyl | acetyl | H | NH2 | NH-cyclopropyl |
H | acetyl | acetyl | H | NH2 | OH |
H | acetyl | acetyl | H | NH2 | F |
H | acetyl | acetyl | H | NH2 | Cl |
acetyl | acetyl | acetyl | H | NH2 | NH2 |
acetyl | acetyl | acetyl | H | NH2 | NH-cyclopropyl |
acetyl | acetyl | acetyl | H | NH2 | OH |
acetyl | acetyl | acetyl | H | NH2 | F |
acetyl | acetyl | acetyl | H | NH2 | Cl |
monophosphate | acetyl | acetyl | H | NH2 | NH2 |
monophosphate | acetyl | acetyl | H | NH2 | NH-cyclopropyl |
monophosphate | acetyl | acetyl | H | NH2 | OH |
monophosphate | acetyl | acetyl | H | NH2 | F |
monophosphate | acetyl | acetyl | H | NH2 | Cl |
diphosphate | acetyl | acetyl | H | NH2 | NH2 |
diphosphate | acetyl | acetyl | H | NH2 | NH-cyclopropyl |
diphosphate | acetyl | acetyl | H | NH2 | OH |
diphosphate | acetyl | acetyl | H | NH2 | F |
diphosphate | acetyl | acetyl | H | NH2 | Cl |
triphosphate | acetyl | acetyl | H | NH2 | NH2 |
triphosphate | acetyl | acetyl | H | NH2 | NH-cyclopropyl |
triphosphate | acetyl | acetyl | H | NH2 | OH |
triphosphate | acetyl | acetyl | H | NH2 | F |
triphosphate | acetyl | acetyl | H | NH2 | Cl |
H | H | H | H | Cl | H |
H | H | H | H | Cl | H |
H | H | H | H | Cl | NH2 |
H | H | H | H | Cl | NH-cyclopropyl |
H | H | H | H | Cl | NH-methyl |
H | H | H | H | Cl | NH-ethyl |
H | H | H | H | Cl | NH-acetyl |
H | H | H | H | Cl | OH |
H | H | H | H | Cl | OMe |
H | H | H | H | Cl | OEt |
H | H | H | H | Cl | O-cyclopropyl |
H | H | H | H | Cl | O-acetyl |
H | H | H | H | Cl | SH |
H | H | H | H | Cl | SMe |
H | H | H | H | Cl | SEt |
H | H | H | H | Cl | S-cyclopropyl |
monophosphate | H | H | H | Cl | NH2 |
monophosphate | H | H | H | Cl | NH-acetyl |
monophosphate | H | H | H | Cl | NH-cyclopropyl |
monophosphate | H | H | H | Cl | NH-methyl |
monophosphate | H | H | H | Cl | NH-ethyl |
monophosphate | H | H | H | Cl | OH |
monophosphate | H | H | H | Cl | O-acetyl |
monophosphate | H | H | H | Cl | OMe |
monophosphate | H | H | H | Cl | OEt |
monophosphate | H | H | H | Cl | O-cyclopropyl |
monophosphate | H | H | H | Cl | SH |
monophosphate | H | H | H | Cl | SMe |
monophosphate | H | H | H | Cl | SEt |
monophosphate | H | H | H | Cl | S-cyclopropyl |
diphosphate | H | H | H | Cl | NH2 |
diphosphate | H | H | H | Cl | NH-acetyl |
diphosphate | H | H | H | Cl | NH-cyclopropyl |
diphosphate | H | H | H | Cl | NH-methyl |
diphosphate | H | H | H | Cl | NH-ethyl |
diphosphate | H | H | H | Cl | OH |
diphosphate | H | H | H | Cl | O-acetyl |
diphosphate | H | H | H | Cl | OMe |
diphosphate | H | H | H | Cl | OEt |
diphosphate | H | H | H | Cl | O-cyclopropyl |
diphosphate | H | H | H | Cl | SH |
diphosphate | H | H | H | Cl | SMe |
diphosphate | H | H | H | Cl | SEt |
diphosphate | H | H | H | Cl | S-cyclopropyl |
triphosphate H | H | H | Cl | NH2 | |
triphosphate | H | H | H | Cl | NH-acetyl |
triphosphate | H | H | H | Cl | NH-cyclopropyl |
triphosphate | H | H | H | Cl | NH-methyl |
triphosphate | H | H | H | Cl | NH-ethyl |
triphosphate | H | H | H | Cl | OH |
triphosphate | H | H | H | Cl | OMe |
triphosphate | H | H | H | Cl | OEt |
triphosphate | H | H | H | Cl | O-cyclopropyl |
triphosphate | H | H | H | Cl | O-acetyl |
triphosphate | H | H | H | Cl | SH |
triphosphate | H | H | H | Cl | SMe |
triphosphate | H | H | H | Cl | SEt |
triphosphate | H | H | H | Cl | S-cyclopropyl |
monophosphate | monophosphate | monophosphate | H | Cl | NH2 |
monophosphate | monophosphate | monophosphate | H | Cl | NH-cyclopropyl |
monophosphate | monophosphate | monophosphate | H | Cl | OH |
diphosphate | diphosphate | diphosphate | H | Cl | NH2 |
diphosphate | diphosphate | diphosphate | H | Cl | NH-cyclopropyl |
diphosphate | diphosphate | diphosphate | H | Cl | OH |
triphosphate | triphosphate | triphosphate | H | Cl | NH2 |
triphosphate | triphosphate | triphosphate | H | Cl | NH-cyclopropyl |
triphosphate | triphosphate | triphosphate | H | Cl | OH |
H | H | H | F | Cl | NH2 |
H | H | H | F | Cl | NH-cyclopropyl |
H | H | H | F | Cl | OH |
H | H | H | Cl | Cl | NH2 |
H | H | H | Cl | Cl | NH-cyclopropyl |
H | H | H | Cl | Cl | OH |
H | H | H | Br | Cl | NH2 |
H | H | H | Br | Cl | NH-cyclopropyl |
H | H | H | Br | Cl | OH |
H | H | H | NH2 | Cl | NH2 |
H | H | H | NH2 | Cl | NH-cyclopropyl |
H | H | H | NH2 | Cl | OH |
H | H | H | SH | Cl | NH2 |
H | H | H | SH | Cl | NH-cyclopropyl |
H | H | H | SH | Cl | OH |
acetyl | H | H | H | Cl | NH2 |
acetyl | H | H | H | Cl | NH-cyclopropyl |
acetyl | H | H | H | Cl | OH |
acetyl | H | H | F | Cl | NH2 |
acetyl | H | H | F | Cl | NH-cyclopropyl |
acetyl | H | H | F | Cl | OH |
H | acetyl | acetyl | H | Cl | NH2 |
H | acetyl | acetyl | H | Cl | NH-cyclopropyl |
H | acetyl | acetyl | H | Cl | OH |
acetyl | acetyl | acetyl | H | Cl | NH2 |
acetyl | acetyl | acetyl | H | Cl | NH-cyclopropyl |
acetyl | acetyl | acetyl | H | Cl | OH |
monophosphate | acetyl | acetyl | H | Cl | NH2 |
monophosphate | acetyl | acetyl | H | Cl | NH-cyclopropyl |
monophosphate | acetyl | acetyl | H | Cl | OH |
diphosphate | acetyl | acetyl | H | Cl | NH2 |
diphosphate | acetyl | acetyl | H | Cl | NH-cyclopropyl |
diphosphate | acetyl | acetyl | H | Cl | OH |
triphosphate | acetyl | acetyl | H | Cl | NH2 |
triphosphate | acetyl | acetyl | H | Cl | NH-cyclopropyl |
triphosphate | acetyl | acetyl | H | Cl | OH |
H | H | H | H | Cl | NH2 |
H | H | H | H | Cl | NH-cyclopropyl |
H | H | H | H | Cl | OH |
H | H | H | H | Br | NH2 |
H | H | H | H | Br | NH-cyclopropyl |
H | H | H | H | Br | OH |
Alternatively, the following nucleosides of Formula VI are prepared, using the appropriate sugar and pyrimidine or purine bases.
(VI) | |
|
|
wherein: |
R1 | R2 | R3 | X1 | Y |
H | H | H | H | H |
H | H | H | H | NH2 |
H | H | H | H | NH-cyclopropyl |
H | H | H | H | NH-methyl |
H | H | H | H | NH-ethyl |
H | H | H | H | NH-acetyl |
H | H | H | H | OH |
H | H | H | H | OMe |
H | H | H | H | OEt |
H | H | H | H | O-cyclopropyl |
H | H | H | H | O-acetyl |
H | H | H | H | SH |
H | H | H | H | SMe |
H | H | H | H | SEt |
H | H | H | H | S-cyclopropyl |
monophosphate | H | H | H | NH2 |
monophosphate | H | H | H | NH-acetyl |
monophosphate | H | H | H | NH-cyclopropyl |
monophosphate | H | H | H | NH-methyl |
monophosphate | H | H | H | NH-ethyl |
monophosphate | H | H | H | OH |
monophosphate | H | H | H | O-acetyl |
monophosphate | H | H | H | OMe |
monophosphate | H | H | H | OEt |
monophosphate | H | H | H | O-cyclopropyl |
monophosphate | H | H | H | SH |
monophosphate | H | H | H | SMe |
monophosphate | H | H | H | SEt |
monophosphate | H | H | H | S-cyclopropyl |
diphosphate | H | H | H | NH2 |
diphosphate | H | H | H | NH-acetyl |
diphosphate | H | H | H | NH-cyclopropyl |
diphosphate | H | H | H | NH-methyl |
diphosphate | H | H | H | NH-ethyl |
diphosphate | H | H | H | OH |
diphosphate | H | H | H | O-acetyl |
diphosphate | H | H | H | OMe |
diphosphate | H | H | H | OEt |
diphosphate | H | H | H | O-cyclopropyl |
diphosphate | H | H | H | SH |
diphosphate | H | H | H | SMe |
diphosphate | H | H | H | SEt |
diphosphate | H | H | H | S-cyclopropyl |
triphosphate | H | H | H | NH2 |
triphosphate | H | H | H | NH-acetyl |
triphosphate | H | H | H | NH-cyclopropyl |
triphosphate | H | H | H | NH-methyl |
triphosphate | H | H | H | NH-ethyl |
triphosphate | H | H | H | OH |
triphosphate | H | H | H | OMe |
triphosphate | H | H | H | OEt |
triphosphate | H | H | H | O-cyclopropyl |
triphosphate | H | H | H | O-acetyl |
triphosphate | H | H | H | SH |
triphosphate | H | H | H | SMe |
triphosphate | H | H | H | SEt |
triphosphate | H | H | H | S-cyclopropyl |
monophosphate | monophosphate | monophosphate | H | NH2 |
monophosphate | monophosphate | monophosphate | H | NH-cyclopropyl |
monophosphate | monophosphate | monophosphate | H | OH |
diphosphate | diphosphate | diphosphate | H | NH2 |
diphosphate | diphosphate | diphosphate | H | NH-cyclopropyl |
diphosphate | diphosphate | diphosphate | H | OH |
triphosphate | triphosphate | triphosphate | H | NH2 |
triphosphate | triphosphate | triphosphate | H | NH-cyclopropyl |
triphosphate | triphosphate | triphosphate | H | OH |
H | H | H | F | NH2 |
H | H | H | F | NH-cyclopropyl |
H | H | H | F | OH |
H | H | H | Cl | NH2 |
H | H | H | Cl | NH-cyclopropyl |
H | H | H | Cl | OH |
H | H | H | Br | NH2 |
H | H | H | Br | NH-cyclopropyl |
H | H | H | Br | OH |
H | H | H | NH2 | NH2 |
H | H | H | NH2 | NH-cyclopropyl |
H | H | H | NH2 | OH |
H | H | H | SH | NH2 |
H | H | H | SH | NHcyclopropyl |
H | H | H | SH | OH |
acetyl | H | H | H | NH2 |
acetyl | H | H | H | NH-cyclopropyl |
acetyl | H | H | H | OH |
acetyl | H | H | F | NH2 |
acetyl | H | H | F | NH-cyclopropyl |
acetyl | H | H | F | OH |
H | acetyl | acetyl | H | NH2 |
H | acetyl | acetyl | H | NH-cyclopropyl |
H | acetyl | acetyl | H | OH |
acetyl | acetyl | acetyl | H | NH2 |
acetyl | acetyl | acetyl | H | NH-cyclopropyl |
acetyl | acetyl | acetyl | H | OH |
monophosphate | acetyl | acetyl | H | NH2 |
monophosphate | acetyl | acetyl | H | NH-cyclopropyl |
monophosphate | acetyl | acetyl | H | OH |
diphosphate | acetyl | acetyl | H | NH2 |
diphosphate | acetyl | acetyl | H | NH-cyclopropyl |
diphosphate | acetyl | acetyl | H | OH |
triphosphate | acetyl | acetyl | H | NH2 |
triphosphate | acetyl | acetyl | H | NH-cyclopropyl |
triphosphate | acetyl | acetyl | H | OH |
Alternatively, the following nucleosides of Formula XIII are prepared, using the appropriate sugar and pyrimidine or purine bases.
(XIII) | |
|
|
wherein: |
R1 | R2 | R3 | R6 | X | Base |
H | H | H | CH3 | O | 2,4-O- |
Diacetyluracil | |||||
H | H | H | CH3 | O | Hypoxanthine |
H | H | H | CH3 | O | 2,4-O- |
Diacetylthymine | |||||
H | H | H | CH3 | O | Thymine |
H | H | H | CH3 | O | Cytosine |
H | H | H | CH3 | O | 4-(N-mono- |
acetyl)cytosine | |||||
H | H | H | CH3 | O | 4-(N,N- |
diacetyl)cytosine | |||||
H | H | H | CH3 | O | Uracil |
H | H | H | CH3 | O | 5-Fluorouracil |
H | H | H | CH3 | |
2,4-O- |
Diacetyluraci | |||||
H | H | H | CH3 | S | Hypoxanthine |
H | H | H | CH3 | |
2,4-O- |
Diacetylthymine | |||||
H | H | H | CH3 | S | Thymine |
H | H | H | CH3 | S | Cytosine |
H | H | H | CH3 | S | 4-(N-mono- |
acetyl)cytosine | |||||
H | H | H | CH3 | S | 4-(N,N- |
diacetyl)cytosine | |||||
H | H | H | CH3 | S | Uracil |
H | H | H | CH3 | S | 5-Fluorouracil |
monophosphate | H | H | CH3 | |
2,4-O- |
Diacetyluracil | |||||
monophosphate | H | H | CH3 | O | Hypoxanthine |
monophosphate | H | H | CH3 | |
2,4-O- |
Diacetylthym | |||||
monophosphate | H | H | CH3 | O | Thymine |
monophosphate | H | H | CH3 | O | Cytosine |
monophosphate | H | H | CH3 | O | 4-(N-mono- |
acetyl)cytosine | |||||
monophosphate | H | H | CH3 | O | 4-(N,N- |
diacetyl)cytosine | |||||
monophosphate | H | H | CH3 | O | Uracil |
monophosphate | H | H | CH3 | O | 5-Fluorouracil |
monophosphate | H | H | CH3 | S | 2,4-O- |
Diacetyluracil | |||||
monophosphate | H | H | CH3 | S | Hypoxanthine |
monophosphate | H | H | CH3 | S | 2,4-O- |
Diacetylthym | |||||
monophosphate | H | H | CH3 | S | Thymine |
monophosphate | H | H | CH3 | S | Cytosine |
monophosphate | H | H | CH3 | S | 4-(N-mono- |
acetyl)cytosine | |||||
monophosphate | H | H | CH3 | S | 4-(N,N- |
diacetyl)cytosine | |||||
monophosphate | H | H | CH3 | S | Uracil |
monophosphate | H | H | CH3 | S | 5-Fluorouracil |
diphosphate | H | H | CH3 | O | 2,4-O- |
Diacetyluracil | |||||
diphosphate | H | H | CH3 | O | Hypoxanthine |
diphosphate | H | H | CH3 | O | 2,4-O- |
Diacetylthymine | |||||
diphosphate | H | H | CH3 | O | Thymine |
diphosphate | H | H | CH3 | O | Cytosine |
diphosphate | H | H | CH3 | O | 4-(N-mono- |
acetyl)cytosine | |||||
diphosphate | H | H | CH3 | O | 4-(N,N- |
diacetyl)cytosine | |||||
diphosphate | H | H | CH3 | O | Uracil |
diphosphate | H | H | CH3 | O | 5-Fluorouracil |
diphosphate | H | H | CH3 | S | 2,4-O- |
Diacetyluracil | |||||
diphosphate | H | H | CH3 | S | Hypoxanthine |
diphosphate | H | H | CH3 | S | 2,4-O- |
Diacetylthym | |||||
diphosphate | H | H | CH3 | S | Thymine |
diphosphate | H | H | CH3 | S | Cytosine |
triphosphate | H | H | CH3 | O | 2,4-O- |
Diacetyluracil | |||||
triphosphate | H | H | CH3 | O | Hypoxanthine |
triphosphate | H | H | CH3 | O | 2,4-O- |
Diacetylthymine | |||||
triphosphate | H | H | CH3 | O | Thymine |
triphosphate | H | H | CH3 | O | Cytosine |
triphosphate | H | H | CH3 | O | 4-(N-mono- |
acetyl)cytosine | |||||
triphosphate | H | H | CH3 | O | 4-(N,N- |
diacetyl)cytosine | |||||
triphosphate | H | H | CH3 | O | Uracil |
triphosphate | H | H | CH3 | O | 5-Fluorouracil |
triphosphate | H | H | CH3 | |
2,4-O- |
Diacetyluracil | |||||
triphosphate | H | H | CH3 | S | Hypoxanthine |
triphosphate | H | H | CH3 | |
2,4-O- |
Diacetylthymine | |||||
triphosphate | H | H | CH3 | S | Thymine |
triphosphate | H | H | CH3 | S | Cytosine |
monophosphate | monophosphate | monophosphate | CF3 | O | 2,4-O- |
Diacetyluracil | |||||
monophosphate | monophosphate | monophosphate | CF3 | O | Hypoxanthine |
monophosphate | monophosphate | monophosphate | CF3 | O | 2,4-O- |
Diacetylthymine | |||||
monophosphate | monophosphate | monophosphate | CF3 | O | Thymine |
monophosphate | monophosphate | monophosphate | CF3 | O | Cytosine |
monophosphate | monophosphate | monophosphate | CF3 | O | 4-(N-mono- |
acetyl)cytosine | |||||
monophosphate | monophosphate | monophosphate | CF3 | O | 4-(N,N- |
diacetyl)cytosine | |||||
monophosphate | monophosphate | monophosphate | CF3 | O | Uracil |
monophosphate | monophosphate | monophosphate | CF3 | O | 5-Fluorouracil |
monophosphate | monophosphate | monophosphate | CF3 | S | 2,4-O- |
Diacetyluracil | |||||
monophosphate | monophosphate | monophosphate | CF3 | S | Hypoxanthine |
monophosphate | monophosphate | monophosphate | CF3 | S | 2,4-O- |
Diacetylthymine | |||||
monophosphate | monophosphate | monophosphate | CF3 | S | Thymine |
monophosphate | monophosphate | monophosphate | CF3 | S | Cytosine |
monophosphate | monophosphate | monophosphate | CF3 | S | 4-(N-mono- |
acetyl)cytosine | |||||
monophosphate | monophosphate | monophosphate | CF3 | S | 4-(N,N- |
diacetyl)cytosine | |||||
monophosphate | monophosphate | monophosphate | CF3 | S | Uracil |
monophosphate | monophosphate | monophosphate | CF3 | S | 5-Fluorouracil |
acetyl | acetyl | acetyl | CF3 | O | 4-(N,N- |
diacetyl)cytosine | |||||
acetyl | acetyl | acetyl | CF3 | S | 4-(N,N- |
diacetyl)cytosine | |||||
acetyl | acetyl | acetyl | 2-bromo- | O | 4-(N,N- |
vinyl | diacetyl)cytosine | ||||
acetyl | acetyl | acetyl | 2-bromo- | S | 4-(N,N- |
vinyl | diacetyl)cytosine | ||||
H | H | H | CH3 | O | 2-(N,N-diacetyl)- |
guanine | |||||
H | H | H | CH3 | O | 6-O-acetyl |
guanine | |||||
H | H | H | CH3 | O | 8-fluoroguanine |
H | H | H | CH3 | O | guanine |
H | H | H | CH3 | O | 6-(N,N-diacetyl)- |
adenine | |||||
H | H | H | CH3 | O | 2-fluoroadenine |
H | H | H | CH3 | O | 8-fluoroadenine |
H | H | H | CH3 | O | 2,8-difluoro- |
adenine | |||||
H | H | H | CH3 | O | adenine |
H | H | H | CH3 | S | 2-(N,N-diacetyl)- |
guanine | |||||
H | H | H | CH3 | S | 6-O-acetyl |
guanine | |||||
H | H | H | CH3 | S | 8-fluoroguanine |
H | H | H | CH3 | S | guanine |
H | H | H | CH3 | S | 6-(N,N-diacetyl)- |
adenine | |||||
H | H | H | CH3 | S | 2-fluoroadenine |
H | H | H | CH3 | S | 8-fluoroadenine |
H | H | H | CH3 | |
2,8-difluoro- |
adenine | |||||
H | H | H | CH3 | S | adenine |
monophosphate | H | H | CH3 | O | 2-(N,N-diacetyl)- |
guanine | |||||
monophosphate | H | H | CH3 | O | 6-O-acetyl |
guanine | |||||
monophosphate | H | H | CH3 | O | 8-fluoroguanine |
monophosphate | H | H | CH3 | O | guanine |
monophosphate | H | H | CH3 | O | 6-(N,N-diacetyl)- |
adenine | |||||
monophosphate | H | H | CH3 | O | 2-fluoroadenine |
monophosphate | H | H | CH3 | O | 8-fluoroadenine |
monophosphate | H | H | CH3 | O | 2,8-difluoro- |
adenine | |||||
monophosphate | H | H | CH3 | O | adenine |
monophosphate | H | H | CH3 | S | 2-(N,N-diacetyl)- |
guanine | |||||
monophosphate | H | H | CH3 | S | 6-O-acetyl |
guanine | |||||
monophosphate | H | H | CH3 | S | 8-fluoroguanine |
monophosphate | H | H | CH3 | S | guanine |
monophosphate | H | H | CH3 | S | 6-(N,N-diacetyl)- |
adenine | |||||
monophosphate | H | H | CH3 | S | 2-fluoroadenine |
monophosphate | H | H | CH3 | S | 8-fluoroadenine |
monophosphate | H | H | CH3 | S | 2,8-difluoro- |
ademnine | |||||
monophosphate | H | H | CH3 | S | adenine |
diphosphate | H | H | CH3 | O | 2-(N,N-diacetyl)- |
guanine | |||||
diphosphate | H | H | CH3 | O | 6-O-acetyl |
guanine | |||||
diphosphate | H | H | CH3 | O | 8-fluoroguanine |
diphosphate | H | H | CH3 | O | guanine |
diphosphate | H | H | CH3 | O | 6-(N,N-diacetyl)- |
adenine | |||||
diphosphate | H | H | CH3 | O | 2-fluoroadenine |
diphosphate | H | H | CH3 | O | 8-fluoroadenine |
diphosphate | H | H | CH3 | O | 2,8-difluoro- |
adenine | |||||
diphosphate | H | H | CH3 | O | adenine |
diphosphate | H | H | CH3 | S | 2-(N,N-diacetyl)- |
guanine | |||||
diphosphate | H | H | CH3 | S | 6-O-acetyl |
guanine | |||||
diphosphate | H | H | CH3 | S | 8-fluoroguanine |
diphosphate | H | H | CH3 | S | guanine |
diphosphate | H | H | CH3 | S | 6-(N,N-diacetyl)- |
adenine | |||||
diphosphate | H | H | CH3 | S | 2-fluoroadenine |
diphosphate | H | H | CH3 | S | 8-fluoroadenine |
diphosphate | H | H | CH3 | S | 2,8-difluoro- |
adenine | |||||
diphosphate | H | H | CH3 | S | adenine |
triphosphate | H | H | CH3 | O | 2-(N,N-diacetyl)- |
guanine | |||||
triphosphate | H | H | CH3 | O | 6-O-acetyl |
guanine | |||||
triphosphate | H | H | CH3 | O | 8-fluoroguanine |
triphosphate | H | H | CH3 | O | guanine |
triphosphate | H | H | CH3 | O | 6-(N,N-diacetyl)- |
adenine | |||||
triphosphate | H | H | CH3 | O | 2-fluoroadenine |
triphosphate | H | H | CH3 | O | 8-fluoroadenine |
triphosphate | H | H | CH3 | O | 2,8-difluoro- |
adenine | |||||
triphosphate | H | H | CH3 | O | 2-(N,N-diacetyl)- |
guanine | |||||
triphosphate | H | H | CH3 | S | 6-O-acetyl |
guanine | |||||
triphosphate | H | H | CH3 | S | 8-fluoroguanine |
triphosphate | H | H | CH3 | S | guanine |
triphosphate | H | H | CH3 | S | 6-(N,N-diacetyl)- |
adenine | |||||
triphosphate | H | H | CH3 | S | 2-fluoroadenine |
triphosphate | H | H | CH3 | S | 8-fluoroadenine |
triphosphate | H | H | CH3 | |
2,8-difluoro- |
adenine | |||||
triphosphate | H | H | CH3 | S | adenine |
monophosphate | monophosphate | monophosphate | CF3 | O | 2-(N,N-diacetyl)- |
guanine | |||||
monophosphate | monophosphate | monophosphate | CF3 | O | 6-O-acetyl |
guanine | |||||
monophosphate | monophosphate | monophosphate | CF3 | O | 8-fluoroguanine |
monophosphate | monophosphate | monophosphate | CF3 | O | guanine |
monophosphate | monophosphate | monophosphate | CF3 | O | 6-(N,N-diacetyl)- |
adenine | |||||
monophosphate | monophosphate | monophosphate | CF3 | O | 2-fluoroadenine |
monophosphate | monophosphate | monophosphate | CF3 | O | 8-fluoroadenine |
monophosphate | monophosphate | monophosphate | CF3 | O | 2,8-difluoro- |
adenine | |||||
monophosphate | monophosphate | monophosphate | CF3 | O | adenine |
monophosphate | monophosphate | monophosphate | CF3 | S | 2-(N,N-diacetyl)- |
guanine | |||||
monophosphate | monophosphate | monophosphate | CF3 | S | 6-O-acetyl |
guanine | |||||
monophosphate | monophosphate | monophosphate | CF3 | S | 8-fluoroguanine |
monophosphate | monophosphate | monophosphate | CF3 | S | guanine |
monophosphate | monophosphate | monophosphate | CF3 | S | 6-(N,N-diacetyl)- |
adenine | |||||
monophosphate | monophosphate | monophosphate | CF3 | S | 2-fluoroadenine |
monophosphate | monophosphate | monophosphate | CF3 | S | 8-fluoroadenine |
monophosphate | monophosphate | monophosphate | CF3 | S | 2,8-difluoro- |
adenine | |||||
monophosphate | monophosphate | monophosphate | CF3 | S | adenine |
acetyl | acetyl | acetyl | CF3 | O | guanine |
acetyl | acetyl | acetyl | CF3 | S | guanine |
acetyl | acetyl | acetyl | 2-bromo- | O | guanine |
vinyl | |||||
acetyl | acetyl | acetyl | 2-bromo- | S | guanine |
vinyl | |||||
Alternatively, the following nucleosides of Formula XIV are prepared, using the appropriate sugar and pyrimidine or purine bases.
(XIV) | |
|
|
wherein: |
R1 | R2 | R6 | X | Base |
H | H | CH3 | O | 2,4-O-Diacetyluracil |
H | H | CH3 | O | Hypoxanthine |
H | H | CH3 | O | 2,4-O-Diacetylthymine |
H | H | CH3 | O | Thymine |
H | H | CH3 | O | Cytosine |
H | H | CH3 | O | 4-(N-mono-acetyl)cytosine |
H | H | CH3 | O | 4-(N,N-diacetyl)cytosine |
H | H | CH3 | O | Uracil |
H | H | CH3 | O | 5-Fluorouracil |
H | H | CH3 | S | 2,4-O-Diacetyluracil |
H | H | CH3 | S | Hypoxanthine |
H | H | CH3 | S | 2,4-O-Diacetylthymine |
H | H | CH3 | S | Thymine |
H | H | CH3 | S | Cytosine |
H | H | CH3 | S | 4-(N-mono-acetyl)cytosin |
H | H | CH3 | S | 4-(N,N-diacetyl)cytosine |
H | H | CH3 | S | Uracil |
H | H | CH3 | S | 5-Fluorouracil |
monophosphate | H | CH3 | |
2,4-O-Diacetyluracil |
monophosphate | H | CH3 | O | Hypoxanthine |
monophosphate | H | CH3 | O | 2,4-O-Diacetylthym |
monophosphate | H | CH3 | O | Thymine |
monophosphate | H | CH3 | O | Cytosine |
monophosphate | H | CH3 | O | 4-(N-mono-acetyl)cytosine |
monophosphate | H | CH3 | O | 4-(N,N-diacetyl)cytos |
monophosphate | H | CH3 | O | Uracil |
monophosphate | H | CH3 | O | 5-Fluorouracil |
monophosphate | H | CH3 | S | 2,4-O-Diacetyluracil |
monophosphate | H | CH3 | S | Hypoxanthine |
monophosphate | H | CH3 | S | 2,4-O-Diacetylthym |
monophosphate | H | CH3 | S | Thymine |
monophosphate | H | CH3 | S | Cytosine |
monophosphate | H | CH3 | S | 4-(N-mono-acetyl)cytosine |
monophosphate | H | CH3 | S | 4-(N,N-diacetyl)cytosine |
monophosphate | H | CH3 | S | Uracil |
monophosphate | H | CH3 | S | 5-Fluorouracil |
diphosphate | H | CH3 | O | 2,4-O-Diacetyluracil |
diphosphate | H | CH3 | O | Hypoxanthine |
diphosphate | H | CH3 | O | 2,4-O-Diacetylthymine |
diphosphate | H | CH3 | O | Thymine |
diphosphate | H | CH3 | O | Cytosine |
diphosphate | H | CH3 | O | 4-(N-mono-acetyl)cytosine |
diphosphate | H | CH3 | O | 4-(N,N-diacetyl)cytosine |
diphosphate | H | CH3 | O | Uracil |
diphosphate | H | CH3 | O | 5-Fluorouracil |
diphosphate | H | CH3 | S | 2,4-O-Diacetyluracil |
diphosphate | H | CH3 | S | Hypoxanthine |
diphosphate | H | CH3 | S | 2,4-O-Diacetylthymine |
diphosphate | H | CH3 | S | Thymine |
diphosphate | H | CH3 | S | Cytosine |
triphosphate | H | CH3 | O | 2,4-O-Diacetyluracil |
triphosphate | H | CH3 | O | Hypoxanthine |
triphosphate | H | CH3 | O | 2,4-O-Diacetylthymine |
triphosphate | H | CH3 | O | Thymine |
triphosphate | H | CH3 | O | Cytosine |
triphosphate | H | CH3 | O | 4-(N-mono-acetyl)cytosine |
triphosphate | H | CH3 | O | 4-(N,N-diacetyl)cytosine |
triphosphate | H | CH3 | O | Uracil |
triphosphate | H | CH3 | O | 5-Fluorouracil |
triphosphate | H | CH3 | S | 2,4-O-Diacetyluracil |
triphosphate | H | CH3 | S | Hypoxanthine |
triphosphate | H | CH3 | |
2,4-O-Diacetylthymine |
triphosphate | H | CH3 | S | Thymine |
triphosphate | H | CH3 | S | Cytosine |
monophosphate | monophosphate | CF3 | O | 2,4-O-Diacetyluracil |
monophosphate | monophosphate | CF3 | O | Hypoxanthine |
monophosphate | monophosphate | CF3 | O | 2,4-O-Diacetylthymine |
monophosphate | monophosphate | CF3 | O | Thymine |
monophosphate | monophosphate | CF3 | O | Cytosine |
monophosphate | monophosphate | CF3 | O | 4-(N-mono-acetyl)cytosine |
monophosphate | monophosphate | CF3 | O | 4-(N,N-diacetyl)cytosine |
monophosphate | monophosphate | CF3 | O | Uracil |
monophosphate | monophosphate | CF3 | O | 5-Fluorouracil |
monophosphate | monophosphate | CF3 | S | 2,4-O-Diacetyluracil |
monophosphate | monophosphate | CF3 | S | Hypoxanthine |
monophosphate | monophosphate | CF3 | S | 2,4-O-Diacetylthymine |
monophosphate | monophosphate | CF3 | S | Thymine |
monophosphate | monophosphate | CF3 | S | Cytosine |
monophosphate | monophosphate | CF3 | S | 4-(N-mono-acetyl)cytosine |
monophosphate | monophosphate | CF3 | S | 4-(N,N-diacetyl)cytosine |
monophosphate | monophosphate | CF3 | S | Uracil |
monophosphate | monophosphate | CF3 | S | 5-Fluorouracil |
acetyl | acetyl | CF3 | O | 4-(N,N-diacetyl)cytosine |
acetyl | acetyl | CF3 | S | 4-(N,N-diacetyl)cytosine |
acetyl | acetyl | 2-bromo- | O | 4-(N,N-diacetyl)cytosine |
vinyl | ||||
acetyl | acetyl | 2-bromo- | S | 4-(N,N-diacetyl)cytosine |
vinyl | ||||
Alternatively, the following nucleosides of Formula XV are prepared, using the appropriate sugar and pyrimidine or purine bases.
(XV) | |
|
|
wherein: |
R1 | R6 | X | Base |
H | CH3 | O | 2,4-O-Diacetyluracil |
H | CH3 | O | Hypoxanthine |
H | CH3 | O | 2,4-O-Diacetylthymine |
H | CH3 | O | Thymine |
H | CH3 | O | Cytosine |
H | CH3 | O | 4-(N-mono-acetyl)cytosine |
H | CH3 | O | 4-(N,N-diacetyl)cytosine |
H | CH3 | O | Uracil |
H | CH3 | O | 5-Fluorouracil |
H | CH3 | S | 2,4-O-Diacetyluracil |
H | CH3 | S | Hypoxanthine |
H | CH3 | S | 2,4-O-Diacetylthymine |
H | CH3 | S | Thymine |
H | CH3 | S | Cytosine |
H | CH3 | S | 4-(N-mono-acetyl)cytosine |
H | CH3 | S | 4-(N,N-diacetyl)cytosine |
H | CH3 | S | Uracil |
H | CH3 | S | 5-Fluorouracil |
monophosphate | CH3 | |
2,4-O-Diacetyluracil |
monophosphate | CH3 | O | Hypoxanthine |
monophosphate | CH3 | O | 2,4-O-Diacetylthymine |
monophosphate | CH3 | O | Thymine |
monophosphate | CH3 | O | Cytosine |
monophosphate | CH3 | O | 4-(N-mono-acetyl)cytosine |
monophosphate | CH3 | O | 4-(N,N-diacetyl)cytosine |
monophosphate | CH3 | O | Uracil |
monophosphate | CH3 | O | 5-Fluorouracil |
monophosphate | CH3 | S | 2,4-O-Diacetyluracil |
monophosphate | CH3 | S | Hypoxanthine |
monophosphate | CH3 | S | 2,4-O-Diacetylthymine |
monophosphate | CH3 | S | Thymine |
monophosphate | CH3 | S | Cytosine |
monophosphate | CH3 | S | 4-(N-mono-acetyl)cytosine |
monophosphate | CH3 | S | 4-(N,N-diacetyl)cytosine |
monophosphate | CH3 | S | Uracil |
monophosphate | CH3 | S | 5-Fluorouracil |
diphosphate | CH3 | O | 2,4-O-Diacetyluracil |
diphosphate | CH3 | O | Hypoxanthine |
diphosphate | CH3 | O | 2,4-O-Diacetylthylmine |
diphosphate | CH3 | O | Thymine |
diphosphate | CH3 | O | Cytosine |
diphosphate | CH3 | O | 4-(N-mono-acetyl)cytosine |
diphosphate | CH3 | O | 4-(N,N-diacetyl)cytosine |
diphosphate | CH3 | O | Uracil |
diphosphate | CH3 | O | 5-Fluorouracil |
diphosphate | CH3 | S | 2,4-O-Diacetyluracil |
diphosphate | CH3 | S | Hypoxanthine |
diphosphate | CH3 | S | 2,4-O-Diacetylthymine |
diphosphate | CH3 | S | Thymine |
diphosphate | CH3 | S | Cytosine |
triphosphate | CH3 | O | 2,4-O-Diacetyluracil |
triphosphate | CH3 | O | Hypoxanthine |
triphosphate | CH3 | O | 2,4-O-Diacetylthymine |
triphosphate | CH3 | O | Thymine |
triphosphate | CH3 | O | Cytosine |
triphosphate | CH3 | O | 4-(N-mono-acetyl)cytosine |
triphosphate | CH3 | O | 4-(N,N-diacetyl)cytosine |
triphosphate | CH3 | O | Uracil |
triphosphate | CH3 | O | 5-Fluorouracil |
triphosphate | CH3 | |
2,4-O-Diacetyluracil |
triphosphate | CH3 | S | Hypoxanthine |
triphosphate | CH3 | |
2,4-O-Diacetylthymine |
triphosphate | CH3 | S | Thymine |
triphosphate | CH3 | S | Cytosine |
monophosphate | CF3 | O | 2,4-O-Diacetyluracil |
monophosphate | CF3 | O | Hypoxanthine |
monophosphate | CF3 | O | 2,4-O-Diacetylthymine |
monophosphate | CF3 | O | Thymine |
monophosphate | CF3 | O | Cytosine |
monophosphate | CF3 | O | 4-(N-mono-acetyl)cytosine |
monophosphate | CF3 | O | 4-(N,N-diacetyl)cytosine |
monophosphate | CF3 | O | Uracil |
monophosphate | CF3 | O | 5-Fluorouracil |
monophosphate | CF3 | S | 2,4-O-Diacetyluracil |
monophosphate | CF3 | S | Hypoxanthine |
monophosphate | CF3 | S | 2,4-O-Diacetylthymine |
monophosphate | CF3 | S | Thymine |
monophosphate | CF3 | S | Cytosine |
monophosphate | CF3 | S | 4-(N-mono-acetyl)cytosine |
monophosphate | CF3 | S | 4-(N,N-diacetyl)cytosine |
monophosphate | CF3 | S | Uracil |
monophosphate | CF3 | S | 5-Fluorouracil |
acetyl | CF3 | O | 4-(N,N-diacetyl)cytosine |
acetyl | CF3 | S | 4-(N,N-diacetyl)cytosine |
acetyl | 2-bromo-vinyl | O | 4-(N,N-diacetyl)cytosine |
acetyl | 2-bromo-vinyl | S | 4-(N,N-diacetyl)cytosine |
Alternatively, the following nucleosides of Formula XVIII are prepared, using the appropriate sugar and pyrimidine or purine bases.
(XVIII) | |
| |
wherein: |
R1 | R6 | R7 | X | Base | R8 | R9 |
H | CH3 | OH | O | 2,4-O-Diacetyluracil | H | Me |
H | CH3 | OH | O | Hypoxanthine | H | Me |
H | CH3 | OH | O | 2,4-O-Diacetylthymine | H | Me |
H | CH3 | OH | O | Thymine | H | Me |
H | CH3 | OH | O | Cytosine | H | Me |
H | CH3 | OH | O | 4-(N-mono-acetyl)cytosine | H | Me |
H | CH3 | OH | O | 4-(N,N-diacetyl)cytosine | H | Me |
H | CH3 | OH | O | Uracil | H | Me |
H | CH3 | OH | O | 5-Fluorouracil | H | Me |
H | CH3 | OH | S | 2,4-O-Diacetyluracil | H | Me |
H | CH3 | OH | S | Hypoxanthine | H | Me |
H | CH3 | OH | S | 2,4-O-Diacetylthymine | H | Me |
H | CH3 | OH | S | Thymine | H | Me |
H | CH3 | OH | S | Cytosine | H | Me |
H | CH3 | OH | S | 4-(N-mono-acetyl)cytosine | H | Me |
H | CH3 | OH | S | 4-(N,N-diacetyl)cytosine | H | Me |
H | CH3 | OH | S | Uracil | H | Me |
H | CH3 | OH | S | 5-Fluorouracil | H | Me |
monophosphate | CH3 | OH | O | 2,4-O-Diacetyluracil | H | Me |
monophosphate | CH3 | OH | O | Hypoxanthine | H | Me |
monophosphate | CH3 | OH | O | 2,4-O-Diacetylthymine | H | Me |
monophosphate | CH3 | OH | O | Thymine | H | Me |
monophosphate | CH3 | OH | O | Cytosine | H | Me |
monophosphate | CH3 | OH | O | 4-(N-mono-acetyl)cytosine | H | Me |
monophosphate | CH3 | OH | O | 4-(N,N-diacetyl)cytosine | H | Me |
monophosphate | CH3 | OH | O | Uracil | H | Me |
monophosphate | CH3 | OH | O | 5-Fluorouracil | H | Me |
monophosphate | CH3 | OH | S | 2,4-O-Diacetyluracil | H | Me |
monophosphate | CH3 | OH | S | Hypoxanthine | H | Me |
monophosphate | CH3 | OH | S | 2,4-O-Diacetylthymine | H | Me |
monophosphate | CH3 | OH | S | Thymine | H | Me |
monophosphate | CH3 | OH | S | Cytosine | H | Me |
monophosphate | CH3 | OH | S | 4-(N-mono-acetyl)cytosine | H | Me |
monophosphate | CH3 | OH | S | 4-(N,N-diacetyl)cytosine | H | Me |
monophosphate | CH3 | OH | S | Uracil | H | Me |
monophosphate | CH3 | OH | S | 5-Fluorouracil | H | Me |
diphosphate | CH3 | OH | O | 2,4-O-Diacetyluracil | H | Me |
diphosphate | CH3 | OH | O | Hypoxanthine | H | Me |
diphosphate | CH3 | OH | O | 2,4-O-Diacetylthymine | H | Me |
diphosphate | CH3 | OH | O | Thymine | H | Me |
diphosphate | CH3 | OH | O | Cytosine | H | Me |
diphosphate | CH3 | OH | O | 4-(N-mono-acetyl)cytosine | H | Me |
diphosphate | CH3 | OH | O | 4-(N,N-diacetyl)cytosine | H | Me |
diphosphate | CH3 | OH | O | Uracil | H | Me |
diphosphate | CH3 | OH | O | 5-Fluorouracil | H | Me |
diphosphate | CH3 | OH | S | 2,4-O-Diacetyluracil | H | Me |
diphosphate | CH3 | OH | S | Hypoxanthine | H | Me |
diphosphate | CH3 | OH | S | 2,4-O-Diacetylthymine | H | Me |
diphosphate | CH3 | OH | S | Thymine | H | Me |
diphosphate | CH3 | OH | S | Cytosine | H | Me |
triphosphate | CH3 | OH | O | 2,4-O-Diacetyluracil | H | Me |
triphosphate | CH3 | OH | O | Hypoxanthine | H | Me |
triphosphate | CH3 | OH | O | 2,4-O-Diacetylthymine | H | Me |
triphosphate | CH3 | OH | O | Thymine | H | Me |
triphosphate | CH3 | OH | O | Cytosine | H | Me |
triphosphate | CH3 | OH | O | 4-(N-mono-acetyl)cytosine | H | Me |
triphosphate | CH3 | OH | O | 4-(N,N-diacetyl)cytosine | H | Me |
triphosphate | CH3 | OH | O | Uracil | H | Me |
triphosphate | CH3 | OH | O | 5-Fluorouracil | H | Me |
triphosphate | CH3 | OH | | 2,4-O-Diacetyluracil | H | Me |
triphosphate | CH3 | OH | S | Hypoxanthine | H | Me |
triphosphate | CH3 | OH | | 2,4-O-Diacetylthymine | H | Me |
triphosphate | CH3 | OH | S | Thymine | H | Me |
triphosphate | CH3 | OH | S | Cytosine | H | Me |
monophosphate | CF3 | OH | O | 2,4-O-Diacetyluracil | H | Me |
monophosphate | CF3 | OH | O | Hypoxanthine | H | Me |
monophosphate | CF3 | OH | O | 2,4-O-Diacetylthymine | H | Me |
monophosphate | CF3 | OH | O | Thymine | H | Me |
monophosphate | CF3 | OH | O | Cytosine | H | Me |
monophosphate | CF3 | OH | O | 4-(N-mono-acetyl)cytosine | H | Me |
monophosphate | CF3 | OH | O | 4-(N,N-diacetyl)cytosine | H | Me |
monophosphate | CF3 | OH | O | Uracil | H | Me |
monophosphate | CF3 | OH | O | 5-Fluorouracil | H | Me |
monophosphate | CF3 | OH | S | 2,4-O-Diacetyluracil | H | Me |
monophosphate | CF3 | OH | S | Hypoxanthine | H | Me |
monophosphate | CF3 | OH | S | 2,4-O-Diacetylthymine | H | Me |
monophosphate | CF3 | OH | S | Thymine | H | Me |
monophosphate | CF3 | OH | S | Cytosine | H | Me |
monophosphate | CF3 | OH | S | 4-(N-mono-acetyl)cytosine | H | Me |
monophosphate | CF3 | OH | S | 4-(N,N-diacetyl)cytosine | H | Me |
monophosphate | CF3 | OH | S | Uracil | H | Me |
monophosphate | CF3 | OH | S | 5-Fluorouracil | H | Me |
acetyl | CH3 | OH | O | 4-(N,N-diacetyl)cytosine | H | Br |
acetyl | CH3 | OH | S | 4-(N,N-diacetyl)cytosine | H | Br |
VII. Anti-Flavivirus or Pestivirus Activity
Compounds can exhibit anti-flavivirus or pestivirus activity by inhibiting flavivirus or pestivirus polymerase, by inhibiting other enzymes needed in the replication cycle, or by other pathways.
The test compounds were dissolved in DMSO at an initial concentration of 200 μM and then were serially diluted in culture medium.
Unless otherwise stated, baby hamster kidney (BHK-21) (ATCC CCL-10) and Bos Taurus (BT) (ATCC CRL 1390) cells were grown at 37° C. in a humidified CO2 (5%) atmosphere. BHK-21 cells were passaged in Eagle MEM additioned of 2 mM L-glutamine, 10% fetal bovine serum (FBS, Gibco) and Earle's BSS adjusted to contain 1.5 g/L sodium bicarbonate and 0.1 mM non-essential amino acids. BT cells were passaged in Dulbecco's modified Eagle's medium with 4 mM L-glutamine and 10% horse serum (HS, Gibco), adjusted to contain 1.5 g/L sodium bicarbonate, 4.5 g/L glucose and 1.0 mM sodium pyruvate. The vaccine strain 17D (YFV-17D) (Stamaril®, Pasteur Merieux) and Bovine Viral Diarrhea virus (BVDV) (ATCC VR-534) were used to infect BHK and BT cells, respectively, in 75 cm2 bottles. After a 3 day incubation period at 37° C., extensive cytopathic effect was observed. Cultures were freeze-thawed three times, cell debris were removed by centrifugation and the supernatant was aliquoted and stored at −70° C. YFV-17D and BVDV were titrated in BHK-21 and BT cells, respectively, that were grown to confluency in 24-well plates.
To determine the cellular metabolism of the compounds, HepG2 cells were obtained from the American Type Culture Collection (Rockville, Md.), and were grown in 225 cm2 tissue culture flasks in minimal essential medium supplemented with non-essential amino acids, 1% penicillin-streptomycin. The medium was renewed every three days, and the cells were subcultured once a week. After detachment of the adherent monolayer with a 10 minute exposure to 30 mL of trypsin-EDTA and three consecutive washes with medium, confluent HepG2 cells were seeded at a density of 2.5×106 cells per well in a 6-well plate and exposed to 10 μM of [3H] labeled active compound (500 dpm/pmol) for the specified time periods. The cells were maintained at 37° C. under a 5% CO2 atmosphere. At the selected time points, the cells were washed three times with ice-cold phosphate-buffered saline (PBS). Intracellular active compound and its respective metabolites were extracted by incubating the cell pellet overnight at −20° C. with 60% methanol followed by extraction with an additional 20 μL of cold methanol for one hour in an ice bath. The extracts were then combined, dried under gentle filtered air flow and stored at −20° C. until HPLC analysis. The preliminary results of the HPLC analysis are tabulated in Table 1.
TABLE 1 | |
[pmol/million cells] |
β-D-2′-CH3- | β-D-2′-CH3- | β-D-2′-CH3- | β-D-2′-CH3- | |
Time (h) | riboA-TP | riboU-TP | riboC-TP | riboG- |
2 | 33.1 | 0.40 | 2.24 | |
4 | 67.7 | 1.21 | 3.99 | |
8 | 147 | 1.57 | 9.76 | 2.85 |
24 | 427 | 6.39 | 34.9 | 0.91 |
30 | 456 | 7.18 | 36.2 | 3.22 |
48 | 288 | 9.42 | 56.4 | 6.26 |
Within 1 week prior to the study initiation, the cynomolgus monkey was surgically implanted with a chronic venous catheter and subcutaneous venous access port (VAP) to facilitate blood collection and underwent a physical examination including hematology and serum chemistry evaluations and the body weight was recorded. Each monkey (six total), received approximately 250 uCi of 3H activity with each dose of active compound, namely β-D-2′-CH3-riboG at a dose level of 10 mg/kg at a dose concentration of 5 mg/mL, either via an intravenous bolus (3 monkeys, IV), or via oral gavage (3 monkeys, PO). Each dosing syringe was weighed before dosing to gravimetrically determine the quantity of formulation administered. Urine samples were collected via pan catch at the designated intervals (approximately 18-0 hours pre-dose, 0-4, 4-8 and 8-12 hours post-dosage) and processed. Blood samples were collected as well (pre-dose, 0.25, 0.5, 1, 2, 3, 6, 8, 12 and 24 hours post-dosage) via the chronic venous catheter and VAP or from a peripheral vessel if the chronic venous catheter procedure should not be possible. The blood and urine samples were analyzed for the maximum concentration (Cmax), time when the maximum concentration was achieved (Tmax), area under the curve (AUC), half life of the dosage concentration (T1/2), clearance (CL), steady state volume and distribution (Vss) and bioavailability (F), which are tabulated in Tables 2 and 3, and graphically illustrated in FIGS. 2 and 3 , respectively.
TABLE 2 |
Oral Bioavailability in Monkeys |
Mean Norm | ||||||
Norm AUC | AUC | |||||
Dose | AUC (ng/ | (ng/mL × | (ng/mL × | |||
(mg) | mL × h) | h/mg) | h/mg) | F (%) | ||
IV Monkey 1 | 46.44 | 13614 | 293.2 | ||
IV Monkey 2 | 24.53 | 6581 | 268.3 | ||
IV Monkey 3 | 20.72 | 6079 | 293.4 | 284.9 | |
PO Monkey 1 | 29.04 | 758 | 26.1 | ||
PO Monkey 2 | 30.93 | 898 | 29.0 | ||
PO Monkey 3 | 30.04 | 1842 | 61.3 | 38.8 | 13.6 |
TABLE 3 |
Experimental Pharmacokinetics of β-D-2′-CH3-riboG |
in Cynomolgus Monkeys |
IV | PO | |
Dose/Route (mg/kg) | 10 | 10 | |
Cmax (ng/mL) | 6945.6 ± 1886.0 | 217.7 ± 132.1 | |
Tmax (hr) | 0.25 ± 0.00 | 2.00 ± 1.00 | |
AUC (ng/mL × hr) | 8758.0 ± 4212.9 | 1166.0 ± 589.6 | |
T1/2 (hr) | 7.9 ± 5.4 | 10.3 ± 4.1 | |
CL (L/hr/kg) | 1.28 ± 0.48 | ||
Vss (L/kg) | 2.09 ± 0.54 |
F (%) | 13.8 | |
Human bone marrow cells were collected from normal healthy volunteers and the mononuclear population was separated by Ficoll-Hypaque gradient centrifugation as described previously by Sommadossi J-P, Carlisle R. “Toxicity of 3′-azido-3′-deoxythymidine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine for normal human hematopoietic progenitor cells in vitro” Antimicrobial Agents and Chemotherapy 1987; 31:452-454; and Sommadossi J-P, Schinazi R F, Chu C K, Xie M-Y. “Comparison of cytotoxicity of the (−)- and (+)-enantiomer of 2′,3′-dideoxy-3′-thiacytidine in normal human bone marrow progenitor cells” Biochemical Pharmacology 1992; 44:1921-1925. The culture assays for CFU-GM and BFU-E were performed using a bilayer soft agar or methylcellulose method. Drugs were diluted in tissue culture medium and filtered. After 14 to 18 days at 37° C. in a humidified atmosphere of 5% CO2 in air, colonies of greater than 50 cells were counted using an inverted microscope. The results in Table 4 are presented as the percent inhibition of colony formation in the presence of drug compared to solvent control cultures.
TABLE 4 |
Human Bone Marrow Toxicity CFU-GM |
and BFU-E Clonogenic Assays |
IC50 in μM |
Treatment | CFU-GM | BFU-E | |
ribavirin | ~5 | ~1 | |
β-D-2′-CH3-riboA | >100 | >100 | |
β-D-2′-CH3-riboU | >100 | >100 | |
β-D-2′-CH3-riboC | >10 | >10 | |
β-D-2′-CH3-riboG | >10 | >100 | |
HepG2 cells were cultured in 12-well plates as described above and exposed to various concentrations of drugs as taught by Pan-Zhou X-R, Cui L, Zhou X-J, Sommadossi J-P, Darley-Usmer V M. “Differential effects of antiretroviral nucleoside analogs on mitochondrial function in HepG2 cells” Antimicrob Agents Chemother 2000; 44:496-503. Lactic acid levels in the culture medium after 4 day drug exposure was measured using a boehringer lactic acid assay kit. Lactic acid levels were normalized by cell number as measured by hemocytometer count. The preliminary results from this assay are tabulated in Table 5
TABLE 5 |
Mitochondrial Toxicity Study (L-lactic acid assay) |
Conc. (μM) | lactate (mg/106 cell) | % of Control | |
Control | 2.18 | ||
FIAU | 10 | 3.73 | 170.4 |
β-D-2′-CH3- |
1 | 2.52 | 115.3 |
10 | 2.36 | 107.9 | |
50 | 2.26 | 103.4 | |
100 | 2.21 | 101.2 |
|
FIAU |
|
β-D-2′-CH3-riboC |
Cells were seeded at a rate of between 5×103 and 5×104/well into 96-well plates in growth medium overnight at 37° C. in a humidified CO2 (5%) atmosphere. New growth medium containing serial dilutions of the drugs was then added. After incubation for 4 days, cultures were fixed in 50% TCA and stained with sulforhodamine B. The optical density was read at 550 nm. The cytotoxic concentration was expressed as the concentration required to reduce the cell number by 50% (CC50). The data is tabulated in Table 6.
TABLE 6 |
MDBK versus Human Hepatoma |
CC50, μM | ||||
Compound | MDBK | Huh7 | HepG2 | |
β-D-2′-CH3- |
20 | 40 | 50-60 | |
β-D-2′-CH3-riboU | >250 | >250 | >250 | |
β-D-2′-CH3- |
100 | >250 | 150 | |
β-D-2′-CH3- |
100 | >250 | >250 | |
|
5 | 25 | 150 | |
The assay was performed essentially as described by Baginski, S. G.; Pevear, D. C.; Seipel, M.; Sun, S. C. C.; Benetatos, C. A.; Chunduru, S. K.; Rice, C. M. and M. S. Collett “Mechanism of action of a pestivirus antiviral compound” PNAS USA 2000, 97(14), 7981-7986. MDBK cells (ATCC) were seeded onto 96-well culture plates (4,000 cells per well) 24 hours before use. After infection with BVDV (strain NADL, ATCC) at a multiplicity of infection (MOI) of 0.02 plaque forming units (PFU) per cell, serial dilutions of test compounds were added to both infected and uninfected cells in a final concentration of 0.5% DMSO in growth medium. Each dilution was tested in quadruplicate. Cell densities and virus inocula were adjusted to ensure continuous cell growth throughout the experiment and to achieve more than 90% virus-induced cell destruction in the untreated controls after four days post-infection. After four days, plates were fixed with 50% TCA and stained with sulforhodamine B. The optical density of the wells was read in a microplate reader at 550 nm. The 50% effective concentration (EC50) values were defined as the compound concentration that achieved 50% reduction of cytopathic effect of the virus. The results are tabulated in Table 7. FIGS. 4 and 5 provide a graphical illustration of the methodology used to arrive at the 50% effective concentration (EC50) values for β-D-2′-CH3-riboG and ribavirin. FIG. 6 compares the results of the CPA for β-D-2′-CH3-riboG, β-D-2′-CH3-riboC, β-D-2′-CH3-riboU, β-D-2′-CH3-riboA and ribavirin
TABLE 7 |
Cell Protection Assay |
EC50, μM | CC50, μM | |
β-D-2′-CH3- |
2 | 20 | |
β-D-2′-CH3- |
20 | >250 | |
β-D-2′-CH3- |
2 | 100 | |
β-D-2′-CH3- |
4 | 100 | |
Ribavirin | >3 | 5 | |
For each compound the effective concentration was determined in duplicate 24-well plates by plaque reduction assays. Cell monolayers were infected with 100 PFU/well of virus. Then, serial dilutions of test compounds in MEM supplemented with 2% inactivated serum and 0.75% of methyl cellulose were added to the monolayers. Cultures were further incubated at 37° C. for 3 days, then fixed with 50% ethanol and 0.8% Crystal Violet, washed and air-dried. Then plaques were counted to determine the concentration to obtain 90% virus suppression and tabulated in Table 8. FIG. 7 is a graphical illustration of the results from the Plaque Reduction Assay. FIG. 8 is an image of BVDV plaque formation in the presence of increasing concentrations of β-D-2′-CH3-riboU.
TABLE 8 |
Viral Suppression via Plaque Reduction Assay |
EC90, μM | |
β-D-2′-CH3-riboA | <3 | |
β-D-2′-CH3-riboU | <81 | |
β-D-2′-CH3-riboC | <9 | |
β-D-2′-CH3-riboG | <9 | |
For each compound the concentration to obtain a 6-log reduction in viral load was determined in duplicate 24-well plates by yield reduction assays. The assay was performed as described by Baginski, S. G.; Pevear, D. C.; Seipel, M.; Sun, S. C. C.; Benetatos, C. A.; Chunduru, S. K.; Rice, C. M. and M. S. Collett “Mechanism of action of a pestivirus antiviral compound” PNAS USA 2000, 97(14), 7981-7986, with minor modifications. Briefly, MDBK cells were seeded onto 24-well plates (2×105 cells per well) 24 hours before infection with BVDV (NADL strain) at a multiplicity of infection (MOI) of 0.1 PFU per cell. Serial dilutions of test compounds were added to cells in a final concentration of 0.5% DMSO in growth medium. Each dilution as tested in triplicate. After three days, cell cultures (cell monolayers and supernatants) were lysed by three freeze-thaw cycles, and virus yield was quantified by plaque assay. Briefly, MDBK cells were seeded onto 6-well plates (5×105 cells per well) 24 h before use. Cells were inoculated with 0.2 mL of test lysates for 1 hour, washed and overlaid with 0.5% agarose in growth medium. After 3 days, cell monolayers were fixed with 3.5% formaldehyde and stained with 1% crystal violet (w/v in 50% ethanol) to visualize plaques. The plaques were counted to determine the concentration to obtain a 6-log reduction in viral load as tabulated in Table 9. FIG. 9 is a graphical illustration of the results from the Yield Reduction Assay. FIG. 8 is an image of BVDV yield reduction in the presence of increasing concentrations of β-D-2′-CH3-riboC.
TABLE 9 |
Concentration to Obtain 6-log Reduction |
Conc. for 6-log Reduction (μM) | |
β-D-2′-CH3-riboU | 120 | |
β-D-2′-CH3- |
20 | |
β-D-2′-CH3- |
20 | |
β-D-2′-CH3- |
9 | |
Table 10 summarizes the cytoxicity of two compounds of this invention, β-D-1′-CH3-riboA and β-D-2′-CH3-riboA, in comparison to RBV (“ribavirin”), in various cell systems.
TABLE 10 |
Comparative Cytotoxicity* (CC50) |
BD | BHK | VERO | MT-4 | |
β-D-1′-CH3-riboA | >100 | 200 | >100 | 18 | |
β-D-2′-CH3-riboA | 75 | 22 | 22 | 6.6 | |
RBV | ND | 50 | 11 | ND | |
*Compound concentration (μM) required to reduce the viability of cells by 50%. |
The chemical structures for β-D-1′-CH3-riboA and β-D-2′-CH3-riboA are as follows:
Table 11 summarizes the antiviral activity of β-D-1′-CH3-riboA and β-D-2′-CH3-riboA against several viruses within the flavivirus and pestivirus genuses.
TABLE 11 |
Comparative Antiviral Activity* (EC50) |
BVDV | YFV | PICO | VSV | HIV-1 | ||
β-D-1′-CH3- |
10 | 7.0 | 51 | >100 | >18 | |
β-D-2′-CH3-riboA | 0.1 | 0.2 | 5.0 | >100 | >6.6 | |
| ND | 30 | >30 | ND | ND | |
*Compound concentration (μM) required to reduce the plaque number by 50%. The following virus-cell system were used: BVDC-BT, YFV-BHK, PICO (Cosxackie B1 and Polio Sabin)/VSV - Vero. |
Table 12 summarizes the antiviral activity and toxicity of β-D-2′-methyl-riboG, β-D-2′-methyl-riboC and β-D-2′-methyl-riboU, against a couple of viruses within the flavivirus and pestivirus genuses.
TABLE 12 |
Comparative Antiviral Activity* (EC50) |
BVDV | YFV |
EC50* | CC50** | EC50* | CC50** | |||
β-D-2′-CH3- |
2 | >100 | 1.2 | 20 | ||
β-D-2′-CH3-riboC | 3.7 | >100 | 70 | >100 | ||
β-D-2′-CH3- |
20 | >100 | 33 | >100 | ||
*Compound concentration (μM) required to reduce the plaque number by 50%. The following virus-cell system were used: BVDC-BT and YFV-BHK. | ||||||
*Compound concentration (μM) required to reduce the viability of cells by 50%. |
The chemical structures for β-D-2′-CH3-riboG, β-D-2′-CH3-riboC and β-D-2′-CH3-riboU are as follows:
Table 13 summarizes the anti-viral activity of several compounds of this invention against BVDV in three different assays.
TABLE 13 |
for BVDV |
Cytotox- |
Cell | Plaque | Yield Reduction | |
Protection | Reduction |
6 log10 | Huh7 cells | ||||
(EC50, | (EC90, | EC90, | reduction | (EC50, | |
Compound | μM) | μM) | μM | (μM) | μM) |
β-D-2′-CH3- |
2 | <3 | <2 | 9 | 50 |
β-D-2′-CH3-riboT | >250 | ND | ND | ND | >250 |
β-D-2′-CH3- |
20 | <81 | 24 | 120 | >250 |
β-D-2′-CH3- |
2 | <9 | <4 | 20 | >250 |
β-D-2′-CH3- |
4 | <9 | 3 | 20 | >250 |
β-D-2′-CH3-riboI | 45 | ND | ND | ND | >250 |
Ribavirin | >3 | >200 | >20 | toxic | 20 |
This invention has been described with reference to its preferred embodiments. Variations and modifications of the invention, will be obvious to those skilled in the art from the foregoing detailed description of the invention.
Claims (10)
1. A method for the treatment of a flavivirus or pestivirus infection in a host, comprising contacting a cell infected with a flavivirus or a pestivirus with an anti-virally effective amount of a compound of Formula X, XI or XII:
or a phosphate thereof, or a pharmaceutically acceptable salt or ester thereof, wherein:
Base is a purine or pyrimidine base as defined herein;
R1, R2 and R3 are independently H; phosphate; monophosphate; diphosphate; triphosphate; or a stabilized phosphate prodrug; acyl; alkyl; lower alkyl; sulfonate ester; alkyl sulfonyl; arylalkyl sulfonyl; methanesulfonyl; and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid; a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1, R2 or R3 is independently H or phosphate;
R6 is alkyl; or cyano;
R7 is OR3 or hydroxy; and
X is O, S, SO2 or CH2.
2. A method for the treatment of a flavivirus or pestivirus infection in a host, comprising contacting a cell infected with a flavivirus or a pestivirus with an anti-virally effective amount of a compound of Formula XVII:
or a phosphate thereof, or a pharmaceutically acceptable salt or ester thereof, wherein:
Base is a purine or pyrimidine base;
R1 and R2 are independently H; phosphate; monophosphate; diphosphate; triphosphate; or a stabilized phosphate prodrug; acyl; alkyl; sulfonate ester; alkyl sulfonyl; arylalkyl sulfonyl; methanesulfonyl; and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid; a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1 or R2 is independently H or phosphate;
R6 is alkyl, or cyano;
R7 is OR2 or hydroxy;
R9 is hydrogen, OR2, hydroxy, alkyl; azido, cyano, alkenyl, alkynyl, Br-vinyl, —C(O)O(alkyl), —C(O)O(lower alkyl), —O(acyl), —O(lower acyl), —O(alkyl), —O(lower alkyl), —O(alkenyl), chlorine, bromine, iodine, NO2, NH2, —NH(lower alkyl), —NH(acyl), —N(lower alkyl)2, —N(acyl)2;
R10 is H, alkyl, chlorine, bromine or iodine;
alternatively, R7 and R9, or R7 and R10 can come together to form a bond; and
X is O, S, SO2 or CH2.
3. The method of claim 2 , wherein the compound is
or a phosphate thereof, or a pharmaceutically acceptable salt or ester thereof, wherein
R1, R2 and R3 are independently H; phosphate; monophosphate, diphosphate, triphosphate, a stabilized phosphate prodrug; acyl; alkyl; sulfonate ester; alkyl sulfonyl; arylalkyl sulfonyl; methanesulfonyl; benzylsulfonyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid; a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1, R2 or R3 is independently H or phosphate;
Y is hydrogen, bromo, chloro, fluoro, iodo, OR4, NR4R5 or SR4;
X1 and X2 are independently selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, chloro, bromo, fluoro, iodo, OR4, NR4NR5 or SR5; and
R4 and R5 are independently hydrogen, acyl; alkyl; methyl, ethyl, propyl or cyclopropyl.
4. The method of claim 2 , wherein the compound is
or a phosphate thereof, or a pharmaceutically acceptable salt or ester thereof, wherein
R1, R2 and R3 are independently H; phosphate; monophosphate, diphosphate, triphosphate, a stabilized phosphate prodrug; acyl; alkyl; sulfonate ester; alkyl sulfonyl; arylalkyl sulfonyl; methanesulfonyl; benzylsulfonyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid; a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1, R2 or R3 is independently H or phosphate;
Y is hydrogen, bromo, chloro, fluoro, iodo, OR4, NR4R5 or SR4;
X1 is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, chloro, bromo, fluoro, iodo, OR4, NR4NR5 or SR5; and
R4 and R5 are independently hydrogen, acyl; alkyl; methyl, ethyl, propyl or cyclopropyl.
5. The method of claim 2 , wherein the compound is in the form of a dosage unit.
6. The method of claim 5 , wherein the dosage unit contains 10 to 1500 mg of said compound.
7. The method of claim 5 or 6 , wherein said dosage unit is a tablet or capsule.
8. The method of claim 1 , wherein the compound is combined with a pharmaceutically acceptable carrier.
9. The method of claim 8 , wherein the carrier is suitable for oral delivery.
10. The method of claim 9 , wherein the carrier is suitable for intravenous, parenteral, intradermal, subcutaneous or topical delivery.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/527,124 US8343937B2 (en) | 2000-05-26 | 2006-09-25 | Methods and compositions for treating flaviviruses and pestiviruses |
US13/675,937 US9968628B2 (en) | 2000-05-26 | 2012-11-13 | Methods and compositions for treating flaviviruses and pestiviruses |
US13/956,287 US20130315863A1 (en) | 2000-05-26 | 2013-07-31 | Methods and compositions for treating flaviviridae infections |
US15/952,117 US20180235993A1 (en) | 2000-05-26 | 2018-04-12 | Methods and compositions for treating flaviviruses and pestiviruses |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20767400P | 2000-05-26 | 2000-05-26 | |
US28327601P | 2001-04-11 | 2001-04-11 | |
US09/863,816 US6812219B2 (en) | 2000-05-26 | 2001-05-23 | Methods and compositions for treating flaviviruses and pestiviruses |
US10/602,135 US7163929B2 (en) | 2000-05-26 | 2003-06-20 | Methods and compositions for treating flaviviruses and pestiviruses |
US11/527,124 US8343937B2 (en) | 2000-05-26 | 2006-09-25 | Methods and compositions for treating flaviviruses and pestiviruses |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/602,135 Continuation US7163929B2 (en) | 2000-05-26 | 2003-06-20 | Methods and compositions for treating flaviviruses and pestiviruses |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/675,937 Continuation US9968628B2 (en) | 2000-05-26 | 2012-11-13 | Methods and compositions for treating flaviviruses and pestiviruses |
Publications (2)
Publication Number | Publication Date |
---|---|
US20070037773A1 US20070037773A1 (en) | 2007-02-15 |
US8343937B2 true US8343937B2 (en) | 2013-01-01 |
Family
ID=26902464
Family Applications (9)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/863,816 Expired - Lifetime US6812219B2 (en) | 2000-05-26 | 2001-05-23 | Methods and compositions for treating flaviviruses and pestiviruses |
US10/602,694 Expired - Lifetime US7105493B2 (en) | 2000-05-26 | 2003-06-20 | Methods and compositions for treating flaviviruses and pestiviruses |
US10/602,692 Expired - Lifetime US7101861B2 (en) | 2000-05-26 | 2003-06-20 | Methods and compositions for treating flaviviruses and pestiviruses |
US10/602,135 Expired - Lifetime US7163929B2 (en) | 2000-05-26 | 2003-06-20 | Methods and compositions for treating flaviviruses and pestiviruses |
US10/602,693 Expired - Lifetime US7148206B2 (en) | 2000-05-26 | 2003-06-20 | Methods and compositions for treating flaviviruses and pestiviruses |
US11/527,124 Active 2025-06-11 US8343937B2 (en) | 2000-05-26 | 2006-09-25 | Methods and compositions for treating flaviviruses and pestiviruses |
US13/675,937 Expired - Fee Related US9968628B2 (en) | 2000-05-26 | 2012-11-13 | Methods and compositions for treating flaviviruses and pestiviruses |
US13/956,287 Abandoned US20130315863A1 (en) | 2000-05-26 | 2013-07-31 | Methods and compositions for treating flaviviridae infections |
US15/952,117 Abandoned US20180235993A1 (en) | 2000-05-26 | 2018-04-12 | Methods and compositions for treating flaviviruses and pestiviruses |
Family Applications Before (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/863,816 Expired - Lifetime US6812219B2 (en) | 2000-05-26 | 2001-05-23 | Methods and compositions for treating flaviviruses and pestiviruses |
US10/602,694 Expired - Lifetime US7105493B2 (en) | 2000-05-26 | 2003-06-20 | Methods and compositions for treating flaviviruses and pestiviruses |
US10/602,692 Expired - Lifetime US7101861B2 (en) | 2000-05-26 | 2003-06-20 | Methods and compositions for treating flaviviruses and pestiviruses |
US10/602,135 Expired - Lifetime US7163929B2 (en) | 2000-05-26 | 2003-06-20 | Methods and compositions for treating flaviviruses and pestiviruses |
US10/602,693 Expired - Lifetime US7148206B2 (en) | 2000-05-26 | 2003-06-20 | Methods and compositions for treating flaviviruses and pestiviruses |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/675,937 Expired - Fee Related US9968628B2 (en) | 2000-05-26 | 2012-11-13 | Methods and compositions for treating flaviviruses and pestiviruses |
US13/956,287 Abandoned US20130315863A1 (en) | 2000-05-26 | 2013-07-31 | Methods and compositions for treating flaviviridae infections |
US15/952,117 Abandoned US20180235993A1 (en) | 2000-05-26 | 2018-04-12 | Methods and compositions for treating flaviviruses and pestiviruses |
Country Status (24)
Country | Link |
---|---|
US (9) | US6812219B2 (en) |
EP (2) | EP1736478B1 (en) |
JP (2) | JP5230052B2 (en) |
KR (2) | KR20080021797A (en) |
CN (2) | CN101099745A (en) |
AP (2) | AP1727A (en) |
AR (1) | AR032883A1 (en) |
AU (2) | AU2001272923A1 (en) |
BR (1) | BR0111196A (en) |
CA (1) | CA2410579C (en) |
CZ (1) | CZ301182B6 (en) |
EA (2) | EA200601591A1 (en) |
IL (1) | IL153020A0 (en) |
MA (1) | MA26916A1 (en) |
MX (1) | MXPA02011691A (en) |
NO (1) | NO327249B1 (en) |
NZ (2) | NZ536570A (en) |
OA (1) | OA12382A (en) |
PE (1) | PE20020051A1 (en) |
PL (1) | PL359169A1 (en) |
TW (1) | TW200425898A (en) |
WO (1) | WO2001092282A2 (en) |
YU (1) | YU92202A (en) |
ZA (2) | ZA200210112B (en) |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130149283A1 (en) * | 2000-05-23 | 2013-06-13 | Universita Degli Studi Di Cagliari | Methods and compositions for treating hepatitis c virus |
US20130315863A1 (en) * | 2000-05-26 | 2013-11-28 | Universita' Degli Studi Di Cagliari | Methods and compositions for treating flaviviridae infections |
US8673926B2 (en) | 2012-02-14 | 2014-03-18 | University Of Georgia Research Foundation, Inc. | Spiro[2.4]heptanes for treatment of flaviviridae infections |
US20140140955A1 (en) * | 2010-12-29 | 2014-05-22 | University College Of Cardiff Consultants Limited | Substituted purine nucleosides, phosphoroamidate and phosphorodiamidate derivatives for treatment of viral infections |
US8877905B2 (en) | 2008-06-11 | 2014-11-04 | Lasergen, Inc. | Nucleotides and nucleosides and methods for their use in DNA sequencing |
US9206412B2 (en) | 2012-05-31 | 2015-12-08 | Colorado State University Research Foundation | Thioxothiazolidine inhibitors |
US9447132B2 (en) | 2013-04-12 | 2016-09-20 | Achillion Pharmaceuticals, Inc. | Highly active nucleoside derivative for the treatment of HCV |
US9676797B2 (en) | 2015-09-02 | 2017-06-13 | Abbvie Inc. | Anti-viral compounds |
WO2017197046A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
WO2017197055A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
WO2017197036A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
US9828410B2 (en) | 2015-03-06 | 2017-11-28 | Atea Pharmaceuticals, Inc. | β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment |
WO2018013937A1 (en) | 2016-07-14 | 2018-01-18 | Atea Pharmaceuticals, Inc. | Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection |
WO2018048937A1 (en) | 2016-09-07 | 2018-03-15 | Atea Pharmaceuticals, Inc. | 2'-substituted-n6-substituted purine nucleotides for rna virus treatment |
US10287311B2 (en) | 2003-05-30 | 2019-05-14 | Gilead Pharmasset Llc | Modified fluorinated nucleoside analogues |
US10874687B1 (en) | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
US11690860B2 (en) | 2018-04-10 | 2023-07-04 | Atea Pharmaceuticals, Inc. | Treatment of HCV infected patients with cirrhosis |
Families Citing this family (213)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100387237C (en) * | 1998-08-10 | 2008-05-14 | 艾丹尼克斯(开曼)有限公司 | Beta-L-2'deoxy-nucleosides for the treatment of hepatitis B |
US6444652B1 (en) | 1998-08-10 | 2002-09-03 | Novirio Pharmaceuticals Limited | β-L-2'-deoxy-nucleosides for the treatment of hepatitis B |
US20020056123A1 (en) * | 2000-03-09 | 2002-05-09 | Gad Liwerant | Sharing a streaming video |
KR20090089922A (en) * | 2000-10-18 | 2009-08-24 | 파마셋 인코포레이티드 | Modified nucleosides for treatment of viral infections and abnormal cellular proliferation |
JP3914156B2 (en) | 2001-01-22 | 2007-05-16 | メルク エンド カムパニー インコーポレーテッド | Nucleoside derivatives as RNA-dependent RNA viral polymerase inhibitors |
US8481712B2 (en) | 2001-01-22 | 2013-07-09 | Merck Sharp & Dohme Corp. | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase |
US7105499B2 (en) | 2001-01-22 | 2006-09-12 | Merck & Co., Inc. | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase |
GB0114286D0 (en) * | 2001-06-12 | 2001-08-01 | Hoffmann La Roche | Nucleoside Derivatives |
US6949522B2 (en) | 2001-06-22 | 2005-09-27 | Pharmasset, Inc. | β-2′- or 3′-halonucleosides |
WO2003026675A1 (en) * | 2001-09-28 | 2003-04-03 | Idenix (Cayman) Limited | Methods and compositions for treating flaviviruses and pestiviruses using 4'-modified nucleoside |
WO2003051898A1 (en) * | 2001-12-17 | 2003-06-26 | Ribapharm Inc. | Unusual nucleoside libraries, compounds, and preferred uses as antiviral and anticancer agents |
US7217815B2 (en) * | 2002-01-17 | 2007-05-15 | Valeant Pharmaceuticals North America | 2-beta -modified-6-substituted adenosine analogs and their use as antiviral agents |
WO2003062256A1 (en) * | 2002-01-17 | 2003-07-31 | Ribapharm Inc. | 2'-beta-modified-6-substituted adenosine analogs and their use as antiviral agents |
WO2003062255A2 (en) * | 2002-01-17 | 2003-07-31 | Ribapharm Inc. | Sugar modified nucleosides as viral replication inhibitors |
EP1476169B1 (en) * | 2002-02-13 | 2013-03-20 | Merck Sharp & Dohme Corp. | Inhibiting orthopoxvirus replication with nucleoside compounds |
US7247621B2 (en) * | 2002-04-30 | 2007-07-24 | Valeant Research & Development | Antiviral phosphonate compounds and methods therefor |
US20040063658A1 (en) * | 2002-05-06 | 2004-04-01 | Roberts Christopher Don | Nucleoside derivatives for treating hepatitis C virus infection |
AU2003269892A1 (en) * | 2002-06-27 | 2004-01-19 | Isis Pharmaceuticals, Inc. | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
JP5087211B2 (en) | 2002-06-28 | 2012-12-05 | イデニクス(ケイマン)リミテツド | 2 'and 3'-nucleoside prodrugs for the treatment of flavivirus infection |
RS113904A (en) * | 2002-06-28 | 2007-02-05 | Idenix (Cayman) Limited | 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
US7608600B2 (en) * | 2002-06-28 | 2009-10-27 | Idenix Pharmaceuticals, Inc. | Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections |
PL374831A1 (en) * | 2002-06-28 | 2005-10-31 | Idenix (Cayman) Limited | Modified 2' and 3' -nucleoside prodrugs for treating flaviridae infections |
CN101172993A (en) * | 2002-06-28 | 2008-05-07 | 埃迪尼克斯(开曼)有限公司 | 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
AU2003269902A1 (en) * | 2002-07-16 | 2004-02-02 | Isis Pharmaceuticals, Inc. | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
AU2003256619A1 (en) * | 2002-07-24 | 2004-02-09 | Isis Pharmaceuticals, Inc. | Pyrrolopyrimidine thionucleoside analogs as antivirals |
EP1545545A4 (en) | 2002-08-01 | 2008-09-03 | Pharmasset Inc | COMPOUNDS WITH THE BICYCLO 4.2.1 NONANE SYSTEM FOR THE TREATMENT OF i FLAVIVIRIDAE /i INFECTIONS |
US20040067877A1 (en) | 2002-08-01 | 2004-04-08 | Schinazi Raymond F. | 2', 3'-Dideoxynucleoside analogues for the treatment or prevention of Flaviviridae infections |
BR0315795A (en) | 2002-10-31 | 2005-09-13 | Metabasis Therapeutics Inc | Cytarabine Monophosphate prodrugs |
HUE033832T2 (en) | 2002-11-15 | 2018-01-29 | Idenix Pharmaceuticals Llc | 2'-methyl nucleosides in combination with interferon and flaviviridae mutation |
US7034167B2 (en) | 2002-12-06 | 2006-04-25 | Merck & Co., Inc. | Process to ribofuranose sugar derivatives as intermediates to branched-chain nucleosides |
US7598373B2 (en) * | 2002-12-12 | 2009-10-06 | Idenix Pharmaceuticals, Inc. | Process for the production of 2-C-methyl-D-ribonolactone |
BR0316868A (en) * | 2002-12-23 | 2005-10-25 | Idenix Cayman Ltd | Process for the Production of Nucleoside-3 'Prodrugs |
AR043006A1 (en) | 2003-02-12 | 2005-07-13 | Merck & Co Inc | PROCESS TO PREPARE RAMIFIED RIBONUCLEOSIDS |
CA2529311A1 (en) * | 2003-03-28 | 2004-10-07 | Pharmasset, Inc. | Compounds for the treatment of flaviviridae infections |
US20040259934A1 (en) * | 2003-05-01 | 2004-12-23 | Olsen David B. | Inhibiting Coronaviridae viral replication and treating Coronaviridae viral infection with nucleoside compounds |
JP2007501185A (en) | 2003-07-25 | 2007-01-25 | イデニクス(ケイマン)リミテツド | Purine nucleoside analogues for treating flavivirus related diseases including hepatitis C |
WO2005018330A1 (en) * | 2003-08-18 | 2005-03-03 | Pharmasset, Inc. | Dosing regimen for flaviviridae therapy |
EP1660511B1 (en) | 2003-08-27 | 2010-11-03 | Biota Scientific Management Pty. Ltd. | Novel tricyclic nucleosides or nucleotides as therapeutic agents |
GB0500020D0 (en) | 2005-01-04 | 2005-02-09 | Novartis Ag | Organic compounds |
US20050182252A1 (en) * | 2004-02-13 | 2005-08-18 | Reddy K. R. | Novel 2'-C-methyl nucleoside derivatives |
AU2005254057B2 (en) | 2004-06-15 | 2011-02-17 | Isis Pharmaceuticals, Inc. | C-purine nucleoside analogs as inhibitors of RNA-dependent RNA viral polymerase |
EP1912643A2 (en) * | 2004-06-23 | 2008-04-23 | Idenix (Cayman) Limited | 5-aza-7-deazapurine derivatives for treating infections with flaviviridae |
WO2006012078A2 (en) * | 2004-06-24 | 2006-02-02 | Merck & Co., Inc. | Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection |
CN101023094B (en) * | 2004-07-21 | 2011-05-18 | 法莫赛特股份有限公司 | Preparation of alkyl-substituted 2-deoxy-2-fluoro-d-ribofuranosyl pyrimidines and purines and their derivatives |
SI3109244T1 (en) | 2004-09-14 | 2019-06-28 | Gilead Pharmasset Llc | Preparation of 2'fluoro-2'-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives |
US7524831B2 (en) | 2005-03-02 | 2009-04-28 | Schering Corporation | Treatments for Flaviviridae virus infection |
AU2006222563A1 (en) | 2005-03-08 | 2006-09-14 | Biota Scientific Management Pty Ltd. | Bicyclic nucleosides and nucleotides as therapeutic agents |
US20090156545A1 (en) * | 2005-04-01 | 2009-06-18 | Hostetler Karl Y | Substituted Phosphate Esters of Nucleoside Phosphonates |
US7879797B2 (en) | 2005-05-02 | 2011-02-01 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
KR20080033274A (en) | 2005-06-17 | 2008-04-16 | 노파르티스 아게 | Use of sanglifehrin in hcv |
AR057456A1 (en) | 2005-07-20 | 2007-12-05 | Merck & Co Inc | HCV PROTEASA NS3 INHIBITORS |
KR20080036598A (en) | 2005-08-01 | 2008-04-28 | 머크 앤드 캄파니 인코포레이티드 | Macrocyclic peptides as hcv ns3 protease inhibitors |
US20070185063A1 (en) * | 2005-08-23 | 2007-08-09 | Idenix Pharmaceuticals, Inc. | Seven-membered ring nucleosides |
WO2007044468A2 (en) * | 2005-10-05 | 2007-04-19 | The Cbr Institute For Biomedical Research, Inc. | Method to treat flavivirus infection with sirna |
UA91255C2 (en) | 2005-12-09 | 2010-07-12 | Ф. Хоффманн-Ля Рош Аг | Antiviral nucleosides |
CA2634749C (en) * | 2005-12-23 | 2014-08-19 | Idenix Pharmaceuticals, Inc. | Process for preparing a synthetic intermediate for preparation of branched nucleosides |
US8895531B2 (en) | 2006-03-23 | 2014-11-25 | Rfs Pharma Llc | 2′-fluoronucleoside phosphonates as antiviral agents |
CN101460488A (en) * | 2006-04-04 | 2009-06-17 | 弗·哈夫曼-拉罗切有限公司 | 3',5'-di-o-acylated nucleosides for hcv treatment |
ES2543840T3 (en) | 2006-04-11 | 2015-08-24 | Novartis Ag | Spirocyclic HCV / HIV inhibitors and their uses |
GB0609492D0 (en) | 2006-05-15 | 2006-06-21 | Angeletti P Ist Richerche Bio | Therapeutic agents |
US8058260B2 (en) * | 2006-05-22 | 2011-11-15 | Xenoport, Inc. | 2′-C-methyl-ribofuranosyl cytidine prodrugs, pharmaceutical compositions and uses thereof |
GB0612423D0 (en) | 2006-06-23 | 2006-08-02 | Angeletti P Ist Richerche Bio | Therapeutic agents |
MX2009003795A (en) | 2006-10-10 | 2009-06-18 | Pharmasset Inc | Preparation of nucleosides ribofuranosyl pyrimidines. |
AP2009004812A0 (en) | 2006-10-10 | 2009-04-30 | Medivir Ab | HCV nucleoside inhibitor |
EP2076278B1 (en) | 2006-10-24 | 2015-05-06 | Merck Sharp & Dohme Corp. | Macrocyclic HCV NS3 protease inhibitors |
JP5345941B2 (en) | 2006-10-24 | 2013-11-20 | メルク・シャープ・アンド・ドーム・コーポレーション | HCV NS3 protease inhibitor |
WO2008051475A2 (en) | 2006-10-24 | 2008-05-02 | Merck & Co., Inc. | Hcv ns3 protease inhibitors |
US8377874B2 (en) | 2006-10-27 | 2013-02-19 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
BRPI0718161A2 (en) | 2006-10-27 | 2013-11-26 | Merck & Co Inc | COMPOUND, PHARMACEUTICAL COMPOSITION, AND, USE OF THE COMPOUND. |
CN101528717B (en) | 2006-11-09 | 2013-04-24 | 弗·哈夫曼-拉罗切有限公司 | Thiazole and oxazole-substituted arylamides |
GB0623493D0 (en) | 2006-11-24 | 2007-01-03 | Univ Cardiff | Chemical compounds |
US7897737B2 (en) | 2006-12-05 | 2011-03-01 | Lasergen, Inc. | 3′-OH unblocked, nucleotides and nucleosides, base modified with photocleavable, terminating groups and methods for their use in DNA sequencing |
GB0625283D0 (en) * | 2006-12-19 | 2007-01-24 | Cyclacel Ltd | Combination |
WO2008075103A1 (en) | 2006-12-20 | 2008-06-26 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Antiviral indoles |
GB0625345D0 (en) | 2006-12-20 | 2007-01-31 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
GB0625349D0 (en) | 2006-12-20 | 2007-01-31 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
US20080261913A1 (en) * | 2006-12-28 | 2008-10-23 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of liver disorders |
US8071568B2 (en) | 2007-01-05 | 2011-12-06 | Merck Sharp & Dohme Corp. | Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection |
NZ598927A (en) * | 2007-01-12 | 2013-09-27 | Biocryst Pharm Inc | Antiviral nucleoside analogs |
AU2008219622A1 (en) | 2007-02-28 | 2008-09-04 | Conatus Pharmaceuticals, Inc. | Methods for the treatment of liver diseases using specified matrix metalloproteinase (MMP) inhibitors |
PT2308514E (en) | 2007-03-23 | 2013-09-06 | To Bbb Holding B V | Conjugates for targeted drug delivery across the blood-brain barrier |
US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
EP2178886A1 (en) | 2007-07-17 | 2010-04-28 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Macrocyclic indole derivatives for the treatment of hepatitis c infections |
CA2699891C (en) | 2007-07-19 | 2013-10-22 | Nigel Liverton | Macrocyclic compounds as antiviral agents |
CA2708228C (en) | 2007-12-17 | 2016-06-21 | F. Hoffmann-La Roche Ag | Tetrazole-substituted arylamide derivatives and their use as p2x3 and/or p2x2/3 purinergic receptor antagonists |
CN101903348B (en) | 2007-12-17 | 2013-08-14 | 霍夫曼-拉罗奇有限公司 | Pyrazole-substituted arylamides |
CA2708791C (en) | 2007-12-17 | 2016-06-21 | F. Hoffmann-La Roche Ag | Imidazole-substituted arylamides and uses thereof as p2x receptor antagonists |
EP2607356B1 (en) | 2007-12-17 | 2015-04-29 | F. Hoffmann-La Roche AG | Triazole-substituted arylamide derivatives and their use as P2x3 and /or P2x2/3 purinergic receptor antagonists |
US8846636B2 (en) | 2008-03-18 | 2014-09-30 | Lcb Pharma Inc. | Nucleoside analogues with quaternary carbon stereogenic centers and methods of use |
TW200946541A (en) * | 2008-03-27 | 2009-11-16 | Idenix Pharmaceuticals Inc | Solid forms of an anti-HIV phosphoindole compound |
CA2722177C (en) | 2008-04-23 | 2016-08-16 | Gilead Sciences, Inc. | 1'-substituted carba-nucleoside analogs for antiviral treatment |
US8461107B2 (en) | 2008-04-28 | 2013-06-11 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
EP2307002B1 (en) | 2008-06-09 | 2013-01-02 | Cyclacel Limited | Combinations of sapacitabine or cndac with dna methyltransferase inhibitors such as decitabine and procaine |
US8173621B2 (en) | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
CN102177172A (en) * | 2008-07-02 | 2011-09-07 | 埃迪尼克斯医药公司 | Compounds and pharmaceutical compositions for the treatment of viral infections |
WO2010002877A2 (en) | 2008-07-03 | 2010-01-07 | Biota Scientific Management | Bycyclic nucleosides and nucleotides as therapeutic agents |
DK2540350T3 (en) | 2008-07-22 | 2014-08-04 | Merck Sharp & Dohme | COMBINATIONS OF A MACROCYCLIC QUINOXAL COMPOUND, WHICH IS ANHCV-NS3 PROTEASE INHIBITOR WITH OTHER HCV AGENTS |
NZ603854A (en) * | 2008-08-29 | 2015-03-27 | Boehringer Ingelheim Vetmed | West nile virus vaccine |
EP2671888A1 (en) | 2008-12-23 | 2013-12-11 | Gilead Pharmasset LLC | 3',5'-cyclic nucleoside phosphate analogues |
CA2748057C (en) | 2008-12-23 | 2018-07-03 | Pharmasset, Inc. | Nucleoside phosphoramidates |
NZ617066A (en) | 2008-12-23 | 2015-02-27 | Gilead Pharmasset Llc | Nucleoside analogs |
PE20120013A1 (en) * | 2009-01-09 | 2012-02-02 | Univ Cardiff | GUANOSINE-DERIVED PHOSPHORAMIDATE NUCLEOSIDE COMPOUNDS FOR TREATMENT OF VIRAL INFECTIONS |
WO2010082050A1 (en) | 2009-01-16 | 2010-07-22 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Macrocyclic and 7-aminoalkyl-substituted benzoxazocines for treatment of hepatitis c infections |
GB0900914D0 (en) | 2009-01-20 | 2009-03-04 | Angeletti P Ist Richerche Bio | Antiviral agents |
EP2403860B1 (en) | 2009-03-04 | 2015-11-04 | IDENIX Pharmaceuticals, Inc. | Phosphothiophene and phosphothiazole as hcv polymerase inhibitors |
BRPI1009324A2 (en) * | 2009-03-20 | 2015-11-24 | Alios Biopharma Inc | and / or pharmaceutically acceptable compounds thereof, pharmaceutical composition and their uses |
US20110182850A1 (en) | 2009-04-10 | 2011-07-28 | Trixi Brandl | Organic compounds and their uses |
US8512690B2 (en) | 2009-04-10 | 2013-08-20 | Novartis Ag | Derivatised proline containing peptide compounds as protease inhibitors |
WO2010135520A1 (en) * | 2009-05-20 | 2010-11-25 | Chimerix, Inc. | Compounds, compositions and methods for treating viral infection |
TWI576352B (en) | 2009-05-20 | 2017-04-01 | 基利法瑪席特有限責任公司 | Nucleoside phosphoramidates |
US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
EP2445868B1 (en) | 2009-06-22 | 2013-12-18 | F.Hoffmann-La Roche Ag | Biphenyl amides useful as p2x3 and/or p2x2/3 receptors modulators |
EP2445897B1 (en) | 2009-06-22 | 2014-03-19 | F.Hoffmann-La Roche Ag | Novel indazole arylamides as p2x3 and/or p2x2/3 antagonists |
WO2010149541A1 (en) | 2009-06-22 | 2010-12-29 | F. Hoffmann-La Roche Ag | Novel oxazolone and pyrrolidinone-substituted arylamides |
US8828930B2 (en) | 2009-07-30 | 2014-09-09 | Merck Sharp & Dohme Corp. | Hepatitis C virus NS3 protease inhibitors |
JP2013501068A (en) | 2009-08-05 | 2013-01-10 | アイディニックス ファーマシューティカルズ インコーポレイテッド | Macrocyclic serine protease inhibitor |
MX2012003126A (en) | 2009-09-21 | 2012-06-19 | Gilead Sciences Inc | Processes and intermediates for the preparation of 1'-substituted carba-nucleoside analogs. |
KR20120104239A (en) | 2009-11-14 | 2012-09-20 | 에프. 호프만-라 로슈 아게 | Biomarkers for predicting rapid response to hcv treatment |
WO2011063076A1 (en) | 2009-11-19 | 2011-05-26 | Itherx Pharmaceuticals, Inc. | Methods of treating hepatitis c virus with oxoacetamide compounds |
KR20120085877A (en) | 2009-12-02 | 2012-08-01 | 에프. 호프만-라 로슈 아게 | Biomarkers for predicting sustained response to hcv treatment |
TW201136942A (en) | 2009-12-18 | 2011-11-01 | Idenix Pharmaceuticals Inc | 5,5-fused arylene or heteroarylene hepatitis C virus inhibitors |
CL2011000716A1 (en) | 2010-03-31 | 2012-04-20 | Gilead Pharmasset Llc | Crystalline forms 1 6 of (s) -isopropyl-2 - (((s) - (((2r.3r.4r.5r) -5- (2,4-dioxo-3,4-dihydropyrimidin-1 (2h) -yl) -4-fluoro-3-hydroxy-4-methyl tetrahydrofuran-2-yl) methoxy) (phenoxy) phosphoryl) amino) propanoate; pharmaceutical composition and combination; and its use to treat a hepatitis c virus infection. |
PL3290428T3 (en) | 2010-03-31 | 2022-02-07 | Gilead Pharmasset Llc | Tablet comprising crystalline (s)-isopropyl 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihydropyrimidin-1 (2h)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate |
JP2013523765A (en) | 2010-04-01 | 2013-06-17 | イデニク プハルマセウティカルス,インコーポレイテッド | Compounds and pharmaceutical compositions for the treatment of viral infections |
JP5937073B2 (en) | 2010-07-19 | 2016-06-22 | ギリード・サイエンシズ・インコーポレーテッド | Process for the preparation of diastereomeric pure phosphoramidate prodrugs |
SI2595980T1 (en) | 2010-07-22 | 2014-11-28 | Gilead Sciences, Inc. | Methods and compounds for treating paramyxoviridae virus infections |
JP6012605B2 (en) | 2010-09-22 | 2016-10-25 | アリオス バイオファーマ インク. | Substituted nucleotide analogs |
EP2624826B1 (en) | 2010-10-08 | 2018-07-18 | Novartis AG | Vitamin e formulations of sulfamide ns3 inhibitors |
AU2011336632B2 (en) | 2010-11-30 | 2015-09-03 | Gilead Pharmasset Llc | Compounds |
WO2012080050A1 (en) | 2010-12-14 | 2012-06-21 | F. Hoffmann-La Roche Ag | Solid forms of a phenoxybenzenesulfonyl compound |
AR085352A1 (en) | 2011-02-10 | 2013-09-25 | Idenix Pharmaceuticals Inc | MACROCICLIC INHIBITORS OF SERINA PROTEASA, ITS PHARMACEUTICAL COMPOSITIONS AND ITS USE TO TREAT HCV INFECTIONS |
ES2842595T3 (en) | 2011-03-14 | 2021-07-14 | Boehringer Ingelheim Animal Health Usa Inc | Equine rhinitis vaccine |
US20120252721A1 (en) | 2011-03-31 | 2012-10-04 | Idenix Pharmaceuticals, Inc. | Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor |
CN103842369A (en) | 2011-03-31 | 2014-06-04 | 埃迪尼克斯医药公司 | Compounds and pharmaceutical compositions for the treatment of viral infections |
EP2697242B1 (en) | 2011-04-13 | 2018-10-03 | Merck Sharp & Dohme Corp. | 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
BR112013026345A2 (en) | 2011-04-13 | 2019-04-24 | Merck Sharp & Dohe Corp. | compound, pharmaceutical composition, use of a compound, and method for treating an hcv infected patient |
US9150603B2 (en) | 2011-04-13 | 2015-10-06 | Merck Sharp & Dohme Corp. | 2′-cyano substituted nucleoside derivatives and methods of use thereof useful for the treatment of viral diseases |
ES2743691T3 (en) | 2011-04-14 | 2020-02-20 | Cyclacel Ltd | Dosage regimen for sapacitabine and decitabine in combination to treat acute myeloid leukemia |
CN102775458B (en) * | 2011-05-09 | 2015-11-25 | 中国人民解放军军事医学科学院毒物药物研究所 | The preparation of β-D-(2 ' R)-2 '-deoxidation-2 '-fluoro-2'CmeC derivative and purposes |
WO2013009737A1 (en) | 2011-07-13 | 2013-01-17 | Merck Sharp & Dohme Corp. | 5'-substituted nucleoside analogs and methods of use thereof for the treatment of viral diseases |
US9416154B2 (en) | 2011-07-13 | 2016-08-16 | Merck Sharp & Dohme Corp. | 5′-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
EP2755985B1 (en) | 2011-09-12 | 2017-11-01 | Idenix Pharmaceuticals LLC | Compounds and pharmaceutical compositions for the treatment of viral infections |
AR088441A1 (en) | 2011-09-12 | 2014-06-11 | Idenix Pharmaceuticals Inc | SUBSTITUTED CARBONYLOXYMETHYLPHOSPHORAMIDATE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS |
EP3670523B1 (en) | 2011-09-13 | 2021-08-11 | Agilent Technologies, Inc. | 3'-oh unblocked, fast photocleavable terminating nucleotides and their use in methods for nucleic acid sequencing |
HUE036588T2 (en) | 2011-09-16 | 2018-07-30 | Gilead Pharmasset Llc | Methods for treating hcv |
US8507460B2 (en) | 2011-10-14 | 2013-08-13 | Idenix Pharmaceuticals, Inc. | Substituted 3′,5′-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections |
WO2013074386A2 (en) | 2011-11-15 | 2013-05-23 | Merck Sharp & Dohme Corp. | Hcv ns3 protease inhibitors |
US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
CA3131037A1 (en) | 2011-11-30 | 2013-06-06 | Emory University | Antiviral jak inhibitors useful in treating or preventing retroviral and other viral infections |
AU2012358804B2 (en) | 2011-12-22 | 2018-04-19 | Alios Biopharma, Inc. | Substituted phosphorothioate nucleotide analogs |
US20140356325A1 (en) | 2012-01-12 | 2014-12-04 | Ligand Pharmaceuticals Incorporated | Novel 2'-c-methyl nucleoside derivative compounds |
WO2013133927A1 (en) | 2012-02-13 | 2013-09-12 | Idenix Pharmaceuticals, Inc. | Pharmaceutical compositions of 2'-c-methyl-guanosine, 5'-[2-[(3-hydroxy-2,2-dimethyl-1-oxopropyl)thio]ethyl n-(phenylmethyl)phosphoramidate] |
NZ631601A (en) | 2012-03-21 | 2016-06-24 | Alios Biopharma Inc | Solid forms of a thiophosphoramidate nucleotide prodrug |
NZ630805A (en) | 2012-03-22 | 2016-01-29 | Alios Biopharma Inc | Pharmaceutical combinations comprising a thionucleotide analog |
US9296778B2 (en) | 2012-05-22 | 2016-03-29 | Idenix Pharmaceuticals, Inc. | 3′,5′-cyclic phosphate prodrugs for HCV infection |
PE20150132A1 (en) | 2012-05-22 | 2015-02-14 | Idenix Pharmaceuticals Inc | D-AMINO ACID COMPOUNDS FOR HEPATIC DISEASE |
EP2852604B1 (en) | 2012-05-22 | 2017-04-12 | Idenix Pharmaceuticals LLC | 3',5'-cyclic phosphoramidate prodrugs for hcv infection |
US9422323B2 (en) | 2012-05-25 | 2016-08-23 | Janssen Sciences Ireland Uc | Uracyl spirooxetane nucleosides |
EP2900682A1 (en) | 2012-09-27 | 2015-08-05 | IDENIX Pharmaceuticals, Inc. | Esters and malonates of sate prodrugs |
CA2887578A1 (en) | 2012-10-08 | 2014-04-17 | Idenix Pharamaceuticals, Inc. | 2'-chloro nucleoside analogs for hcv infection |
US20140112886A1 (en) | 2012-10-19 | 2014-04-24 | Idenix Pharmaceuticals, Inc. | Dinucleotide compounds for hcv infection |
WO2014066239A1 (en) | 2012-10-22 | 2014-05-01 | Idenix Pharmaceuticals, Inc. | 2',4'-bridged nucleosides for hcv infection |
WO2014078427A1 (en) | 2012-11-14 | 2014-05-22 | Idenix Pharmaceuticals, Inc. | D-alanine ester of rp-nucleoside analog |
EP2938624A1 (en) | 2012-11-14 | 2015-11-04 | IDENIX Pharmaceuticals, Inc. | D-alanine ester of sp-nucleoside analog |
US9211300B2 (en) | 2012-12-19 | 2015-12-15 | Idenix Pharmaceuticals Llc | 4′-fluoro nucleosides for the treatment of HCV |
PT2935303T (en) | 2012-12-21 | 2021-04-30 | Alios Biopharma Inc | Substituted nucleosides, nucleotides and analogs thereof |
MY172166A (en) | 2013-01-31 | 2019-11-15 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
US10034893B2 (en) | 2013-02-01 | 2018-07-31 | Enanta Pharmaceuticals, Inc. | 5, 6-D2 uridine nucleoside/tide derivatives |
WO2014121417A1 (en) | 2013-02-07 | 2014-08-14 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c |
WO2014121418A1 (en) | 2013-02-07 | 2014-08-14 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c |
EP2970358B1 (en) | 2013-03-04 | 2021-06-30 | Idenix Pharmaceuticals LLC | 3'-deoxy nucleosides for the treatment of hcv |
US9339541B2 (en) | 2013-03-04 | 2016-05-17 | Merck Sharp & Dohme Corp. | Thiophosphate nucleosides for the treatment of HCV |
WO2014160484A1 (en) | 2013-03-13 | 2014-10-02 | Idenix Pharmaceuticals, Inc. | Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv |
RU2534613C2 (en) | 2013-03-22 | 2014-11-27 | Александр Васильевич Иващенко | Alkyl2-{[(2r,3s,5r)-5-(4-amino-2-oxo-2h-pyrimidine-1-yl)- -hydroxy- tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-proptonates, nucleoside inhibitors of rna-polymerase hcv ns5b, methods for producing and using them |
WO2014165542A1 (en) | 2013-04-01 | 2014-10-09 | Idenix Pharmaceuticals, Inc. | 2',4'-fluoro nucleosides for the treatment of hcv |
WO2014197578A1 (en) | 2013-06-05 | 2014-12-11 | Idenix Pharmaceuticals, Inc. | 1',4'-thio nucleosides for the treatment of hcv |
WO2015017713A1 (en) | 2013-08-01 | 2015-02-05 | Idenix Pharmaceuticals, Inc. | D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease |
EP4005560A1 (en) | 2013-08-27 | 2022-06-01 | Gilead Pharmasset LLC | Combination formulation of two antiviral compounds |
LT3043803T (en) | 2013-09-11 | 2022-08-10 | Emory University | Nucleotide and nucleoside compositions and their uses |
WO2015042375A1 (en) | 2013-09-20 | 2015-03-26 | Idenix Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
WO2015061683A1 (en) | 2013-10-25 | 2015-04-30 | Idenix Pharmaceuticals, Inc. | D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv |
WO2015066370A1 (en) | 2013-11-01 | 2015-05-07 | Idenix Pharmaceuticals, Inc. | D-alanine phosphoramidate pronucleotides of 2'-methyl 2'-fluoro guanosine nucleoside compounds for the treatment of hcv |
US20170198005A1 (en) | 2013-11-27 | 2017-07-13 | Idenix Pharmaceuticals Llc | 2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection |
WO2015095419A1 (en) | 2013-12-18 | 2015-06-25 | Idenix Pharmaceuticals, Inc. | 4'-or nucleosides for the treatment of hcv |
CN114404427A (en) | 2014-02-13 | 2022-04-29 | 配体药物公司 | Prodrug compound and use thereof |
US20170066779A1 (en) | 2014-03-05 | 2017-03-09 | Idenix Pharmaceuticals Llc | Solid forms of a flaviviridae virus inhibitor compound and salts thereof |
US20170066795A1 (en) | 2014-03-05 | 2017-03-09 | Idenix Pharmaceuticals Llc | Solid prodrug forms of 2'-chloro-2'-methyl uridine for hcv |
WO2015134561A1 (en) | 2014-03-05 | 2015-09-11 | Idenix Pharmaceuticals, Inc. | Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection |
WO2015161137A1 (en) | 2014-04-16 | 2015-10-22 | Idenix Pharmaceuticals, Inc. | 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv |
CN106687118A (en) | 2014-07-02 | 2017-05-17 | 配体药物公司 | Prodrug compounds and uses thereof |
US9675632B2 (en) | 2014-08-26 | 2017-06-13 | Enanta Pharmaceuticals, Inc. | Nucleoside and nucleotide derivatives |
TWI740546B (en) | 2014-10-29 | 2021-09-21 | 美商基利科學股份有限公司 | Methods for the preparation of ribosides |
WO2016073756A1 (en) | 2014-11-06 | 2016-05-12 | Enanta Pharmaceuticals, Inc. | Deuterated nucleoside/tide derivatives |
US9732110B2 (en) | 2014-12-05 | 2017-08-15 | Enanta Pharmaceuticals, Inc. | Nucleoside and nucleotide derivatives |
CA2972259A1 (en) | 2014-12-26 | 2016-06-30 | Emory University | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
WO2017049060A1 (en) | 2015-09-16 | 2017-03-23 | Gilead Sciences, Inc. | Methods for treating arenaviridae and coronaviridae virus infections |
US10202412B2 (en) | 2016-07-08 | 2019-02-12 | Atea Pharmaceuticals, Inc. | β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections |
US20190169221A1 (en) * | 2016-08-12 | 2019-06-06 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
SG11201906163TA (en) | 2017-02-01 | 2019-08-27 | Atea Pharmaceuticals Inc | Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus |
EP4331677A2 (en) | 2017-03-14 | 2024-03-06 | Gilead Sciences, Inc. | Methods of treating feline coronavirus infections |
EP3618929B1 (en) | 2017-05-01 | 2022-12-07 | Gilead Sciences, Inc. | A crystalline form of (s) 2 ethylbutyl 2 (((s) (((2r,3s,4r,5r) 5 (4 aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2 yl)methoxy)(phenoxy) phosphoryl)amino)propanoate |
CN110799727B (en) | 2017-06-26 | 2023-06-27 | Hrl实验室有限责任公司 | System and method for generating output to a borehole inertia measurement unit |
US10675296B2 (en) | 2017-07-11 | 2020-06-09 | Gilead Sciences, Inc. | Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections |
BR112020010581A2 (en) | 2017-12-07 | 2020-11-10 | Emory University | pharmaceutical composition, pressurized container, and, methods to treat or prevent a viral infection and to treat or prevent human coronavirus, sars, coronavirus mers, eastern equine encephalitis virus, western equine encephalitis virus, Venezuelan equine encephalitis virus, chikungunya virus and infection by ross river infection, orthomyxoviridae virus or paramyxoviridae virus or rsv virus, or infection by influenza a virus and influenza b virus or filoviridae virus or ebola virus. |
JP2022512751A (en) * | 2018-10-17 | 2022-02-07 | リャオ,シビン | 6-Mercaptopurine nucleoside analog |
TW202313067A (en) | 2020-01-27 | 2023-04-01 | 美商基利科學股份有限公司 | Methods for treating sars cov-2 infections |
CA3169340A1 (en) | 2020-03-12 | 2021-09-16 | Pavel R. Badalov | Methods of preparing 1'-cyano nucleosides |
KR20220164784A (en) | 2020-04-06 | 2022-12-13 | 길리애드 사이언시즈, 인코포레이티드 | Inhalation Formulations of 1′-Cyano Substituted Carbanucleoside Analogues |
US20210393653A1 (en) | 2020-05-29 | 2021-12-23 | Gilead Sciences, Inc. | Remdesivir treatment methods |
BR112022026321A2 (en) | 2020-06-24 | 2023-01-17 | Gilead Sciences Inc | 1'-CYAN NUCLEOSIDE ANALOGS AND USES THEREOF |
JP2023540225A (en) | 2020-08-27 | 2023-09-22 | ギリアード サイエンシーズ, インコーポレイテッド | Compounds and methods for the treatment of viral infections |
WO2022115615A1 (en) * | 2020-11-25 | 2022-06-02 | Northeastern University | Cyclic peptides with antimicrobial properties |
WO2023167944A1 (en) | 2022-03-02 | 2023-09-07 | Gilead Sciences, Inc. | Compounds and methods for treatment of viral infections |
Citations (157)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3074929A (en) | 1955-08-11 | 1963-01-22 | Burroughs Wellcome Co | Glycosides of 6-mercaptopurine |
GB924246A (en) | 1958-12-23 | 1963-04-24 | Wellcome Found | Purine derivatives and their preparation |
US3116282A (en) | 1960-04-27 | 1963-12-31 | Upjohn Co | Pyrimidine nucleosides and process |
GB984877A (en) | 1962-08-16 | 1965-03-03 | Waldhof Zellstoff Fab | Improvements in and relating to 6-halonucleosides |
FR1521076A (en) | 1966-05-02 | 1968-04-12 | Merck & Co Inc | Substituted purine nucleosides |
GB1163102A (en) | 1965-11-15 | 1969-09-04 | Merck & Co Inc | D-Ribofuranose Derivatives |
GB1163103A (en) | 1965-11-15 | 1969-09-04 | Merck & Co Inc | Ribofuranosyl Purine Derivatives |
FR1581628A (en) | 1967-07-03 | 1969-09-19 | ||
GB1187824A (en) | 1966-05-02 | 1970-04-15 | Merck & Co Inc | Nucleosides and their Preparation |
DE1919307C (en) | 1969-04-11 | 1972-04-27 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | Process for the production of nucleo sides |
US3798209A (en) | 1971-06-01 | 1974-03-19 | Icn Pharmaceuticals | 1,2,4-triazole nucleosides |
US3891623A (en) | 1971-05-04 | 1975-06-24 | Schering Ag | Process for preparing cytidines |
US4022889A (en) | 1974-05-20 | 1977-05-10 | The Upjohn Company | Therapeutic compositions of antibiotic U-44,590 and methods for using the same |
US4058602A (en) | 1976-08-09 | 1977-11-15 | The United States Of America As Represented By The Department Of Health, Education And Welfare | Synthesis, structure, and antitumor activity of 5,6-dihydro-5-azacytidine |
USRE29835E (en) | 1971-06-01 | 1978-11-14 | Icn Pharmaceuticals | 1,2,4-Triazole nucleosides |
GB1542442A (en) | 1975-02-24 | 1979-03-21 | Schering Ag | Process for the manufacture of nucleosides |
US4209613A (en) | 1977-12-20 | 1980-06-24 | Schering Aktiengesellschaft | Process for the preparation of nucleosides |
US4239753A (en) | 1978-12-12 | 1980-12-16 | The Upjohn Company | Composition of matter and process |
US4294766A (en) | 1978-12-06 | 1981-10-13 | Basf Aktiengesellschaft | Preparation of pure potassium ribonate and ribonolactone |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4605659A (en) | 1985-04-30 | 1986-08-12 | Syntex (U.S.A.) Inc. | Purinyl or pyrimidinyl substituted hydroxycyclopentane compounds useful as antivirals |
US4689404A (en) | 1985-03-05 | 1987-08-25 | Takeda Chemical Industries, Ltd. | Production of cytosine nucleosides |
US4754026A (en) | 1985-06-04 | 1988-06-28 | Takeda Chemical Industries, Ltd. | Conversion of uracil derivatives to cytosine derivatives |
EP0180276B1 (en) | 1984-10-24 | 1988-12-28 | Stamicarbon B.V. | Dioxaphosphorinanes, their preparation and use for resolving optically active compounds |
US4880784A (en) | 1987-12-21 | 1989-11-14 | Brigham Young University | Antiviral methods utilizing ribofuranosylthiazolo[4,5-d]pyrimdine derivatives |
EP0352248A1 (en) | 1988-07-20 | 1990-01-24 | Medivir Aktiebolag | Nucleoside derivatives |
US4952740A (en) | 1984-04-10 | 1990-08-28 | Societe Nationale Elf Aquitaine | Cyclic phosphonites |
US4957924A (en) | 1987-08-15 | 1990-09-18 | Burroughs Wellcome Co. | Therapeutic valine esters of acyclovir and pharmaceutically acceptable salts thereof |
US5034394A (en) | 1988-06-27 | 1991-07-23 | Burroughs Wellcome Co. | Therapeutic nucleosides |
US5122517A (en) | 1988-06-10 | 1992-06-16 | Regents Of The University Of Minnesota | Antiviral combination comprising nucleoside analogs |
EP0494119A1 (en) | 1991-01-03 | 1992-07-08 | Biochem Pharma Inc. | Use of 1,3-oxathiolane nucleoside analogues in the treatment of hepatitis B |
FR2662165B1 (en) | 1990-05-18 | 1992-09-11 | Univ Paris Curie | BRANCHED NUCLEOSIDE DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR USE AS MEDICAMENTS. |
US5149794A (en) | 1990-11-01 | 1992-09-22 | State Of Oregon | Covalent lipid-drug conjugates for drug targeting |
US5157027A (en) | 1991-05-13 | 1992-10-20 | E. R. Squibb & Sons, Inc. | Bisphosphonate squalene synthetase inhibitors and method |
EP0288847B1 (en) | 1987-04-30 | 1992-12-09 | BASF Aktiengesellschaft | Continuous process for the epimerization of sugars, in particular of d-arabinose into d-ribose |
US5194654A (en) | 1989-11-22 | 1993-03-16 | Vical, Inc. | Lipid derivatives of phosphonoacids for liposomal incorporation and method of use |
US5200514A (en) | 1990-01-19 | 1993-04-06 | University Of Georgia Research Foundation, Inc. | Synthesis of 2'-deoxypyrimidine nucleosides |
US5223263A (en) | 1988-07-07 | 1993-06-29 | Vical, Inc. | Liponucleotide-containing liposomes |
US5246924A (en) | 1987-09-03 | 1993-09-21 | Sloan-Kettering Institute For Cancer Research | Method for treating hepatitis B virus infections using 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-ethyluracil |
US5256641A (en) | 1990-11-01 | 1993-10-26 | State Of Oregon | Covalent polar lipid-peptide conjugates for immunological targeting |
US5256797A (en) | 1992-06-22 | 1993-10-26 | Eli Lilly And Company | Process for separating 2-deoxy-2,2-difluoro-D-ribofuranosyl alkylsulfonate anomers |
EP0526655A4 (en) | 1991-02-22 | 1993-12-15 | Japan Tobacco Inc. | Process for producing 3-dpa-lactone |
DE4224737A1 (en) | 1992-07-27 | 1994-02-03 | Herbert Prof Dr Schott | New cytosine analogues with lipophilic protected amino gps. - for treatment of cancer and virus diseases e.g. AIDS, are more protected against enzymatic des-amination and can be used in higher doses than unprotected cpds. |
US5371210A (en) | 1992-06-22 | 1994-12-06 | Eli Lilly And Company | Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides |
US5372808A (en) | 1990-10-17 | 1994-12-13 | Amgen Inc. | Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect |
US5391769A (en) | 1991-07-22 | 1995-02-21 | Japan Tobacco Incorporated | Method of preparing 3-DPA-lactone |
US5401861A (en) | 1992-06-22 | 1995-03-28 | Eli Lilly And Company | Low temperature process for preparing alpha-anomer enriched 2-deoxy-2,2-difluoro-D-ribofuranosyl sulfonates |
US5411947A (en) | 1989-06-28 | 1995-05-02 | Vestar, Inc. | Method of converting a drug to an orally available form by covalently bonding a lipid to the drug |
US5463092A (en) | 1989-11-22 | 1995-10-31 | Vestar, Inc. | Lipid derivatives of phosphonacids for liposomal incorporation and method of use |
EP0587364B1 (en) | 1992-09-01 | 1996-06-05 | Eli Lilly And Company | A process for anomerizing nucleosides |
US5539116A (en) | 1990-02-01 | 1996-07-23 | Emory University | Method and compositions for the synthesis of BCH-189 and related compounds |
US5543389A (en) | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization | Covalent polar lipid-peptide conjugates for use in salves |
US5543390A (en) | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | Covalent microparticle-drug conjugates for biological targeting |
US5554728A (en) | 1991-07-23 | 1996-09-10 | Nexstar Pharmaceuticals, Inc. | Lipid conjugates of therapeutic peptides and protease inhibitors |
US5565438A (en) | 1994-01-28 | 1996-10-15 | University Of Ga Research Foundation | L-nucleosides for the treatment of epstein-bar virus |
US5606048A (en) | 1992-06-22 | 1997-02-25 | Eli Lilly And Company | Stereoselective glycosylation process for preparing 2'-Deoxy-2', 2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides |
US5616567A (en) * | 1990-06-15 | 1997-04-01 | Sankyo Company, Limited | 2'-Cyano pyrimidine nucleoside compounds |
US5676942A (en) | 1992-02-10 | 1997-10-14 | Interferon Sciences, Inc. | Composition containing human alpha interferon species proteins and method for use thereof |
US5696277A (en) | 1994-11-15 | 1997-12-09 | Karl Y. Hostetler | Antiviral prodrugs |
US5738845A (en) | 1989-03-02 | 1998-04-14 | The Women's Research Institute | Human interferon τ proteins and methods of use |
US5744600A (en) | 1988-11-14 | 1998-04-28 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Phosphonomethoxy carbocyclic nucleosides and nucleotides |
US5750676A (en) | 1995-04-03 | 1998-05-12 | Hoechst Aktiengesellschaft | Process for preparing nucleosides with unprotected sugars |
US5763418A (en) | 1994-12-13 | 1998-06-09 | Akira Matsuda | 3'-substituted nucleoside derivatives |
US5780617A (en) | 1990-05-29 | 1998-07-14 | Nexstar Pharmaceuticals, Inc. | Synthesis of liponucleotides |
US5789608A (en) | 1990-06-13 | 1998-08-04 | Drug Innovation And Design, Inc. | Phosphorus prodrugs |
US5821357A (en) | 1992-06-22 | 1998-10-13 | Eli Lilly And Company | Stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoropurine and triazole nucleosides |
US5830455A (en) | 1992-12-22 | 1998-11-03 | Glaxo Wellcome Inc. | Method of treatment using a therapeutic combination of α interferon and free radical scavengers |
US5849696A (en) | 1991-09-13 | 1998-12-15 | The Board Of Governors Of Wayne State University | Composition and method of treating hepatitis C |
US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
US5928636A (en) | 1996-05-13 | 1999-07-27 | Hoffmann-La Roche Inc. | Use of IL-12 and IFNα for the treatment of infectious diseases |
US5977061A (en) | 1995-04-21 | 1999-11-02 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | N6 - substituted nucleotide analagues and their use |
US5977325A (en) | 1988-11-15 | 1999-11-02 | Merrell Pharmaceuticals Inc. | 2'-halomethylidene, 2'-ethenylidene and 2'-ethynyl cytidine, uridine and guanosine derivatives |
US5980884A (en) | 1996-02-05 | 1999-11-09 | Amgen, Inc. | Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon |
CA2252144A1 (en) | 1998-10-16 | 2000-04-16 | University Of Alberta | Dual action anticancer prodrugs |
US6063628A (en) | 1996-10-28 | 2000-05-16 | University Of Washington | Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA |
US6153594A (en) | 1993-04-05 | 2000-11-28 | Norsk Hydro As | 5'-O-acylated antiviral nucleosides |
US6156501A (en) | 1993-10-26 | 2000-12-05 | Affymetrix, Inc. | Arrays of modified nucleic acid probes and methods of use |
US6172046B1 (en) | 1997-09-21 | 2001-01-09 | Schering Corporation | Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection |
US6248878B1 (en) | 1996-12-24 | 2001-06-19 | Ribozyme Pharmaceuticals, Inc. | Nucleoside analogs |
US6252060B1 (en) | 1988-07-07 | 2001-06-26 | Nexstar Pharmaceuticals, Inc. | Antiviral liponucleosides: treatment of hepatitis B |
US6271212B1 (en) | 1995-09-07 | 2001-08-07 | University Of Georgia Research Foundation Inc. | Prodrug azide compositions and compounds |
US6277830B1 (en) | 1998-10-16 | 2001-08-21 | Schering Corporation | 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon |
US6312662B1 (en) | 1998-03-06 | 2001-11-06 | Metabasis Therapeutics, Inc. | Prodrugs phosphorus-containing compounds |
US6340690B1 (en) | 1999-02-22 | 2002-01-22 | Bio-Chem Pharma Inc. | Antiviral methods using [1,8]naphthyridine derivatives |
US20020019363A1 (en) | 2000-02-18 | 2002-02-14 | Ismaili Hicham Moulay Alaoui | Method for the treatment or prevention of flavivirus infections using nucleoside analogues |
US6348587B1 (en) | 1998-02-25 | 2002-02-19 | Emory University | 2′-Fluoronucleosides |
US20020035085A1 (en) | 2000-05-26 | 2002-03-21 | Jean-Pierre Sommadossi | Methods of treating hepatitis delta virus infection with beta-l-2'-deoxy-nucleosides |
US6369040B1 (en) | 1990-01-11 | 2002-04-09 | Isis Pharmaceuticals, Inc. | Pyrimidine nucleosides |
US20020055483A1 (en) | 2000-04-13 | 2002-05-09 | Watanabe Kyoichi A. | 3'-or 2'-hydroxymethyl substituted nucleoside derivatives for treatment of hepatites virus infections |
US20020055473A1 (en) | 2000-04-20 | 2002-05-09 | Ganguly Ashit K. | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
US6395716B1 (en) | 1998-08-10 | 2002-05-28 | Novirio Pharmaceuticals Limited | β-L-2′-deoxy-nucleosides for the treatment of hepatitis B |
US20020095033A1 (en) | 1996-10-16 | 2002-07-18 | Icn Pharmaceuticals, Inc. | Monocyclic L-nucleosides, analogs and uses thereof |
US6436437B1 (en) | 1990-11-01 | 2002-08-20 | Oregon Health And Science University | Covalent polar lipid conjugates with neurologically active compounds for targeting |
US6444652B1 (en) | 1998-08-10 | 2002-09-03 | Novirio Pharmaceuticals Limited | β-L-2'-deoxy-nucleosides for the treatment of hepatitis B |
US6448392B1 (en) | 1985-03-06 | 2002-09-10 | Chimerix, Inc. | Lipid derivatives of antiviral nucleosides: liposomal incorporation and method of use |
US20020127203A1 (en) | 2000-10-18 | 2002-09-12 | Albrecht Janice K. | Ribavirin-pegylated interferon alfa HCV combination therapy |
US6455508B1 (en) | 2000-02-15 | 2002-09-24 | Kanda S. Ramasamy | Methods for treating diseases with tirazole and pyrrolo-pyrimidine ribofuranosyl nucleosides |
US6458773B1 (en) | 1998-11-05 | 2002-10-01 | Emory University | Nucleoside with anti-hepatitis B virus activity |
US6458772B1 (en) | 1909-10-07 | 2002-10-01 | Medivir Ab | Prodrugs |
US20020147160A1 (en) | 2001-01-22 | 2002-10-10 | Balkrishen Bhat | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase |
US20020156030A1 (en) | 2000-02-15 | 2002-10-24 | Kanda Ramasamy | Heterocyclic aromatic compounds and uses thereof |
US6472373B1 (en) | 1997-09-21 | 2002-10-29 | Schering Corporation | Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection |
US20020173490A1 (en) | 1999-12-22 | 2002-11-21 | Metabasis Therapeutics, Inc. | Novel bisamidate phosphonate prodrugs |
US6495677B1 (en) | 2000-02-15 | 2002-12-17 | Kanda S. Ramasamy | Nucleoside compounds |
US20030008841A1 (en) | 2000-08-30 | 2003-01-09 | Rene Devos | Anti-HCV nucleoside derivatives |
US20030028013A1 (en) | 1998-05-26 | 2003-02-06 | Guangyi Wang | Novel nucleosides having bicyclic sugar moiety |
US20030053986A1 (en) | 1998-06-08 | 2003-03-20 | Friederike Zahm | Method of treating hepatitis C infection |
US20030055013A1 (en) | 2001-09-20 | 2003-03-20 | Schering Corporation | HCV combination therapy |
US20030083307A1 (en) | 2001-05-23 | 2003-05-01 | Devos Rene Robert | Anti-HCV nucleoside derivatives |
US20030083306A1 (en) | 2000-06-15 | 2003-05-01 | Jean-Louis Imbach | 3'-prodrugs of 2'-deoxy-beta-L-nucleosides |
US20030087873A1 (en) | 2000-10-18 | 2003-05-08 | Lieven Stuyver | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation |
US6566365B1 (en) | 1999-11-04 | 2003-05-20 | Biochem Pharma Inc. | Method for the treatment of Flaviviridea viral infection using nucleoside analogues |
US20030124512A1 (en) | 2000-10-18 | 2003-07-03 | Lieven Stuyver | Simultaneous quantification of nucleic acids in diseased cells |
US6599887B2 (en) | 1988-07-07 | 2003-07-29 | Chimerix, Inc. | Methods of treating viral infections using antiviral liponucleotides |
US20030225029A1 (en) | 2002-02-14 | 2003-12-04 | Stuyver Lieven J. | Dosing regimen for gemcitabine HCV therapy |
US20030236216A1 (en) | 2001-06-12 | 2003-12-25 | Devos Rene Robert | 4'-substituted nucleoside derivatives as inhibitors of HCV RNA replication |
US20040002596A1 (en) | 2000-06-16 | 2004-01-01 | Zhi Hong | Nucleoside compounds and uses thereof |
US20040006002A1 (en) | 2001-09-28 | 2004-01-08 | Jean-Pierre Sommadossi | Methods and compositions for treating flaviviruses and pestiviruses using 4'-modified nucleoside |
US20040023921A1 (en) | 2002-04-30 | 2004-02-05 | Zhi Hong | Antiviral phosphonate compounds and methods therefor |
US20040059104A1 (en) | 2002-02-28 | 2004-03-25 | Cook Phillip Dan | Nucleotide mimics and their prodrugs |
US20040063658A1 (en) | 2002-05-06 | 2004-04-01 | Roberts Christopher Don | Nucleoside derivatives for treating hepatitis C virus infection |
US6748161B2 (en) | 1998-03-06 | 2004-06-08 | Samsung Electronics Co., Ltd | Storage medium storing catalog information and corresponding audio data |
US20040110717A1 (en) | 2001-01-22 | 2004-06-10 | Carroll Steven S. | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
US6752981B1 (en) | 1999-09-08 | 2004-06-22 | Metabasis Therapeutics, Inc. | Prodrugs for liver specific drug delivery |
US20040121980A1 (en) | 2002-11-19 | 2004-06-24 | Roche Palo Alto Llc | Antiviral nucleoside derivatives |
US20040147464A1 (en) | 2002-09-30 | 2004-07-29 | Genelabs Technologies, Inc. | Nucleoside derivatives for treating hepatitis C virus infection |
US6787526B1 (en) | 2000-05-26 | 2004-09-07 | Idenix Pharmaceuticals, Inc. | Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides |
US6812219B2 (en) * | 2000-05-26 | 2004-11-02 | Idenix Pharmaceuticals, Inc. | Methods and compositions for treating flaviviruses and pestiviruses |
US20040229839A1 (en) | 2003-05-14 | 2004-11-18 | Biocryst Pharmaceuticals, Inc. | Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases |
US6831069B2 (en) | 1999-08-27 | 2004-12-14 | Ribapharm Inc. | Pyrrolo[2,3-d]pyrimidine nucleoside analogs |
US20040259934A1 (en) | 2003-05-01 | 2004-12-23 | Olsen David B. | Inhibiting Coronaviridae viral replication and treating Coronaviridae viral infection with nucleoside compounds |
US20040266996A1 (en) | 2003-03-20 | 2004-12-30 | Rabi Jaime A | Methods of manufacture of 2'-deoxy-beta-L-nucleosides |
US20040266723A1 (en) | 2000-12-15 | 2004-12-30 | Otto Michael J. | Antiviral agents for treatment of Flaviviridae infections |
US20050009737A1 (en) | 2003-05-30 | 2005-01-13 | Jeremy Clark | Modified fluorinated nucleoside analogues |
US20050031588A1 (en) | 2002-11-15 | 2005-02-10 | Jean-Pierre Sommadossi | 2'-branched nucleosides and Flaviviridae mutation |
US20050038240A1 (en) | 2003-06-19 | 2005-02-17 | Roche Palo Alto Llc | Processes for preparing 4'-azido-nucleoside derivatives |
US20050090463A1 (en) | 2003-10-27 | 2005-04-28 | Genelabs Technologies, Inc. | Nucleoside compounds for treating viral infections |
US20050107312A1 (en) | 2003-10-27 | 2005-05-19 | Genelabs Technologies, Inc. | Nucleoside compounds for treating viral infections |
US20050119200A1 (en) | 2002-09-30 | 2005-06-02 | Roberts Christopher D. | Nucleoside derivatives for treating hepatitis C virus infection |
US20050124532A1 (en) | 2000-05-23 | 2005-06-09 | Jean-Pierre Sommadossi | Methods and compositions for treating hepatitis C virus |
US6908924B2 (en) | 2001-12-14 | 2005-06-21 | Pharmasset, Inc. | N4-acylcytosine-1,3-dioxolane nucleosides for treatment of viral infections |
US20050137141A1 (en) | 2003-10-24 | 2005-06-23 | John Hilfinger | Prodrug composition |
US6927291B2 (en) | 2001-03-01 | 2005-08-09 | Pharmasset, Ltd. | Method for the synthesis of 2′,3′-dideoxy-2′,3′-didehydronucleosides |
US6949522B2 (en) | 2001-06-22 | 2005-09-27 | Pharmasset, Inc. | β-2′- or 3′-halonucleosides |
US20050215511A1 (en) | 2003-10-27 | 2005-09-29 | Genelabs Technologies, Inc. | Nucleoside compounds for treating viral infections |
US6965066B1 (en) | 2002-01-16 | 2005-11-15 | Actodyne General, Inc. | Elongated string support for a stringed musical instrument |
US20060040890A1 (en) | 2004-08-23 | 2006-02-23 | Roche Palo Alto Llc | Anti-viral nucleosides |
US20060111311A1 (en) | 2004-11-22 | 2006-05-25 | Genelabs Technologies, Inc. | 5-nitro-nucleoside compounds for treating viral infections |
US20060194835A1 (en) | 2005-02-09 | 2006-08-31 | Migenix Inc. | Compositions and methods for treating or preventing flaviviridae infections |
US20060199783A1 (en) | 2004-07-21 | 2006-09-07 | Pharmassett, Inc. | Preparation of alkyl-substituted 2-deoxy-2-fluoro-D-ribofuranosyl pyrimidines and purines and their derivatives |
DE102005012681A1 (en) | 2005-03-18 | 2006-09-21 | Weber, Lutz, Dr. | New 1,5-dihydro-pyrrol-2-one compounds are HDM2 inhibitors, useful for treating e.g. stroke, heart infarct, ischemia, multiple sclerosis, Alzheimer's disease, degenerative disease, viral infection and cancer |
US20060241064A1 (en) | 2005-04-25 | 2006-10-26 | Genelabs Technologies, Inc. | Nucleoside compounds for treating viral infections |
US20070015905A1 (en) | 2002-06-28 | 2007-01-18 | Lacolla Paola | 2' and 3'-nucleoside prodrugs for treating Flaviviridae infections |
US20070027104A1 (en) | 2002-06-28 | 2007-02-01 | Lacolla Paola | Modified 2' and 3'-nucleoside prodrugs for treating Flaviviridae infections |
US20070203334A1 (en) | 2005-12-23 | 2007-08-30 | Mayes Benjamin A | Process for preparing a synthetic intermediate for preparation of branched nucleosides |
US7582618B2 (en) * | 2002-06-28 | 2009-09-01 | Idenix Pharmaceuticals, Inc. | 2′-C-methyl-3′-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
US7598373B2 (en) | 2002-12-12 | 2009-10-06 | Idenix Pharmaceuticals, Inc. | Process for the production of 2-C-methyl-D-ribonolactone |
Family Cites Families (184)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US87873A (en) * | 1869-03-16 | Perry prettyman | ||
US8841A (en) * | 1852-03-30 | Sice-httxieb | ||
US28013A (en) * | 1860-04-24 | Improved bullet-ladle | ||
US83307A (en) * | 1868-10-20 | Improvement in wash-boilehs | ||
JPS4848495A (en) | 1971-09-21 | 1973-07-09 | ||
DD140254A1 (en) | 1978-12-04 | 1980-02-20 | Dieter Baerwolff | METHOD OF PREPARING 4-SUBSTITUTED PYRIMIDIN NUCLEOSIDES |
KR880000094B1 (en) | 1984-12-07 | 1988-02-23 | 보령제약 주식회사 | Preparation process for nucleoside derivative |
JPS61212592A (en) | 1985-03-19 | 1986-09-20 | Tokyo Tanabe Co Ltd | Production of d-ribose |
JPS61263995A (en) | 1985-05-16 | 1986-11-21 | Takeda Chem Ind Ltd | Production of cytosine nucleoside |
US5455339A (en) | 1986-05-01 | 1995-10-03 | University Of Georgia Research Foundation, Inc. | Method for the preparation of 2',3'-dideoxy and 2',3'-dideoxydide-hydro nucleosides |
JPS63215894A (en) | 1987-03-04 | 1988-09-08 | Hitachi Ltd | Motor pump with intensifier |
JPH0699467B2 (en) | 1987-03-04 | 1994-12-07 | ヤマサ醤油株式会社 | 2 ▲ '▼ -Deoxy-2 ▲' ▼ (S) -alkylpyrimidine nucleoside derivative |
AU2526188A (en) | 1987-09-22 | 1989-04-18 | Regents Of The University Of California, The | Liposomal nucleoside analogues for treating aids |
US4996308A (en) * | 1988-03-25 | 1991-02-26 | Merrell Dow Pharmaceuticals Inc. | Derivatives with unsaturated substitutions for the 5'-hydroxymethyl group |
NZ229453A (en) | 1988-06-10 | 1991-08-27 | Univ Minnesota & Southern Rese | A pharmaceutical composition containing purine derivatives with nucleosides such as azt, as antiviral agents |
US5118672A (en) | 1989-07-10 | 1992-06-02 | University Of Georgia Research Foundation | 5'-diphosphohexose nucleoside pharmaceutical compositions |
US5026687A (en) | 1990-01-03 | 1991-06-25 | The United States Of America As Represented By The Department Of Health And Human Services | Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds |
WO1991016920A1 (en) | 1990-05-07 | 1991-11-14 | Vical, Inc. | Lipid prodrugs of salicylate and nonsteroidal anti-inflammatory drugs |
EP0531452A4 (en) | 1990-05-29 | 1993-06-09 | Vical, Inc. | Synthesis of glycerol di- and triphosphate derivatives |
JP3347723B2 (en) | 1990-06-13 | 2002-11-20 | グラツィエル,アーノルド | Phosphorus-containing prodrug |
HUT64844A (en) | 1991-03-06 | 1994-03-28 | Wellcome Found | Application of 5-fluorine-2'-desoxi-3'-thia-cytidine for treatment of hepatitis b |
WO1992018517A1 (en) | 1991-04-17 | 1992-10-29 | Yale University | Method of treating or preventing hepatitis b virus |
JPH07500573A (en) | 1991-07-12 | 1995-01-19 | ネクススター・ファーマシューティカルズ・インコーポレイテッド | Antiviral liponucleosides: treatment of hepatitis B |
DE4207363A1 (en) | 1992-03-04 | 1993-09-09 | Max Delbrueck Centrum | ANTIVIRAL NUCLEOSIDE ANALOGS, THEIR PRODUCTION AND THEIR PHARMACEUTICAL USE |
WO1994001117A1 (en) | 1992-07-02 | 1994-01-20 | The Wellcome Foundation Limited | Therapeutic nucleosides |
US5256924A (en) * | 1992-08-10 | 1993-10-26 | Allied-Signal Inc. | Superconducting commutator for DC machines |
US6391542B1 (en) | 1992-09-10 | 2002-05-21 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of Hepatitis C virus-associated diseases |
US6433159B1 (en) | 1992-09-10 | 2002-08-13 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of Hepatitis C virus associated diseases |
EP0662157B1 (en) | 1992-09-10 | 2001-06-20 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of hepatitis c virus-associated diseases |
US6174868B1 (en) | 1992-09-10 | 2001-01-16 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of hepatitis C virus-associated diseases |
US6423489B1 (en) | 1992-09-10 | 2002-07-23 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of Hepatitis C virus-associated diseases |
JPH06135988A (en) | 1992-10-22 | 1994-05-17 | Toagosei Chem Ind Co Ltd | Nucleotide derivative |
JPH06211890A (en) | 1993-01-12 | 1994-08-02 | Yamasa Shoyu Co Ltd | 2'-deoxy-2'@(3754/24)s)-substituted alkylcytidine derivative |
JPH06228186A (en) | 1993-01-29 | 1994-08-16 | Yamasa Shoyu Co Ltd | 2'-deoxy-@(3754/24)2's)-alkylpyrimidine nucleoside derivative |
ATE181557T1 (en) | 1993-02-24 | 1999-07-15 | Jui H Wang | COMPOSITIONS AND METHODS OF APPLYING REACTIVE ANTIVIRAL POLYMERS |
JP3312951B2 (en) | 1993-04-08 | 2002-08-12 | 三菱化学株式会社 | Olefin-based thermoplastic resin composition |
CA2162574A1 (en) | 1993-05-12 | 1994-11-24 | Karl Y. Hostetler | Acyclovir derivatives for topical use |
AU688344B2 (en) | 1993-07-19 | 1998-03-12 | Mitsubishi-Tokyo Pharmaceuticals, Inc. | Hepatitis C virus proliferation inhibitor |
US5908821A (en) | 1994-05-11 | 1999-06-01 | Procter & Gamble Company | Dye transfer inhibiting compositions with specifically selected metallo catalysts |
WO1996001115A1 (en) | 1994-07-01 | 1996-01-18 | Pro-Neuron, Inc. | Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis |
DE4432623A1 (en) | 1994-09-14 | 1996-03-21 | Huels Chemische Werke Ag | Process for bleaching aqueous surfactant solutions |
GB9505025D0 (en) | 1995-03-13 | 1995-05-03 | Medical Res Council | Chemical compounds |
JP3786447B2 (en) | 1995-03-31 | 2006-06-14 | エーザイ株式会社 | Preventive and therapeutic agent for hepatitis C |
JPH0959292A (en) | 1995-08-25 | 1997-03-04 | Yamasa Shoyu Co Ltd | Production of 4-aminopyrimidine nucleoside |
EP0859833B1 (en) | 1995-09-27 | 2006-03-01 | Emory University | Recombinant hepatitis c virus rna replicase |
US5830905A (en) | 1996-03-29 | 1998-11-03 | Viropharma Incorporated | Compounds, compositions and methods for treatment of hepatitis C |
US5633388A (en) | 1996-03-29 | 1997-05-27 | Viropharma Incorporated | Compounds, compositions and methods for treatment of hepatitis C |
US5891874A (en) | 1996-06-05 | 1999-04-06 | Eli Lilly And Company | Anti-viral compound |
JP3927630B2 (en) | 1996-09-27 | 2007-06-13 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Preventive and therapeutic agents for viral infections |
US5922757A (en) | 1996-09-30 | 1999-07-13 | The Regents Of The University Of California | Treatment and prevention of hepatic disorders |
DE69729887T2 (en) * | 1996-10-16 | 2005-07-28 | ICN Pharmaceuticals, Inc., Costa Mesa | Purine L nucleosides, analogs and their use |
IL129407A0 (en) | 1996-10-18 | 2000-02-17 | Vertex Pharma | Inhibitors of serine proteases particularly hepatitis C virus NS3 protease pharmaceutical compositions containing the same and the use thereof |
GB9623908D0 (en) | 1996-11-18 | 1997-01-08 | Hoffmann La Roche | Amino acid derivatives |
IL130497A0 (en) | 1997-01-17 | 2000-06-01 | Icn Pharmaceuticals | Controlled release preparations to selectively modulate Th1 and Th2 responses |
ES2221164T3 (en) | 1997-03-19 | 2004-12-16 | Emory University | SYNTHESIS AND ACTIVITY OF HUMAN IMMUNODEFICIENCY AND ANTIVIRUS OF HEPATITIS B OF NUCLEOSIDS 1,3-OXASELENOLANO. |
PL193237B1 (en) | 1997-06-30 | 2007-01-31 | Merz Pharma Gmbh & Co Kgaa | Derivatives of 1-aminoalkyl cyclohexane as antagonists of nmda receptor |
AU757072B2 (en) | 1997-08-11 | 2003-01-30 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C inhibitor peptide analogues |
DE69810822T2 (en) | 1997-09-21 | 2003-11-20 | Schering Corp | Combination therapy for the removal of detectable HCV-RNA in patients with chronic hepatitis C infection |
WO1999023104A2 (en) | 1997-10-30 | 1999-05-14 | The Government Of The United States Of America, Represented By The Secretary Of Health And Human Services | Antitumour uridine analogues |
ATE331515T1 (en) | 1998-02-12 | 2006-07-15 | Searle Llc | USE OF N-SUBSTITUTED-1,5-DIDEOXY-1,5-IMINO-D-GLUCITOLEN FOR THE TREATMENT OF HEPATITIS INFECTIONS |
WO1999043690A1 (en) | 1998-02-25 | 1999-09-02 | Rational Drug Design Laboratories | L-4'-arabinofuranonucleoside compound and medicine composition comprising the same |
AU767599B2 (en) | 1998-03-06 | 2003-11-20 | Metabasis Therapeutics, Inc. | Novel prodrugs for phosphorus-containing compounds |
GB9806815D0 (en) | 1998-03-30 | 1998-05-27 | Hoffmann La Roche | Amino acid derivatives |
TW466112B (en) | 1998-04-14 | 2001-12-01 | Lilly Co Eli | Novel use of 2'-deoxy-2',2'-difluorocytidine for immunosuppressive therapy and pharmaceutical composition comprising the same |
KR100694345B1 (en) | 1998-05-15 | 2007-03-12 | 쉐링 코포레이션 | Pharmaceutical composition comprising ribavirin and interferon alpha for antiviral treatment naive patients having chronic hepatitis c infection |
AU768059B2 (en) | 1998-11-05 | 2003-12-04 | Centre National De La Recherche Scientifique | Beta-L-2'-deoxy-nucleosides for the treatment of HIV infection |
EP1140143A2 (en) | 1998-12-18 | 2001-10-10 | Schering Corporation | Ribavirin-pegylated interferon alfa induction hcv combination therapy |
CA2371910A1 (en) | 1999-01-21 | 2000-07-27 | Brian E. Peerce | Inhibitors of intestinal apical membrane na/phosphate co-transportation |
HUP0105476A3 (en) | 1999-02-12 | 2002-08-28 | Univ Cardiff | Phosphoramidate, and mono-, di-, and tri-phosphate esters of (1r, cis)-4-(6-amino-9h-purin-9-yl)-2-cyclopentene-1-methanol as antiviral agents, process for preparation of the compounds and pharmaceutical compositions containing the same |
EP1173161A2 (en) | 1999-02-12 | 2002-01-23 | G.D. SEARLE & CO. | Glucamine compounds for treating hepatitis virus infections |
NZ513728A (en) | 1999-03-05 | 2001-09-28 | Metabasis Therapeutics Inc | Novel phosphorus-containing prodrugs |
BR0007050A (en) | 1999-09-01 | 2001-07-31 | Matsushita Electric Ind Co Ltd | Digital data copyright protection system |
AU2338101A (en) | 1999-12-30 | 2001-07-16 | Biochem Pharma Inc. | Imidazopyrimidine nucleoside analogues with anti-hiv activity |
JP2003522791A (en) | 2000-02-14 | 2003-07-29 | ファルマシア コーポレイション | Use of N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for the treatment of hepatitis virus infection |
FR2806095A1 (en) | 2000-03-10 | 2001-09-14 | Gentech | New polynucleotides for producing transgenic plants resistant to geminivirus infection comprising polynucleotides encoding proteins which interact with at least one of the products of the geminivirus genome |
MY141594A (en) | 2000-06-15 | 2010-05-14 | Novirio Pharmaceuticals Ltd | 3'-PRODRUGS OF 2'-DEOXY-ß-L-NUCLEOSIDES |
CA2409778A1 (en) | 2000-06-20 | 2001-12-27 | Incyte Genomics, Inc. | Secreted proteins |
JP3629187B2 (en) * | 2000-06-28 | 2005-03-16 | 株式会社東芝 | ELECTRIC FUSE, SEMICONDUCTOR DEVICE HAVING THE ELECTRIC FUSE, AND METHOD FOR MANUFACTURING THE SAME |
UA72612C2 (en) | 2000-07-06 | 2005-03-15 | Pyrido[2.3-d]pyrimidine and pyrimido[4.5-d]pyrimidine nucleoside analogues, prodrugs and method for inhibiting growth of neoplastic cells | |
US6316174B1 (en) * | 2000-08-24 | 2001-11-13 | Eastman Kodak Company | Color negative film |
SV2003000617A (en) | 2000-08-31 | 2003-01-13 | Lilly Co Eli | INHIBITORS OF PROTEASA PEPTIDOMIMETICA REF. X-14912M |
WO2002018405A2 (en) | 2000-09-01 | 2002-03-07 | Ribozyme Pharmaceuticals, Incorporated | Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives |
US20030070752A1 (en) | 2001-09-27 | 2003-04-17 | Kevin Bergevin | Method of manufacture for fluid handling barrier ribbon with polymeric tubes |
AU2002330154A1 (en) | 2001-09-28 | 2003-04-07 | Centre National De La Recherche Scientifique | Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides |
WO2003039523A2 (en) | 2001-11-05 | 2003-05-15 | Exiqon A/S | OLIGONUCLEOTIDES MODIFIED WITH NOVEL α-L-RNA ANALOGUES |
WO2003051899A1 (en) | 2001-12-17 | 2003-06-26 | Ribapharm Inc. | Deazapurine nucleoside libraries and compounds |
WO2003062256A1 (en) | 2002-01-17 | 2003-07-31 | Ribapharm Inc. | 2'-beta-modified-6-substituted adenosine analogs and their use as antiviral agents |
WO2003062255A2 (en) | 2002-01-17 | 2003-07-31 | Ribapharm Inc. | Sugar modified nucleosides as viral replication inhibitors |
WO2003061385A1 (en) | 2002-01-17 | 2003-07-31 | Ribapharm Inc. | Tricyclic nucleoside library compounds, synthesis, and use as antiviral agents |
EP1476169B1 (en) | 2002-02-13 | 2013-03-20 | Merck Sharp & Dohme Corp. | Inhibiting orthopoxvirus replication with nucleoside compounds |
AU2003214199A1 (en) | 2002-03-18 | 2003-10-08 | Massachusetts Institute Of Technology | Event-driven charge-coupled device design and applications therefor |
AU2003225181A1 (en) * | 2002-04-26 | 2003-11-10 | Rolls-Royce Corporation | Fuel premixing module for gas turbine engine combustor |
AU2003237249A1 (en) | 2002-05-24 | 2003-12-12 | Isis Pharmaceuticals, Inc. | Oligonucleotides having modified nucleoside units |
WO2003100017A2 (en) | 2002-05-24 | 2003-12-04 | Isis Pharmaceuticals, Inc. | Oligonucleotides having modified nucleoside units |
JP2005533777A (en) | 2002-06-17 | 2005-11-10 | メルク エンド カムパニー インコーポレーテッド | Carbocyclic nucleoside analogs as RNA antiviral agents |
DE10226932A1 (en) | 2002-06-17 | 2003-12-24 | Bayer Ag | Radiation-curing coating agents |
SE0201940D0 (en) | 2002-06-20 | 2002-06-20 | Astrazeneca Ab | New combination II |
WO2004000858A2 (en) | 2002-06-21 | 2003-12-31 | Merck & Co., Inc. | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
AU2003269892A1 (en) | 2002-06-27 | 2004-01-19 | Isis Pharmaceuticals, Inc. | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
JP5087211B2 (en) | 2002-06-28 | 2012-12-05 | イデニクス(ケイマン)リミテツド | 2 'and 3'-nucleoside prodrugs for the treatment of flavivirus infection |
PL374831A1 (en) | 2002-06-28 | 2005-10-31 | Idenix (Cayman) Limited | Modified 2' and 3' -nucleoside prodrugs for treating flaviridae infections |
US20040003476A1 (en) * | 2002-07-08 | 2004-01-08 | Albert Bierria | Portable power driven scarifying tool for pipe ends |
AU2003269902A1 (en) | 2002-07-16 | 2004-02-02 | Isis Pharmaceuticals, Inc. | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
AU2003256619A1 (en) | 2002-07-24 | 2004-02-09 | Isis Pharmaceuticals, Inc. | Pyrrolopyrimidine thionucleoside analogs as antivirals |
US20040067877A1 (en) | 2002-08-01 | 2004-04-08 | Schinazi Raymond F. | 2', 3'-Dideoxynucleoside analogues for the treatment or prevention of Flaviviridae infections |
JP4085742B2 (en) * | 2002-08-22 | 2008-05-14 | 株式会社ニコン | Lens barrel and camera system provided with the lens barrel |
WO2004023921A1 (en) | 2002-09-16 | 2004-03-25 | Kyeong Ho Kim | Decoration band |
US20040229840A1 (en) | 2002-10-29 | 2004-11-18 | Balkrishen Bhat | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase |
US7265096B2 (en) | 2002-11-04 | 2007-09-04 | Xenoport, Inc. | Gemcitabine prodrugs, pharmaceutical compositions and uses thereof |
CA2504929C (en) | 2002-11-05 | 2014-07-22 | Charles Allerson | Compositions comprising alternating 2'-modified nucleosides for use in gene modulation |
EP1563070A4 (en) | 2002-11-05 | 2008-05-28 | Isis Pharmaceuticals Inc | 2'-substituted oligomeric compounds and compositions for use in gene modulations |
BR0316868A (en) | 2002-12-23 | 2005-10-25 | Idenix Cayman Ltd | Process for the Production of Nucleoside-3 'Prodrugs |
US7799908B2 (en) | 2003-01-15 | 2010-09-21 | Valeant Pharmaceuticals North America | Synthesis and use of 2′-substituted-N6 -modified nucleosides |
AR043006A1 (en) | 2003-02-12 | 2005-07-13 | Merck & Co Inc | PROCESS TO PREPARE RAMIFIED RIBONUCLEOSIDS |
AU2003225705A1 (en) | 2003-03-07 | 2004-09-30 | Ribapharm Inc. | Cytidine analogs and methods of use |
CA2529311A1 (en) | 2003-03-28 | 2004-10-07 | Pharmasset, Inc. | Compounds for the treatment of flaviviridae infections |
US7452901B2 (en) | 2003-04-25 | 2008-11-18 | Gilead Sciences, Inc. | Anti-cancer phosphonate analogs |
US7595390B2 (en) | 2003-04-28 | 2009-09-29 | Novartis Ag | Industrially scalable nucleoside synthesis |
EP1656093A2 (en) | 2003-05-14 | 2006-05-17 | Idenix (Cayman) Limited | Nucleosides for treatment of infection by corona viruses, toga viruses and picorna viruses |
WO2005020885A2 (en) | 2003-05-21 | 2005-03-10 | Isis Pharmaceuticals, Inc. | Compositions and methods for the treatment of severe acute respiratory syndrome (sars) |
WO2004106356A1 (en) | 2003-05-27 | 2004-12-09 | Syddansk Universitet | Functionalized nucleotide derivatives |
GB0317009D0 (en) | 2003-07-21 | 2003-08-27 | Univ Cardiff | Chemical compounds |
CA2537140A1 (en) | 2003-08-29 | 2005-03-10 | The Nottingham Trent University | Gastric and prostate cancer associated antigens |
AU2004275770A1 (en) | 2003-09-22 | 2005-04-07 | Acidophil Llc | Small molecule compositions and methods for increasing drug efficiency using compositions thereof |
US6908824B2 (en) * | 2003-11-06 | 2005-06-21 | Chartered Semiconductor Manufacturing Ltd. | Self-aligned lateral heterojunction bipolar transistor |
JP2005302670A (en) | 2004-04-16 | 2005-10-27 | Matsushita Electric Ind Co Ltd | Electronic device |
WO2006016930A2 (en) | 2004-05-14 | 2006-02-16 | Intermune, Inc. | Methods for treating hcv infection |
AU2005254057B2 (en) | 2004-06-15 | 2011-02-17 | Isis Pharmaceuticals, Inc. | C-purine nucleoside analogs as inhibitors of RNA-dependent RNA viral polymerase |
US7560434B2 (en) | 2004-06-22 | 2009-07-14 | Biocryst Pharmaceuticals, Inc. | AZA nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases |
EP1912643A2 (en) | 2004-06-23 | 2008-04-23 | Idenix (Cayman) Limited | 5-aza-7-deazapurine derivatives for treating infections with flaviviridae |
WO2006012078A2 (en) | 2004-06-24 | 2006-02-02 | Merck & Co., Inc. | Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection |
EP2348029A1 (en) | 2004-07-21 | 2011-07-27 | Pharmasset, Inc. | Preparation of alkyl-substituted 2-deoxy-2-fluoro-d-ribofuranosyl pyrimidines and purines and their derivatives |
EP1804811A4 (en) | 2004-09-24 | 2011-04-27 | Idenix Cayman Ltd | Methods and compositions for treating flaviviruses, pestiviruses and hepacivirus |
JP2008515816A (en) | 2004-10-06 | 2008-05-15 | ミジェニックス インコーポレイテッド | Combination antiviral composition containing castanospermine and method of use thereof |
AU2005317081A1 (en) | 2004-10-21 | 2006-06-22 | Merck & Co., Inc. | Fluorinated pyrrolo[2,3-d]pyrimidine nucleosides for the treatment of RNA-dependent RNA viral infection |
EP1828217A2 (en) | 2004-12-16 | 2007-09-05 | Febit Biotech GmbH | Polymerase-independent analysis of the sequence of polynucleotides |
CA2600359A1 (en) | 2005-03-09 | 2006-09-09 | Idenix (Cayman) Limited | Nucleosides with non-natural bases as anti-viral agents |
WO2006097323A1 (en) | 2005-03-18 | 2006-09-21 | Lutz Weber | TETRAHYDRO-ISOQUINOLIN-l-ONES FOR THE TREATMENT OF CANCER |
GT200600119A (en) | 2005-03-24 | 2006-10-25 | PHARMACEUTICAL COMPOSITIONS | |
WO2006121820A1 (en) | 2005-05-05 | 2006-11-16 | Valeant Research & Development | Phosphoramidate prodrugs for treatment of viral infection |
SMAP200700061A (en) | 2005-05-31 | 2007-12-28 | Novartis Ag | Treatment of liver diseases in which iron plays a role in the pathogenesis |
CA2615626A1 (en) | 2005-07-18 | 2007-01-25 | Novartis Ag | Small animal model for hcv replication |
EP1915053A2 (en) | 2005-08-12 | 2008-04-30 | Merck & Co., Inc. | Novel 2'-c-methyl and 4'-c-methyl nucleoside derivatives |
AR057096A1 (en) | 2005-08-26 | 2007-11-14 | Chancellors Masters And Schola | PROCESS TO PREPARE SACARINIC ACIDS AND LACTONS |
UA91255C2 (en) | 2005-12-09 | 2010-07-12 | Ф. Хоффманн-Ля Рош Аг | Antiviral nucleosides |
WO2007095269A2 (en) | 2006-02-14 | 2007-08-23 | Merck & Co., Inc. | Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection |
US20080261913A1 (en) | 2006-12-28 | 2008-10-23 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of liver disorders |
US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
MX2009012433A (en) | 2007-05-14 | 2010-04-30 | Rfs Pharma Llc | Azido purine nucleosides for treatment of viral infections. |
GB0718575D0 (en) | 2007-09-24 | 2007-10-31 | Angeletti P Ist Richerche Bio | Nucleoside derivatives as inhibitors of viral polymerases |
US20090318380A1 (en) | 2007-11-20 | 2009-12-24 | Pharmasset, Inc. | 2',4'-substituted nucleosides as antiviral agents |
CA2722177C (en) | 2008-04-23 | 2016-08-16 | Gilead Sciences, Inc. | 1'-substituted carba-nucleoside analogs for antiviral treatment |
CN102177172A (en) | 2008-07-02 | 2011-09-07 | 埃迪尼克斯医药公司 | Compounds and pharmaceutical compositions for the treatment of viral infections |
GB0815968D0 (en) | 2008-09-03 | 2008-10-08 | Angeletti P Ist Richerche Bio | Antiviral agents |
GB0900914D0 (en) | 2009-01-20 | 2009-03-04 | Angeletti P Ist Richerche Bio | Antiviral agents |
US7973013B2 (en) | 2009-09-21 | 2011-07-05 | Gilead Sciences, Inc. | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment |
JP2013523765A (en) | 2010-04-01 | 2013-06-17 | イデニク プハルマセウティカルス,インコーポレイテッド | Compounds and pharmaceutical compositions for the treatment of viral infections |
WO2012087596A1 (en) | 2010-12-20 | 2012-06-28 | Gilead Sciences, Inc. | Combinations for treating hcv |
CN103842369A (en) | 2011-03-31 | 2014-06-04 | 埃迪尼克斯医药公司 | Compounds and pharmaceutical compositions for the treatment of viral infections |
US9150603B2 (en) | 2011-04-13 | 2015-10-06 | Merck Sharp & Dohme Corp. | 2′-cyano substituted nucleoside derivatives and methods of use thereof useful for the treatment of viral diseases |
BR112013026345A2 (en) * | 2011-04-13 | 2019-04-24 | Merck Sharp & Dohe Corp. | compound, pharmaceutical composition, use of a compound, and method for treating an hcv infected patient |
EP2697242B1 (en) * | 2011-04-13 | 2018-10-03 | Merck Sharp & Dohme Corp. | 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
RU2013125713A (en) | 2011-05-19 | 2015-06-27 | Рфс Фарма, Ллк | PURINMONOPHOSPHATE MEDICINES FOR TREATING VIRAL INFECTIONS |
AR088441A1 (en) | 2011-09-12 | 2014-06-11 | Idenix Pharmaceuticals Inc | SUBSTITUTED CARBONYLOXYMETHYLPHOSPHORAMIDATE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS |
US8507460B2 (en) | 2011-10-14 | 2013-08-13 | Idenix Pharmaceuticals, Inc. | Substituted 3′,5′-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections |
US9296778B2 (en) | 2012-05-22 | 2016-03-29 | Idenix Pharmaceuticals, Inc. | 3′,5′-cyclic phosphate prodrugs for HCV infection |
EP2852604B1 (en) | 2012-05-22 | 2017-04-12 | Idenix Pharmaceuticals LLC | 3',5'-cyclic phosphoramidate prodrugs for hcv infection |
PE20150132A1 (en) | 2012-05-22 | 2015-02-14 | Idenix Pharmaceuticals Inc | D-AMINO ACID COMPOUNDS FOR HEPATIC DISEASE |
EP2900682A1 (en) | 2012-09-27 | 2015-08-05 | IDENIX Pharmaceuticals, Inc. | Esters and malonates of sate prodrugs |
CA2887578A1 (en) | 2012-10-08 | 2014-04-17 | Idenix Pharamaceuticals, Inc. | 2'-chloro nucleoside analogs for hcv infection |
US9242988B2 (en) | 2012-10-17 | 2016-01-26 | Merck Sharp & Dohme Corp. | 2′-cyano substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
US9457039B2 (en) | 2012-10-17 | 2016-10-04 | Merck Sharp & Dohme Corp. | 2′-disubstituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
AR092959A1 (en) | 2012-10-17 | 2015-05-06 | Merck Sharp & Dohme | DERIVATIVES OF NUCLEOSIDS 2-METHYL SUBSTITUTED AND METHODS OF USE OF THE SAME FOR THE TREATMENT OF VIRAL DISEASES |
US20140112886A1 (en) | 2012-10-19 | 2014-04-24 | Idenix Pharmaceuticals, Inc. | Dinucleotide compounds for hcv infection |
WO2014066239A1 (en) | 2012-10-22 | 2014-05-01 | Idenix Pharmaceuticals, Inc. | 2',4'-bridged nucleosides for hcv infection |
WO2014078427A1 (en) | 2012-11-14 | 2014-05-22 | Idenix Pharmaceuticals, Inc. | D-alanine ester of rp-nucleoside analog |
EP2938624A1 (en) | 2012-11-14 | 2015-11-04 | IDENIX Pharmaceuticals, Inc. | D-alanine ester of sp-nucleoside analog |
US9211300B2 (en) | 2012-12-19 | 2015-12-15 | Idenix Pharmaceuticals Llc | 4′-fluoro nucleosides for the treatment of HCV |
US9339541B2 (en) | 2013-03-04 | 2016-05-17 | Merck Sharp & Dohme Corp. | Thiophosphate nucleosides for the treatment of HCV |
WO2014160484A1 (en) | 2013-03-13 | 2014-10-02 | Idenix Pharmaceuticals, Inc. | Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv |
WO2014165542A1 (en) | 2013-04-01 | 2014-10-09 | Idenix Pharmaceuticals, Inc. | 2',4'-fluoro nucleosides for the treatment of hcv |
WO2014197578A1 (en) | 2013-06-05 | 2014-12-11 | Idenix Pharmaceuticals, Inc. | 1',4'-thio nucleosides for the treatment of hcv |
US9765107B2 (en) | 2013-06-18 | 2017-09-19 | Merck Sharp & Dohme Corp. | Cyclic phosphonate substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
WO2015017713A1 (en) | 2013-08-01 | 2015-02-05 | Idenix Pharmaceuticals, Inc. | D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease |
-
2001
- 2001-05-23 CN CNA2007100896090A patent/CN101099745A/en active Pending
- 2001-05-23 MX MXPA02011691A patent/MXPA02011691A/en active IP Right Grant
- 2001-05-23 AP APAP/P/2002/002705A patent/AP1727A/en active
- 2001-05-23 KR KR1020087001618A patent/KR20080021797A/en not_active Application Discontinuation
- 2001-05-23 PL PL01359169A patent/PL359169A1/en not_active Application Discontinuation
- 2001-05-23 NZ NZ536570A patent/NZ536570A/en unknown
- 2001-05-23 EP EP06075198.9A patent/EP1736478B1/en not_active Expired - Lifetime
- 2001-05-23 EP EP01952131A patent/EP1294735A2/en not_active Withdrawn
- 2001-05-23 CA CA2410579A patent/CA2410579C/en not_active Expired - Lifetime
- 2001-05-23 OA OA1200200360A patent/OA12382A/en unknown
- 2001-05-23 EA EA200601591A patent/EA200601591A1/en unknown
- 2001-05-23 NZ NZ547204A patent/NZ547204A/en unknown
- 2001-05-23 AP AP2006003708A patent/AP2006003708A0/en unknown
- 2001-05-23 KR KR1020027015794A patent/KR20030036189A/en not_active Application Discontinuation
- 2001-05-23 CN CNB018131824A patent/CN1315862C/en not_active Expired - Fee Related
- 2001-05-23 WO PCT/US2001/016687 patent/WO2001092282A2/en active Application Filing
- 2001-05-23 YU YU92202A patent/YU92202A/en unknown
- 2001-05-23 CZ CZ20024225A patent/CZ301182B6/en not_active IP Right Cessation
- 2001-05-23 BR BR0111196-5A patent/BR0111196A/en not_active IP Right Cessation
- 2001-05-23 JP JP2002500895A patent/JP5230052B2/en not_active Expired - Lifetime
- 2001-05-23 AU AU2001272923A patent/AU2001272923A1/en not_active Abandoned
- 2001-05-23 IL IL15302001A patent/IL153020A0/en unknown
- 2001-05-23 US US09/863,816 patent/US6812219B2/en not_active Expired - Lifetime
- 2001-05-23 EA EA200201262A patent/EA007867B1/en not_active IP Right Cessation
- 2001-05-25 TW TW093123890A patent/TW200425898A/en unknown
- 2001-05-28 AR ARP010102543A patent/AR032883A1/en unknown
- 2001-05-28 PE PE2001000489A patent/PE20020051A1/en not_active Application Discontinuation
-
2002
- 2002-11-21 NO NO20025600A patent/NO327249B1/en not_active IP Right Cessation
- 2002-12-12 ZA ZA200210112A patent/ZA200210112B/en unknown
- 2002-12-18 MA MA26960A patent/MA26916A1/en unknown
-
2003
- 2003-06-20 US US10/602,694 patent/US7105493B2/en not_active Expired - Lifetime
- 2003-06-20 US US10/602,692 patent/US7101861B2/en not_active Expired - Lifetime
- 2003-06-20 US US10/602,135 patent/US7163929B2/en not_active Expired - Lifetime
- 2003-06-20 US US10/602,693 patent/US7148206B2/en not_active Expired - Lifetime
-
2004
- 2004-06-01 ZA ZA200404307A patent/ZA200404307B/en unknown
-
2006
- 2006-09-25 US US11/527,124 patent/US8343937B2/en active Active
-
2007
- 2007-06-07 AU AU2007202602A patent/AU2007202602A1/en not_active Abandoned
-
2012
- 2012-11-13 US US13/675,937 patent/US9968628B2/en not_active Expired - Fee Related
- 2012-12-06 JP JP2012267194A patent/JP2013079257A/en active Pending
-
2013
- 2013-07-31 US US13/956,287 patent/US20130315863A1/en not_active Abandoned
-
2018
- 2018-04-12 US US15/952,117 patent/US20180235993A1/en not_active Abandoned
Patent Citations (243)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6458772B1 (en) | 1909-10-07 | 2002-10-01 | Medivir Ab | Prodrugs |
US3074929A (en) | 1955-08-11 | 1963-01-22 | Burroughs Wellcome Co | Glycosides of 6-mercaptopurine |
GB924246A (en) | 1958-12-23 | 1963-04-24 | Wellcome Found | Purine derivatives and their preparation |
US3116282A (en) | 1960-04-27 | 1963-12-31 | Upjohn Co | Pyrimidine nucleosides and process |
GB984877A (en) | 1962-08-16 | 1965-03-03 | Waldhof Zellstoff Fab | Improvements in and relating to 6-halonucleosides |
GB1163102A (en) | 1965-11-15 | 1969-09-04 | Merck & Co Inc | D-Ribofuranose Derivatives |
GB1163103A (en) | 1965-11-15 | 1969-09-04 | Merck & Co Inc | Ribofuranosyl Purine Derivatives |
FR1521076A (en) | 1966-05-02 | 1968-04-12 | Merck & Co Inc | Substituted purine nucleosides |
GB1187824A (en) | 1966-05-02 | 1970-04-15 | Merck & Co Inc | Nucleosides and their Preparation |
FR1581628A (en) | 1967-07-03 | 1969-09-19 | ||
US3480613A (en) | 1967-07-03 | 1969-11-25 | Merck & Co Inc | 2-c or 3-c-alkylribofuranosyl - 1-substituted compounds and the nucleosides thereof |
GB1209654A (en) | 1967-07-03 | 1970-10-21 | Merck & Co Inc | Substituted ribofuranosyl pyrimidine nucleosides |
DE1919307C (en) | 1969-04-11 | 1972-04-27 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | Process for the production of nucleo sides |
US3891623A (en) | 1971-05-04 | 1975-06-24 | Schering Ag | Process for preparing cytidines |
DE2122991C2 (en) | 1971-05-04 | 1982-06-09 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | Process for the preparation of cytosine and 6-azacytosine nucleosides |
USRE29835E (en) | 1971-06-01 | 1978-11-14 | Icn Pharmaceuticals | 1,2,4-Triazole nucleosides |
US3798209A (en) | 1971-06-01 | 1974-03-19 | Icn Pharmaceuticals | 1,2,4-triazole nucleosides |
US4022889A (en) | 1974-05-20 | 1977-05-10 | The Upjohn Company | Therapeutic compositions of antibiotic U-44,590 and methods for using the same |
DE2508312C2 (en) | 1975-02-24 | 1987-10-29 | Schering Ag, 1000 Berlin Und 4709 Bergkamen, De | |
GB1542442A (en) | 1975-02-24 | 1979-03-21 | Schering Ag | Process for the manufacture of nucleosides |
US4058602A (en) | 1976-08-09 | 1977-11-15 | The United States Of America As Represented By The Department Of Health, Education And Welfare | Synthesis, structure, and antitumor activity of 5,6-dihydro-5-azacytidine |
US4209613A (en) | 1977-12-20 | 1980-06-24 | Schering Aktiengesellschaft | Process for the preparation of nucleosides |
US4294766A (en) | 1978-12-06 | 1981-10-13 | Basf Aktiengesellschaft | Preparation of pure potassium ribonate and ribonolactone |
US4239753A (en) | 1978-12-12 | 1980-12-16 | The Upjohn Company | Composition of matter and process |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4952740A (en) | 1984-04-10 | 1990-08-28 | Societe Nationale Elf Aquitaine | Cyclic phosphonites |
DE3512781C2 (en) | 1984-04-10 | 1995-07-27 | Elf Aquitaine | Cyclic phosphonites, process for their preparation and their use |
EP0180276B1 (en) | 1984-10-24 | 1988-12-28 | Stamicarbon B.V. | Dioxaphosphorinanes, their preparation and use for resolving optically active compounds |
US4814477A (en) | 1984-10-24 | 1989-03-21 | Oce-Nederland B.V. | Dioxaphosphorinanes, their preparation and use for resolving optically active compounds |
US4689404A (en) | 1985-03-05 | 1987-08-25 | Takeda Chemical Industries, Ltd. | Production of cytosine nucleosides |
US6448392B1 (en) | 1985-03-06 | 2002-09-10 | Chimerix, Inc. | Lipid derivatives of antiviral nucleosides: liposomal incorporation and method of use |
US4605659A (en) | 1985-04-30 | 1986-08-12 | Syntex (U.S.A.) Inc. | Purinyl or pyrimidinyl substituted hydroxycyclopentane compounds useful as antivirals |
US4754026A (en) | 1985-06-04 | 1988-06-28 | Takeda Chemical Industries, Ltd. | Conversion of uracil derivatives to cytosine derivatives |
EP0288847B1 (en) | 1987-04-30 | 1992-12-09 | BASF Aktiengesellschaft | Continuous process for the epimerization of sugars, in particular of d-arabinose into d-ribose |
US4957924A (en) | 1987-08-15 | 1990-09-18 | Burroughs Wellcome Co. | Therapeutic valine esters of acyclovir and pharmaceutically acceptable salts thereof |
US5246924A (en) | 1987-09-03 | 1993-09-21 | Sloan-Kettering Institute For Cancer Research | Method for treating hepatitis B virus infections using 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-ethyluracil |
US4880784A (en) | 1987-12-21 | 1989-11-14 | Brigham Young University | Antiviral methods utilizing ribofuranosylthiazolo[4,5-d]pyrimdine derivatives |
US5122517A (en) | 1988-06-10 | 1992-06-16 | Regents Of The University Of Minnesota | Antiviral combination comprising nucleoside analogs |
US5034394A (en) | 1988-06-27 | 1991-07-23 | Burroughs Wellcome Co. | Therapeutic nucleosides |
US5223263A (en) | 1988-07-07 | 1993-06-29 | Vical, Inc. | Liponucleotide-containing liposomes |
US6599887B2 (en) | 1988-07-07 | 2003-07-29 | Chimerix, Inc. | Methods of treating viral infections using antiviral liponucleotides |
EP0350287B1 (en) | 1988-07-07 | 2000-09-27 | Chimerix, Inc. | Lipid derivatives of antiviral nucleosides, liposomal incorporation and method of use |
US6252060B1 (en) | 1988-07-07 | 2001-06-26 | Nexstar Pharmaceuticals, Inc. | Antiviral liponucleosides: treatment of hepatitis B |
EP0352248A1 (en) | 1988-07-20 | 1990-01-24 | Medivir Aktiebolag | Nucleoside derivatives |
US5744600A (en) | 1988-11-14 | 1998-04-28 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Phosphonomethoxy carbocyclic nucleosides and nucleotides |
US5977325A (en) | 1988-11-15 | 1999-11-02 | Merrell Pharmaceuticals Inc. | 2'-halomethylidene, 2'-ethenylidene and 2'-ethynyl cytidine, uridine and guanosine derivatives |
US5738845A (en) | 1989-03-02 | 1998-04-14 | The Women's Research Institute | Human interferon τ proteins and methods of use |
US5942223A (en) | 1989-03-02 | 1999-08-24 | University Of Florida | Antiviral therapy using ovine or bovine interferon-tau |
US5411947A (en) | 1989-06-28 | 1995-05-02 | Vestar, Inc. | Method of converting a drug to an orally available form by covalently bonding a lipid to the drug |
US5194654A (en) | 1989-11-22 | 1993-03-16 | Vical, Inc. | Lipid derivatives of phosphonoacids for liposomal incorporation and method of use |
US5463092A (en) | 1989-11-22 | 1995-10-31 | Vestar, Inc. | Lipid derivatives of phosphonacids for liposomal incorporation and method of use |
US6369040B1 (en) | 1990-01-11 | 2002-04-09 | Isis Pharmaceuticals, Inc. | Pyrimidine nucleosides |
US5200514A (en) | 1990-01-19 | 1993-04-06 | University Of Georgia Research Foundation, Inc. | Synthesis of 2'-deoxypyrimidine nucleosides |
US5539116A (en) | 1990-02-01 | 1996-07-23 | Emory University | Method and compositions for the synthesis of BCH-189 and related compounds |
FR2662165B1 (en) | 1990-05-18 | 1992-09-11 | Univ Paris Curie | BRANCHED NUCLEOSIDE DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR USE AS MEDICAMENTS. |
US5780617A (en) | 1990-05-29 | 1998-07-14 | Nexstar Pharmaceuticals, Inc. | Synthesis of liponucleotides |
US6140310A (en) | 1990-06-13 | 2000-10-31 | Drug Innovation & Design, Inc. | Phosphorous prodrugs |
US5789608A (en) | 1990-06-13 | 1998-08-04 | Drug Innovation And Design, Inc. | Phosphorus prodrugs |
US5616567A (en) * | 1990-06-15 | 1997-04-01 | Sankyo Company, Limited | 2'-Cyano pyrimidine nucleoside compounds |
US5372808A (en) | 1990-10-17 | 1994-12-13 | Amgen Inc. | Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect |
US5543390A (en) | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | Covalent microparticle-drug conjugates for biological targeting |
US5543391A (en) | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | Covalent microparticle-drug conjugates for biological targeting |
US5256641A (en) | 1990-11-01 | 1993-10-26 | State Of Oregon | Covalent polar lipid-peptide conjugates for immunological targeting |
US5543389A (en) | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization | Covalent polar lipid-peptide conjugates for use in salves |
US5149794A (en) | 1990-11-01 | 1992-09-22 | State Of Oregon | Covalent lipid-drug conjugates for drug targeting |
US6436437B1 (en) | 1990-11-01 | 2002-08-20 | Oregon Health And Science University | Covalent polar lipid conjugates with neurologically active compounds for targeting |
EP0494119A1 (en) | 1991-01-03 | 1992-07-08 | Biochem Pharma Inc. | Use of 1,3-oxathiolane nucleoside analogues in the treatment of hepatitis B |
US5322955A (en) | 1991-02-22 | 1994-06-21 | Japan Tobacco, Inc. | Method of manufacturing 3-DPA-lactone |
EP0526655A4 (en) | 1991-02-22 | 1993-12-15 | Japan Tobacco Inc. | Process for producing 3-dpa-lactone |
US5157027A (en) | 1991-05-13 | 1992-10-20 | E. R. Squibb & Sons, Inc. | Bisphosphonate squalene synthetase inhibitors and method |
US5391769A (en) | 1991-07-22 | 1995-02-21 | Japan Tobacco Incorporated | Method of preparing 3-DPA-lactone |
EP0553358B1 (en) | 1991-07-22 | 1996-11-06 | Japan Tobacco Inc. | Process for producing 3-dpa-lactone |
US5554728A (en) | 1991-07-23 | 1996-09-10 | Nexstar Pharmaceuticals, Inc. | Lipid conjugates of therapeutic peptides and protease inhibitors |
US5849696A (en) | 1991-09-13 | 1998-12-15 | The Board Of Governors Of Wayne State University | Composition and method of treating hepatitis C |
US5676942A (en) | 1992-02-10 | 1997-10-14 | Interferon Sciences, Inc. | Composition containing human alpha interferon species proteins and method for use thereof |
US5606048A (en) | 1992-06-22 | 1997-02-25 | Eli Lilly And Company | Stereoselective glycosylation process for preparing 2'-Deoxy-2', 2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides |
US5256797A (en) | 1992-06-22 | 1993-10-26 | Eli Lilly And Company | Process for separating 2-deoxy-2,2-difluoro-D-ribofuranosyl alkylsulfonate anomers |
US5371210A (en) | 1992-06-22 | 1994-12-06 | Eli Lilly And Company | Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides |
US5401861A (en) | 1992-06-22 | 1995-03-28 | Eli Lilly And Company | Low temperature process for preparing alpha-anomer enriched 2-deoxy-2,2-difluoro-D-ribofuranosyl sulfonates |
US5821357A (en) | 1992-06-22 | 1998-10-13 | Eli Lilly And Company | Stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoropurine and triazole nucleosides |
EP0650371B1 (en) | 1992-07-09 | 2000-11-15 | STATE OF OREGON, acting by and through THE OREGON STATE BOARD OF HIGHER EDUCATION, acting for and on behalf of | Covalent polar lipid-peptide conjugates for biological targeting |
DE4224737A1 (en) | 1992-07-27 | 1994-02-03 | Herbert Prof Dr Schott | New cytosine analogues with lipophilic protected amino gps. - for treatment of cancer and virus diseases e.g. AIDS, are more protected against enzymatic des-amination and can be used in higher doses than unprotected cpds. |
EP0587364B1 (en) | 1992-09-01 | 1996-06-05 | Eli Lilly And Company | A process for anomerizing nucleosides |
US5830455A (en) | 1992-12-22 | 1998-11-03 | Glaxo Wellcome Inc. | Method of treatment using a therapeutic combination of α interferon and free radical scavengers |
US6153594A (en) | 1993-04-05 | 2000-11-28 | Norsk Hydro As | 5'-O-acylated antiviral nucleosides |
US6156501A (en) | 1993-10-26 | 2000-12-05 | Affymetrix, Inc. | Arrays of modified nucleic acid probes and methods of use |
US5587362A (en) | 1994-01-28 | 1996-12-24 | Univ. Of Ga Research Foundation | L-nucleosides |
US5565438A (en) | 1994-01-28 | 1996-10-15 | University Of Ga Research Foundation | L-nucleosides for the treatment of epstein-bar virus |
US5567688A (en) | 1994-01-28 | 1996-10-22 | Univ. Of Ga Research Foundation | L-nucleosides for the treatment of hepatitis B-virus |
US6002029A (en) | 1994-11-15 | 1999-12-14 | Hostetler; Karl Y. | Antiviral prodrugs |
US5696277A (en) | 1994-11-15 | 1997-12-09 | Karl Y. Hostetler | Antiviral prodrugs |
US5763418A (en) | 1994-12-13 | 1998-06-09 | Akira Matsuda | 3'-substituted nucleoside derivatives |
EP0747389B1 (en) | 1994-12-13 | 2003-09-10 | Taiho Pharmaceutical Co., Ltd. | 3'-substituted nucleoside derivatives |
US5750676A (en) | 1995-04-03 | 1998-05-12 | Hoechst Aktiengesellschaft | Process for preparing nucleosides with unprotected sugars |
US5977061A (en) | 1995-04-21 | 1999-11-02 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | N6 - substituted nucleotide analagues and their use |
EP0742287B8 (en) | 1995-05-10 | 2006-05-03 | Affymetrix, Inc. | Modified nucleic acid probes |
US6271212B1 (en) | 1995-09-07 | 2001-08-07 | University Of Georgia Research Foundation Inc. | Prodrug azide compositions and compounds |
US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
US5980884A (en) | 1996-02-05 | 1999-11-09 | Amgen, Inc. | Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon |
US5928636A (en) | 1996-05-13 | 1999-07-27 | Hoffmann-La Roche Inc. | Use of IL-12 and IFNα for the treatment of infectious diseases |
US6642206B2 (en) | 1996-10-16 | 2003-11-04 | Icn Pharmaceuticals, Inc. | Monocyclic L-nucleosides, analogs and uses thereof |
US20020095033A1 (en) | 1996-10-16 | 2002-07-18 | Icn Pharmaceuticals, Inc. | Monocyclic L-nucleosides, analogs and uses thereof |
US6573248B2 (en) | 1996-10-16 | 2003-06-03 | Icn Pharmaceuticals, Inc. | Monocyclic L-nucleosides, analogs and uses thereof |
US6063628A (en) | 1996-10-28 | 2000-05-16 | University Of Washington | Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA |
US6248878B1 (en) | 1996-12-24 | 2001-06-19 | Ribozyme Pharmaceuticals, Inc. | Nucleoside analogs |
US20030039630A1 (en) | 1997-09-21 | 2003-02-27 | Albrecht Janice K. | Combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
US6472373B1 (en) | 1997-09-21 | 2002-10-29 | Schering Corporation | Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection |
US6172046B1 (en) | 1997-09-21 | 2001-01-09 | Schering Corporation | Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection |
US6911424B2 (en) | 1998-02-25 | 2005-06-28 | Emory University | 2′-fluoronucleosides |
US20020198171A1 (en) | 1998-02-25 | 2002-12-26 | Schinazi Raymond F. | 2'-fluoronucleosides |
US6348587B1 (en) | 1998-02-25 | 2002-02-19 | Emory University | 2′-Fluoronucleosides |
US20020052345A1 (en) | 1998-03-06 | 2002-05-02 | Erion Mark D. | Novel prodrugs for phosphorus-containing compounds |
US6748161B2 (en) | 1998-03-06 | 2004-06-08 | Samsung Electronics Co., Ltd | Storage medium storing catalog information and corresponding audio data |
US6312662B1 (en) | 1998-03-06 | 2001-11-06 | Metabasis Therapeutics, Inc. | Prodrugs phosphorus-containing compounds |
US6946115B2 (en) | 1998-03-06 | 2005-09-20 | Metabasis Therapeutics, Inc. | Prodrugs for phosphorus-containing compounds |
US6833361B2 (en) | 1998-05-26 | 2004-12-21 | Ribapharm, Inc. | Nucleosides having bicyclic sugar moiety |
US20030028013A1 (en) | 1998-05-26 | 2003-02-06 | Guangyi Wang | Novel nucleosides having bicyclic sugar moiety |
US20030053986A1 (en) | 1998-06-08 | 2003-03-20 | Friederike Zahm | Method of treating hepatitis C infection |
US20030220290A1 (en) | 1998-08-10 | 2003-11-27 | Centre National Da La Reserche Scientifique | Beta-L-2'-deoxy-nucleosides for the treatment of hepatitis B |
US6444652B1 (en) | 1998-08-10 | 2002-09-03 | Novirio Pharmaceuticals Limited | β-L-2'-deoxy-nucleosides for the treatment of hepatitis B |
US6569837B1 (en) | 1998-08-10 | 2003-05-27 | Idenix Pharmaceuticals Inc. | β-L-2′-deoxy pyrimidine nucleosides for the treatment of hepatitis B |
US6566344B1 (en) | 1998-08-10 | 2003-05-20 | Idenix Pharmaceuticals, Inc. | β-L-2′-deoxy-nucleosides for the treatment of hepatitis B |
US6946450B2 (en) | 1998-08-10 | 2005-09-20 | Idenix Pharmaceuticals, Inc. | β-L-2′-deoxy-nucleosides for the treatment of hepatitis B |
US20030225028A1 (en) | 1998-08-10 | 2003-12-04 | Gilles Gosselin | Beta-L-2'deoxy-nucleosides for the treatment of hepatitis B |
US6395716B1 (en) | 1998-08-10 | 2002-05-28 | Novirio Pharmaceuticals Limited | β-L-2′-deoxy-nucleosides for the treatment of hepatitis B |
US6277830B1 (en) | 1998-10-16 | 2001-08-21 | Schering Corporation | 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon |
CA2252144A1 (en) | 1998-10-16 | 2000-04-16 | University Of Alberta | Dual action anticancer prodrugs |
US6458773B1 (en) | 1998-11-05 | 2002-10-01 | Emory University | Nucleoside with anti-hepatitis B virus activity |
US6340690B1 (en) | 1999-02-22 | 2002-01-22 | Bio-Chem Pharma Inc. | Antiviral methods using [1,8]naphthyridine derivatives |
US20020099072A1 (en) | 1999-02-22 | 2002-07-25 | Biochem Pharma Inc. | [1,8] naphthyridine derivatives having antiviral activity |
US6605614B2 (en) | 1999-02-22 | 2003-08-12 | Biochem Pharma Inc. | [1,8] naphthyridine derivatives having antiviral activity |
US6831069B2 (en) | 1999-08-27 | 2004-12-14 | Ribapharm Inc. | Pyrrolo[2,3-d]pyrimidine nucleoside analogs |
US6752981B1 (en) | 1999-09-08 | 2004-06-22 | Metabasis Therapeutics, Inc. | Prodrugs for liver specific drug delivery |
US6566365B1 (en) | 1999-11-04 | 2003-05-20 | Biochem Pharma Inc. | Method for the treatment of Flaviviridea viral infection using nucleoside analogues |
US20030225037A1 (en) | 1999-11-04 | 2003-12-04 | Biochem Pharma Inc. | Method for the treatment or prevention of Flaviviridea viral infection using nucleoside analogues |
US20020173490A1 (en) | 1999-12-22 | 2002-11-21 | Metabasis Therapeutics, Inc. | Novel bisamidate phosphonate prodrugs |
US6965033B2 (en) | 1999-12-22 | 2005-11-15 | Metabasis Therapeutics, Inc. | Bisamidate phosphonate prodrugs |
US6455508B1 (en) | 2000-02-15 | 2002-09-24 | Kanda S. Ramasamy | Methods for treating diseases with tirazole and pyrrolo-pyrimidine ribofuranosyl nucleosides |
US20020156030A1 (en) | 2000-02-15 | 2002-10-24 | Kanda Ramasamy | Heterocyclic aromatic compounds and uses thereof |
US7056895B2 (en) | 2000-02-15 | 2006-06-06 | Valeant Pharmaceuticals International | Tirazole nucleoside analogs and methods for using same |
US6495677B1 (en) | 2000-02-15 | 2002-12-17 | Kanda S. Ramasamy | Nucleoside compounds |
US6784161B2 (en) | 2000-02-18 | 2004-08-31 | Biochem Pharma, Inc. | Method for the treatment or prevention of flavivirus infections using nucleoside analogues |
US20040248844A1 (en) | 2000-02-18 | 2004-12-09 | Ismaili Hicham Moulay Alaoui | Method for the treatment or prevention of Flavivirus infections using nucleoside analogues |
US20020019363A1 (en) | 2000-02-18 | 2002-02-14 | Ismaili Hicham Moulay Alaoui | Method for the treatment or prevention of flavivirus infections using nucleoside analogues |
US7094770B2 (en) | 2000-04-13 | 2006-08-22 | Pharmasset, Ltd. | 3′-or 2′-hydroxymethyl substituted nucleoside derivatives for treatment of hepatitis virus infections |
US20020055483A1 (en) | 2000-04-13 | 2002-05-09 | Watanabe Kyoichi A. | 3'-or 2'-hydroxymethyl substituted nucleoside derivatives for treatment of hepatites virus infections |
US20020055473A1 (en) | 2000-04-20 | 2002-05-09 | Ganguly Ashit K. | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
US6914054B2 (en) | 2000-05-23 | 2005-07-05 | Idenix Pharmaceuticals, Inc. | Methods and compositions for treating hepatitis C virus |
US20050124532A1 (en) | 2000-05-23 | 2005-06-09 | Jean-Pierre Sommadossi | Methods and compositions for treating hepatitis C virus |
US7157441B2 (en) * | 2000-05-23 | 2007-01-02 | Idenix Pharmaceuticals, Inc. | Methods and compositions for treating hepatitis C virus |
US7169766B2 (en) | 2000-05-23 | 2007-01-30 | Idenix Pharmaceuticals, Inc. | Methods and compositions for treating hepatitis C virus |
US7608597B2 (en) * | 2000-05-23 | 2009-10-27 | Idenix Pharmaceuticals, Inc. | Methods and compositions for treating hepatitis C virus |
US7163929B2 (en) | 2000-05-26 | 2007-01-16 | Idenix Pharmaceuticals, Inc. | Methods and compositions for treating flaviviruses and pestiviruses |
US7148206B2 (en) * | 2000-05-26 | 2006-12-12 | Idenix Pharmaceuticals, Inc. | Methods and compositions for treating flaviviruses and pestiviruses |
US7101861B2 (en) | 2000-05-26 | 2006-09-05 | Indenix Pharmaceuticals, Inc. | Methods and compositions for treating flaviviruses and pestiviruses |
US20020035085A1 (en) | 2000-05-26 | 2002-03-21 | Jean-Pierre Sommadossi | Methods of treating hepatitis delta virus infection with beta-l-2'-deoxy-nucleosides |
US6596700B2 (en) | 2000-05-26 | 2003-07-22 | Idenix Pharmaceuticals Inc. | Methods of treating hepatitis delta virus infection with β-L-2'-deoxy-nucleosides |
US6812219B2 (en) * | 2000-05-26 | 2004-11-02 | Idenix Pharmaceuticals, Inc. | Methods and compositions for treating flaviviruses and pestiviruses |
US7105493B2 (en) * | 2000-05-26 | 2006-09-12 | Idenix Pharmaceuticals, Inc. | Methods and compositions for treating flaviviruses and pestiviruses |
US6787526B1 (en) | 2000-05-26 | 2004-09-07 | Idenix Pharmaceuticals, Inc. | Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides |
US6875751B2 (en) | 2000-06-15 | 2005-04-05 | Idenix Pharmaceuticals, Inc. | 3′-prodrugs of 2′-deoxy-β-L-nucleosides |
US20030083306A1 (en) | 2000-06-15 | 2003-05-01 | Jean-Louis Imbach | 3'-prodrugs of 2'-deoxy-beta-L-nucleosides |
US20050113330A1 (en) | 2000-06-15 | 2005-05-26 | Bryant Martin L. | 3'-Prodrugs of 2'-deoxy-beta-L-nucleosides |
US6815542B2 (en) | 2000-06-16 | 2004-11-09 | Ribapharm, Inc. | Nucleoside compounds and uses thereof |
US20040002596A1 (en) | 2000-06-16 | 2004-01-01 | Zhi Hong | Nucleoside compounds and uses thereof |
US20040110718A1 (en) | 2000-08-30 | 2004-06-10 | Rene Devos | Anti-HCV nucleoside derivatives |
US20030008841A1 (en) | 2000-08-30 | 2003-01-09 | Rene Devos | Anti-HCV nucleoside derivatives |
US20030124512A1 (en) | 2000-10-18 | 2003-07-03 | Lieven Stuyver | Simultaneous quantification of nucleic acids in diseased cells |
US20030087873A1 (en) | 2000-10-18 | 2003-05-08 | Lieven Stuyver | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation |
US20020127203A1 (en) | 2000-10-18 | 2002-09-12 | Albrecht Janice K. | Ribavirin-pegylated interferon alfa HCV combination therapy |
US20040266723A1 (en) | 2000-12-15 | 2004-12-30 | Otto Michael J. | Antiviral agents for treatment of Flaviviridae infections |
US7202224B2 (en) | 2001-01-22 | 2007-04-10 | Merck & Co., Inc. | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase |
US20040067901A1 (en) | 2001-01-22 | 2004-04-08 | Balkrishen Bhat | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase |
US6777395B2 (en) | 2001-01-22 | 2004-08-17 | Merck & Co., Inc. | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase of hepatitis C virus |
US7125855B2 (en) | 2001-01-22 | 2006-10-24 | Merck & Co., Inc. | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase |
US20020147160A1 (en) | 2001-01-22 | 2002-10-10 | Balkrishen Bhat | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase |
US20040110717A1 (en) | 2001-01-22 | 2004-06-10 | Carroll Steven S. | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
US7105499B2 (en) | 2001-01-22 | 2006-09-12 | Merck & Co., Inc. | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase |
US20040072788A1 (en) | 2001-01-22 | 2004-04-15 | Balkrishen Bhat | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase |
US6927291B2 (en) | 2001-03-01 | 2005-08-09 | Pharmasset, Ltd. | Method for the synthesis of 2′,3′-dideoxy-2′,3′-didehydronucleosides |
US6660721B2 (en) | 2001-05-23 | 2003-12-09 | Hoffmann-La Roche Inc. | Anti-HCV nucleoside derivatives |
US20030083307A1 (en) | 2001-05-23 | 2003-05-01 | Devos Rene Robert | Anti-HCV nucleoside derivatives |
US6784166B2 (en) | 2001-06-12 | 2004-08-31 | Syntex (U.S.A.) Llc | 4′-substituted nucleoside derivatives as inhibitors of HCV RNA replication. |
US20040266722A1 (en) | 2001-06-12 | 2004-12-30 | Devos Rene Robert | 4'-Substituted nucleoside derivatives as inhibitors of HCV RNA replication |
US20030236216A1 (en) | 2001-06-12 | 2003-12-25 | Devos Rene Robert | 4'-substituted nucleoside derivatives as inhibitors of HCV RNA replication |
US6949522B2 (en) | 2001-06-22 | 2005-09-27 | Pharmasset, Inc. | β-2′- or 3′-halonucleosides |
US20030055013A1 (en) | 2001-09-20 | 2003-03-20 | Schering Corporation | HCV combination therapy |
US20040006002A1 (en) | 2001-09-28 | 2004-01-08 | Jean-Pierre Sommadossi | Methods and compositions for treating flaviviruses and pestiviruses using 4'-modified nucleoside |
US6908924B2 (en) | 2001-12-14 | 2005-06-21 | Pharmasset, Inc. | N4-acylcytosine-1,3-dioxolane nucleosides for treatment of viral infections |
US6965066B1 (en) | 2002-01-16 | 2005-11-15 | Actodyne General, Inc. | Elongated string support for a stringed musical instrument |
US20040002476A1 (en) | 2002-02-14 | 2004-01-01 | Stuyver Lieven J. | Modified fluorinated nucleoside analogues |
US20030225029A1 (en) | 2002-02-14 | 2003-12-04 | Stuyver Lieven J. | Dosing regimen for gemcitabine HCV therapy |
US20040059104A1 (en) | 2002-02-28 | 2004-03-25 | Cook Phillip Dan | Nucleotide mimics and their prodrugs |
US20040023921A1 (en) | 2002-04-30 | 2004-02-05 | Zhi Hong | Antiviral phosphonate compounds and methods therefor |
US20040063658A1 (en) | 2002-05-06 | 2004-04-01 | Roberts Christopher Don | Nucleoside derivatives for treating hepatitis C virus infection |
US20070027065A1 (en) | 2002-06-28 | 2007-02-01 | Lacolla Paola | Modified 2' and 3'-nucleoside prodrugs for treating Flaviviridae infections |
US7192936B2 (en) | 2002-06-28 | 2007-03-20 | Idenix Pharmaceuticals, Inc. | Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections |
US7662798B2 (en) * | 2002-06-28 | 2010-02-16 | Idenix Pharmaceuticals, Inc. | 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections |
US7635689B2 (en) * | 2002-06-28 | 2009-12-22 | Idenix Pharmaceuticals, Inc. | Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections |
US7625875B2 (en) * | 2002-06-28 | 2009-12-01 | Idenix Pharmaceuticals, Inc. | 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections |
US7608600B2 (en) | 2002-06-28 | 2009-10-27 | Idenix Pharmaceuticals, Inc. | Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections |
US7582618B2 (en) * | 2002-06-28 | 2009-09-01 | Idenix Pharmaceuticals, Inc. | 2′-C-methyl-3′-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
US7547704B2 (en) | 2002-06-28 | 2009-06-16 | Idenix Pharmaceuticals, Inc. | Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections |
US7456155B2 (en) | 2002-06-28 | 2008-11-25 | Idenix Pharmaceuticals, Inc. | 2′-C-methyl-3′-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
US7384924B2 (en) | 2002-06-28 | 2008-06-10 | Idenix Pharmaceuticals, Inc. | Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections |
US7365057B2 (en) | 2002-06-28 | 2008-04-29 | Idenix Pharmaceuticals, Inc. | Modified 2′ and 3′-nucleoside prodrugs for treating Flavivridae infections |
US20070060541A1 (en) | 2002-06-28 | 2007-03-15 | Gilles Gosselin | 2' and 3'-nucleoside prodrugs for treating Flaviviridae infections |
US20070060505A1 (en) | 2002-06-28 | 2007-03-15 | Gilles Gosselin | 2' and 3'-nucleoside prodrugs for treating Flaviviridae infections |
US20070060503A1 (en) | 2002-06-28 | 2007-03-15 | Gilles Gosselin | 2' and 3'-nucleoside prodrugs for treating Flaviviridae infections |
US20070060504A1 (en) | 2002-06-28 | 2007-03-15 | Gilles Gosselin | 2' and 3'-nucleoside prodrugs for treating Flaviviridae infections |
US20070060498A1 (en) | 2002-06-28 | 2007-03-15 | Gilles Gosselin | 2' and 3'-nucleoside prodrugs for treating Flaviviridae infections |
US20070042990A1 (en) | 2002-06-28 | 2007-02-22 | Gilles Gosselin | 2' and 3'-nucleoside prodrugs for treating Flaviviridae infections |
US20070042939A1 (en) | 2002-06-28 | 2007-02-22 | Lacolla Paola | Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae infections |
US20070037735A1 (en) | 2002-06-28 | 2007-02-15 | Gilles Gosselin | 2' and 3'-nucleoside prodrugs for treating Flaviviridae infections |
US20070032449A1 (en) | 2002-06-28 | 2007-02-08 | Lacolla Paola | Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae infections |
US20070027104A1 (en) | 2002-06-28 | 2007-02-01 | Lacolla Paola | Modified 2' and 3'-nucleoside prodrugs for treating Flaviviridae infections |
US20070015905A1 (en) | 2002-06-28 | 2007-01-18 | Lacolla Paola | 2' and 3'-nucleoside prodrugs for treating Flaviviridae infections |
US20050119200A1 (en) | 2002-09-30 | 2005-06-02 | Roberts Christopher D. | Nucleoside derivatives for treating hepatitis C virus infection |
US20040147464A1 (en) | 2002-09-30 | 2004-07-29 | Genelabs Technologies, Inc. | Nucleoside derivatives for treating hepatitis C virus infection |
US20050031588A1 (en) | 2002-11-15 | 2005-02-10 | Jean-Pierre Sommadossi | 2'-branched nucleosides and Flaviviridae mutation |
US20040121980A1 (en) | 2002-11-19 | 2004-06-24 | Roche Palo Alto Llc | Antiviral nucleoside derivatives |
US6846810B2 (en) | 2002-11-19 | 2005-01-25 | Roche Palo Alto Llc | Antiviral nucleoside derivatives |
US7598373B2 (en) | 2002-12-12 | 2009-10-06 | Idenix Pharmaceuticals, Inc. | Process for the production of 2-C-methyl-D-ribonolactone |
US20040266996A1 (en) | 2003-03-20 | 2004-12-30 | Rabi Jaime A | Methods of manufacture of 2'-deoxy-beta-L-nucleosides |
US20040259934A1 (en) | 2003-05-01 | 2004-12-23 | Olsen David B. | Inhibiting Coronaviridae viral replication and treating Coronaviridae viral infection with nucleoside compounds |
US20040229839A1 (en) | 2003-05-14 | 2004-11-18 | Biocryst Pharmaceuticals, Inc. | Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases |
US20050009737A1 (en) | 2003-05-30 | 2005-01-13 | Jeremy Clark | Modified fluorinated nucleoside analogues |
US20050038240A1 (en) | 2003-06-19 | 2005-02-17 | Roche Palo Alto Llc | Processes for preparing 4'-azido-nucleoside derivatives |
US20050137141A1 (en) | 2003-10-24 | 2005-06-23 | John Hilfinger | Prodrug composition |
US20050215511A1 (en) | 2003-10-27 | 2005-09-29 | Genelabs Technologies, Inc. | Nucleoside compounds for treating viral infections |
US7151089B2 (en) | 2003-10-27 | 2006-12-19 | Genelabs Technologies, Inc. | Nucleoside compounds for treating viral infections |
US7157434B2 (en) | 2003-10-27 | 2007-01-02 | Genelabs Technologies, Inc. | Nucleoside compounds for treating viral infections |
US20050090463A1 (en) | 2003-10-27 | 2005-04-28 | Genelabs Technologies, Inc. | Nucleoside compounds for treating viral infections |
US7144868B2 (en) | 2003-10-27 | 2006-12-05 | Genelabs Technologies, Inc. | Nucleoside compounds for treating viral infections |
US20050101550A1 (en) | 2003-10-27 | 2005-05-12 | Genelabs Technologies, Inc. | Nucleoside compounds for treating viral infections |
US20050107312A1 (en) | 2003-10-27 | 2005-05-19 | Genelabs Technologies, Inc. | Nucleoside compounds for treating viral infections |
US20060199783A1 (en) | 2004-07-21 | 2006-09-07 | Pharmassett, Inc. | Preparation of alkyl-substituted 2-deoxy-2-fluoro-D-ribofuranosyl pyrimidines and purines and their derivatives |
US20060040890A1 (en) | 2004-08-23 | 2006-02-23 | Roche Palo Alto Llc | Anti-viral nucleosides |
US20060111311A1 (en) | 2004-11-22 | 2006-05-25 | Genelabs Technologies, Inc. | 5-nitro-nucleoside compounds for treating viral infections |
US20060194835A1 (en) | 2005-02-09 | 2006-08-31 | Migenix Inc. | Compositions and methods for treating or preventing flaviviridae infections |
DE102005012681A1 (en) | 2005-03-18 | 2006-09-21 | Weber, Lutz, Dr. | New 1,5-dihydro-pyrrol-2-one compounds are HDM2 inhibitors, useful for treating e.g. stroke, heart infarct, ischemia, multiple sclerosis, Alzheimer's disease, degenerative disease, viral infection and cancer |
US20060241064A1 (en) | 2005-04-25 | 2006-10-26 | Genelabs Technologies, Inc. | Nucleoside compounds for treating viral infections |
US20070203334A1 (en) | 2005-12-23 | 2007-08-30 | Mayes Benjamin A | Process for preparing a synthetic intermediate for preparation of branched nucleosides |
Non-Patent Citations (403)
Title |
---|
Advisory Action dated Aug. 8, 2007 from U.S. Appl. No. 11/005,443. |
Advisory Action dated Jun. 13, 2007 from U.S. Appl. No. 11/005,466. |
Afdhal, et al., Enhanced antiviral efficacy for valopicitabine pluc PEG-interferon in hepatitis C patients with HCV genotype-1 infection. Journal of Hepatology 2005, vol. 42, Supplement 2, p. 39-40. |
Alt, et al., "Core Specific Antisense Phosphorothioate Oligodeoxynucleotides as Ptent and Specific Inhibitors of Hepatitis C Viral Translation." Arch. Virol. (1997) 142: 589-599. |
Alt, et al., "Specific inhibition of hepatitis C viral gene expression by antisense phosphorothioate oligodeoxynucleotides," Hepatology, 22:707-717 (1995). |
Altmann, et al., "The Synthesis of 1′-Methyl Carbocyclic Thymidine and Its Effect on Nucleic Acid Duplex Stability," Synlett, Thieme Verlag. Stuttgart, De, 10:853-855 (1994). |
Altmann, et al., "The Synthesis of 1'-Methyl Carbocyclic Thymidine and Its Effect on Nucleic Acid Duplex Stability," Synlett, Thieme Verlag. Stuttgart, De, 10:853-855 (1994). |
Altmann, et al., The Effects of 2'- and 3'-Alkyl Substituents on Oligonucleotide Hybridization and Stability, Biorganic & Medicinal Chemistry Letter. Apr. 1994. No. 16. 1969-74. |
Altmann, et al., The Effects of 2′- and 3′-Alkyl Substituents on Oligonucleotide Hybridization and Stability, Biorganic & Medicinal Chemistry Letter. Apr. 1994. No. 16. 1969-74. |
Awano, et al., "Nucleosides and Nucleotides, Part 144 Synthesis and Antiviral Activity of 5-Substituted (2′s)-2′-Deoxy-2′—C-Methylycytidines and -Urdines," Archiv Der Pharmazie, VCH Verlagsgesellschaft Mbh, Weinheim, DE, vol. 329, Feb. 1, 1996, pp. 66-72. |
Awano, et al., "Nucleosides and Nucleotides, Part 144 Synthesis and Antiviral Activity of 5-Substituted (2's)-2'-Deoxy-2'-C-Methylycytidines and -Urdines," Archiv Der Pharmazie, VCH Verlagsgesellschaft Mbh, Weinheim, DE, vol. 329, Feb. 1, 1996, pp. 66-72. |
Bagsky, S.G., et al., "Mechanism of Action of a Pestivirus Antiviral Compound," PNAS USA 2000 97(14), 7981-7986. |
Battaglia, A.M. et al., "Comibination Therapy with Interferon and Ribavirin in the Treatment of Chronic Hepatitis C. Infection", Ann Pharmacother, 34:487-494 (2000). |
Beigelman et al., "A general method for synthesis of 3' -alkylnucleosides," Nucleic Acids Symp. Ser., vol. 9, 1981, pp. 115-118. |
Beigelman et al., "A general method for synthesis of 3′ -alkylnucleosides," Nucleic Acids Symp. Ser., vol. 9, 1981, pp. 115-118. |
Beigelman et al., "Epimerization During the Acetolysis of 3-O-Acetyl-5-O-Benzoyl-1,2-o-Isopropylidene-3-C-Methyl-a, D-Ribofuranose. Synthesis of 3′-C-Methylnucleosides with the B-D-ribo-and a-D-arabino Configurations," Carbohydrate Research, 181:77-88 (1988). |
Beigelman et al., "Epimerization During the Acetolysis of 3-O-Acetyl-5-O-Benzoyl-1,2-o-Isopropylidene-3-C-Methyl-a, D-Ribofuranose. Synthesis of 3'-C-Methylnucleosides with the B-D-ribo-and a-D-arabino Configurations," Carbohydrate Research, 181:77-88 (1988). |
Beigelman et al., "New synthesis of 2′-C-methylnucleosides starting from D-glucose and D-ribose" Carbohydrate Res., 1987.166,.219-232. |
Beigelman et al., "New synthesis of 2'-C-methylnucleosides starting from D-glucose and D-ribose" Carbohydrate Res., 1987.166,.219-232. |
Beigelman et al., Functionally complete analogs of nucleosides. The use of D-gluclose for the synthesis of 2-C-methyl-D-ribose derivatives and related nucleosides. Biorrganicheskaya Khimiya. 1986, vol. 12(10), pp. 1359-1365. |
Berenguer, M., et al., "Hepatitis B and C viruses: Molecular identification and targeted antiviral therapies," Proceedings of the Association of American Physicians, 110(2), 98-112 (1998). |
Berenguer, M., et al., "Hepatitis C virus in the transpinat setting", Antivir. Ther., 3 (Suppl 3):125-136 (1998). |
Berman, E., et al., "Synergistic Cytotoxic Effect of Azidothymidine and Recombinant Interferon Alpha on Normal Human Bone Marrow Progenitor Cells," Blood, 74(4):1281-1286 (1989). |
Bhat et al. (Oral Session V, Hepatitis C Virus, Flaviviridae, 2003 (Oral Session V, Hepatitis C Virus, Flaviviridae; 16th International Conference on Antiviral Research (Apr. 27, 2003, Savannah, GA.); p. A75). |
Bhopale, Girish Mahadeorao, et al., "Emerging drugs for chronic hepatitis C," Hepatology Research (2005), 32(3), 146-153. |
Bianco A., et al. "Synthesis of a New Carbocyclic Nucleoside Analog", Tetrahedron Letters, 38(36):6433-6436, 1997. |
Billich, et al., "Nucleoside Phosphotransferase from Malt Sprouts." Biol. Chem. Hoppe-Seyler, vol. 367, pp. 267-278, Apr. 1986. |
Bio, et al., "Practical Synthesis of a Potent Hepatitis C Virus RNA Replication Inhibitor." Journal of Organic Chemistry (2004), 69(19), 6257-6266. |
Bloch A., et al., "The Role of the 5′-Hydroxyl Group of Adenosine in Determining Substrate Specificity for Adenosine Deaminase," J. Med. Chem., 10(5):908-12 (Sep. 1967). |
Bloch A., et al., "The Role of the 5'-Hydroxyl Group of Adenosine in Determining Substrate Specificity for Adenosine Deaminase," J. Med. Chem., 10(5):908-12 (Sep. 1967). |
Browne, M.J., et al., "2',3'-didehydro-3'-deoxythymidine (d4T) in patients with AIDS or AIDS-Related Complex: A Phase I Trial," J. Infect. Dis., 167(1):21-29 (1993). |
Browne, M.J., et al., "2′,3′-didehydro-3′-deoxythymidine (d4T) in patients with AIDS or AIDS-Related Complex: A Phase I Trial," J. Infect. Dis., 167(1):21-29 (1993). |
Bryant M.L., et al., "Antiviral L-Nucleosides Specific for Hepatitis B Virus Infection," Antimicrobial Agents and Chemotherapy, 45(1):229-235 (Jan. 2001). |
Cappelacci ,et al. "Synthesis, Biological Evaluation, and Molecular Modeling of Ribose-Modified Adenosine Analogues as Adenosine Receptor Agonists." Journal of Medicinal Chemistry (2005), 48(5), 1550-1562. |
Cappelacci, et al. "Ribose-modified nucleosides as ligands for adenosine receptors: Synthesis, conformational analysis, and biological evaluation of 1′-C-methyl denosine analogues," J. Med. Chem., vol. 45, 2002, pp. 1196-1202. |
Cappelacci, et al. "Ribose-modified nucleosides as ligands for adenosine receptors: Synthesis, conformational analysis, and biological evaluation of 1'-C-methyl denosine analogues," J. Med. Chem., vol. 45, 2002, pp. 1196-1202. |
Carroll S.S., et al., "Inhibition of hepatitis C virus RNA replication by 2′-modified nucleoside analogs," J. Biol. Chem., 278(14): 11979-11984 (2003). |
Carroll S.S., et al., "Inhibition of hepatitis C virus RNA replication by 2'-modified nucleoside analogs," J. Biol. Chem., 278(14): 11979-11984 (2003). |
Carroll, S.S., "Nucleoside analog inhibitors of hepatitis C virus replication," Infectious Disorders: Drug Targets (2006), 6(1), 17-29. |
Cavelier, F., et al., "Studies of Selective Boc Removal in the Presence of Silyl Ethers," Tetrahedron Letters, 37: 5131-5134 (1996). |
Chand, Pooran; et al., "Synthesis of (2S,3S,4R,5R)-2-(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-5-(hydroxymethyl)-3-methylpyrrolidine-3,4-diol, an analog of potent HCV inhibitor." Collection Symposium Series (2005), 7(Chemistry of Nucleic Acid Components), 329-332. |
Chen et al., Heterocycles, vol. 28, No. 2, 1989, pp. 593-601. |
Chiacchio, et al., "Stereoselective synthesis of 2′-amino-2′,3′dideoxynucleosides by nitrone 1,3-dipolar cycloaddition: A new efficient entry toward d4T and its 2-methyl analougue," J. Org. Chem., vol. 64, 1999, pp. 28-36. |
Chiacchio, et al., "Stereoselective synthesis of 2'-amino-2',3'dideoxynucleosides by nitrone 1,3-dipolar cycloaddition: A new efficient entry toward d4T and its 2-methyl analougue," J. Org. Chem., vol. 64, 1999, pp. 28-36. |
Chiaramonte, et al., "Inhibition of CMP-Sialic Acid Transport into Golgi Vesicles by Nucleoside Monophates." Biochemistry 2001, 40, 14260-14267. |
Clark, et al., "Design, Synthesis, and Antiviral Activity of 2′-Deoxy-2′-fluoro 2′-C-methylcytidine, a Potent Inhibitor of Hepatitis C Virus Replication." Journal of Medicinal Chemistry (2005), 48(17), 5504-5508. |
Clark, et al., "Design, Synthesis, and Antiviral Activity of 2'-Deoxy-2'-fluoro 2'-C-methylcytidine, a Potent Inhibitor of Hepatitis C Virus Replication." Journal of Medicinal Chemistry (2005), 48(17), 5504-5508. |
Clark, et al., Synthesis and antiviral activity . . . , Bioorganic & Medicinal Chemistry Letters, 16, 2006, 1712-1715. |
Coelmont, Lotte, "Ribavirin antagonizes the in vitro anti-hepatitis C virus activity of 2′-C-methycytidine, the active component of valopicitabine," Antimicrobial Agents and Chemotherapy (2006), 50(10), 3444-3446. |
Coelmont, Lotte, "Ribavirin antagonizes the in vitro anti-hepatitis C virus activity of 2'-C-methycytidine, the active component of valopicitabine," Antimicrobial Agents and Chemotherapy (2006), 50(10), 3444-3446. |
Colacino, J. M., "Review article: Mechanisms for the anti-hepatitis B virus activity and mitochondreal toxiciety of fialurdine (FIAU)," Antiviral Res., 29(2-3): 125-39 (1996). |
Cook, G.S., "Improving the treatment of hepatitis C infection in the UK," Expert Opinion on Pharmacotherapy, (2007) vol. 8, No. 2, pp. 183-191. |
Cornberg, M., et al., "Present and future therapy for hepatitis C virus," Expert review of Anti-Infective Therapy, (2006) vol. 4, No. 5, pp. 781-793. |
Cretton-Scott, E., et al., "Pharmacokinetics of B-L-2′-Deoxyctidine Prodrugs in Monkeys," Antiviral res., 50:A44 (2001). |
Cretton-Scott, E., et al., "Pharmacokinetics of B-L-2'-Deoxyctidine Prodrugs in Monkeys," Antiviral res., 50:A44 (2001). |
Cui, L., et al., "Cellular and molecular events leading to mitochondrial toxicity of 1-(2-deoxy-2-fluoro-1-beta-D-arabinofuranosy1)5-iodouracil in human liver cells," J. Clin. Invest., 95:555-563 (1995). |
Cui, L., et al., "Cellular and molecular events leading to mitochondrial toxicity of 1-(2-deoxy-2-fluoro-1-β-D-arabinofuranosy1)5-iodouracil in human liver cells," J. Clin. Invest., 95:555-563 (1995). |
Czernecki, S., et al., "Synthesis of 2′-deoxy-2′-spirocyclopropyl cytidine as potential inhibitor of ribonucleotide diphosphate reductase," Can. J. Chem., vol. 71, 1993, pp. 413-416. |
Czernecki, S., et al., "Synthesis of 2'-deoxy-2'-spirocyclopropyl cytidine as potential inhibitor of ribonucleotide diphosphate reductase," Can. J. Chem., vol. 71, 1993, pp. 413-416. |
Czernecki, S., et al., "Synthesis of various 3′-branched 2′, 3′-unsaturated pyrimidine nucleosides as potential anti-HIV agents," J. Org. Chem., 57: 7325-7328 (1992). |
Czernecki, S., et al., "Synthesis of various 3'-branched 2', 3'-unsaturated pyrimidine nucleosides as potential anti-HIV agents," J. Org. Chem., 57: 7325-7328 (1992). |
Dalpiaz, et al., "Temperature dependence of the affinity enhancement of selective adenosine A1 receptor agonism: a thermodynamic analysis." European Journal of Pharmacology (2002), 448(2-3), 123-131. |
Daniels et al., "Tautomerism of Uracil and Thymine in Aqueous Solution: Spectroscopic Evidence", Proc. Nat. Acad. Sci. USA, vol. 69, No. 9, pp. 2488-2491, 1972. |
Davis, G.L., "Current therapy for chronic Hepatitis C," Gastroenterology 118:S104-S114 (2000). |
Davis, G.L., "New Therapies: Oral Inhibitors and Immune Modulators," Clinics in Liver Disease, (2006) vol. 10, No. 4, pp. 867-880. |
Davisson, V.J., et al., "Synthesis of Nucleotide 5′-Diphosphates from 5′-O-Tosyl Nucleosides," J. Org. Chem., 52(9):1794-1801 (1987). |
Davisson, V.J., et al., "Synthesis of Nucleotide 5'-Diphosphates from 5'-O-Tosyl Nucleosides," J. Org. Chem., 52(9):1794-1801 (1987). |
De Francesco, et al. "Approaching a new era for hepatitis C virus therapy: Inhibitors of the N53-4A serine protease and the NS5B RNA-dependent RNA polymerase." Antiviral Research, 58: 1-16 (2003). |
De Lombaert, S., et al., "N-Phosphonomethyl dipeptides and their phosphonate prodrugs, a new generation of neutral endopeptidase (NEP, EC 3.4.24.11) inhibitors," J. Med. Chem., 37:498-511 (1994). |
Ding, et al., "Synthesis of 2′-b-C-methyl toyocamycin and sangivamycin analogs as potential HCV inhibitors." Bioorganic & Medicinal Chemistry Letters (2005), 15(3), 725-727. |
Ding, et al., "Synthesis of 2'-b-C-methyl toyocamycin and sangivamycin analogs as potential HCV inhibitors." Bioorganic & Medicinal Chemistry Letters (2005), 15(3), 725-727. |
Ding, et al., "Synthesis of 9-(2-b-C-methyl-b-D-ribofuranosyl)-6-substituted purine derivatives as inhibitors of HCV RNA replication." Bioorganic & Medicinal Chemistry Letters (2005), 15(3), 709-713. |
Dornsife, R.E., et al, "In vitro potency of inhibition by antiviral drugs of hematopoietic progenitor colony formation correlates with exposure at hemotoxic levels in Human Immunodefciency Virus-positive humans," Anrimicrob. Agents Chemother., 40(2):514-519 (1996). |
Dutartre, H., et al., "General catalytic deficiency of hepatitis C virus RNA polymerase with an S282T mutation and mutually exclusive resistance towards 2′-modified nucleotide analogues," Antimicrobial Agents and Chemotherapy, (2006) vol. 50, No. 12, pp. 4161-4169. |
Dutartre, H., et al., "General catalytic deficiency of hepatitis C virus RNA polymerase with an S282T mutation and mutually exclusive resistance towards 2'-modified nucleotide analogues," Antimicrobial Agents and Chemotherapy, (2006) vol. 50, No. 12, pp. 4161-4169. |
Dymock, B.W., et al., "Review: Novel approaches to the treatment of hepatitis C virus infection," Antiviral Chemistry & Chemotherapy, 11(2):79-95 (2000). |
Eldrup et al., "Structure-Activity Relationship of Heterobase-Modified 2′-C-Methyl Ribonucleosides as Inhibitors of Hepatitis C Virus RNA Replication." Department of Medicinal Chemistry, Isis Pharmaceuticals, Carlsbad, CA, USA. Journal of Medicinal Chemistry (2004), 47(21), 5284-5297. |
Eldrup et al., "Structure-Activity Relationship of Heterobase-Modified 2'-C-Methyl Ribonucleosides as Inhibitors of Hepatitis C Virus RNA Replication." Department of Medicinal Chemistry, Isis Pharmaceuticals, Carlsbad, CA, USA. Journal of Medicinal Chemistry (2004), 47(21), 5284-5297. |
Eldrup, et al., "Structure-Activity Relationship of Purine Ribonucleosides for Inhibition of Hepatitis C Virus RNA-Dependent RNA Polymerase.", Department of Medicinal Chemistry, Isis Pharmaceuticals, Carlsbad, CA, USA. Journal of Medicinal Chemistry (2004), 47(9), 2283-2295. |
Eldrup, et al., Oral Session V, Hepatitis C Virus, Flaviviridae; 16th International Conference on Antiviral Research (Apr. 27, 2003, Savannah, GA.) p. A75-77. |
Faivre-Buet, et al., "Synthesis of 1′-Deoxypsicofuanosyl-Dexoynucleosides as Potential Anti-HIV Agents." Nucleosides & Nucleotides, vol. 11, No. 7, 1992, pp. 1411-1424. |
Faivre-Buet, et al., "Synthesis of 1'-Deoxypsicofuanosyl-Dexoynucleosides as Potential Anti-HIV Agents." Nucleosides & Nucleotides, vol. 11, No. 7, 1992, pp. 1411-1424. |
Farkas, J., et al., "Nucleic acids components and their analogues. XCIV. Synthesis of 6-amino0-(1-deoxy-beta-D-psicofuranosyl)p urine" Collection Czechoslov. Chem. Comm., vol. 32, 1967, pp. 2663-2667. |
Farkus, J., et al., "Nucleic acid components and their analogues. LXXIX. Synthesis of methyl 1-deoxy-D-psicofuranosides substituted at C(1) with halo atoms or mercapto group," Collection Czechoslov. Chem. Comm., vol. 31, 1966, pp. 1535-1543. |
Farquhar et al., "Biologically reversible phosphate-protective groups," J. Pharm. Sci., 1983, 72(3): 324. |
Farquhar, D., et al., "Synthesis and biological evaluation of 9-[5'-(2-oxo-1,3,2-oxazaphosphorinan-2-yl)-beta-D-arabinosyl]adenine and 9-[5'-(2-oxo-1,3,2-dioxazaphosphorinan-2-yl)-beta-D-arabinosyl]adenine: Potential neutral precursors of 9-[beta-D-arabinofuranosyl]adenine 5'-monophosphate," J. Med. Chem. 28:1358-1381 (1985). |
Farquhar, D., et al., "Synthesis and biological evaluation of 9-[5′-(2-oxo-1,3,2-oxazaphosphorinan-2-yl)-β-D-arabinosyl]adenine and 9-[5′-(2-oxo-1,3,2-dioxazaphosphorinan-2-yl)-β-D-arabinosyl]adenine: Potential neutral precursors of 9-[β-D-arabinofuranosyl]adenine 5′—monophosphate," J. Med. Chem. 28:1358-1381 (1985). |
Farquhar, D., et al., "Synthesis and biological evaluation of neutral derivatives of 3-fluoro-2′-deoxyuridine 5′-phosphate," J. Med Chem. 26: (1983); 1153-1158. |
Farquhar, D., et al., "Synthesis and biological evaluation of neutral derivatives of 3-fluoro-2'-deoxyuridine 5'-phosphate," J. Med Chem. 26: (1983); 1153-1158. |
Feast, A.A.J., et al., "Studies on the D-Glucosaccharinic Acids," Acta Chemica Scandinavica 19(5):1127-1134 (1965). |
Federov, et al., "3′-C-Branched 2′-deoxy-5-methyluridines: Synthesis, enzyme inhibition, and antiviral properties," J. Med. Chem., vol. 35, 1992, pp. 4567-4575. |
Federov, et al., "3'-C-Branched 2'-deoxy-5-methyluridines: Synthesis, enzyme inhibition, and antiviral properties," J. Med. Chem., vol. 35, 1992, pp. 4567-4575. |
Ferrari R et al., "Characterization of soluble hepatitis C virus RNA-dependent RNA polymerase expressed in Escherichia coli," Journal of Virology, 73(2), 1649-1654 (1999). |
Fischl, M.A., el al., "Zalcitabine compared with zidovudine in patients with advanced HIV-1 infection who received previous zidovudine therapy," Ann. Intern. Med., 18(10):762-769 (1993). |
Fox, J. J., et al., "Thiolation of nucleosides. II. Synthesis of 5-methyl-2′-deoxycytidine and related pyrimidine nucleosides," J. Am. Chem. Soc., 81: 178-187 (Jan. 5, 1959). |
Fox, J. J., et al., "Thiolation of nucleosides. II. Synthesis of 5-methyl-2'-deoxycytidine and related pyrimidine nucleosides," J. Am. Chem. Soc., 81: 178-187 (Jan. 5, 1959). |
Francesco, et al. Antiviral Research 58 (2003) 1-16. |
Franchetti, et al., "2′-C-Methyl analogues of selective adenosine receptor agonists: Synthesis and binding studies," J. Med. Chem., vol. 41(10), 1998, pp. 1708-1715. |
Franchetti, et al., "2'-C-Methyl analogues of selective adenosine receptor agonists: Synthesis and binding studies," J. Med. Chem., vol. 41(10), 1998, pp. 1708-1715. |
Franchetti, et al., "Antitumor Activity of C-Methyl-b-D-ribofuranosyladenine Nucleoside Ribonucleotide Reductase Inhibitors." Journal of Medicinal Chemistry (2005), 48(15), 4983-4989. |
Freed, J.J., et al., "Evidence for acyloxymethyl esters of pyrimidine 5′-deoxyribonucleotides as extracellular sources of alive 5′-deoxyribonucleotides in cultured cells," Biochemical Pharmacology. 38:3193-3198 (1989). |
Freed, J.J., et al., "Evidence for acyloxymethyl esters of pyrimidine 5'-deoxyribonucleotides as extracellular sources of alive 5'-deoxyribonucleotides in cultured cells," Biochemical Pharmacology. 38:3193-3198 (1989). |
Fujimori, et al., "A Convenient and Stereoselective Synthesis of 2′-Deoxy-[beta]-L-nucleosides," Nucleosides & Nucleotides, 11(2-4), 341-349 (1992); only CAPLUS abstract supplied. |
Fujimori, et al., "A Convenient and Stereoselective Synthesis of 2'-Deoxy-[beta]-L-nucleosides," Nucleosides & Nucleotides, 11(2-4), 341-349 (1992); only CAPLUS abstract supplied. |
Furukawa, Y., et al. "A novel method for synthesis of purine nucleosides using Friedel-Crafts catalysts," Chem. Pharm. Bull., 16(6):1076-1080 (Jun. 1968). |
Galderisi, U., et al., "Antisense oligonucleoties as therapeutic agents," Journal of Cellular Physiology, 181(2):251-257 (Nov. 1999). |
Gallo, et al., "2′-C-Methyluridine Phosphoramidite: A New Building Block for the Preparation of RNA Analogues Carrying the 2′-hydroxyl Group." Tetrahedron, 57 (2001), 5707-5713. |
Gallo, et al., "2'-C-Methyluridine Phosphoramidite: A New Building Block for the Preparation of RNA Analogues Carrying the 2'-hydroxyl Group." Tetrahedron, 57 (2001), 5707-5713. |
Gerotto, et al., Effect of retreatment with interferon alone or interferon plus ribavirin on hepatitis C virus quasispecies diversification in nonresponder pateinets with chronic hepatitis C. Journal of Virology, Sep. 1999, vol. 73, No. 9, p. 7241-7247. |
Giradet, et al., "Synthesis and Cytotoxicity of 4-Amino-5-oxopyrido[2,3-d]pyrimidine Nucleosides." Journal of Medicinal Chemistry (2000), 43(20), 3704-3713. |
Gretch, D.R., "Use and interpretation of HCV diagonostic tests in the clinical setting." Clinics in Live Disease, Nov. 1997, vol. 1, No. 3, pp. 547-557. |
Grouiller et al., "Structural studies on a psicofuranosyl nucleoside, a potential antiviral agent." J. Pharm. Belg., 47(4), 381-3 (1992). |
Grouiller, et al., "Novel-p-toluensesulfaonylation and Thionocarbonylation of Unprotected Thymine Nucleosides," Synlett, 1993: 221-222 (1993). |
Grunnagel, et al., "Preparation of D-Tagatose." Justus Liebigs Annalen der Chemie (1969), 721: 234-5. |
Gunic, E., et al, "Synthesis and cytotoxicity of 4′-C-and 5′-C-substituted Toyocamycins," Bioorg. Med. Chem., 9:163-170 (2001). |
Gunic, E., et al, "Synthesis and cytotoxicity of 4'-C-and 5'-C-substituted Toyocamycins," Bioorg. Med. Chem., 9:163-170 (2001). |
Haraguchi, et al., "Preparation and Reactions of 2′-and 3′- Vinyl Bromides of Uracil Nucleosides: Versatile Synthons for Anti-HIV Agents," Tetrahedron Letters, 32(28): 3391-94 (1991). |
Haraguchi, et al., "Preparation and Reactions of 2'-and 3'- Vinyl Bromides of Uracil Nucleosides: Versatile Synthons for Anti-HIV Agents," Tetrahedron Letters, 32(28): 3391-94 (1991). |
Haraguchi, et al., "Stereoselective Synthesis of 1′-C-Branched Uracil Nucleosides from Uridine," Nucleotides & Nucleosides, 14(3-5): 417-420 (1995). |
Haraguchi, et al., "Stereoselective Synthesis of 1'-C-Branched Uracil Nucleosides from Uridine," Nucleotides & Nucleosides, 14(3-5): 417-420 (1995). |
Harry-O'Kuru et al., "A short flexible route toward 2′-C-branched ribonucleosides," Journal of Organic Chemistry, American Chemical Society. Easton, US, vol. 62, No. 6, 1997, pp. 1754-1759. |
Harry-O'Kuru et al., "A short flexible route toward 2'-C-branched ribonucleosides," Journal of Organic Chemistry, American Chemical Society. Easton, US, vol. 62, No. 6, 1997, pp. 1754-1759. |
Harry-O'Kuru, et al., "2′-C-alkylribonucleosides: Design, Synthesis and Conformation," Nucleosides & Nucleotides, vol. 16: 1457-60 (1997). |
Harry-O'Kuru, et al., "2'-C-alkylribonucleosides: Design, Synthesis and Conformation," Nucleosides & Nucleotides, vol. 16: 1457-60 (1997). |
Hassan, et al., "Nucleosides and Nucleotides 151: Conversion of (Z)-2'-(Cyanomethylene)-2'-Deoxyuridines into their (E)-Isomers via Addition of Thiophenol to the Cyanomethylene Moiety Followed by Oxidative Syn-elimination Reactions." J. Org. Chem., vol. 61, 1996, pp. 6261-6267. |
Hassan, et al., "Nucleosides and Nucleotides 151: Conversion of (Z)-2′-(Cyanomethylene)-2′-Deoxyuridines into their (E)-Isomers via Addition of Thiophenol to the Cyanomethylene Moiety Followed by Oxidative Syn-elimination Reactions." J. Org. Chem., vol. 61, 1996, pp. 6261-6267. |
Hassan, et al., "Nucleosides and Nucleotides 156: Chelation-Controlled and Nonchelation-Controlled Diastereofacial Selective Thiophernol Addition Reactions at the 2′-Position of 2′-[(Alkoxycarhonyl)methaylene]-2′-deoxyuridines: Conversion of (Z0-2′[(Alkoxycarbonyl)methylene]-2′-Deoxyuridines into their (E)-Isomers" J. Org. Chem., vol. 62, 1997, pp. 11-17. |
Hassan, et al., "Nucleosides and Nucleotides 156: Chelation-Controlled and Nonchelation-Controlled Diastereofacial Selective Thiophernol Addition Reactions at the 2'-Position of 2'-[(Alkoxycarhonyl)methaylene]-2'-deoxyuridines: Conversion of (Z0-2'[(Alkoxycarbonyl)methylene]-2'-Deoxyuridines into their (E)-Isomers" J. Org. Chem., vol. 62, 1997, pp. 11-17. |
Hattori, H., et al., "Nucleosides and Nucleotides 175. Structural requirements of the sugar moiety for the antitumor activities of new nucleoside antimetabolites, 1-(3-C-ethynyl-b-D-ribo-pentofuranosyl)cytosine and -uracil," J. Med. Chem., 41: 2892-2902 (1998). |
Hattori, II. et al., "Nucleosides and Nucleotides 158" Journal of Medicinal Chemistry, American Chemical Society, vol. 39, 1996, pp. 5005-5001. |
Hayakawa, et al., "Reaction of organometallic reagents with 2'- and 3'-ketouridine derivatives: synthesis of uracil nucleosides branched at the 2'- and 3'-positions." Chemical & Pharmaceutical Bulletin (1987), 35(6), 2605-8. |
Hayakawa, et al., "Reaction of organometallic reagents with 2′- and 3′-ketouridine derivatives: synthesis of uracil nucleosides branched at the 2′- and 3′-positions." Chemical & Pharmaceutical Bulletin (1987), 35(6), 2605-8. |
Hoard, D.E., et al., "Conversion of Mono- and Oligodeoxyribonucleotides to 5′-Triphosphates," J. Am Chem. Soc., 87(8):1785-1788 (Apr. 20, 1965). |
Hoard, D.E., et al., "Conversion of Mono- and Oligodeoxyribonucleotides to 5'-Triphosphates," J. Am Chem. Soc., 87(8):1785-1788 (Apr. 20, 1965). |
Hodge, et al., "Amadori Rearrangement Products." Methods in Carbohydrate Chemistry (1963), 2: 99-107. |
Holy, A., "Nucleic Acid Components and Their Analogs. CLIII. Preparation of 2′-deoxy-L-Ribonucleosides fo the Pyrimidine Series," Collect. Czech. Chem. Commun., 37(12): 4072-4087 (1972). |
Holy, A., "Nucleic Acid Components and Their Analogs. CLIII. Preparation of 2'-deoxy-L-Ribonucleosides fo the Pyrimidine Series," Collect. Czech. Chem. Commun., 37(12): 4072-4087 (1972). |
Hossain, et al., "Synthesis of 2'- and 3'-Spiro-isoxazolidine Derivatives of Thymidine & Their Conversions to 2',3'-dideoxy2', 3'-didehydro-3'-C-substituted nucleosides by Radical Promoted Fragmentation," Tetrahedron vol. 49, No. 44, pp. 10133-10156, (1993). |
Hossain, et al., "Synthesis of 2′- and 3′-Spiro-isoxazolidine Derivatives of Thymidine & Their Conversions to 2′,3′-dideoxy2′, 3′-didehydro-3′-C-substituted nucleosides by Radical Promoted Fragmentation," Tetrahedron vol. 49, No. 44, pp. 10133-10156, (1993). |
Hostetler, K.Y., et al., "Greatly enhanced inhibition of Human Immunodeficiency Virus Type I replication in CEM and HT4-6C cells by 3′-deoxythymidine diphosphate dimyristoylglycerol, a lipid prodrug of 3′-deoxythymidine," Antimicrob. Agents Chemother., 36:2025.2029 (Sep. 1992). |
Hostetler, K.Y., et al., "Synthesis and antiretroviral activity of phospholipids analogs of azidothymidine and other antiviral nucleosides," J. Biol. Chem., 265:6112-6117 (1990). |
Hrebabecky, et al., "Nucleic Acid Components and their Analogs: CXLIX: Synthesis of Pyrimidine Nucleosides Derived from 1-Deoxy-D-Psicose," Coll Czech Chem Corn, 37: 2059-2065 (1972). |
Hrebabecky, et al., "Synthesis of 7- and 9b-D-Psicofuranosylguanine and Their l′-Deoxy Derivatives." Collection Czechoslov. Chem. Commun., vol. 39, 1974, pp. 2115-2123. |
Hu, et al., Viral, host and interferon-related factors modulating the effect of interferon therapy for hepaptitis C virus infection. Journal of Viral Hepatitis, 2001, vol. 8, p. 1-18. |
Hunston, R.N., et al., "Synthesis and biological properties of some cyclic phosphotriesters drived from 2′-deoxy-5-fluorouridine," J. Med Chem. 27:440-444 (1984). |
Iglesias, et al., "Complete and Regioselective Deacetylation of Peracetylated Uridines Using a Lipase." Biotechnology Letters 22: 361-365, 2000. |
Iimori, et al., "2′-C-, 3′-C-, and 5′-C-Methylsangivamycins: conformational lock with the methyl group." Tetrahedron Letters (1991), 32(49), 7273-6. |
Iimori, et al., "A study on conformationally restricted sangivamycins and their inhibitory abilities of protein kinases." Nucleic Acids Symposium Series (1992), 27(Nineteenth Symposium on Nucleic Acids Chemistry, 1992), 169-70. |
Iino T., et al., "Nucleosides and nucleotides 139. Stereoselective synthesis of (2′S) 2′-C-alkyl-2′-deoxyuridines,", Nucleosides & Nucleotides, 15(1-3): 169-181 (1996). |
Ikegashira, K., et al., "Discovery of conformationally constrained tetracylic compounds as potent hepatitis C virus NS5B RNA polymerase inhibitors," Journal of Medicinal Chemistry, (Nov. 30, 2006) vol. 449, No. 24, pp. 6950-6953. |
Imai, K., et al., "Studies on Phosphorylation. IV. Selective Phosphorylation of the Primary Hydroxyl Group in Nucleosides." J. Org. Chem., 34(6): 1547-1550 (Jun. 1969). |
Itoh, et al., "Divergent and Sterocontroed Approach to the Synthesis of Uracil Nucleosides Branched at the Anomeric Position," J Org Chem, 60(3): 656-662 (1995). |
Johnson, C.R., et al., "3′-C-Trifluoromethyl ribonucleosides," Nucleosides & Nucleosides, vol. 14, 1995, pp. 185-194. |
Jones, G. H., et al., "4′-substituted nucleosides. 5. Hydroxymethylation of nucleoside 5′-aidehydes," J. Org. Chem., 44:1309- 1317 (1979). |
Jones, G. H.; Moffatt, J. G., Methods in Carbohydrate Chemistry; Whisler, R. L. And Moffatt, J. L. Eds; Academic Press: New York, 1972; 315-322. |
Kakefuda, et al., "Nucleosides and nucleotides. 120. Stereoselective radical deoxygenation of tert-alcohols in the sugar moiety of nucleosides: synthesis of 2′,3′-dideoxy 2′-C-methyl and 2′-C-ethynyl-b-D-threo-pentofuranosyl pyrimidines and adenine as potential antiviral and antitumor agents." Tetrahedron (1993), 49(38), 8513-28. |
Kamaike, K., et al., "An efficient method for the synthesis of [4-15N]cytidine, 2′-deoxy[4-15N]cytidine, ]6-15N]adenosine, and 2′-deoxy[6-15N]adenosine derivatives," Nuclesodies and Nucleotides, 15(1-3—: 749-769 (1996). |
Kaneko, M., et al., "A convenient synthesis of cytosine nucleosides," Chem. Pharm. Bull., 20:1050-1053 (1972). |
Kawana, et al, "The Deoxygenatio of Tosylated Adenosine Derivatives with Grignard Reagents," Nucleic Acids Symp Ser, 17:37-40 (1986). |
Kempe, T., et al., "Selective 2′-Benzoylation at the Cis 2′, 3′-diols of Protected Ribonucleosides. New Solid Phase Synthesis of RNA and DNA-RNA Mixtures," Nucleic Acids Res., 10(21):6695-6714 (Nov. 11, 1982). |
Kerr, S.G., et al., "N-(Dialkylamino)Methylene Derivatives of 2′-Deoxycytidine and Arabinocytidine: Physicochemical Studies for Potential Prodrug Applications," J. Pharm. Sci., 83(4): 582-586 (Apr. 1994). |
Khamnei, S., "Neighboring group catalysis in the design of nucleotide prodrugs," J. Med Chem., 39:4109-4115 (1996). |
Kim, et al., "A Novel Nucleoside Prodrug-Activating Enzyme: Substrate Specificity of Biphenyl Hydrolase-like Protein," Molecular Pharmaceutics (2004), 1(2), 117-127. |
Klumpp, et al., "The Novel Nucleoside Analog R1479 (4′-Azidocytidine) is a Potent Inhibitor of NS5B-dpendent RNA Synthesis and Hepatits C Virus Replication in Cell Culture." The Journal of Biological Chemistry, vol. 281, No. 7, pp. 3793-3799, Feb. 17, 2006. |
Kohn, et al., "A new method for the synthesis of furanose derivatives of aldohexoses," J Am. Chem. Soc., 1965, 87(23): 5475-80. |
Kotra, L., et al., "Structure-Activity Relationships of 2′-Deoxy-2′,2′-difluoro-L-erythro-pentofuranosyl Nucleosdes." J. Med. Chem. 1997, 40, 3635-3644. |
Kucera, L.S., et al., "Novel membrane-interactive ether lipid analogs that inhibit infectious HIV-1 production and induce defective virus formation," AIDS Res. Hum. Retro Viruses, 6.491-501 (1990). |
Kuhn, R., et al., "Uber eine molekulare Umlagerung von N-Glucosides." Jahrg. 69, 1936, p. 1745-1754. |
Kurtzberg J., et al, "Differential, toxicity of carbovir and AZT to human bone marrow hematopoietic progenitor cells in vitro," Exp. Hematol., 18(10):1094-1096 (1990). |
Lai, V.C.H., et al., "Mutational analysis of bovine viral diarrhea virus RNA-dependant RNA polymerase," J. Virol., 73(12):10129-101136 (Dec. 1999). |
Landowski, "Nucleoside ester prodrug substrate specificity of liver carboxylesterase," Journal of Pharmacology and Experimental Therapeutics (2006), 316(2), 572-580. |
Lavaire, S., et al., "3′-deoxy-3′-C-trifluoromethyl nucleosides: Synthesis and antiviral evaluation," Nucleosides & Nucleotides, 17(12): 2267-2280 (1998). |
Le Pogam, et al., "In Vitro Selected Conl Subgenomic Replicons Resistant to 2′-C-Methyl-Cytidine or to R1479 Show Lack of Cross Resistance." Virology 351 (2006), 349-359. |
Le Pogam, et al., "Selection and Characterization of Replicon Variants Dually Resistant to Thumb- and Palm-Binding Nonnucleoside Polymeras Inhibitors of the Hepatitis C Virus." Journal of Virology, vol. 80, No. 12, Jun. 2006, p. 6146-6154. |
Leonard, N. J., et al., "5-Amino-5-deoxyribose derivatives. Synthesis and use in the preparation of "reversed" nucleosides" J. Heterocycl. Chem., 3:485-489 (Dec. 1966). |
Lerza, R, et al., "In vitro synergistic inhibition of human bone marrow hemopoictic progenitor growth by a 3′-azido-3′- deoxy-thymidine, 2′,3′-dideoxycytidine combination," Exp. Hematol., 25(3):252-255 J (1997). |
Lewis W, et al., "Zidovudine induces molecular, biochemical, and ultrastructural changes in rat skeletal muscle mitochondria," J. Clin. Invest., 89(4):1354-1360 (1992). |
Lewis, L. D., et al., "Ultrastructural changes associated with reduced mitochondrial DNA and impaired mitochondrial function in the presence of 2′3′-dideoxycytidine," Antimicrob. Agents Chemother, 36(9):2061-2065 (1992). |
Lewis, W., et al., "Fialuridine an dits metabolites inhibit DNA polymerase γ at sites of ultiple adjacent analog incorporation, decrease mtDNA abundance, and cause mitochondrial structural defects in cultured hepatoblasts," Proceedings of the National Academy of Sciences, USA, 93(8): 3592-7 (1996). |
Leyssen, P., et at., "Perspectives for the treatment of infections with Flaviviridae," Clinical Microbiology Reviews (Washington D.C.) 13(1): 67-82 (Jan. 2000). |
Li, et al., "2′-C-Branched ribonucleosides. 2. Synthesis of 2′-C-beta-trifluormethyl pyrimidine ribonucleosides," Org. Lett., vol. 3, 2001, pp. 1025-1028. |
Lin, T.S., et al., "Synthesis of Several Pyrimidine L-Nucleoside Analogues as Potential Antiviral Agents," Tethrahedron Letters, 51(4): 1055-1068 (1995). |
Lohmann V., et al., "Biochemical and kinetic analyses ofNSSB RNA-dependent RNA polymerase of the Hepatitis C virus," Virology, 249,108-118 (1998). |
Lopez Aparicio, F.J., et al., "Synthesis of Saccarinic Acid Derivatives," Carbohydrate Res., 129:99 (1984). |
Lopez-Herrera, F.J., et al., "A New Synthesis of 2-C Methyl-D-Ribono-1, 4-Lactone and the C-(/C-13 Fragment of Methynolide," J. Carbohydrate Chemistry, 13(5): 767-775 (1994). |
Luh, T.-Y., et al., "A convenient method for the selective esterification of amino-alcohols," Synthetic Communications, 8(5):327-333 (1978). |
Maga, Giovanni, et al., Lack of stereospecificity of suid pseudorabies virus thymidine kinase, Biochem. J., 294(2): 381-385 (1993). |
Mahmoudian, M., et al., "A Versatile Procedure for the Generation of Nucleoside 5′-Carboxylic Acids Using Nucleoside Oxidase," Tetrahedron, Elsevier Science Publishers Amsterday, NL, vol. 54, No. 28, 8171-8182 Jul. 9, 1998. |
Mansour, T.S., et al., "Editorial," Anti-Ineffective Agents in Medicinal Chemistry, (2007) vol. 6, No. 1, pp. 1. |
Markland W., et al., "Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon," Antimicrobial Agents and Chemotherapy, Apr. 2000, vol. 44, No. 4, pp. 859-866. |
Martin, J., et al., Synthesis and Antiviral Activity of Monofluoro and Difluoro Analogues of Pyrimidine Deoxyribonucleosides Against Human Immnodeficiency Virus (HIV-1). J. Med. Chem. 1990, 33, 2137-2145. |
Martin, X., et al., "Intramolecular hydrogen bonding in primary hydroxyl of thymine 1-(1-deoxy-β-D-piscofuranosyl)nucleoside," Tetrahedron, 50(22): 6689-6694 (1994). |
Matsuda, et al., "Alkyl Addition Reaction of Pyrimidine 2′-Ketaonucleosides: Synthesis of 2′-Branched-Chain Sugar Pyrimidne Nucleosides (Nucleosides and Nucleotides. LXXXI" Chem Pharm Bull, vol. 36(3):945-53 (1988). |
Matsuda, et al., "Nucleosides and Nucleotides 104. Radical and Palladium-Catalyzed Deoxygenation of the Allylic Alcohol Systems in the Sugar Moiety of Pyrimidine Nucleosides." Nucleosides & Nucleotides, Dekker, New York, NY, U.S., vol. 11, No. 2/4, 1992, pp. 197-226. |
Matsuda, et al., "Nucleosides and Nucleotides 94. Radical deoxygenation of tert-alcohols in 1-(2-C-alkylpentafuranosyl) pyrimidines: Synthesis of (2′S)-2-deoxy 2′ C methylcytidine, and antileukemic nucleoside," Journal of Medicinal Chemistry, American Chemical Society Washington, US, vol. 34, 1991, pp. 234-239. |
Matsuda, et al., "Radical deoxygenation of tent-alcohols in 2′—branched-chain sugar pyrimidine nucleosides: synthesis and antileukemic activity of 2′—deoxy-2′ (S)-methylcytidine," Chem. Pharm. Bull., vol. 35, 1987, pp. 3967-3970. |
McCormick, J., et al., "Structure and Total Synthesis of HF-7, a Neuraoactive Glyconucleoside Disultate from the Funnel-Web Spider Hololena curia," Journal of the American Chemical Society, 1999, vol. 121, pp. 5661-5665. |
McFarlin, et al., "The Reaction of Lithium Aluminum Hydride with Alcohols. Lithium Tri-t—,-butoxyaluminohydride as a New Selective Reducing Agent," J. Am. Chem. Soc. 1958, 80, 5372-76. |
McKenzie, R., et al., "Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B", N. Engl. J. Med., 333(17):1099-1105 (1995). |
Medina, D, J., et al., "Comparison of mitochondrial morphology, mitochondrial DNA content, and cell viability in cultured cells treated with three anti-Human immunodeficiency Virus dideoxynucleosides," Antimicrob. Agents Chemother., 38(8):1824-8 (1994). |
Meier, C., et al., "Cyclic saligenyl phosphotriesters of 2′,3′-dideoxy-2′,3′-didehydrothymidine (d4T)—A new pro-nucleic approach." Bioorganic & Med. Chem. Letters 7(2):99-104 (1997). |
Meyer, RB., Jr., et al., "2′-O-Acyl-6-thioinosine cyclic 3′,5′-phosphates as prodrugs of thioinosinic acid," J. Med. Chem, 22: 811-815 (1979). |
Mikhailov, S.N., et al., "Hydrolysis of 2′- and 3′-C-mcthyluridinc 2′-, 3′-monophosphates and Interconversion and dephosphorylation of the resulting 2′- and 3′-monophosphates: Comparison with the reactions of Uridine monophosphates," J. Org. Chem., vol. 57: 4122-26 (1992). |
Mikhailov, S.N., et al., "Substrate properties of C′-methylnucleoside and C′-methyl-2′-deoxynucleoside 5′-triphosphates in RNA and DNA synthesis reactions catalysed by RNA and DNA polymerases," Nucleosides & Nucleotides, 10(1-3): 339-343 (1991). |
Mikhailov, S.N., et al., "Synthesis and properties of 3′ C-methylnucleosides and their phosphoric esters," Carbohydrate Research, vol. 124, 1983, pp. 75-96 |
Miles, et al., "Circular Dichroism of Nucleoside Derivatives. IX. Vicinal Effects on the Circular Dichrosim of Pyrimidine Nucleosides." J. Am. Chem. Soc. 92(13): 3872-3881 (1970). |
Moiseyev, et al., "Determination of the nucleotide conformation in the productive enzyme-substrate complexes of RNA-depolymerases." FEBS Letters (1997), 404(2,3), 169-172. |
Moore, et al., "Synthesis of Nucleotide Analogues That Potently and Selectively Inhibit Human DNA Primase." Biochemistry (2002), 41(47), 14066-14075. |
Murai et al., "A synthesis and an x-ray analysis of 2′-C-,3′-C- and 5′-C-methylsangivamycins," Heterocycles (1992), 33(1), 391-404. |
Neidlein, R., et al., "Mild preparationof I-benzyuloxyiminoalkylphosphonic dichlorides: Application to the synthesis of cyclic phosphonic diesters and cyclic monoester amides," Heterocycles 35:1185-1203 (1993). |
Nishiguchi, S., et al., "Methods to Detect Substitutions in the Interferon-Sensitivity-Determining Region of Hepatitis C virus lb for Prediction of Response to Interferon Therapy," Hepatology. Jan. 2001, vol. 33, No. 1, pp. 241-247. |
Nishimura, T. et al. "Studies on Sythetic Nuclesides. Trimethylsilyl Derivatives of Pyrmidine and Purines," Chemical & Pharmaceutical Bulletin (1964), vol. 12, pp. 352-356. |
Notice of Allowance dated Apr. 7, 2009 from U.S. Appl. No. 10/608,907. |
Notice of Allowance dated Apr. 7, 2009 from U.S. Appl. No. 10/609,298. |
Notice of Allowance dated Aug. 22, 2007 from U.S. Appl. No. 11/005,447. |
Notice of Allowance dated Aug. 22, 2007 from U.S. Appl. No. 11/005,467. |
Notice of Allowance dated Aug. 22, 2007 from U.S. Appl. No. 11/005,470. |
Notice of Allowance dated Aug. 8, 2006 from U.S. Appl. No. 11/005,473. |
Notice of Allowance dated Dec. 27, 2005 from U.S. Appl. No. 10/602,693. |
Notice of Allowance dated Dec. 27, 2005 from U.S. Appl. No. 10/602,694. |
Notice of Allowance dated Dec. 28, 2005 from U.S. Appl. No. 10/602,692. |
Notice of Allowance dated Feb. 12, 2007 from U.S. Appl. No. 11/005,447. |
Notice of Allowance dated Feb. 19, 2004 from U.S. Appl. No. 09/864,078. |
Notice of Allowance dated Jan. 19, 2007 from U.S. Appl. No. 10/607,909. |
Notice of Allowance dated Jan. 8, 2008 from U.S. Appl. No. 11/005,441. |
Notice of Allowance dated Jul. 10, 2008 from U.S. Appl. No. 10/607,909. |
Notice of Allowance dated Jun. 11, 2009 from U.S. Appl. No. 11/516,928. |
Notice of Allowance dated Jun. 15, 2009 from U.S. Appl. No. 10/602,691. |
Notice of Allowance dated Jun. 22, 2007 from U.S. Appl. No. 11/005,441. |
Notice of Allowance dated Mar. 23, 2004 from U.S. Appl. No. 09/863,816. |
Notice of Allowance dated Mar. 30, 2009 from U.S. Appl. No. 11/005,445. |
Notice of Allowance dated Mar. 7, 2007 from U.S. Appl. No. 11/005,470. |
Notice of Allowance dated Mar. 9, 2006 from U.S. Appl. No. 10/602,136. |
Notice of Allowance dated May 17, 2005 from U.S. Appl. No. 10/602,135. |
Notice of Allowance dated May 6, 2009 from the U.S. Appl. No. 10/735,408. |
Notice of Allowance dated May 9, 2006 from U.S. Appl. No. 10/607,909. |
Notice of Allowance dated Oct. 11, 2006 from U.S. Appl. No. 11/005,447. |
Notice of Allowance dated Oct. 12, 2006 from U.S. Appl. No. 11/005,470. |
Notice of Allowance dated Oct. 13, 2005 from U.S. Appl. No. 10/602,976. |
Notice of Allowance dated Sep. 17, 2009 from U.S. Appl. No. 11/005,445. |
Novak, J.J.K. & Sorm, F., "Nucleic Acid Components and Their Analogues. CXX. 2-C-Methyl-D-Ribose and Its Derivatives," Collection Czechoslay. Chem. Commun., 34:857-866 (1969). |
Novak, J.J.K., "Chiroptical Properties of 2-Methyl-1,4-Lactones; Revised Absolute Configuration of 2-Deoxy-2-C-Methyl-Erythro-D-Pentono-1, 4-Lactones," Collection Czechoslay. Chem. Commun., 39:869-882 (1974). |
Nutt, R. F., et al. "Branched-chain sugar nucleosides. III. 3′-C-methyladenine," J. Org. Chem. 33:1789-95 (1968). |
Office Action dated Apr. 5, 2005 from U.S. Appl. No. 10/602,135. |
Office Action dated Apr. 5, 2005 from U.S. Appl. No. 10/602,692. |
Office Action dated Apr. 6, 2005 from U.S. Appl. No. 10/602,693. |
Office Action dated Apr. 6, 2005 from U.S. Appl. No. 10/602,694. |
Office Action dated Aug. 15, 2006 from U.S. Appl. No. 10/608,907. |
Office Action dated Aug. 18, 2006 from U.S. Appl. No. 11/005,467. |
Office Action dated Aug. 2, 2006 from U.S. Appl. No. 10/609,298. |
Office Action dated Aug. 20, 2007 from U.S. Appl. No. 11/005,446. |
Office Action dated Aug. 21, 2006 from U.S. Appl. No. 11/005,441. |
Office Action dated Aug. 21, 2007 from the U.S. Appl. No. 10/735,408. |
Office Action dated Aug. 22, 2007 from U.S. Appl. No. 10/602,691. |
Office Action dated Aug. 24, 2007 from U.S. Appl. No. 10/609,298. |
Office Action dated Aug. 27, 2003 from U.S. Appl. No. 09/864,078. |
Office Action dated Aug. 7, 2006 from U.S. Appl. No. 11/005,442. |
Office Action dated Dec. 10, 2008 from U.S. Appl. No. 10/602,142. |
Office Action dated Dec. 22, 2006 from the U.S. Appl. No. 10/735,408. |
Office Action dated Dec. 29, 2006 from U.S. Appl. No. 10/602,691. |
Office Action dated Dec. 5, 2006 from U.S. Appl. No. 11/005,440. |
Office Action dated Dec. 5, 2006 from U.S. Appl. No. 11/005,444. |
Office Action dated Dec. 5, 2006 from U.S. Appl. No. 11/005,446. |
Office Action dated Dec. 5, 2006 from U.S. Appl. No. 11/005,472. |
Office Action dated Feb. 26, 2008 from U.S. Appl. No. 10/602,142. |
Office Action dated Feb. 26, 2008 from U.S. Appl. No. 10/602,691. |
Office Action dated Feb. 26, 2008 from U.S. Appl. No. 11/005,445. |
Office Action dated Feb. 28, 2008 from U.S. Appl. No. 11/005,471. |
Office Action dated from Jun. 28, 2007 U.S. Appl. No. 10/607,909. |
Office Action dated Jan. 24, 2008 from U.S. Appl. No. 10/607,909. |
Office Action dated Jan. 28, 2008 from U.S. Appl. No. 10/608,907. |
Office Action dated Jan. 9, 2008 from the U.S. Appl. No. 10/735,408. |
Office Action dated Jul. 10, 2008 from U.S. Appl. No. 10/609,298. |
Office Action dated Jul. 17, 2007 from U.S. Appl. No. 11/005,445. |
Office Action dated Jul. 18, 2007 from U.S. Appl. No. 11/005,469. |
Office Action dated Jul. 18, 2007 from U.S. Appl. No. 11/005,471. |
Office Action dated Jul. 28, 2006 from U.S. Appl. No. 10/602,142. |
Office Action dated Jun. 13, 2007 from U.S. Appl. No. 11/005,440. |
Office Action dated Jun. 13, 2007 from U.S. Appl. No. 11/005,444. |
Office Action dated Jun. 13, 2007 from U.S. Appl. No. 11/005,472. |
Office Action dated Jun. 14, 2007 from U.S. Appl. No. 11/005,468. |
Office Action dated Mar. 12, 2007 from U.S. Appl. No. 11/005,443. |
Office Action dated Mar. 16, 2009 from the U.S. Appl. No. 10/735,408. |
Office Action dated Mar. 17, 2008 from U.S. Appl. No. 11/005,446. |
Office Action dated Mar. 24, 2008 from U.S. Appl. No. 11/005,469. |
Office Action dated Mar. 29, 2007 from U.S. Appl. No. 10/602,142. |
Office Action dated May 16, 2007 from U.S. Appl. No. 11/005,442. |
Office Action dated May 19, 2005 from U.S. Appl. No. 10/602,976. |
Office Action dated May 30, 2006 from U.S. Appl. No. 10/602,691. |
Office Action dated May 31, 2007 from U.S. Appl. No. 10/608,907. |
Office Action dated Nov. 15, 2005 from U.S. Appl. No. 10/602,142. |
Office Action dated Nov. 20, 2006 from U.S. Appl. No. 11/005,466. |
Office Action dated Nov. 25, 2005 from U.S. Appl. No. 11/005,473. |
Office Action dated Nov. 26, 2008 from U.S. Appl. No. 10/608,907. |
Office Action dated Nov. 28, 2007 from U.S. Appl. No. 11/005,442. |
Office Action dated Nov. 7, 2005 from U.S. Appl. No. 10/602,691. |
Office Action dated Oct. 1, 2003 from U.S. Appl. No. 09/863,816. |
Office Action dated Oct. 12, 2005 from U.S. Appl. No. 11/005,444. |
Office Action dated Oct. 12, 2005 from U.S. Appl. No. 11/005,466. |
Office Action dated Oct. 12, 2005 from U.S. Appl. No. 11/005,472. |
Office Action dated Oct. 16, 2007 from U.S. Appl. No. 11/005,440. |
Office Action dated Oct. 2, 2007 from U.S. Appl. No. 11/005,468. |
Office Action dated Oct. 2, 2008 from U.S. Appl. No. 11/516,928. |
Office Action dated Oct. 5, 2005 from U.S. Appl. No. 11/005,440. |
Office Action dated Oct. 5, 2005 from U.S. Appl. No. 11/005,443. |
Office Action dated Oct. 5, 2005 from U.S. Appl. No. 11/005,446. |
Office Action dated Oct. 5, 2006 from U.S. Appl. No. 11/005,469. |
Office Action dated Oct. 6, 2006 from U.S. Appl. No. 11/005,445. |
Office Action dated Oct. 6, 2008 from U.S. Appl. No. 11/005,444. |
Office Action dated Oct. 7, 2008 from U.S. Appl. No. 10/602,691. |
Office Action dated Oct. 7, 2008 from U.S. Appl. No. 11/005,445. |
Office Action dated Oct. 9, 2007 from U.S. Appl. No. 11/005,444. |
Office Action dated Oct. 9, 2007 from U.S. Appl. No. 11/005,466. |
Office Action dated Oct. 9, 2007 from U.S. Appl. No. 11/005,472. |
Office Action dated Sep. 10, 2004 from U.S. Appl. No. 10/602,976. |
Office Action dated Sep. 20, 2007 from U.S. Appl. No. 10/602,142. |
Office Action dated Sep. 24, 2008 from the U.S. Appl. No. 10/735,408. |
Office Action dated Sep. 24, 2009 from U.S. Appl. No. 11/644,304. |
Office Action dated Sep. 26, 2006 from U.S. Appl. No. 11/005,468. |
Office Action dated Sep. 5, 2008 from U.S. Appl. No. 11/005,443. |
Oivanen, M., et al., "Additional evidence for the exceptional mechanism of the acid-catalyzed hydrolysis of 4-oxopyrimidine nucleosides: Hydrolysis of 1-(1-alkoxyalkyl)uracils, seconucleosides, 3′-C-alkyl nucleosides and nucleoside 3′, 5′-cyclic monophosphates," J. Chem. Soc. Perkin Trans. 2, 1994: 309-314 (1994). |
Olsen et al. (Oral Session V, Hepatitis C Virus, Flaviviridae; 16th International Conference on Antiviral Research (Apr. 27, 2003, Savannah, Ga.) p. A76). |
Ong, S.P., et al., "Synthesis of 3′-C-methyladenosine and 3′-C-methyluridine diphosphates and their interaction with the ribonucleoside diphosphate reductase from Corynebacterium nephridii," Biochemistry, vol. 31, 1992, pp. 11210-11215. |
Pagliaro, L., et al., "[Hepatology: Old, recent and (maybe) future stories. A narrative review]. Epatologia: Ieri, Oggi E (Forse) Domani," Recenti Progressi in Medicina, (2006) vol. 97, No. 12, pp. 741-750. |
Pan-Zholt, X-R, et al., "Differential effects of antiretroviral nucleoside analogs on mitochnodrial function in HepG2 cells," Antimicroh Agents Chemother 2000; 44:496-503. |
Piantadosi, C., et al., "Synthesis and evaluation of novel ether lipid nucleoside conjugates for anti-HIV-1 activity, "J. Med. Chem. 34:1408-1414 (1991). |
Pierra, C., et al., "Comparative Studies of Selected Potential Prodrugs of B-L-dC, A Potent and Selective Anti-HBV Agent," Antiviral Res., 50:A79 (2001), Abstract No. 138. |
Pierra, C., et al., "NM 283, and efficient prodrug of the potent anti-HCV agent 2′-C-methylcytidine," Nucleosides, Nucleotides and Nucleic Acids (2005), 24(5-7), 767-770. |
Pierra, C., et al., "Synthesis and Pharmacokinetics of Valopicitabine (NM283), and Efficient Prodrug of the Potent Anti-HCV Agent 2′-C-Methylcytidine," Journal of Medicinal Chemistry (2006), 49(22), 6614-6620. |
Reist, et al., "Potential anticancer agents. LXXVII. Synthesis of nucleosides of purine-6-thiol(6-mercaptopurine) containing "fraudulent" sugars." Journal of Organic Chemistry (1962), 27 3279-83. |
Richman, D.D., et al., "The toxicity ofazidothymidine (AZT) in the treatment of patients with AIDS and AIDS-Related Complex," N. Engl. J. Med., 317(4):192-197 (1987). |
Robins, et al., "Purine Nucleosides. XXIX. The Synthesis of 2′-Deoxy-L-adenosine and 2′-Deoxy-L-guanosine and Their [alpha] Anomers," Journal of Organic Chemistry, 35(3), 636-639 (Mar. 1970). |
Rong, et al., "The Synthesis and Conformation of 2′-and 3′-Hypermodified Tricyclic Nucleosides and Their Use in the Synthesis of Novel 2′- or 3′-Isomeric 4(7)-Substituted Isoxazolidine-nucleosides," Tetrahedron vol. 50, No. 16, pp. 4921-4936. (1994). |
Roque-Afonso, AM, et al., "Performance of TRUGENE hepatitis C virus5′ noncoding genotyping kit, a new CLIP sequencing-based assay for hepatitis C virus genotype determination," Journal of Viral Hepatitis. Sep. 2002, vol. 9, Issue 5, pp. 385-389. |
Rosenthal, et al., "Branched-chain sugar nucleosides. Synthesis of 3′-C-ethyl (and 3′-C-butyl) uridine," Carbohydrate Research, vol. 79, 1980, pp. 235-242. |
Sakthivel et al., "Direct SNAr amination of fluorinated imidazo[4,5- c]pyridine nucleosides: efficient syntheses of 3- fluoro-3deazaadenosine analogs." Tetrahedron Letters (2005), 46(22), 3883-3887. |
Sakthivel, et al. "Electrophilic fluorination of 5-(cyanomethyl)imidazole-4-carboxylate nucleosides: Facile entry to 3-fluoro-3-deazaguanosine analogues." Synlett (2005), (10), 1586-1590. |
Salidino, R., et al., "A new and efficient synthesis of cytidine and adenosine derivatives by dimethyldioxirane oxidation of thiopyrimidine and thiopurine nucleosides," J. chem. Soc., Perkin Trans. I., 21: 3053-3054 (1994). |
Samano, et al., "Nucleic Acid Related Compounds. 77. 2′,3′-Didehydro-2′, 3′-Dideoxy-2′ (and 3′)-Methylnucleosides Via [3,3]-Sigmatropic Rearrangements of 2′(and 3′)-Methylene-3′(and 2′)-O-Thiocarbonyl Derivatives and Radical Reuction of a 2′-Chloro-3′Methylene Analogue," Can. J. Chem., 71: 186-191 (1993). |
Samano, et al., "Synthesis and Radical-Induced Ring-Opening Reactions of 2′-Deoxyadenosine-2′-Spirocyclopropane and its Uridine analogue. Mechanistic Probe for Ribonucleotide Reductases," J Am Chem Soc, 114: 4007-08 (1992). |
Sandhu, et al., "Evaluation of microdosing strategies for studies in preclinical drug development: Demonstration of linear pharmacokinetics in dogs of a nucleoside analog over a 50-fold dose range." Drug Metabolism and Disposition (2004), 32(11), 1254-1259. |
Sato, et al., "C-Nucleoside synthesis. 10. Synthesis of 2′-methylated pyrimidine C-nucleosides." Tetrahedron Letters (1980), 21(20), 1971-4. |
Sato, et al., "C-Nucleoside synthesis. 19. Stereocontrolled general synthesis of pyrimidine C-nucleosides having branched-chain sugar moieties." Bulletin of the Chemical Society of Japan (1983), 56(9), 2680-99. |
Savochkina, et al., "Substrate properties of c—methylnucleoside triphosphates in RNA syntheses catalyzed by E. coli RNA—polymeruse" Molecular Biology, 1989, v. 23, No. 6. |
Scheibler, C., "Ueber das Saccharin and die Saccharinsaure," Chemische Berichte, 13:2212-2217 (1880). In German. |
Schiff, E.R., "Emerging strategies for pegylated interferon combination therapy," Nature Clinical Practice Gastoenterology and Hepatology, (2007) vol. 4, No. Suppl. 1, pp. S17-S21. |
Sciimit, C., et al., "Synthesis of 2′-Deoxy-2′-Alpha-Monofluoromethyl and Trifluoromethylnucleosides," Synlett, Thieme Verlag, Stuttgart, DE, No. 4, 1994, pp. 241-242. |
Serafinowski, P.J., et al., "New method for the preparation of some 2′-and 3′-trifluoromethy1-2′,3′-dideoxyuridine derivatives," Tetrahedron, 56(2):333-339 (1999). |
Shalaby, et al., "Conformations and Structure Studies of Sugar Lactones in the Solid State. Part 11. The Molecular Structure of a-D-Glucosaccharino-Y-Lactone: 2-C-Mehtyl-D-Ribo-Pentono-1,4-lactone." Carbohydrate Research (1994), 264(2), 191-8. |
Sharma, et al., "Synthesis of 3′-Trifluoromethyl Nucleosides as Potential Antiviral Agents," Nucleosides, Nucleotides and Nucleic Acids, Marcel Dekker, Ann Harbor, MI, US, vol. 19, No. 4, 2000, pp. 757-774. |
Shi, et al., Synthesis and in vitro Anti-HCV Activity of β-d- and 1-2′-Deoxy-2′-Fluororibonucleosides, Nucleosides, Nucleotides & Nucleic Acids 2005, vol. 23, Nos. 5-7, pp. 875-879. |
Shim, Jae H., "Recent patents on nucleoside and nucleotide inhibitors for HCV," Recetn Patents on Anti-Infective Drug Discovery (2006), 1(3), 323-331. |
Sinko, et al., Carrier-Mediated Intestinal Absorption of Valacyclovir, the L-Valyl Ester Prodrug of Acyclovir. Biopharmaceutics & Drug Disposition 1998, vol. 19, pp. 209-217. |
Sinkula et al., "Rationale for design of biologically reversible drug derivatives: prodrugs," J. Pharm. Sci., 1975,64: 181-210. |
Smith, et al., "Synthesis of new 2′-b-C-methyl related triciribine analogues as anti-HCV agents." Valeant Pharmaceuticals International, Costa Mesa, CA, USA. Bioorganic & Medicinal Chemistry Letters (2004), 14(13), 3517-3520. |
Sommadossi, J-P., et al., "Comparison of cytotoxicity of the (−)-and(+)-enantiomer of 2′,3′-dideoxy-3′-thiacytidine in normal human bone marrow progenitor cells," Biochemical Pharmacology 1992; 44:1921-1925. |
Sommadossi, J-P., et al., "Toxicity of 3′-azido-3′-deoxythymidine and 9-(1-3-dihydroxy-2-propoxymethyl)guanine for normal human hematopoietic progenitor cells in vitro" Antimicrobial Agents and Chemotherapy 1987; 31:452-454. |
Song, et al., Amino Acid Ester Prodrugs of the Anticancer Agent Gemcitabine: Synthesis, Bioconversion, Metabolic Bioevasion, and hPEPT1-Medicated Transport, Moleculare Pharmaceutics (2005), 2(2), 157-167. |
Sorbera, L.A., et al., "Valopicitabine: anti-hepatitis C virus drug RNA—directed RNA polymerase (NS5B) inhibitor," Drugs of the Future (2006), 31 (4), 320-324. |
Sowden, J., "The Saccharinic Acids," Adv. Carbohydrate Chem., 12:43-46 (1957). |
Spardari, et al., "L-Thmidine is Phosphorylated by Herpes Simplex Virus Type 1 Thymidine Kinase and Inhibits Viral Growth," Journal of Medicinal Chemistry, 35(22), 4214-4220 (1992). |
Standring, D.N., et al., "Antiviral Beta-L-Nucleosides Specific for Hepatitis B Virus Infection," Antiviral Chem. & Chemother., 12 (Suppl. 1): 119-129 (2001). |
Starrett, J.E.Jr., et al., "Synthesis, oral bioavailability determination, and in vitro evaluation of prodrugs of the antiviral agents 9-(2-(phosphonomethoxy)ethylladenine (PMEA)," J. Med Chem. 37:1857-1864 (1994). |
Stuyver, et al., "Ribonucleoside Analogue That Block Replication of Bovine Viral Diarrhea and Hepatits C Viruses in Culture." Antimicrobial Agents and Chemotherapy, vol. 47, No. 1, Jan. 2003, p. 244-254. |
Sundberg, et al., Advanced Organic Chemistry, Part b, 1990, pp. 232 and 236. |
Takenuki, et al., "Nucleosides and nucleotides. XLIII. On the stereoselectivity of alkyl addition reaction of pyrimidine 2′-ketonucleosides." Chemical & Pharmaceutical Bulletin (1990), 38(11), 2947-52. |
Tang, X.-Q., et al., "2′-C-Branched Ribonucleosides: Synthesis of the Phophoramidite Derivatives of 2′-C-B-Methylcytidine and Their Incorporation into Oligonucleotides," J. Org. Chem., 64(3): 747-754 (1999). |
The Merck Index, 12th edition, 1996, p. 275. |
Tritsch, D., et al., "3′-β-ethynyl and 2′-deoxy-3′-β-ethynyl adenosines: First 3′-β-branched adenosine substrates of adenosine deaminase," Bioorg. & Med. Chem. Lett., 10: 139-141 (2000). |
Tronchet, et al. "72. Synthese et desamination enzymatique des C-hydroxymethyl-3′-et C-methyl-3′-beta-D-xylofurannosyl-9-adenin es," Helv. Chim. Acta, vol. 62, 1979, pp. 689-695. |
Tunitskaya, V.L., et al., "Substrate properties of C′-methyl UTP derivatives in T7 RNA polymerase reactions. Evidence for N-type NTP conformation," FEBS Letters, 400: 263-266 (1997). |
Tyrsted, G., et al., "Inhibition of the synthesis of 5-phosphoribosyl-1-pyrophosphate by 3′-deoxyadenosine and structurally related nucleoside analogs," Biochem. Biophys. Acta., 155(2): 619-622 (Feb. 26, 1968). |
U.S. Appl. No. 10/845,976, filed May 14, 2004, Storer, et al. |
U.S. Appl. No. 11/005,443, filed Dec. 6, 2004, Gosselin, et al. |
U.S. Appl. No. 12/504,601, filed Jul. 16, 2009, Sommadossi, et al. |
Usui, H., et al., "Synthesis of 2′-deoxy-8,2′-ethanoadenosine and 3′-deoxy-8,3′-ethanoadenosine (Nucleotides & Nucleosides. LXIV)," Chem. Pharm. Bull., 34(1):15-23 (1986). |
Vassilev, V., et al., "Bovine Viral Diarrhea Virus Induced Apoptosis Correlates with Increased Intracellular Viral RNA Accumulation." Virus Research, 69: 95-107 (2000). |
Velazquiez, et al., "Synthesis of ‘1-’3′,5′-bis-0-(tort-butyldimethylsily)-beta-D-arabino-and beta-D-ribofuransoyl !cytosine!-2′-Spiro-5″-(4″-amino-1″,2″-oxathiole-2″,2″-dioxide). Analogues of the highly specific anti-HIV-1 agent TSAO-T," Tetrahedron, vol. 50, 1994, pp. 11013-11022. |
Verri, A., et al., "Lack of enantiospecificity of human 2′-deoxycytidine kinase: relevance for the activetion of B-L-deoxyctidine analogs as antineolastic and antiviral agents," Molecular Pharmacology, 51(1): 132-138 (Jan. 1997). |
Verri, A., et al., "Relaxed Enantioselectivity of Human Mitochondrial Thymidine Knase and Chemotherapeutic Uses of L-Nucleoside Analogues," Biochem. J., 328(1): 317-320 (Nov. 15, 1997). |
Von Buren, et al., "Branched oligodeoxynucleotides: automated synthesis and triple helical hybridization studies." Tetrahedron (1995), 51(31), 8491-506. |
Von Janta-Lipinski, M., et al., "Newly Synthesized L-Enantiomers of 3′-Fluoro-Modified B-2′-Deoxyribonucleoside 5′-Triphosphates Inhibit Hepatitis B DNA Polymerase but not the Five Cellular SNA Polymerases a, B, y, d and E nor HIV-1 Reverse Transciptase," J. Medicinal Chemistry, 41(12): 2040-2046 (May 21, 1998). |
Wagner, D., et al., "Preparation and Synthetic Utility of Some Organotin Derivatives of Nucleosides," J. Org. Chem., 39(1):24-30 (1974). |
Walczak, K., et al., "Synthesis of 1-(3-alkyl-2,3-dideoxy-D-pentofuranosyOuracils with potential anti-HIV activity," Acta Chemica Scand., 45: 930-934 (1991). |
Walton et al., "Branched-chain sugar nucleosides. A new type of biologically active nucleoside," J. Am. Chem. Soc., 88(19): 4524-25 (1966). |
Walton, et al., "Branched-Chain Sugar Nucleosides: V. Synthesis and Antiviral Properties of Several Branched-Chain Sugar Nucleosides," Antiviral Nucleosides, vol. 12: 306-309 (1969). |
Weinberg, R.S., et al., "Effect of antiviral drugs and hematopoietic growth factors on in vitro erythropoiesis," Mt. Sinai J. Med 1998;65(1):5-13. |
Whistler, R. L., and BeMiller, J.N., "[118] ‘A’-D-Glucosaccharino-1,4-Lactone," Methods in Carbohydrate Chemistry, 2:484-485 (1963). |
Wohnsland, A., et al., "Viral determinants of resistance to treatment in patients with hepatitis C," Clinical Microbiology reviews, (2007) vol. 20, No. 1, pp. 23-38. |
Wolf, et al., "New 2′-C-Branched-Chain Sugar Nucleoside Analogs With Potential Antiviral or Antitumor Activity," Synthesis, Georg Thieme Verlag. Stuttgart, DE, No. 8, Aug. 1992, pp. 773-778. |
Wolfe, et al., Tetrahedron Letters, vol. 36(42): 7611-14 (1995). |
Wu, et al., "A New Stereospecific Synthesis of [3.1.0] Cicyclic Cyclopropano Analog of 2′,3′-Dideoxyuridine." Tetrahedron, vol. 46, 1990, pp. 2587-2592. |
Wu, et al., Targeting NS5B RNA-dependent RNA polymerase for anti-HCV chemotherapy. Current Drug Targets—Infectious Disorders 2003, vol. 3, p. 207-219. |
Yarchoan, R., et al. "Long-term toxicity / activity profile of 2′,3′-dideoxyinusine in AIDS or AIDS-related complex," The Lancet, 336(8714):526-529 (1990). |
Yoshida Y, et al., "Reversal of azidothymidine-induced bone marrow suppression by 2′ ,3′-dideoxythymidine as studied by hemopoietic clonal culture," AIDS Res. Hum. Retroviruses, 6(7):929-932 (1990). |
Zedeck et al., "Inhibition of the steroid induced synthesis of Δ5-3-ketosteroid isomerase in Pseudomonas testosteroni by a new purine deoxyribonucleoside analog: 6-chloro-Raza-9-cyclopentylpurinc," Mol. Phys., 3(4):386-95 (1967). |
Zemlicka, J., et al. "Aminoacyl Derivatives of Nucleosides, Nucleotides, and polynucleotides. VIII. The Preparation of 2′(3)-O-L-Phenylalanyluridine, -cytidenie, -Adensonine, -inosine, -guanosine and 2′-Deoxy-3′ O-L-Phenylalanyladenosine," Collection Czecoslov, Chem. Commun. 1969, vol. 43, No. 13, 3755-3767. |
Zemlicka, J., et al., "Substrate Specificity of Ribosomal Peptidyltransferase. Peditidyltranferase. Effect of Modifications in the Heterocyclic, Carbohydrate and Amino Acid Moiety of 2′(3)-O-L-Phenyladenosine." Biochemistry. Dec. 2, 1975, vol. 14, No. 24, 5239-5249. |
Zhou, et al., Pharmacokinetics and pharmacodynamics of valopicitabine. Journal of Hepatology 2005, vol. 42 (Suppl. 2), p. 229. |
Zinchenko, et al., "2′, 3′& .5′—uridine methyl derivatives in microbiological transelicozilation." Doklady Akad Nauk v.297(3), pp. 731-734 (1987). |
Zinchenko, et al., "Substrate Specificity of Uridine and Purine Nucleoside Phosphorylases of the Whole Cells of Escherichia coli." Nucleic Acids Research, Symposium Series No. 18., 1987, pp. 137-140. |
Zinchenko, et al., "Substrate specificity of uridine and purine nucleoside phosporlases in whole cells of E. coli" Bioplymers & a cell, 1988, v. 4, No. 6. |
Zon, G., "Cyclophosphamide Analogues," Chapter 4 in Progress in Medicinal Chemistry, vol. 19, G.P Ellis and G.B. West, Eds., pp. 205-246 (1982). |
Cited By (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130315862A1 (en) * | 2000-05-23 | 2013-11-28 | Universita' Degli Studi Di Cagliari | Methods and compositions for treating hepatitis c virus |
US10363265B2 (en) * | 2000-05-23 | 2019-07-30 | Idenix Pharmaceuticals Llc | Methods and compositions for treating hepatitis C virus |
US10758557B2 (en) | 2000-05-23 | 2020-09-01 | Idenix Pharmaceuticals Llc | Methods and compositions for treating hepatitis C virus |
US20130149283A1 (en) * | 2000-05-23 | 2013-06-13 | Universita Degli Studi Di Cagliari | Methods and compositions for treating hepatitis c virus |
US20180235993A1 (en) * | 2000-05-26 | 2018-08-23 | Idenix Pharmaceuticals Llc | Methods and compositions for treating flaviviruses and pestiviruses |
US20130315863A1 (en) * | 2000-05-26 | 2013-11-28 | Universita' Degli Studi Di Cagliari | Methods and compositions for treating flaviviridae infections |
US10287311B2 (en) | 2003-05-30 | 2019-05-14 | Gilead Pharmasset Llc | Modified fluorinated nucleoside analogues |
US9200319B2 (en) | 2008-06-11 | 2015-12-01 | Lasergen, Inc. | Nucleotides and nucleosides and methods for their use in DNA sequencing |
US8877905B2 (en) | 2008-06-11 | 2014-11-04 | Lasergen, Inc. | Nucleotides and nucleosides and methods for their use in DNA sequencing |
US9351989B2 (en) * | 2010-12-29 | 2016-05-31 | Inhibitex, Inc. | Substituted purine nucleosides, phosphoroamidate and phosphorodiamidate derivatives for treatment of viral infections |
US20140140955A1 (en) * | 2010-12-29 | 2014-05-22 | University College Of Cardiff Consultants Limited | Substituted purine nucleosides, phosphoroamidate and phosphorodiamidate derivatives for treatment of viral infections |
US8946242B2 (en) | 2012-02-14 | 2015-02-03 | University Of Georgia Research Foundation, Inc. | Spiro[2.4]heptanes for treatment of flaviviridae infections |
US8921384B2 (en) | 2012-02-14 | 2014-12-30 | Unversity Of Georgia Research Foundation, Inc. | Spiro[2.4]heptanes for treatment of flaviviridae infections |
US8673926B2 (en) | 2012-02-14 | 2014-03-18 | University Of Georgia Research Foundation, Inc. | Spiro[2.4]heptanes for treatment of flaviviridae infections |
US9206412B2 (en) | 2012-05-31 | 2015-12-08 | Colorado State University Research Foundation | Thioxothiazolidine inhibitors |
US9447132B2 (en) | 2013-04-12 | 2016-09-20 | Achillion Pharmaceuticals, Inc. | Highly active nucleoside derivative for the treatment of HCV |
US10815266B2 (en) | 2015-03-06 | 2020-10-27 | Atea Pharmaceuticals, Inc. | β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment |
US10870672B2 (en) | 2015-03-06 | 2020-12-22 | Atea Pharmaceuticals, Inc. | β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment |
US10875885B2 (en) | 2015-03-06 | 2020-12-29 | Atea Pharmaceuticals, Inc. | β-d-2′-deoxy-2′-α-fluoro-2′-β-c-substituted-2-modified-n6-substituted purine nucleotides for HCV treatment |
US10000523B2 (en) | 2015-03-06 | 2018-06-19 | Atea Pharmaceuticals, Inc. | β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment |
US10005811B2 (en) | 2015-03-06 | 2018-06-26 | Atea Pharmaceuticals, Inc. | β-D-2′-deoxy-2′-α-fluoro-2′β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment |
US10870673B2 (en) | 2015-03-06 | 2020-12-22 | Atea Pharmaceuticals, Inc. | β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment |
US9828410B2 (en) | 2015-03-06 | 2017-11-28 | Atea Pharmaceuticals, Inc. | β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment |
US10239911B2 (en) | 2015-03-06 | 2019-03-26 | Atea Pharmaceuticals, Inc. | Beta-D-2′-deoxy-2′-alpha-fluoro-2′-beta-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment |
US9676797B2 (en) | 2015-09-02 | 2017-06-13 | Abbvie Inc. | Anti-viral compounds |
US10053474B2 (en) * | 2015-09-02 | 2018-08-21 | Abbvie Inc. | Anti-viral compounds |
WO2017197055A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
WO2017197046A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
WO2017197036A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
WO2018013937A1 (en) | 2016-07-14 | 2018-01-18 | Atea Pharmaceuticals, Inc. | Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection |
WO2018048937A1 (en) | 2016-09-07 | 2018-03-15 | Atea Pharmaceuticals, Inc. | 2'-substituted-n6-substituted purine nucleotides for rna virus treatment |
US10946033B2 (en) | 2016-09-07 | 2021-03-16 | Atea Pharmaceuticals, Inc. | 2′-substituted-N6-substituted purine nucleotides for RNA virus treatment |
EP3865136A1 (en) | 2016-09-07 | 2021-08-18 | ATEA Pharmaceuticals, Inc. | 2'-substituted-n6-substituted purine nucleotides for corona virus treatment |
EP4088725A1 (en) | 2016-09-07 | 2022-11-16 | ATEA Pharmaceuticals, Inc. | 2'-substituted-n6-substituted purine nucleotides for the treatment of a virus from the picornaviridae family |
US11690860B2 (en) | 2018-04-10 | 2023-07-04 | Atea Pharmaceuticals, Inc. | Treatment of HCV infected patients with cirrhosis |
US10874687B1 (en) | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
US11707480B2 (en) | 2020-02-27 | 2023-07-25 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
US11738038B2 (en) | 2020-02-27 | 2023-08-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
US11813278B2 (en) | 2020-02-27 | 2023-11-14 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20180235993A1 (en) | Methods and compositions for treating flaviviruses and pestiviruses | |
US10758557B2 (en) | Methods and compositions for treating hepatitis C virus | |
US20040006002A1 (en) | Methods and compositions for treating flaviviruses and pestiviruses using 4'-modified nucleoside | |
US20080280850A1 (en) | Methods and Compositions for Treating Flaviviruses, Pestiviruses and Hepacivirus | |
WO2004096197A2 (en) | 5-aza-7-deazapurine nucleosides for treating flaviviridae |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
AS | Assignment |
Owner name: IDENIX PHARMACEUTICALS LLC, MASSACHUSETTS Free format text: CHANGE OF NAME;ASSIGNOR:IDENIX PHARMACEUTICALS, INC.;REEL/FRAME:047149/0206 Effective date: 20150427 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 8 |